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Part I: Chemical Biology 
 
I.1 Photocontrol of Glutamate Receptors 
 Optochemical genetics uses small photo-
switchable molecules to control the activity of native or 
genetically modified receptors. To this end, our group 
has adapted the concepts of photochromic ligands 
(PCLs) and photoswitched-tethered ligands (PTLs) to 
the ionotropic glutamate receptors (iGluRs). For 
guidance in the design of such molecules, we have 
compiled comprehensive lists of crystal structures 
featuring receptor-bound ligands. Among other 
molecules, we now present a new PCL named ATA-3, 
which only acts on AMPA receptors, typically considered the workhorses of mammalian 
glutamatergic synapses. We show, that ATA-3 is capable of stimulating neurons and bipolar 
cells in “blind” retinae. As such, it has become a promising lead-structure in our attempts of 
using small photoswitchable molecules for the restoration of vision. 
Furthermore we report our progress toward a universal photoswitch for AMPA and kainate 
receptors and the first light-controlled metabotropic glutamate receptor (LimGluR), which 
uses the PTL DMAG-0 as photoswitchable unit. To this end, we have developed a scalable 
and reliable route for the synthesis of the PTL. Together with our collaborators at UC 
Berkeley, we report the performance of the DMAG-0•mGluR2 conjugate both in vitro and in 
vivo, and compare it to other methods for the control of G-protein coupled receptors. 
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I.2 Toward an Orthogonal Receptor-Ligand Pair 
In the mammalian brain, the majority of excitatory neurotransmission is mediated by 
ionotropic glutamate receptors (iGluRs) and their dysfunction is related to many neurologic 
diseases. Therefore, a detailed understanding of their structure and their mode of action is 
very important for neuroscience. Introduction of artificial proteins to probe native neural 
systems however often interferes with the natural “landscape” of receptors. 
In this project we therefore aim at creating a receptor for the orthogonal activation of 
glutamatergic synapses, which does not respond to the endogenous ligand, L-glutamate. In 
order to render the receptor unresponsive to glutamate, but sensitive toward an artificial 
ligand, we employ the so-called “bump-hole” approach. Hence, we created a “hole” in the 
receptor’s ligand-binding domain (LBD) by exchanging an amino acid for a sterically less 
demanding one. At the same time, we synthesized ligands that bear bulky groups, i.e. 
“bumps”, to fill the gap generated by the mutation. So far we have focused our attention on 
two types of mutation: a) E738D in GluK2 introduced by Fleck et al. and b) mutations of 
L671 in GluA2. The first has already yielded a receptor that is unresponsive to glutamate, but 
when used in conjunction with the C439C mutation can be activated to a certain extent by 
light, using the photochromic-tethered ligand MAG-0. 
The second set of mutations (L671) has created modified AMPA receptors, which show a 
marked increase in affinity toward kainate-type agonists. One of them (L671G) efficiently 
functions as a “MAG”-receptor, i.e. it has a higher affinity for the kainate-type ligand MAG-0 
than for L-glutamate. Therefore it is a promising lead for the design of an orthogonal receptor-
ligand pair. 
 In a complementary 
approach, we have designed a yeast 
assay for glutamate receptor activity 
(“YAGA”), which allows for the 
screening of both ligands and 
modified receptors. We plan to use 
this system, which is based on the 
conditional rescue of a yeast strain 
lacking both low- and high-affinity 
potassium transporters (SGY1528), for a directed evolution of ionotropic glutamate receptors 
toward a designer receptor-ligand pair. Thus we seek to provide an orthogonal toolset for the 
dissection of neural networks.  
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Part II: Toward the Total Synthesis of Herquline A & B 
The piperazine alkaloids herquline A & B were 
isolated in 1979 by Omura and coworkers from the 
penicilium strain penecilium herquei (Fg-372). Even 
though their biosynthesis is believed to involve two 
molecules of L-tyrosine, we decided to address their 
synthesis using a different approach. Our retrosynthetic 
analysis shows, that both herqulines can be synthesized 
from two molecules of pyroglutamic acid, two molecules of methyl vinyl ketone (MVK) and 
an additional C1-source. The key-step of the synthesis is the transition-metal-mediated 
intramolecular coupling of two α-iodo enones. 
We here describe our synthetic progress toward these highly unusual natural products and the 
surprises and pitfalls that lie in the formation of the 12-membered ring present in herquline A 
and B. 
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Common Abbreviations 
Å Angstrom (10-10 m) 
Ac Acetyl 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
Bu Butyl 
Bz Benzoyl 
CDI Carbonyldiimidazole 
CH2Cl2 Dichloromethane 
COD 1,5-Cyclooctadiene 
conc. concentrated 
DEAD Diethyl azodicarboxylate 
DMAP 4-Dimethylaminopyridine 
DME Dimethoxy ethane 
DMF N,N-dimethylformamide 
DMSO Dimethyl sulfoxide 
dppe 1,2-Bis(diphenylphosphino)ethane 
dppf 1,1'-Bis(diphenylphosphino)ferrocene 
dr diastereomeric ratio 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EI Electron ionization/electron impact (HRMS) 
ESI Electrospray ionisation (HRMS) 
Et Ethyl 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
EtOH Ethanol 
FA Formic acid 
g Gram(s) 
h Hour (s) 
HBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HMDS Bis(trimethylsilyl)amine 
HRMS High resolution mass spectrometry 
i-Pr Iso-propyl 
IR Infrared 
LiAlH4 Lithium aluminium hydride 
M Molar (concentration) 
Me Methyl 
MeOH Methanol 
min Minute (s) 
mp Melting point 
MVK Methyl vinyl ketone 
N Normal (concentration) 
n Normal (isomers) 
NMR Nuclear magnetic resonance 
o Ortho 
p Para 
PE Petrol ether (iso-hexanes) 
Ph Phenyl 
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Pin Pinacol 
PPh3 Triphenylphosphine 
ppm Parts per million (NMR) 
Pr Propyl 
Py Pyridine 
PYBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Rf Retention factor (TLC) 
Rt Retention time (HPLC) 
RT Room temperature 
t Tertiary (isomer) 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMS Trimethylsilyl 
UV Ultra-violet 
δ Chemical shift (NMR) 
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I.1 Photocontrol of Glutamate Receptors 
 
1) The Glutamatergic Synapse 
 
The human brain contains approximately 86 billion neurons, which form an estimate of 150 
trillion contacts with one another.[1] These specific interactions called synapses, are crucial for 
both the transmission and the processing of information which is passed on at these sites 
either electrically or chemically. Electrical synapses, i.e. “gap junctions”, had long been 
overlooked. Recently however, there was a resurge in interest in these relatively small (1-
4 nm) synapses, which rather seem to be a cooperative than an alternative way of transmission 
of information to the exchange of chemicals.[2] The latter happens at chemical synapses, were 
so-called neurotransmitters are exchanged. The most prevalent excitatory neurotransmitter in 
the mammalian central nervous system (CNS) is L-glutamate, which is released from the 
presynaptic neuron into the synaptic cleft and received by specialized receptors at the 
postsynaptic neuron (Fig. 1). To ensure repetitive action of the synapse, specialized cells, i.e. 
glia cells, surround the neurons. Despite their name (greek γλία = glue) these cells not only 
hold the neurons together, but they rather actively cooperate with them.[3] 
 
	  
Figure 1. Schematic view of a glutamatergic synapse. Movements are indicated in dashed, 
transformations or regulatory influences are indicated as solid arrows (adapted from different sources). 
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Astrocytes for example, the most abundant glia cell type in the mammalian CNS, are 
responsible for clearing the excess of neurotransmitter from the synaptic cleft via excitatory 
amino acid transporters (EAATs). L-glutamate is then transformed into L-glutamine and fed 
back to the neurons where it can be recycled (Fig. 1).[4] 
The glutamate-sensitive receptors of neurons can be divided into two groups: 
metabotropic and ionotropic glutamate receptors (mGluRs and iGluRs). While the latter are 
ligand-gated ion channels, mGluRs are G-protein coupled receptors. Thus, the response to L-
glutamate differs vastly depending on which class of glutamate receptor is being activated. 
iGluRs are cation-channels and therefore are responsible for the transmission of information 
by depolarizing the neuron upon action of glutamate. There are three types of ionotropic 
glutamate receptors: NMDA (GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, 
GluN3B), AMPA (GluA1-4) and kainate (GluK1-5) receptors. While GluAs and GluKs are 
selective for Na+ and K+, NMDA receptors are permeable to Ca2+, too, and thus represent an 
additional way of communication via this second messenger (Fig. 1). mGluRs, which are 
categorized into group I, group II and group III, on the other hand are G-protein coupled 
receptors and therefore do not contribute to the depolarization of a neuron directly. By 
coupling of the G-protein subunits (α, βγ) to different pathways, they can instead regulate and 
influence a variety of cellular processes. Their widespread expression – not only in neurons 
(Fig. 1) – makes metabotropic glutamate receptors an interesting target for both research and 
medical applications.[5] 
It is obvious, that such research has always been tightly linked to the development of 
new techniques. From the silver-staining experiments of Ramon y Cajal in 1888 to the 
development of patch-clamp electrophysiology by Neher and Sakmann in 1976, new 
technology has always provided us with an even more detailed understanding of the cellular 
processes associated with memory, learning and processing of information. It is therefore with 
no surprise, that biotechnology has claimed its part of neuronal research, since it can provide 
solutions for both localized (i.e. neuron-centered) and network-associated problems. Without 
a doubt, by harnessing the spatiotemporal control of light, the use of photosensitive proteins 
like channelrhodopsin and halorhodopsin has revolutionized the way scientists can control the 
behavior and state of neurons. This new field termed optogenetics,[6] however poses an 
immediate problem to both the application in humans and the research of native neuronal 
processes, as it uses proteins from other species to control the activity of cells, rather than by 
exploiting their native machinery. 
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Our group therefore uses an alternative approach toward the photocontrol of neuronal 
signaling: the direct control of the receptors, like mGluRs and iGluRs, which are responsible 
for neurotransmission and processing of information in chemical synapses. To this end, we 
use small photoswitchable molecules that change their pharmacological properties (e.g. 
affinity, efficacy) upon irradiation with light of different wavelengths. We call this concept 
“optochemical genetics” since it employs small chemical substances to carry out optogenetic 
tasks.[7] 
The design of such molecules requires a detailed understanding of both the structure 
and the pharmacology of the target-receptors. Accordingly, we like to base our design of new 
molecules on crystal structures, as they provide additional information beyond simple 
structure-activity relationships obtained from electrophysiological recordings. This approach 
has served us well in the past and we therefore decided to compile comprehensive lists of the 
x-ray structures of iGluRs and mGluRs available and to link them to the known receptor 
pharmacology. With the information gained, we were able to synthesize new selective 
molecules for the control of both the ionotropic and the metabotropic glutamate receptors. 
The results of our literature survey regarding crystal structures of ionotropic glutamate 
receptors are summarized in the following chapter and have been published in 2010.[8] 
 
Note: The formatting of schemes and figures and the citations of the original manuscript has 
been adjusted to fit the format of this thesis. 
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2) Pharmacology of Ionotropic Glutamate Receptors: A Structural Perspective 
 
Philipp Stawski, Harald Janovjak and Dirk Trauner 
 
(This work was published in Bioorg. & Med. Chem. 2010, 18, 7759–7772) 
 
1. Introduction 
 
Ionotropic glutamate receptors (iGluRs) mediate the fast response to the most prominent 
excitatory neurotransmitter of the mammalian nervous system. They are tetrameric, ligand-
gated, cation-selective ion channels that are found throughout the animal kingdom and have 
homologs in plants and presumed ancestors in prokaryotes.[5] Many human neurological 
disorders, such as epilepsy and certain forms of mental retardation, as well as stroke, can be 
linked to iGluRs. As such, their pharmacology, molecular physiology and expression have 
been studied in great detail.[9] Due to a wealth of recent data stemming from structural 
biology, they now belong to the best-understood types of receptors.[10] Important topics of 
pharmacology, such as agonism vs. antagonism, allosteric modulation, or receptor 
desensitization can be beautifully illustrated using iGluRs. These crystallographic studies 
began with cleverly engineered soluble constructs representing the clamshell-like 
extracellular ligand-binding domain (LBD) of iGluRs[11] and recently culminated in a full-
fledged structure of GluA2 – one of the most formidable achievements in structural biology to 
date.[12] 
The purpose of this article is to provide an overview of the various small-molecule 
ligands, i.e. agonists, antagonists and modulators, that target iGluRs and that have been 
structurally characterized together with their binding sites. We will not attempt to 
comprehensively review the pharmacology of iGluRs (a truly monumental task) but rather 
discuss recent crystallographic results that allow for the interpretation of the available 
structure-activity relationships and the design of new and improved molecules. Computational 
investigations, which provide a complimentary approach, are beyond the scope of this 
review.[13] The same is true for the extensive pharmacology and emerging structural biology 
of metabotropic glutamate receptors (mGluRs), which mediate the slow response to 
glutamate. Since our review is “ligand-centric”, we will only briefly touch on the wealth of 
biophysical and biochemical data that have been accumulated to explain important receptor 
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functions, such as activation, desensitization and trafficking, and we refer the reader to 
excellent accounts on these topics.[5, 9]  
Table 1, which is at the heart of this review, lists the names and functional roles of the 
ligands and their corresponding accession numbers in the Protein Data Bank (pdb)[14] in the 
order of their receptor subtypes. References with further details on the origin, pharmacology, 
and medical use of the ligands are also provided. The corresponding chemical structures can 
be found in Figures 4-13. For good measure, we also list the known apo structures of receptor 
LBDs and the structures of amino-terminal domains (vide infra). Occasionally, we will 
discuss popular agonists and antagonists for iGluRs that have not (yet) been crystallized with 
their receptors. Their binding mode can be often inferred from the existing structural data. 	  
Table 1. X-Ray structures of iGluR-LBDs and their ligands. A, ant and mod denote agonists, 
antagonists and modulators, resp. Structures marked with * are not published. 
Type PDB code Ligand(s) Functional Mutant(s) Citation 
      
GluR0 1IIW  apo  [15] 
GluR0 1II5 glutamic acid (1) a  [15] 
GluR0 1IIT L-serine  a  [15] 
GluR0 2PYY glutamic acid (1) a  [16] 
      
GluA2 1FTO  apo  [17] 
GluA2 1MXV Zn2+ apo  [18] 
GluA2 1MXW Zn2+ apo  [18] 
GluA2 1MXX Zn2+ apo  [18] 
GluA2 1MXY Zn2+ apo  [18] 
GluA2 1MXZ Zn2+ apo  [18] 
GluA2 1MY0 Zn2+ apo  [18] 
GluA2 1MY1 Zn2+ apo  [18] 
GluA2 1FTJ glutamic acid (1) a  [17] 
GluA2 1FTK kainic acid (17) a  [17] 
GluA2 1FW0 kainic acid (17) a  [17] 
GluA2 1LB8 AMPA (10) a L483Y, flop [19] 
GluA2 1LBB kainic acid (17) a N754D [19] 
GluA2 1M5B 2-Me-TetAMPA (8) a  [20] 
GluA2 1M5C Br-HIBO (13) a flop [20] 
GluA2 1M5D Br-HIBO (13) a flop [20] 
GluA2 1M5E ACPA (10) a flop [20] 
GluA2 1M5F ACPA (10) a flop [20] 
GluA2 1MM6 quisqualate (14) a  [21] 
GluA2 1MM7 quisqualate (14), Zn2+ a  [21] 
GluA2 1MQD  (S)-des-Me-AMPA (5), Li2SO4 a  [22] 
GluA2 1MQG iodo-willardiine (15e) a  [23] 
GluA2 1MQH bromo-willardiine (15d) a  [23] 
GluA2 1MQI fluoro-willardiine (15b) a  [23] 
GluA2 1MQJ willardiine (15a) a  [23] 
GluA2 1MS7 (S)-des-Me-AMPA (5), Zn(OAc)2 a  [22] 
GluA2 1MXU bromo-willardiine (15d) a  [18] 
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Type PDB code Ligand(s) Functional Mutant(s) Citation 
GluA2 1MY2 AMPA a  [23] 
GluA2 1MY3 bromo-willardiine (15d) a  [23] 
GluA2 1MY4 iodo-willardiine (15e) a  [23] 
GluA2 1N0T ATPO (35) a  [24] 
GluA2 1NNK ATPA (6) a  [25] 
GluA2 1NNP ATPA (6) a  [25] 
GluA2 1P1N kainic acid (17) a L138T [26] 
GluA2 1P1O quisqualate (14) a L138T [26] 
GluA2 1P1Q AMPA (4) A L138T [26] 
GluA2 1P1U AMPA (4) a L138T [26] 
GluA2 1P1W AMPA (4) a L94Y, L138T [26] 
GluA2 1SYH CPW399 (16) a  [27] 
GluA2 1SYI CPW399 (16) a Y702F [27] 
GluA2 1WVJ 4-AHCP (11) a  [28] 
GluA2 1XHY kainic acid (17) a Y702F, flop [27] 
GluA2 2AIX thio-ATPA (7) a  * 
GluA2 2AL4 quisqualate (14) a  [29] 
GluA2 2ANJ kainic acid (17) a Y61W [30] 
GluA2 2GFE glutamic acid (1) a A476E S673D [31] 
GluA2 2I3V glutamic acid (1) a G725C [32] 
GluA2 2I3W glutamic acid (1) a G729C [32] 
GluA2 2P2A BnTetAMPA (9) a  [33] 
GluA2 2UXA glutamic acid (1) a flip [34] 
GluA2 3B6Q glutamic acid (1) a T686A [35] 
GluA2 3B6T quisqualate (14) a T686A [35] 
GluA2 3B6W glutamic acid (1) a T686S [35] 
GluA2 3BFT TDPA (12) a  [36] 
GluA2 3BFU TDPA (12) a  [36] 
GluA2 3DP6 glutamic acid (1) a  [37] 
GluA2 3LSL glutamic acid (1), piracetam (74) a  [38] 
GluA2 2CMO glutamic acid (1), NS-1209 (47) a, ant  [39] 
GluA2 3KGC 
glutamic acid (1), Z-200775 (44), LY-
404187 (71) 
a, ant, mod  [12] 
GluA2 1LBC glutamic acid (1), cyclothiazide (61) a, mod N775S [19] 
GluA2 2AL5 fluoro-willardiine (15b), aniracetam (75) a, mod  [29] 
GluA2 2XHD glutamic acid (1), 73 a, mod  [40] 
GluA2 3BBR glutamic acid (1), 70 a, mod  [41] 
GluA2 3H6T glutamic acid (1), cyclothiazide (61) a, mod  [42] 
GluA2 3H6U glutamic acid (1), NS-1493 (67) a, mod  [42] 
GluA2 3H6V glutamic acid (1), NS-5206 (68) a, mod  [42] 
GluA2 3H6W glutamic acid (1), NS-5217 (69) a, mod  [42] 
GluA2 3IJO glutamic acid (1), althiazide (65) a, mod  [43] 
GluA2 3IJX glutamic acid (1), IDRA-21 (64) a, mod  [43] 
GluA2 3IK6 glutamic acid (1), chlorothiazide (66) a, mod  [43] 
GluA2 3IL1 glutamic acid (1), IDRA-21 (64) a, mod  [43] 
GluA2 3ILT glutamic acid (1), trichlormethiazide (63) a, mod  [43] 
GluA2 3ILU glutamic acid (1), hydroflumethiazide (62) a, mod  [43] 
GluA2 3LSF glutamic acid (1), piracetam (74) a, mod  [38] 
GluA2 1LB9 DNQX (40) ant L483Y [19] 
GluA2 3B7D CNQX (41) ant  [44] 
GluA2 3H03 UBP277 (36a) ant  [37] 
GluA2 3H06 UBP282 (36b) ant  [37] 
      
      
Pharmacology of Ionotropic Glutamate Receptors: A Structural Perspective 
19 
Type PDB code Ligand(s) Functional Mutant(s) Citation 
GluA2 3KG2 ZK-200775 (44) ant 
N241E, N385D, 
N392Q, K410A, 
E413A, M414A, 
E416A, C589A 
[12] 
GluA2 3BKI FQX (46) 
ant, 
photoproduct 
 [45] 
      
GluA3 3DLN glutamic acid (1) a  [46] 
GluA3 3DP4 AMPA (4) a  [46] 
GluA3 3M3K glutamic acid (1) a flop [47] 
GluA3 3M3L glutamic acid (1), PEPA (72) a, mod  [47] 
      
GluA4 3EN3 kainic acid (17) a  [48] 
GluA4 3FAS glutamic acid (1) a flip [49] 
GluA4 3FAT AMPA (4) a flip [49] 
GluA4 3KEI glutamic acid (1) a L651V [50] 
GluA4 3KFM kainic acid (17) a L651V [50] 
      
GluK1 3C31 Li+ apo  [51] 
GluK1 3C32 Na+ apo  [51] 
GluK1 3C33 K+ apo  [51] 
GluK1 3C34 Rb+ apo  [51] 
GluK1 3C35 Cs+ apo  [51] 
GluK1 3C36 NH4+ apo  [51] 
GluK1 1TXF glutamic acid (1) a  [52] 
GluK1 1YCJ glutamic acid (1) a  [53] 
GluK1 2F36 glutamic acid (1) a  [52] 
GluK1 2PBW domoic acid (18) a  [54] 
GluK1 2WKY 4-AHCP (11) a  [55] 
GluK1 2ZNS glutamic acid (1) a  * 
GluK1 2ZNT dysiherbaine A (26a) a  * 
GluK1 2ZNU dysiherbaine A (26a) a  * 
GluK1 3FUZ glutamic acid (1) a  * 
GluK1 3FV1 dysiherbaine A (26a) a  * 
GluK1 3FV2 neodysiherbaine A (26b) a  * 
GluK1 3FVG MSVIII-19 (26c) a  * 
GluK1 3FVK 8-deoxy-neodysiherbaine A (26d) a  * 
GluK1 3FVN 9-deoxy-neodysiherbaine A (26e) a  * 
GluK1 3FVO 8-epi-neodysiherbaine A (26f) a  * 
GluK1 3GBA dysiherbaine A (26a) a  [56] 
GluK1 3GBB MSVIII-19 (26c) a  [56] 
GluK1 1VSO ATPO (35) ant  [54] 
GluK1 2F34 UBP-310 (36d) ant  [52] 
GluK1 2F35 UBP-302 (36c) ant  [52] 
GluK1 2OJT UBP-310 (36d) ant  [57] 
GluK1 2QS1 UBP-315 (36e) ant  [56] 
GluK1 2QS2 UBP-318 (36g) ant  * 
GluK1 2QS3 UBP-316 (36f) ant  * 
GluK1 2QS4 LY-466195 (37) ant  * 
      
GluK2 1S7Y glutamic acid (1) a  [52] 
GluK2 1S9T quisqualate (14) a  [52] 
GluK2 1SD3 (2S,4R)-4-methyl glutamic acid (21) a  [52] 
GluK2 1TT1 kainic acid (17) a  [52] 
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Type PDB code Ligand(s) Functional Mutant(s) Citation 
GluK2 1YAE domoic acid (18) a  [58] 
GluK2 2I0B glutamic acid (1) a 
K494E, I749L, 
Q753K, E757Q 
[59] 
GluK2 2I0C glutamic acid (1) a 
S775E, Y490C, 
L752C 
(crosslinked) 
[59] 
GluK2 3G3F glutamic acid (1) a  [60] 
GluK2 3G3G glutamic acid (1) a K665R [60] 
GluK2 3G3H glutamic acid (1) a 
K665R, I749L, 
Q753K 
[60] 
GluK2 3G3I glutamic acid (1) a 
I442H, K494E, 
I749L, Q753K 
[60] 
GluK2 3G3J glutamic acid (1) a 
I442H, K494E, 
K665R, I749L, 
Q753K 
[60] 
GluK2 3G3K glutamic acid (1) a 
I442H, K494E, 
K665R, I749L, 
Q753K, E757Q 
[60] 
      
GluD2 2V3T  apo  [61] 
GluD2 2V3U D-serine (3) a  [61] 
      
GluN1 1PB7 glycine (2) a  [62] 
GluN1 1PB8 D-serine (3) a  [62] 
GluN1 1PB9 D-cycloserine (27) a  [62] 
GluN1 1Y1M cycloleucine (31) a  [63] 
GluN1 1Y1Z ACBC (30) a  [63] 
GluN1 1Y20 ACPC (29) a  [63] 
GluN1 1PBQ 5,7-dichlorokynureniuc acid (54) ant  [62] 
      
GluN1/GluN2A 2A5T glycine (2), glutamic acid (1) a, a  [64] 
GluN2A 2A5S glutamic acid (1) a  [64] 
      
GluA2 ATD 3H5V    [65] 
GluA2 ATD 3H5W    [65] 
GluK2 ATD 3H6G    [66] 
GluK2 ATD 3H6H    [66] 
GluA2 ATD 3HSY    * 
 
2. An overview of iGluRs 
 
Historically, iGluRs have been grouped according to their distinct responses to certain small 
molecule agonists, namely AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic 
acid), kainate, and NMDA (N-methyl-D-aspartate).[5, 9] This classification had been upheld in 
light of more recent sequence data although the pharmacologically defined boundary between 
AMPA and kainate receptors has blurred over time and now they are often grouped into the 
so-called “non-NMDA receptor” superfamily. According to a modern nomenclature,[67] the 
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iGluRs comprise AMPA-type receptors (GluA1–GluA4), kainate receptors (GluK1–GluK5) 
and NMDA receptors (GluN1, GluN2A–GluN2D, GluN3A–GluN3B) (Fig. 2). Two orphan 
members of the iGluR gene family, GluD1 and GluD2, are also known, but their 
physiological role remains somewhat mysterious. In addition to this, a prokaryotic, 
potassium-selective glutamate receptor (GluR0) has been cloned and structurally 
characterized.[68]  
AMPA receptors are the workhorses of fast synaptic transmission and are widely 
expressed throughout the mammalian central nervous system. Potentiation of synaptic 
responses is achieved through insertion of an increasing number of AMPA receptors at the 
post-synaptic membrane or the modulation of single channel conductance.[69] By contrast, 
kainate receptors assume more of a modulatory role and are active both on the postsynaptic 
and presynaptic side. They are also involved in generating synaptic plasticity but have a 
narrower distribution.[70] NMDA receptors primarily function as coincidence detectors and are 
critical for learning and memory. They are inactive at resting membrane potentials due to a 
voltage-dependent block of the channel pore by magnesium ions. Activation of AMPA 
receptors and membrane depolarization releases this inhibition. Unlike most AMPA and 
kainate receptors, NMDA receptors are permeable to calcium ions which triggers various 
intracellular signaling cascades.[71] Alternative splicing and RNA editing, whose most notable 
effects are on trafficking and Ca2+ permeability, complicate the genetic and functional 
analysis of iGluRs.[72] 
Ionotropic glutamate receptors function as a complex of four individual subunits. 
Whereas the NMDA-receptors are obligate heterotetramers, the AMPA and kainate receptors 
can exist as homo- and heterotetramers within one subfamily. For example, the major kainate 
receptor in the human brain consists of GluK2 and GluK5.[73] NMDA receptors are composed 
of subunits that bind to glycine or D-serine (NR1 and NR3) and subunits that are activated by 
glutamate (NR2). NR1 and NR2A are the most abundant forms in the fully developed human 
brain.[74]  
Each individual subunit of an iGluR features an extracellular amino-terminal domain 
(ATD), which is involved in subfamily-specific tetramerization, an extracellular LBD that 
interacts with the neurotransmitter, a transmembrane domain (TMD) that forms the cation-
selective pore and a cytoplasmatic carboxy-terminal domain (CTD) involved in receptor 
localization and modulation. The ATD and LBD of iGLuRs have often been compared to 
clamshells (or Venus fly-traps). Starting from the N-terminus, the polypeptide first forms the 
ATD followed by a part of both lobes of the LBD clamshell, then dips into the membrane as 
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transmembrane helix 1, the pore loop, and transmembrane helix 2, then rises again to the 
extracellular side to complete the remainder of the LBD clamshell, and finally crosses the 
membrane once more as transmembrane helix 1 to end up as a CTD of varying length. 
Structurally, the LBD clamshell can be easily dissected in an “upper lobe” (relative to the cell 
membrane), which is also known as D1, and a “lower lobe”, known as D2.  
 
	  
Figure 2. a) Maximum likelihood phylogeny of human iGluRs where the branch lengths are 
proportional to the amount of inferred evolutionary change. Sequences were aligned with Muscle[75] 
and phylogeny was calculated using FastTree.[76] b) Domain structure of eukaryotic iGluRs. ADT = 
amino-terminal domain, LBD = ligand-binding domain, D1 = upper lobe of the LBD, D2 = lower lobe of 
the LBD, TMD = transmembrane domain, P = pore helix. 
 
3. The three-dimensional structure of iGluRs and the LBD clamshell 
 
Very recently, the whole crystal structure of a functional tetrameric AMPA receptor complete 
with its ATD, LBD and TMD was disclosed (pdb 3KG2, Fig. 3).[12] This structure reveals that 
homotetrameric iGluRs are approximately C4-symmetric in their TMDs and C2-symmetric 
with respect to extracellular domains. The first two helices and re-entrant loop of the TMD 
closely resemble those of potassium channels. Due to this “symmetry mismatch” (or, rather, 
reduction in symmetry), the four sequence-identical chains of iGluRs fall into two 
conformational subtypes, which is reflected in two types of LBD clamshells. Although the 
fold of these clamshells is very similar overall, they are oriented at different angles with 
respect to the C2-axis of symmetry and it is the ipsilateral clamshells that form a dimer 
exclusively via contacts in the D1 lobes. Upon activation, the clamshells close and the 
separation of their D2 lobes increases. This movement is mechanically linked to the second 
transmembrane helix and opens a gate in the TMD. It also creates mechanical tension within 
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the LBD multimer, which is alleviated by subsequent separation of the D1 lobes, a process 
that results in receptor desensitization and channel inactivation.[32] 
The crystallization and functional analysis of individual LBD clamshells has been 
greatly aided by soluble constructs (so called S1-S2 constructs) that capture most of their 
essential structural features and have allowed for the development of the above gating model. 
Coordinates of these constructs are available for two prokaryotic glutamate receptors, the 
AMPA receptors GluA2, GluA3, and GluA4, the kainate receptors GluK1 and GluK2, the 
NMDA receptor subunits GluN1, GluN3 (glycine sites), and GuN2A (glutamate site), as well 
as the orphan receptor GluD2. These have been crystallized as monomers or dimers and with 
a variety of agonists, antagonists and – in the case of AMPA receptors - several modulators 
that are know to influence receptor desensitization. A handful of apo structures are also 
available (Table 1). 
Since the human vocabulary concerning clamshells is somewhat limited compared 
with our ability to describe our own anatomy, we occasionally find it useful to speak of the 
LBD in terms of a human head and mouth. A “nose”-like loop can be found in all crystal 
structures of iGluR LBDs and we orient the clamshell in Figs. 3 and 5 such that the nose 
protrudes to the left. We prefer this orientation for the comparative analysis of the X-ray 
structures since the “mouth” (or cleft) of the LBD points towards the spectator and provides a 
perspective of glutamate and its congeners that corresponds to Fig. 4 (vide infra). The cleft of 
the clamshell is lined by “lips”, which can be fully closed or partially open to accommodate 
portions of a ligand. 
 
	  
Figure 3. a) Overall structure of iGluRs exemplified by GluA2 (pdb 3KG2). b) Close-up of a clamshell 
with important residues highlighted (GluA2 S1S2 from pdb 1FTM) 
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4. The binding mode of endogenous ligands: Glutamate, glycine and D-serine 
 
The binding-mode and conformation of glutamate is highly conserved in AMPA, kainate and 
NMDA receptors (Fig. 4). The most conspicuous interaction is a salt-bridge between a 
positively charged arginine side-chain protruding from the roof of D1 and the negatively 
charged C1-carboxylate of glutamate (A in Fig. 4c). This interaction is found in all functional 
eukaryotic iGluRs and mutation of the Arg residue leads to complete loss of channel 
function.[77] The protonated alpha-amino group of the ligand primarily interacts with a 
conserved glutamate residue at the C-terminal end of an antiparallel beta sheet on the D2 lobe 
(D in Fig. 4c). Conservative mutants wherein this residue is replaced with an aspartate have 
much lower affinity for the neurotransmitter.[78], [79], [80] Together, these highly conserved 
residues form what we call the “amino acid clamp”, which brings the two lobes of the 
clamshell together upon binding of the ligand (Fig. 4b). In addition to these primary 
interactions, there is an aromatic residue on D1 that forms the ceiling of the binding site and is 
in hydrophobic contact with the beta-methylene (C-3) of glutamate and its derivatives (B in 
Fig. 4c). This residue is a tyrosine in all structurally characterized AMPA/kainate receptors, a 
phenylalanine in GluN1 and a histidine in GluN2A. A hydrogen bond involving the ligand’s 
ammonium group and the backbone carbonyl of a proline residue provides additional affinity 
to the D1 lobe (C in Fig. 4c).  
 
	  
Figure 4. a) Endogenous ligands for AMPA, kainate and NMDA receptors. b) The amino acid-clamp. 
c) Schematic diagram of the major interactions of glutamate with residues on D1 and D2. 
d) Schematic diagram of the glycine and D-serine binding site. 
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On the other side, the C-5-carboxylate of the glutamate ligand mostly interacts with a 
threonine residue that sits at the C-terminal end of the so-called “helix F” in the D2 lobe. In 
all structurally characterized iGluRs (with the exception of GluR0), this helix features a Ser-
Thr or Ala-Thr motif at its tip (E in Fig. 4c). Interestingly, the helix dipole is oriented with its 
positive end toward the negatively charged carboxylate of glutamate or corresponding 
bioisosteric groups in agonists. 
Glycine and D-serine bind to the GluN1 and GluN3 LBDs in a very similar manner 
(Fig. 4d). The canonical amino acid-clamp is present, save that the glutamate in position D is 
replaced by an aspartate (cf. pdb 1PB7). The aromatic lid is a phenylalanine side chain and the 
proline backbone-carbonyl interacts with the ammonium group as usual. The helix dipole of 
helix F now points toward the alpha amino carboxylate. Overall, this creates a more 
compressed binding pocket, in accordance with the smaller ligands it accommodates. The 
hydroxymethyl side chain of D-serine, which has been recently identified as an endogenous 
ligand released by glial cells,[81] interacts with the serine side chain that is part of the Ser-Thr 
motif on top of this helix (cf. pdb 1PB8).  
 
5. Binding modes of agonists and antagonists 
 
A large number of agonists and antagonists bound to iGluR LBDs have been crystallized and 
several trends can be deduced from these data. Generally, agonists bind deeply within the 
cleft of the clamshell and allow the clamshell to close to a large degree. The degree of 
clamshell-closure more or less correlates with the efficacy of the agonists (Fig. 5).[11] 
Accordingly, partial agonists, such as substituted willardiines (for AMPA receptors) or 
domoic acid (for kainate receptor), close the clamshell to a lesser degree than full agonists. 
This is a somewhat simplified picture since the ligand-induced response and coupling to the 
TMD is complex, the clamshells function as dimers of dimers, and heteromultimeric iGluRs 
must be taken into account. It should be noted that in partially closed LBDs there are several 
”exit tunnels” that allow substituents to protrude between the lips.  
By contrast, competitive antagonists strongly bind to interaction sites A-C on D1 and 
to a lesser extent to residues on D2. In most cases, they literally pry the clamshell open 
(Fig. 5b).[11] This “foot in the door” mechanism explains how relatively minor changes can 
turn an agonist into an antagonist and provides a general paradigm for antagonists in 
clamshell-containing receptors.  
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Figure 5. a) Binding mode of a typical agonist, AMPA, to GluA2 (pdb 1MY2) . b) The foot-in-the-door 
mechanism of antagonism.  Structure of the GluA2 LBD bound to AMPA (pdb 1MY2), a selective 
agonist, overlaid with the LBD bound to ZK-200775 (44), a selective antagonist (pdb 3KG2).  
c) Structure of the GluA2 LBD bound to glutamate (pdb 1MY2) overlaid with the GluA2 LBD occupied 
by the AMPA-derived antagonist ATPO (pdb 1N0T). 
 	  
6.  Agonists for AMPA/kainate receptors 
 
Structurally, agonists and partial agonists of AMPA and kainate receptors are more or less 
directly derived from glutamate. They invariably feature the alpha-amino acid moiety of the 
neurotransmitter and bind to the amino acid-clamp in the canonical fashion (cf. Fig. 4b,c). 
Their other end interacts with helix F and other residues of D2, sometimes mediated by water 
molecules. There is considerable structural variety with respect to this part of the molecules 
and there are several positions where the parent glutamate backbone can be substituted 
without loosing agonist activity. The configuration at these positions is crucial and can be 
easily explained by the available X-ray structures. 
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Figure 6 provides an overview of agonists for AMPA-kainate receptors, which can be 
classified as follows:  
 
a) Glutamate derivatives wherein C-4 and C-5 have been replaced by flat, conformationally 
rigid heterocycles (Fig. 6; 2-16). All of these compounds bind with their alpha-amino moiety 
in the usual fashion and interact with helix F on D2 with their heterocyclic moieties (E in 
Fig. 4). These are in most cases negatively charged and function as bioisosters of the C-5-
carboxylate. The classical agonist AMPA (4) and its derivatives (5-10), as well as 4-ACP 
(11), TDBA (12), bromo-HIBO (13), and the natural products quisqualic acid (14) and 
willardiine (15a) belong to this class. A series of substituted willardiines has been prepared 
with increasingly bulky halogen substituents (15b-e). These progressively loose potency as 
the substituents prevent closure of the clamshell to an increasing degree.[23] 
Many derivatives of AMPA have been synthesized and the structure-activity 
relationships of this class of agonists are well defined. The isoxazole ring can be substituted 
with a variety of residues at position 5’, which can even result in selectivity within receptor 
families. For instance, the bulky tert-butyl substituent on the heterocycle in ATPA (7) 
provides very high selectivity for GluK1.[82] Bn-Tet-AMPA, which has a slimmer and more 
elongated substituent, was found to be selective for GluA2-4.[33] The benzyl substituent of the 
latter substituent protrudes into a region of the clamshell that is not occupied by other agonists 
(cf. pdb 2P2A). ACPA (10) and 4-AHCP (11) are expanded and enlarged versions of AMPA 
that still function as agonists.  
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Figure 6. Chemical structures of AMPA/kainate receptor agonists. Compounds marked with an 
asterisk have not yet been crystallized with their receptors. 
 
b) L-Glutamate derivatives wherein C-3 has been substituted and is D-configured (Fig. 6; 17-
20). Compounds of this type often feature a secondary amine as part of a pyrrolidine ring and 
resemble the natural excitotoxin kainic acid (17), which is in itself a conformationally 
rigidified version of glutamate. Interestingly, the selectivity of kainic acid itself for kainate 
receptors is rather poor. Indeed, X-ray structures exist for kainic acid bound to GluA2 and 
GluK2 (pdb 2ANJ and 1TT1). The natural products domoic acid (18) and acromelic acid (19) 
are kainic acid derivatives with elongated and heterocyclic side chains, respectively. Only 18 
has been cocrystallized with the GluK1 and GluK2 LBDs but it is unlikely that acromelic acid 
A (19) and its many natural and synthetic variants[83] will yield surprises. Interestingly, the 
long unsaturated side chain of the partial agonist 18 protrudes out of the closed clamshell of 
GluK2 and is partially solvent exposed (pdb 1YAE). Simple glutamate derivatives alkylated 
in position 3, such as 20, have been barely explored structurally although the pharmacological 
profile of 20 looks promising.[84] Similarly, N-substituted derivatives of L-glutamate, such as 
N-methyl-L-glutamate, have not been systematically evaluated to date,[85] although the crystal 
structures suggest that some substituents could be tolerated. 
 
c) Compounds wherein C-4 of glutamate has been substituted and is L-configured (Fig. 6, 21-
26). These glutamate derivatives, such as 4-methyl glutamate (21) or LY-339434 (23), are 
often selective for kainate receptors.[84] Their substituents at C-4 point towards the cleft of the 
clamshell and can be quite large. They have guided the development of several azobenzene 
derivatives (e.g. L-MAG1 24, and 4-GluAzo, 25), which have been used to convert iGluRs 
into photoreceptors.[86] The extremely potent seizurogenic natural product 
dysiherbaine A (26a) and its natural and semisynthetic derivatives (26b-f) also belong to this 
class, demonstrating that the glutamate scaffold can tolerate a quaternary center at the C-4 
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position. The relatively complex heterobicyclic ring system of the dysiherbaines is deeply 
buried in the LBD of GluK1 (e.g. pdb 3FV1) and its exact composition determines selectivity 
for GluK1 vs. GluK2.[10c] 
Fig. 7 shows the conformation of bound glutamate and several agonists in a Newman 
projection along (C-2)-(C-3). It is apparent that this conformation is highly conserved and the 
(C-1)-(C-2)-(C-3)-(C-4) dihedral angle is always close to 180° with all agonists and in all 
receptors. By contrast the (C-2)-(C-3)-(C-4)-(C-5) dihedral angle varies to a larger degree and 
is ca. 60° for glutamate and ca. 90° for kainate, respectively, in GluA2 (pdb 1FTJ, 2ANJ). 
 
	  
Figure 7. Conformation of selected agonists in the binding site. 
 
Despite the large number of agonist-bound X-ray structures, it is difficult to come up 
with selectivity rules for AMPA vs. kainate receptors, in accordance with their diminishing 
pharmacological discrimination. Looking at the structure of selective agonists bound to their 
receptor LBD, it seems that kainate receptors can “chew a bigger chunk”. However, when the 
structures of GluA2 and GluK1 bound to the same ligand are overlaid, there seems to be little 
difference with respect to the peptide backbone (glutamate: pdb 1FTJ and pdb 3FUZ, kainate: 
pdb 1FW0 and pdb 1TT1). Therefore, selectivity has to be assessed on a case-to-case basis 
and the exact arrangement of non-conserved residues lining the clamshell cleft has to be taken 
into account. For instance, specific residues have been identified that confer selectivity e.g. 
for ATPA to GluK1[82b] and for Bn-tet-AMPA (9) to GluA2-4.[33] 
 
7. Agonists for NMDA receptors 
 
Selective agonists of NMDA receptors are usually simple amino acids or amino acid 
derivatives. Of course, one needs to distinguish between compounds that primarily target the 
glycine sites (GluN1 or GluN3) and those that bind preferentially to the glutamate sites 
(GluN2), with their various subtypes. Whereas a wide range of agonists for glycine sites have 
been crystallized together with their receptor LBDs (3, 27, 29-31, Fig. 8), there are only two 
structures of the glutamate site (GluN2A), bothwith glutamate itself (pdb 2A5T, 2A5S). None 
of the well-established synthetic agonists shown in Fig. 9 have been crystallized with their 
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receptors. In particular, there is no structure to date featuring NMDA (32), which would be 
useful in explaining the high selectivity of the eponymous ligand. 
 
	  
Figure 8. Agonists targeting the glycine site of NMDA receptors (GluN1 and GluN3). Compounds 
marked with an asterisk have not yet been crystallized with their receptors. 
 
	  
Figure 9. Agonists targeting the glutamate site of NMDA receptors (GluN2). Compounds marked with 
an asterisk have not yet been crystallized with their receptors. 
 
8. Antagonists for AMPA/Kainate receptors 
 
Antagonists of AMPA and kainate receptors show a much wider structural variety than 
agonists and can belong to one of two major structural classes (Fig. 10): 
 
a) Expanded versions of agonists (Fig. 10; 35-39). These bear the canonical alpha-amino acid 
motif of agonists but have their negatively charged other end moved further away. As 
elongated molecules, they still interact with the amino acid-clamp and the top of helix F thus 
prying the clamshell open. The phosphonate ATPO (35), derived from ATPA, and the 
willardiine derivatives 36a-g are typical representatives of this category. A number of kainate 
receptor-selective cis-decahydroisoquinolines, such as LY-466195 (37), tezampanel (38) or 
LY-294486 (39), also belong to this group. They are, in a sense, ring-expanded and 
homologated versions of kainic acid. LY-466195 (37) has been crystallized together with 
GluK1 and shows the typical amino acid-clamp binding and interaction with helix F in the 
largely open clamshell (pdb 2QS4).  
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b) Quinoxalines (Fig. 10; 40-46). These are classical antagonists of AMPA receptors, 
represented by DNQX (40) and it congeners CNQX (41), NBQX (42), YM-90K (43) and ZK-
200775 (44). Quinoxaline antagonists interact with the canonical D1-arginine but do not 
appear to make much contact with the conserved D2-glutamate residue. The “aromatic lid” on 
the S1 lobe of the receptor (usually a tyrosine) stacks tightly against the flat and 
conformationally rigid aromatic core of these antagonists (e.g. pdb 1LB9). With the exception 
of the high affinity antagonist ZK-200775 (44), which contains an additional phosphonate 
moiety, the quinoxalines do not appear to interact strongly with the top of helix F or any other 
residue in D2 but they do form hydrogen bonds to the backbone carbonyl of the highly 
conserved proline residue on D1. A special case is the quinoxaline FQX (46), which is one of 
the photoproducts of the azide ANQX (45). ANQX was developed as a photoaffinity-label 
and used to study AMPA-receptor trafficking.[87], [88] 
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Figure 10. Chemical structures of AMPA/kainate receptor antagonists. Compounds marked with an 
asterisk have not yet been crystallized with their receptors.  
 
In addition to this, there is one structural outlier, NS-1209 (47), which has been crystallized 
together with glutamate in a GluA2 clamshell dimer (pdb 2CMO). The carboxylate and the 
oxime ether nitrogen of this clinically interesting antagonist interact with the D1 arginine, 
whereas the central aromatic ring stacks tightly against the lid-tyrosine. 
To date, there are no crystal structures available for 2,3-benzodiazepines, such as 
GYKI-52466 (48), GYKI-53655 (49), or GKYI-47261 (50), which are highly selective 
antagonists of AMPA/kainate receptors. These compounds, as well their congeners SYM-
2206 (51) and CP-46022 (52), are non-competitive antagonists and presumably bind to an 
allosteric site on the receptor. Unfortunately, there is also currently no structure featuring the 
natural product kaitocephalin (53), which has been characterized as an AMPA receptor 
antagonist but is also a potent inhibitor of NMDA receptors.[89], [90] As a twofold D-amino acid 
and an L-amino acid with a quaternary stereocenter and a benzoyl residue it would be very 
interesting to see how (or if) this compound binds to the clamshell.  
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9.  Antagonists for NMDA receptors 
 
A large number of antagonists targeting NMDA receptors have been developed in academia 
and industry but only one of these has been crystallized together with its receptor: 1,3-
Dichlorokynurenic acid (55) binds to the GluN1 clamshell and interacts with the conserved 
arginine and the proline carbonyl, but makes few polar contacts otherwise (Fig. 11; pdb 
1PBQ). It stacks against the aromatic lid (a phenylalanine) and appears to be stabilized by the 
helix-dipole of helix F. The compound is a halogenated derivative of the tryptophan 
metabolite kynurenic acid (54), which was initially isolated from the urine of dogs by Justus 
von Liebig.[91] There are no structures featuring the very potent antagonist L-689560 (56) or 
the quinoxaline derivative CGP-78608 (57). It should be noted that quinoxalines more 
commonly associated with AMPA receptors, such as CNQX (41), also target the glycine site 
of NMDA receptors.[92] 
 
	  
Figure 11. Antagonists targeting the glycine site of NMDA receptors (GluN1 and GluN3). Compounds 
marked with an asterisk have not yet been crystallized with their receptors. 
 
Unfortunately, no structures are available for antagonists bound to the glutamate binding-site 
of NMDA receptors, in particular the widely used antagonist AP-5 (58) and its congeners 59 
and 60 (Fig. 12). The NMDA-receptor selectivity of these aminophosphonates is presently 
difficult to understand. 
 
	  
Figure 12. Antagonists targeting the glutamate site of NMDA receptors (GluN2). None of these have 
been crystallized with their receptors. 	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10. Modulators and channel blockers of iGluRs 
 
Like most ion channels, iGluRs desensitize following prolonged activation. This event takes 
place relatively rapidly (within milliseconds) in AMPA/kainate receptors but requires more 
time (tens to hundreds of milliseconds) in NMDA receptors.[5] Due to its important role in 
physiology, desensitization has been studied in great detail and many modulators have been 
developed.[32] There are several crystal structures of GluA2 receptor LBDs that have helped 
define the mechanism of desensitization (Fig. 13). Modulators generally bind to the LBD 
interface between the D1 lobes, thus inhibiting or slowing down their separation in the course 
of desensitization. 
Modulators display a wide structural variety but certain chemotypes can be identified 
(Fig. 13): a) Benzothiadiazine derivatives, such as cyclothiazide (61), and its congeners 62-
69; b) linear sulfonamides, e.g. the C2-symmetrical bis-sulfonamide 70, LY-404187 (71) and 
PEPA (72); and c) pyrrolidones and acyl pyrroles, e.g. piracetam (74), aniracetam (75) or CX-
614 (76). The structure of cyclothiazide (61) bound between the D1-lobes of two clamshells is 
shown in Fig. 14. 
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Figure 13. Modulators of AMPA receptors. 
	  
Figure 14. Structure of cyclothiazide (61) bound to an LBD dimer (pdb 3H6T). The clamshell dimer is 
seen from the intracellular side and bound glutamate is displayed as red spheres. 
 
With only one structure of an iGluR featuring a TMD available (pdb 3KG2), it comes 
as no surprise that the binding-sites of NMDA-receptor blockers, such as MK-801 (77), 
phencylidine (78), ketamine (79) or the recently discovered natural product 
lophocladine A (80)[93], have not yet been structurally characterized (Fig. 15).  
  
 	  
Figure 15. Compounds that block the TMD of the NMDA receptors or target the ATD of iGluRs. None 
of these have been crystallized with the TMD or ATD. 
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However, since blockers of fourfold-symmetrical potassium channels are amenable to 
structural studies,[94] it seems possible that we will soon understand how these important 
blockers operate. Related structural studies could also explain the voltage-dependent block of 
NMDA receptors by Mg2+ and of non-NMDA receptors by spermine. Finally, several 
structures of the ATD of iGluRs have been published (Table 1) but, to date, none of these 
feature a functionally important ligand, such as Zn2+, a polyamine, or the developmental drug 
ifenprodil (81) which interacts with GluN3 and functions as an NMDA receptor antagonist.[95] 
 
9.  Conclusion  
 
Almost 150 structures of agonists, antagonist and modulators bound to LBDs of iGluRs, as 
well as several apo structures, are now available and many more can be expected in future 
years (Table 1). Hopefully, crystal structures of GluA1 and GluK3-5 or a full-fledged NMDA 
receptor will soon emerge in this rapidly moving field. Structural studies of the C-terminal 
domain of iGluRs could help answer questions regarding receptor localization and 
modulation. On the ligand side, we are still missing coordinates for several important and 
interesting agonists and antagonists (e.g. NMDA, AP-5, kaitocephalin, 4-GluAzo, GYKI-
52466). Nevertheless, we are beginning to understand which molecular features determine 
subtype-selectivity as far as this is possible using detailed but static crystal structures. After 
all, one should bear in mind that affinities, let alone efficacies, cannot be reliably calculated 
with our current techniques, even when multiple crystal structures are available for calibration 
and comparison. However, the existing crystal structures provide guidance where to substitute 
known ligands (e.g. glutamate itself, AMPA, or kainate) to achieve the desired effect. They 
certainly offer a rationale for the development of new and possibly more selective agonists 
and antagonists, exploiting spaces in the clamshell and its cleft that have not been occupied by 
existing types and interactions with non-conserved amino acid residues that have not been 
addressed. The design of ligands with new functional properties, e.g. responsiveness to light, 
will also benefit from continued structural studies. Finally, this wealth of structural 
information could allow for the design of orthogonal receptors that cease to respond to the 
natural agonists but can be activated by unnatural, orthogonal ligands. 
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3) Photocontrol of Glutamate Receptors – The PCL and PTL Concepts 
 
Given the wealth of structural information presented in the previous chapter, one can easily be 
mislead to believe, that the design of more selective drugs acting on iGluRs has become an 
easy task. Admittedly, both ligand- and structure-based approaches have been facilitated by 
the plethora of x-ray structures and pharmacologically described ligands, but at the same time 
it has become evident, that the interactions of iGluR and ligand are highly sensitive toward 
manipulation. As such, even with modern, computer-based approaches like docking, attempts 
to synthesize new ligands still can fail. Unfortunately, such results are rarely published,[96] 
even though they nicely highlight the limitation of the aforementioned methods. 
 It is our believe, that in addition to ligand- and structure-based approaches, a detailed 
understanding of molecular function, based on atoms themselves, is a prerequisite for success 
in chemical biology in general and in the research of ionotropic glutamate receptors in 
particular. Therefore, chemical and biological education go side-by-side in our group, which 
has a longstanding interest to provide neuroscience with new chemical tools for the dissection 
of neuronal networks. With great success we have developed both photochromic and 
photoswitched tethered ligands (PCLs and PTLs), which have been used in a variety of 
applications.[86b, 97] The concept of these two photosensitization strategies, as well as the 
general make-up of a photoswitch are illustrated in Scheme 1. 
 
	  
Scheme 1. Three different photosensitization strategies: a) the photochromic ligand (PCL), b) the 
photoswitchable tethered ligand (PTL) and c) the caged ligand (CL) approach. d) The general make-
up of a PCL/PTL.  
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The design of PCLs and PTLs is simple: a pharmacologically active molecule is fused 
to a suitable photoswitch, which allows the resulting conjugate to change its affinity and/or 
efficacy to the biological target upon irradiation with light. In PTLs, the photoswitch is 
connected to an additional group, which allows covalent linking of the photoswitchable ligand 
to the target protein (Scheme 1a,b,d). To this end, suitable attachment-sites either have to be 
present in the receptor or have to be introduced by genetic manipulation. In contrast to the 
classical method of photosensitization by caged molecules (Scheme 1c),[98] the PCL/PTL 
concept offers the advantage of reversibility, i.e. PCLs and PTLs essentially act as “reversibly 
caged” molecules. Unlike other strategies to induce biological effects with light 
(photosensitive proteins,[6a, 99] crosslinking of protein structures with photoswitches,[100] or 
incorporation of unnatural, photoswitchable amino acids)[101] this method only requires a 
minimum of manipulation of both target protein and cell. For PCLs, selectivity can be 
achieved just by variation of the pharmacologically active group and for PTLs either innate 
attachment-sites present in the native receptor, or single-point mutations can be used to 
provide suitable sites for bioconjugation.[102] 
A seminal work by Erlanger in 1968 introduced azobenzenes as the photoswitchable 
unit of choice for photochromic ligands.[103] They fused diphenylcarbamyl chloride, a potent 
inactivator of chemotrypsin, to the diazobenzene unit in order to yield carbamyl chloride 82 
that light-dependently inactivates chemotrypsin (Scheme 2a). Later, they synthesized the first 
PCL and the first PTL of nicotinic acetylcholine receptors (nAChRs) called BisQ (83) and 
QBr (84).[104] These quaternary ammonium ions (Scheme 2b) act by binding to the 
acetylcholine binding-site of nAChRs, a class of pentameric ligand-gated ion channels. The 
PTL-version, QBr (84), was covalently attached to a native cysteine residue close to the active 
site after reduction of the extracellular cysteins. 
 
	  
Scheme 2. a) Switching of PADPCC (82), a light-dependent inactivator of chemotrypsine. b) BisQ (83) 
and QBr (84) the first PCL and PTL of nAChRs. c) Schematic mode of action of 84 on nAChRs.  
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 Since Erlanger’s groundbreaking work, diazobenzenes have proven themselves as 
suitable photoswitchable units for biological application, even though they are not the only 
small molecules capable of this task. Hemithioindogos (85), spiropyrans (86), 1,2-
dithienylethenes (87) and stilbenes (88) are some alternatives to azobenzenes and in some 
aspects like switching-speed, absorption coefficients, or toxicity problems they can even 
outperform them (Scheme 3a).[105] Yet we and others have generally found diazobenzenes to 
be a good choice for PCLs and PTLs,[106] since they are easily substituted, stable under a 
variety of chemical transformations (e.g. Pd-catalyzed couplings, acids, bases, oxidations and 
reductions), exert a strong mechanical force upon photoisomerization and show high quantum 
yields (up to 0.6 for the cis-trans isomerization).[107] In general, there are four types of 
azobenzenes: regular (i.e. scarcely substituted), amino-, pseudo-stilbene- (i.e. push-pull 
substituted) and cyclic azobenzenes (Scheme 3b-c).[108] 
 
	  
Scheme 3. a) Assorted photoswitchable molecules. b) Spectral and photophysical properties of 
increasingly red-shifted azobenzenes. c) Cyclic, i.e. thermally cis-stable azobenzens.  
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The photophysical properties of these chromophores are highly dependent on their 
substitution pattern. While for regular (and for tetra-ortho substituted) azobenzenes the trans 
and the cis state are reasonably stable and even can be separated,[109] for aminoazobenzenes 
and the pseudo-stilbene (push-pull) type, the cis state becomes thermally lest stable and the 
absorption spectra are substantially redshifted.[108] For biological applications this is of course 
highly desired, since it allows for the use of visible light instead of UV to promote the 
isomerization, which however comes at the cost of having to rely on thermal relaxation from 
the cis to the trans form. This is due to their interesting mode of photoisomerization. In 
general, trans-azobenzens adopt a planar structure with C2h symmetry, while cis-azobenzens 
prefer a non-planar conformation with C2 symmetry (Scheme 4).[110] There are four possible 
modes of interconversion between the trans- and cis-state (Scheme 4). It is generally accepted 
however, that the trans to cis isomerization proceeds via an inversion from the S1 state. For 
the cis to trans interconversion studies seem to suggest a rotational pathway for the 
photoisomerization and inversion for thermal relaxation.[108] The UV absorption spectra of 
trans azobenzenes consist of a strong band resulting from the π- π* transition (320 nm for 
unsubstituted molecules) and a less strong absorbing (since symmetry-forbidden) n-π* band. 
For cis-azobenzenes the absorption of the n-π* band is significantly stronger while the π-π* 
loses intensity. The n-π* transition excites azobenzenes to their S1, the π-π* to their S2 
states.[109, 111] 
 
	  
Scheme 4. Four different interconversion pathways from trans- to cis-azobenzenes. 
 
In addition to the obvious conformational changes accompanying the isomerization, the 
dipole moment increases from nearly 0 Debye for trans- to ca. 3 Debye for cis-azobenzenes. 
Moreover, the carbon tail-to-tail distance changes by about 3.5 Å.[112] These properties make 
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diazobenzenes very useful molecular machines for optochemical tools,[106] especially for 
PCLs and PTLs. 
It is because of the high variability of azobenzenes that our group decided to use them 
for the design of more selective ligands and to expand the scope of the PCL/PTL-concept to 
the other members of the iGluR family: the NMDA and AMPA receptors. Given the unique 
role of GluAs (cf. Chapter 1), they are one of the most interesting targets for optochemical 
genetics.[7] Our efforts toward an AMPA-selective photochromic ligand and their results are 
described in the following chapter and have been published in 2012.[113] 
 
Note: The numbering, the outline of figures and schemes, and the citations of the original 
paper have been adjusted to fit the format of this thesis. 
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4) A Photochromic Agonist of AMPA Receptors 
 
Philipp Stawski, Martin Sumser and Dirk Trauner 
 
(This work was published in Angew. Chem. Int. Ed. 2012, 51, 5748-5751 and Angew. Chem. 
2012, 124, 5847-5850.) 
 
Optochemical genetics uses small photoswitchable molecules to control neuronal activity. 
These can be attached covalently or non-covalently to their target proteins which can be 
ligand or voltage-gated ion channels as well as G-protein coupled receptors. The integration 
of the resulting hybrid photoreceptors into excitable cells allows for the control of neural 
networks with the temporal and spatial precision that only light provides.[7] 
Among different targets for optochemical genetics, ionotropic glutamate receptors 
(iGluRs) stand out due to their central role in synaptic transmission. These ion channels are 
gated by glutamate (1) and fall into three major classes, each of which is marked by a distinct 
pharmacology (Fig. 16b).[9] The so-called AMPA receptors (GluAs), named after the selective 
agonist 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid (4), can be considered 
the workhorses of glutamatergic synapses. They are responsible for the major part of the 
excitatory neurotransmission in the mammalian central nervous system and are mostly 
positioned at the center of the postsynaptic density. Kainate receptors (GluKs), named after 
kainic acid (17), in contrast are located primarily on the periphery of the synaptic cleft and 
play more of a supporting and modulatory role. NMDA-receptors, named after their selective 
response to the agonist N-methyl-D-aspartate (32), are both voltage and ligand sensitive ion 
channels and function as coincidence detectors of postsynaptic depolarization and synaptic 
glutamate release.[5] 
Our group has a longstanding interest in converting iGluRs into photoreceptors for 
optochemical applications. So far, our efforts have been focused on kainate receptors due to 
the well-defined architecture of their clamshell-like ligand-binding domain (LBD) and their 
readily interpretable pharmacology (Fig. 16a). Our efforts have yielded LiGluR, a light-gated 
ionotropic glutamate receptor, wherein a derivative of glutamate was covalently tethered to 
the surface of the LBD through a photoswitchable linker (PTL).[86a] Shortly thereafter we 
introduced a photochromic ligand (PCL) for kainate receptors that functions as a “reversibly 
caged glutamate”.[86b] This molecule, termed 4-GluAzo (25), is an azobenzene derivative of 
glutamate that changes its affinity and efficacy to GluK1 and GluK2 upon photoisomerization. 
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As such, it can be used to reversibly control neuronal activity with different wavelengths of 
light (Fig. 16c and d). 
 
 
Figure 16. a) General structure of a glutamate receptor (derived from pdb 3KG2) with a close-up of 
the LBD. b) The four principal ligands of iGluRs. c) Schematic mode of action of a photochromic 
ligand. d) 4-GluAzo (25), a PCL acting on kainate receptors. 
 
The rational design of suitable photoswitches for AMPA, kainate and NMDA 
receptors has been greatly facilitated by the availability of numerous X-ray crystal 
structures.[8] The clamshell-like ligand-binding domains of these receptors have been 
crystallized in conjunction with a variety of agonists, such as AMPA and domoic acid, 
antagonists such as DNQX, as well as modulators such as cyclothiazide. Very recently, the 
crystal structure of a full tetrameric GluA2 receptor assembly has been disclosed.[12] This 
seminal structure provided insights into the overall architecture and symmetry of AMPA 
receptors in particular and ionotropic glutamate receptors in general.  
Although the clamshell-like LBDs of AMPA and kainate receptors share a similar overall 
architecture there are subtle differences that apparently prevent 4-(R)-substituted glutamate 
derivatives such as 4-GluAzo (25) to act as agonists. One of the reasons for this may be that 
the LBD of AMPA receptors is closed more tightly around the ligand in their activated form. 
Thus side chains attached to a glutamate molecule cannot be as easily accommodated as in the 
case of GluKs. Therefore, glutamate derivatives with a photoswitchable side chain like 4-
GluAzo (25) were eventually deemed unsuitable for the light-dependent stimulation of 
AMPA receptors. In spite of extensive structural and functional data and considerable efforts, 
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our attempts to develop photochromic agonists for AMPA receptors had so far been 
unsuccessful. Accordingly	  we	  decided	  to	  radically	  change	  our	  molecular	  design	  resulting	  in	  a	  new	  class	  of	  molecules	  we	  named	  ATAs	  (Azobenzene-­‐Tetrazolyl-­‐AMPAs,	  89a-­‐d,	  Fig.	  17).	   These	   compounds	   are	  photochromic	  derivatives	   of	  AMPA	   itself,	  which	   selectively	  target	  GluA	  receptors	  expressed	  in	  HEK	  cells	  and	  neurons.	  One	  of	  them	  (89c)	  effectively	  triggers	  neuronal	   firing	   in	   the	  dark	  and	  quickly	   inactivates	  when	   irradiated	  with	  blue-­‐green	  light.	  As	  such,	  it	  could	  be	  a	  useful	  tool	  for	  the	  study	  of	  neural	  circuitry	  controlled	  by	  AMPA	   receptors	   and	   a	   potential	   therapeutic	   tool	   for	   the	   restoration	   of	   vision	  with	  artificial	  photoswitches	  in	  the	  retina. 
The design of 89a-d is based on a recently published X-ray structure of the GluA2 
LBD in conjunction with the potent and highly selective agonist BnTetAMPA (9), developed 
by the Clausen group.[114] This molecule is a derivative of AMPA, wherein the methyl 
substituent on the isoxazole ring is replaced with a tetrazole that is benzylated in the N-2-
position. As seen in the crystal structure, the benzyl substituent occupies a cleft in the receptor 
that is different from the “exit tunnel” that we previously exploited in the kainate receptors 
(Fig. 17). 
	  
Figure 17. The structure of BnTetAMPA (9) and its complex with the GluA2 LBD and the structures of 
ATA-1 (89a) and ATA-2-4 (89b-d) shown in their respective trans-form. The green circle indicates the 
previous, whereas the orange circle shows the approximate location of the newly identified “exit 
tunnel”. 
 
This structure suggested to us that extending the benzene to an azobenzene would allow the 
molecule to reach the solvent exposed surface while still permitting the ligand binding 
domain (LBD) to close sufficiently for receptor activation. It could also be deduced from this 
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structure that this elongation would require a meta-substitution with respect to the first 
benzene ring of the azobenzene unit. 
 To test our hypothesis that ATAs would function as photochromic agonists we 
synthesized several versions 89a-d (Fig. 17). These molecules have different substitution 
patterns and photophysical properties due to the presence or absence of substituents in the 4′-
position of the azobenzene. The dimethylamino substituent in ATA-3 (89c), for instance, 
shifts the action spectrum of the azobenzene toward the red (λmax = 456 nm), which allows for 
the use of longer wavelengths that are better tolerated by cells during prolonged exposure. 
The representative synthesis of ATA-3 (89c) was modeled after the published route to 
BnTetAMPA (9) [114] (Schemes 5 and 6). It commenced with the known hydroxyl isoxazole 
90,[115] which was protected as the allyl ether to ensure facile removal of the protective group 
at a later stage of the synthesis.[116] The resulting methyl ester 91 was then converted to the 
corresponding nitrile 92 in a two-step procedure.[117] Lithiation of the latter followed by 
conjugate addition of the obtained organolithium compound to dehydroalanine 93 yielded 
racemic AMPA derivative 94. This step required careful optimization but could be carried out 
reliably and on large scale at very low temperatures. A 1,3-dipolar cycloaddition of nitrile 94 
with in-situ generated hydrazoic acid then furnished tetrazole 95, which served as a key 
intermediate in the synthesis of all ATAs (89a-d). 
 
	  
Scheme 5. Synthesis of the racemic key intermediate 95. 
 
 Mitsunobu-coupling of tetrazole 95 with diethyl azodicarboxylate (DEAD) gave the 
N-2-alkylated tetrazole 97 as the major isomer (Scheme 6). The undesired, N-1-alkylated 
regio-isomer could be separated by HPLC after removal of the allyl group using Pd(PPh3)4 in 
methanol/K2CO3,[118] which yielded hydroxy isoxazole 98. Subsequent global deprotection 
using trifluoroacetic acid (TFA) gave ATA-3 (89c) after purification. The synthesis of 
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analogs 89b and 89d as well as the para-substituted control compound 89a was carried out 
analogously.[119] 
 
	  
Scheme 6. Synthesis of the PCL ATA-3 (89c). 
 
As anticipated, ATA-3 (89c) and ATA-4 (89d) showed significant red-shifted 
absorption spectra compared to ATA-1 (89a) and ATA-2 (89b).[119] For all molecules except 
89c switching from trans to cis and vice versa could be observed in the UV when irradiated 
with the appropriate wavelengths.[119] ATA-3 (89c) could not be actively switched from its 
cis- to its trans-state in physiological buffer solution because of the complete overlap of the 
π- π* and n- π* absorption bands. Thermal relaxation however was later found to be 
sufficiently fast under these conditions (vide infra). 
With 89a-d in hand we assessed their biological activity in mouse cortical slices and 
HEK293T cells using whole-cell patch-clamp electrophysiology (Fig. 18 and 19). While 
ATA-1 (89a) was found to be completely inactive in both cell types compounds 89b-d proved 
to be effective trans-agonists of GluA2 transiently expressed in HEK293T cells. This 
confirmed that the meta-substitution at the azobenzene moiety is a necessary structural 
requirement. 
 Since ATA-3 (89c) showed the highest activity and best kinetics we decided to focus 
our further investigations on this PCL. Its action spectrum at GluA2 recorded in HEK293T 
cells is shown in Figure 18. As designed, 89c elicited the strongest inward current in its dark-
adapted trans-state. Irradiation with varying wavelengths of light then produced 
photostationary states that gave less or no current at all (Fig. 18a). 
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In addition, the kinetics of ATA-3 (89c) currents in the dark and at different 
wavelengths of light were determined (Fig. 18b). We found that the fastest abrogation of 
current was achieved by switching from darkness to 480 nm light (τoff = 47.2 ± 7.7 ms).[119] 
By contrast when 89c was tested against GluK2 no response (neither agonistic nor 
antagonistic) was observed.[119] This demonstrates the selectivity of the ATA chemotype for 
AMPA over kainate receptors. 
 
	  
Figure 18. a) Action spectrum of ATA-3 (89c) acting on GluA2 expressed in HEK cells. b) Action 
spectrum recorded with intermittent darkness from a different GluA2 expressing cell (c = 50 µM). 
 
 As a final characterization step, we determined the efficacy of ATA-3 (89c) at GluA2. 
The compound acts as a partial agonist with an EC50 of 24 µM in the dark and is virtually 
inactive at 480 nm illumination.[119] One should bear in mind that enantiopure material will 
likely show considerably higher activity as has been observed for other AMPA-
derivatives.[82a, 120] 
We then evaluated the ability of 89c to control action potentials (APs) in excitable 
cells. APs were recorded from layer 2/3 neurons in mouse cortical slices. When ATA-3 (89c) 
was applied at 50 µM concentration trains of APs could be generated reliably upon switching 
from 480 nm light to darkness (Fig. 19). Due to the moderate intensity of the light used 
(20.3 mW/mm2) recordings could be performed over prolonged periods of time without any 
apparent photodamage. 
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Figure 19. Reversible generation of action potentials by 89c in mouse cortical neurons (clamped at  
-65 mV). 
 
The activity of ATA-3 (89c) in neural networks was further probed using known 
glutamate receptor pharmacology. GYKI-52466,[121] an AMPA-selective antagonist, blocked 
the effect of the PTL as did the AMPA/kainate antagonist CNQX. Additional experiments 
with the selective NMDA antagonist AP-5[122] failed to prevent AP firing.[119] This 
demonstrates that 89c can discriminate between all three subtypes of iGluRs and selectively 
acts on AMPA receptors. 
In summary, we have developed a photochromic agonist of AMPA receptors that 
stimulates neurons in the dark but can be rapidly turned off when irradiated with blue-green 
light at moderate intensities. ATA-3 (89c) uses a novel “exit tunnel” that should allow for the 
design of new, highly AMPA-selective ligands. Given the prominence of AMPA receptors in 
synaptic transmission, this molecule could be used as an effective tool to optically control 
neuronal activity in a wide variety of networks. Its response to light matches the logic of 
OFF-bipolar cells, and by extension OFF retinal ganglion cells, which increase firing in the 
darkness and show decreased activity when light reaches their receptive field. As such,  
ATA-3 (89c) could be a useful component of our ongoing efforts to restore vision with small 
photochromic molecules. 
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5) The Subtype-Selectivity of ATAs 
 
As mentioned before, the PCL 4-GluAzo (25) had been found to be a potent GluK1/GluK2 
agonist.[86b] It was found later however, that it is also a GluA2 antagonist.[123] To rule out 
similar cross-activities of the ATA PCLs, the subtype-selectivity of ATA-3 (89c) was further 
investigated. In the experiments discussed earlier, the selectivity of 89c was shown in cortical 
slice preparations using the AMPA-selective, noncompetitive antagonist GYKI-52466.[121] 
Accordingly, we were pleased to find, that ATA-3 (89c) did not show any activity at GluK2 
receptors expressed in HEK293T cells either (Fig. 20a). 
 
	  
Figure 20. a) Voltage-clamp recording of a HEK293T cell expressing GluK2. b) Comparison of L-
glutamate (L-Glu) induced currents at GluK2 with or without co-administration of ATA-3 (89c). 
 
With the agonism of ATA-3 (89c) at GluK2 ruled out, we assessed the possibility of its 
antagonism at the named receptor. To our relief, glutamate-induced currents at GluK2 were 
the same in the presence and in the absence of 89c under varying illumination (Fig. 20b), thus 
indicating no competitive antagonistic effects. 
 These results once more proved the high variability of the PCL approach. Given a 
valid binding mode, selection of a subtype-specific pharmacophore can be used to target 
PCLs efficiently to selected receptor subtypes without the imminent danger of cross-activity.
Triazolyl Substituted AMPA Derivatives 
52 
6) Triazole-Substituted AMPA Derivatives 
 
Encouraged by the results of the azobenzene substituted tetrazolyl AMPAs (ATAs), we asked 
ourselves, whether the synthesis of AMPA-selective PCLs based on BnTetAMPA could be 
further simplified. Due to the low selectivity of the alkylation of the H-tetrazoles during the 
synthesis of the ATAs, we explored options to carry out this reaction by more regioselective 
means. A literature survey however showed, that there are only a few methods for the 
selective formation of 2,5-substituted tetrazoles. All the procedures found were either not 
compatible with our synthetic strategy, did not work in our hands,[124] or were selective for the 
wrong, i.e. the 1,5-regiochemistry.[125] We therefore turned away from the tetrazole motif and 
planned to assemble the PCLs via a copper-mediated 1,3-dipolar Huisgen cycloaddition 
between an alkyne and an azide (i.e. “click-chemistry”),[126] effectively replacing the tetrazole 
with a triazole (Scheme 7). As these kind of reactions are known to proceed with high 
regioselectivity and under mild conditions,[127] we were positive, that we could assemble the 
Azobenzene Tetrazolyl AMPAs (ATeAs, 99) from benzyl azides 100 and the alkyne 101. The 
latter could be synthesized from a common precursor to all ATAs, nitrile 95 (Scheme 7b). 
 
	  
Scheme 7. a) Comparison of ATAs and ATeAs. b) Retrosynthetic analysis of ATeAs (99). 
 
 Starting from AMPA-derivative 95, a variety of reduction methods to convert the 
heterocyclic nitrile into the corresponding aldehyde (DIBAL-H, Red-Al®, LiAlH4, LiAlH(Ot-
Bu)3, Raney-Ni) were screened.[128] Most notably, DIBAL-H, which is otherwise known to 
carry out the selective reduction of nitriles to aldehydes,[129] led to complete decomposition of 
the starting material. It was only with RedAl®, that the transformation could be carried out 
reliably. We assumed, that the difference in the reactivity is due to the softer nature of the 
hydride donor, while still preserving enough reactivity to carry out the desired transformation. 
After reduction and purification, the resulting aldehyde was efficiently converted into an 
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alkyne using the Ohira-Bestman reagent 103[130] yielding alkyne 101 in acceptable yields over 
two steps from nitrile 95 (Scheme 8). 
 
	  
Scheme 8. Synthesis of the ATeA prototype 105. 
 
 With alkyne 101 in hand, the triazole formation by click-reaction was carried out in 
high yields using benzyl azide and copper(I) generated in situ from copper(II) sulfate and 
sodium ascorbate (Scheme 8).[131] The subsequent deprotection was carried out analogously to 
the synthesis of ATA-3 (89c). Using Pd(PPh3)4 and hydrochloric acid in ethyl acetate allyl 
ether 104 was deprotected to give the archetype of triazolyl-substituted AMPAs, 105, in 60% 
over two steps (Scheme 8). 
 Unfortunately, when 105 was applied to mouse cortical neurons (puff-application; data 
not shown), no activity could be observed. Despite the high similarity to BnTetAMPA (9), 
substitution of the N-1-nitrogen with a CH-group had rendered triazole 105 inactive in 
ionotropic glutamate receptors. This can be rationalized by investigating the binding-mode of 
BnTetAMPA (9) in GluA2 (Figure 21).[33] 
 
	  
Figure 21. BnTetAMPA (9) bound to GluA2 (pdb accession code 2P2A). 
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As indicated in Figure 21, an intramolecular hydrogen bond between the NH2-group and N-1 
stabilizes and locks BnTetAMPA (9) in a conformation, that allows the benzyl substituent to 
occupy the entrance to the new “exit tunnel”. As this is not possible for molecules of the 
ATeA-type, the triazolyl substituted AMPA derivatives were eventually deemed unsuitable as 
AMPA PCLs. 
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7) Activity of ATAs in the Blind Retina 
 
Since we had shown that ATAs are effective agonists of GluA2 and can be used to control the 
activity of neurons, it was time to explore its utility beyond the mere proof-of-concept. A 
problem, which all photoswitchable molecules used in optochemical genetics have to face 
when moving from single, isolated cells to functional networks, is the absorption of light by 
the surrounding tissue. Even though solutions to this problem such as light delivery by optical 
fibers,[132] stimulation by radio frequencies,[133] or two-photon excitation do exist,[134] we have 
not yet been able to shift the absorption spectra of our azobenzenes to harness the low 
absorption of biological tissue between 700 nm and 1400 nm, often referred to as “optical 
window” (Fig. 22a).[135] There is one part of the mammalian body however, that not only 
permits the access of light, but is built most efficiently to perceive it: the eye (Fig. 22b). Light 
enters though the cornea and the pupil, is focused by the lens, passes the vitreous humor and 
finally reaches the retina.[136] 
 
	  
Figure 22. a) The absorption coefficients of different tissue constituents according to Hamblin[135].  
b) General makeup of the mammalian eye (adapted from Purves[136]). 
 
 Evolutionary, the retina is part of the central nervous system, but its structure is 
significantly less complex than other tissues of the CNS, like e.g. the brain. There are only 
five types of neurons present in the retina, which are stacked in different layers: specialized 
photoreceptors (i.e. rods and cones), horizontal, bipolar, amacrine and ganglion cells. The 
latter connect the signals received by the photoreceptors and passed on to the bipolar cells to 
the optical nerve. Interestingly, the cellular makeup of the retina is such that the light first 
passes through the ganglion, amacrine, bipolar and horizontal cells, before reaching the rods 
and cones. In order to maintain vision for a long time, the retina is surrounded by the retinal 
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pigment epithelium, a thin layer that plays a critical role in both support and preservation of 
the photoreceptors. 
 Rods and cones harbor light sensitive pigments in membranous discs, which are the 
reason of their photosensitivity. Unlike other neurons in the CNS, photoreceptors do not fire 
action potential, but rather gradually change their membrane potential, thus modulating their 
neurotransmitter release. The molecular source of phototransduction is rhodopsin 
(Scheme 9a), a G-protein coupled receptor, which binds 11-cis-retinal as its pigment. Upon 
excitation by a photon, it is isomerized to 11-trans retinal and the accompanying structural 
changes result in an exchange of GDP for GTP at its bound G-protein, transducin. Its Gα 
subunit couples to phosphodiesterase 6 (PDE), which in turn catalyzes the hydrolysis of 
cGMP to GMP thus depleting its intracellular concentration. Since cyclic nucleotides serve as 
ligands for so-called cyclic-nucleotide-gated channels (cNGCs), activation of rhodopsin 
ultimately results in less glutamate release by the photoreceptor cell due to the 
hyperpolarization caused by closure of cGMP-gated channels (Scheme 9a). 
 
	  
Scheme 9. a) The vision cascade. From the isomerization of 11-cis retinal (106) to glutamate release 
from the photoreceptor cells (adapted from [136]). b) The role of different glutamate receptors during 
the transmission of information via off- and on-bipolar cells. 
 
 Following their release, the neurotransmitters are sensed by glutamate receptors 
located at the postsynaptic termini of bipolar cells (Scheme 9b). There are two types of 
bipolar cells connecting to the photoreceptors: On- and Off-bipolar cells. While the On-cells 
become more activated upon perception of light (by an inverted coupling of mGluR6 to 
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cNGCs via Gi/o), Off-bipolar cells become more quiescent (due to less glutamate released by 
the photoreceptor). Both bipolar cell types stimulate ganglion cells in the end and due to their 
opposing polarity, they play an important role in the computational circuitry of the retina.[136] 
 Since the sole reason for the eye’s photosensitivity are the rods and cones, loss of the 
latter inevitably results in blindness, because there is no input signal generated for the bipolar 
cells (Scheme 10a). In fact, degeneration of the photoreceptor cells due to a diverse group of 
hereditary disorders – commonly referred to as retinitis pigmentosa (RP) – is affecting as 
much as up to 1 out of 7000 people worldwide.[137] A main reason for the degeneration of rods 
and cones is a nonfunctional retinal pigment epithelium (Scheme 10b). 
 
	  
Scheme 10. a) Consequences of loss of photoreceptors and possible starting points for artificial 
stimulation of the remaining bipolar cells. b) Typical view of an RP-diseased retina.[138] c) The logic of 
the AMPA-selective PCL ATA-3 (89c) matches the one found in off-bipolar cells. 
 
In our group there is an effort to use small photoswitchable molecules to restore input 
to the cut-off bipolar (or other) cells in the retina and thus to treat blindness as caused by RP. 
In a rodent model, collaborators were able to show, that the PTL approach (LiGluR) can be 
used to restore visual responses.[139] Obviously, for an application in humans PCLs seem to be 
better suited, since they don’t require genetic manipulation. Instead, they require a high 
degree of pharmacological selectivity in order to only target certain receptors, which ere 
expressed in the retina. 
mGluR6 is one of the most evident targets for the PCL approach since it is exclusively 
expressed in on-bipolar cells. Recent studies have however shown, that bipolar cells in RP-
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diseased retinae lose their mGluR6 and iGluR-mediated responses both in humans and in 
rodent models. Ganglion and amacrine cells, interneurons that provide inhibitory input to 
ganglion cells upon excitation from bipolar cells, however retain their glutamate-
sensitivity.[140] We were therefore excited to investigate the effect of the AMPA-selective 
PTL ATA-3 (89c) in the blind retina, since its logic matches the one of off-bipolar cells (i.e. 
activation in the dark and inactivation when irradiated with 480 nm light; vide supra) and for 
that reason off-ganglion cells, too (Scheme 10c). 
Triple knock-out mice retinae (cng-/-, rho-/-, opn4-/-) were treated with ATA-3 (89c) 
at 25 µM and their responses to darkness and blue light were recorded from ganglion cells 
using a multielectrode array (MEA) setup. We were pleased to find, that the recordings of the 
individual 64 channels – when in contact with a ganglion cell – showed a marked increase in 
spiking rate upon switching from 480 nm light to darkness (Fig. 23). 
 
	  
Figure 23. Exemplary data of a cng-/-, rho-/-, opn4-/- retina treated with 25 µM ATA-3 (89c) in the dark 
and under 480 nm illumination. The top traces represent the mean over all channels. 	  
The statistics indicate that the activation of ATA-3 (89c) results in a five-fold increase of 
spiking rate and that the effect is indeed connected to the AMPA-selective PCL. Control 
experiments in retinae without ATA-3 (89c) showed no increase in the spike-rate when 
switching from blue light to darkness (Fig. 24).  
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Figure 24. Spiking rate in the presence and in the absence of 25 µM ATA-3 (89c) under 480 nm 
illumination and in the dark. 
 
Moreover, we were pleased to find that ATA-3 (89c) is able to elicit both on- and off-
responses in triple knockout retinae, thus suggesting the presence of an intact visual circuitry. 
A detailed analysis and pharmacological investigation of 89c’s mode of action will follow in 
due course.[141] Especially we are interested by which cells of the knock-out retina  
ATA-3 (89c) elicits its effect. This will determine its potential as a lead structure in the 
restoration of vision using small molecules. Ideally, we would like to target the Off-bipolar 
cells to further investigate their role in the vision process. However, as studies have shown 
that a direct stimulation of retinal ganglion cells (RGCs) with epiretinal electrode implants is 
a viable strategy for the restoration of vision,[142] we will investigate the response of RGCs to 
ATA-3, too. Owing to these promising first results, it can be expected that ATA-3 (89c) will 
prove to be a new and highly potent tool for the research of retinal neuronal networks. 
Investigations of its potential as a therapeutic lead for chemical approaches to restoring vision 
(CARV) are currently underway.[141]  
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8) Toward a Universal Photoswitch for AMPA and Kainate Receptors 
 
In our attempt to synthesize a photochromic agonist of AMPA receptors, we surveyed the 
known GluA receptor pharmacology and found that – besides glutamate – kainic acid (17) 
could be used as a scaffold, from which to build a PCL that acts on both AMPA and kainate 
receptors (Scheme 11, left). Moreover, upon close inspection of the binding mode of 17 in 
GluA2 and GluK2, we concluded, that 3-D-substituted glutamate derivatives like 108, should 
follow the same logic (Scheme 11, right). Given the wealth of information on 4-substituted 
glutamic acid analogues,[83b, 84, 143] we were surprised to find that their 3-alkylated congeners 
are severely underexplored and that there is no report on their subtype-selectivity.[144] We 
therefore decided to follow these two approaches in order to come up with a “universal” 
photoswitch for both AMPA and kainate receptors. 
 
	  
Scheme 11. A kainate-derived, universal PCL 107 and 3-D-substituted glutamate analogues 108. 	  
a) A Kainate-Derived Photoswitch 
 
 Kainic acid (17) is a marine alkaloid isolated from the Japanese seaweed “kainin-sou” 
(diginea simplex).[145] Along with domoic acid (18) and the acromelic acids (19) it resembles 
a conformationally restricted version of L-glutamate (Fig. 25).  
 
	  
Figure 25. Kainic acid (17), domoic acid (18) and acromelic acid A (19). 
 
Due to their interesting pharmacological properties, many synthetic analogues of kanic acid 
have been prepared.[83a, 146] For these, natural kainic acid has commonly been used as starting 
material and the shortage in supply of 17 from natural sources has therefore prompted many 
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chemists to develop synthetic strategies toward this alkaloid.[147] Moreover, the challenging 
construction of the three contiguous stereocenters has led to several methodology-oriented 
syntheses, too. Among them are such “classics“ as Oppolzers 1982 approach, in which an 
Alder ene-reaction is used to form the pyrrolidine ring.[148] 
 In order to access synthetically useful quantities of 17 however, we decided to rely on 
a more recent route, which was published by Fukuyama and coworkers in 2011.[149] Starting 
from (+)-carvone (109), we obtained kainic acid on a gram-scale in just 13 steps and protected 
it according to known literature procedures (Scheme 12a).[83a] We then planned to degrade the 
isopropenyl group to a vinyl group in order to use it as a functional handle in our studies 
(Scheme 12b).  
 
	  
Scheme 12. a) Total synthesis of kainic acid (17) from (+)-carvone (109) and its protection to diester 
110. b) Envisioned synthesis of nor-kainic acid derivative 111 and a derived PCL and PTL. 
 
After ozonolysis of 110 and reductive workup, we obtained the known ketone 114 in 
excellent yields (Scheme 13).[83a] Unfortunately, all our attempts to transform 110 into an 
alkene using reduction-elimination,[150] or Bamford-Stevens/Shapiro protocols[151] failed. We 
therefore screened conditions for the coupling of enol-triflate 115 to a hydride source.[152] 
None of the conditions however yielded nor-kainic acid 111 in synthetically useful yields 
(Scheme 13) even though we tested various methods for the formation of 115 from ketone 
114 using different bases (LiHKMS/KHMDS) and triflate sources (Tf2O, PhNTf2, Comins-
reagent).[153] We therefore decided to abandon this route in favor of a different approach 
toward substituted kainoids.  
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Scheme 13. Degradation of kainic acid (17) to protected nor-kainic acid 111  
 
 We were pleased to find, that a number of direct modifications of the isopropenyl 
group in kainic acid have been reported.[83a, 146a, 146d] Among these, a certain set of Jeffery 
modified Heck conditions (n-Bu4NCl, NaHCO3, DMF)[154] immediately caught our attention 
(Scheme 14a)[146a] and we decided to use this methodology to synthesize a kainate-based 
PCL. 
Aryl-substituted kainic acids like the m-nitrophenyl analogue 117 are known to elicit 
activity at kainate receptors even though they do not follow the substitution pattern of domoic 
acid (18), but rather its initially proposed structure (Scheme 14b).[146e] 
 
	  
Scheme 14. a) Palladium-catalized synthesis of the aryl-substituted kainic acid analogues 116, 117 
and 118. b) Structure of domoic acid (18) and its originally published structure. 
 
 Using the Heck conditions described earlier,[146a] we coupled protected kainic acid 
analogue 110 to 1-(3-iodophenyl)-2-phenyl diazene[155] and obtained azobenzene 119 as a 
single diastereomer, yet in low yields. Subsequent deprotection by saponification in 1 M 
aqueous KOH, finally yielded the kainate-based PCL AzKA (107) as its sodium salt in 60% 
after reversed phase purification (Scheme 15). A structural analysis of 107 using NMR 
(NOESY) proved the cis-relationship of the azobenzene moiety and the former isopropenyl 
methyl group. 
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Scheme 15. Synthesis of diazobenzene-substituted kainic acid analogue AzKa (107). 
 
 With diazo-kainic acid 107 synthesized, we evaluated its activity in mouse cortical 
neurons and HEK293-T cells by patch-clamp electrophysiology. We found that AzKa (107) 
acts as a relatively potent agonist of kainate receptors in HEK293T-cells (Fig. 26), but shows 
only weak photoswitching (3.8 ± 0.3%, n = 3). Conversely, there was hardly any effect in the 
slice preparation. While other PCLs (4-GluAzo, ATA-3) seem to suppress receptor 
desensitization, we reasoned that 107 might not do the same. 
 
	  
Figure 26. Voltage-clamp recording of AzKa (107) acting on GluK2 at 100 µM. 
 
To investigate this hypothesis, we tested the effect of AzKA (107) in cortical neurons in the 
presence of ConA (TTX-treated to prevent AP-firing) to find an enhanced activity of the 
kainate-based PCL. Additionally we found, that 107 is more efficacious in hippocampal NA1 
neurons. To fully understand these phenomena, we will investigate the effect of sterically 
more demanding (meta-substituted) and redshifted versions of AzKA (107).
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b) 3-D-Substituted Glutamate Analogues 
 
In addition to our experiments with the kainic acid-derived photoswitch 107, we were 
positive that the underexplored class of 3-D-substituted glutamic acid analogues (120), which 
essentially can be regarded as seco-kainic acids (Scheme 16a), would be a useful platform 
from which to build a universal PCL/PTL for both kainate and AMPA receptors. 
Retrosynthetically, 3-alkylated glutamic acids can be accessed either by 1,4-addition of 
nucleophiles to a pyroglutamate-derived enone 121, or by Michael addition to α,β-
unsaturated esters 122 derived from Garner’s aldehyde (123; Scheme 16b). Both routes are 
literature-known,[144, 156] yet while the first requires several red-ox manipulations and suffers 
from low yields and diastereoselectivity, the second is high yielding and reasonably selective 
in terms of stereochemistry at the 3 position. In fact, a couple of 3-D-substituted glutamate 
analogues (124-127) have been prepared using this general approach (Scheme 16c).[144, 156] 
Their mode of action and especially their receptor subtype selectivity however were 
unfortunately never elucidated. 
 
	  
Scheme 16. a) 3-D-substituted glutamic acids 120 are seco-kainoids. b) Two retrosynthetic routes to 
3-alkylated glutamate analogues. c) Four literature-known 3-D-substituted glutamates (124-127). 
 
 Modeling our synthesis according to known protocols, [144, 156], we started our 
synthesis of 3-D-susbtituted glutamic acid analogues from D-serine, which was converted into 
Garner’s aldehyde (123).[157] After a Horner-Wadsworth-Emmons (HWE) olefination of 
aldehyde 123 with trimethyl phosphonoacetate,[144b] the α,β-unsaturated ester 122 was 
obtained as a mixture of E/Z-isomers. Remarkably, the ratio of E vs. Z of approximately 3:1, 
was quite high for a stabilized HWE reagent, but fortunately the two diastereomers could be 
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separated by column chromatography and only the major E-isomers was used in the following 
Michael addition. For this, we prepared allyllithium from tetraallyl tin and transmetallated it 
to the cuprate using copper(I)bromide dimethylsulfide complex.[158] After a smooth 1,4-
addition of the obtained Gilman cuprate to enone 122a in the presence of trimethylsilyl 
chloride and dimethyl sulfide (Scheme 17a), we obtained hemi-aminal 128 (unlike pevious 
reports) as a single diastereomer. This seems to suggest, that the Michael addition is more 
selective for the trans-isomer 122a, since in the synthesis by Wermuth and coworkers, a 
mixture of 122a and 122b was used.[144b] Fortunately, we could prove the relative 
stereochemistry of the Michael adduct 128 to be L by X-ray christallography (Scheme 17a, 
inset). With the structure of oxazolidine 128 confirmed, careful cleavage of the hemi-aminal 
with an excess of Jones reagent,[159] followed by oxidation of the primary alcohol and 
protection of the resulting carboxylic acid using trimethylsilyl diazomethane,[160] gave diester 
129 in high yields over two steps (Scheme 17a). Standard deprotection manipulations finally 
yielded (3R)-allyl glutamic acid (125) as the TFA salt (Scheme 17b). Its analogues, 127 and 
124 were prepared by hydrogenation of 125 and by the literature known addition of 
benzylmagnesisum bromide to enone 122b, followed by the same oxidation-deprotection 
sequence.[144b] 
 
	  
Scheme 17. a) Synthesis of protected (3R)-allyl glutamate 129 via oxazolidin 128 and X-ray structure 
of 128. b) Exemplary deprotection of 129 to glutamate analogue 125. c) Two additional, literature 
known 3-D-alkylated glutamic acids 124 and 127.  
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Since the subtype-selectivity of the 3-D-alkylated glutamates 124, 125 and 126 was 
still unknown, we decided to evaluate their properties in the most prevalent kainate and 
AMPA receptors – GluK2 and GluA2 – expressed in HEK293T cells. To our surprise, all 
three molecules proved to be highly kainate-selective ligands with no detectable activity in 
GluA2 even up to 1 mM (Figure 27). This might be rationalized by the fact, that kainic acid 
(17) only shows week partial agonism at AMPA receptors, too.[26] Experiments regarding the 
subtype selectivity in mouse cortical slice preparations using selective iGluR antagonists (data 
not shown) were unfortunately inconclusive and we therefore decided to only probe their 
pharmacological profile in iGluRs expressed in HEK293T cells. 
The relative activity of the three ligands, which had not been investigated at defined 
iGluR populations before,[156] can be ranked in the order benzyl > allyl > propyl with 
benzylated glutamate 124 acting as a full and the others acting as partial agonists of GluK2 
(Fig. 27). While there was no obvious structure-activity relationship (SAR) between the 
aromatic- and the alkene-substituted glutamate analogue, it is noteworthy, that the sp2-
hybridization at carbon C2 of the sidechain seems to be a prerequisite for high receptor 
activity as shown previously by Hashimoto and coworkers, too.[156] 
 
	  
Figure 27. Potency of glutamate analogues 124, 125 and 127 (1 mM) relative to saturating glutamate 
(500 µM) at GluK2 and GluA2 (data ± SEM; n = 5). 
 
Since to us substitution of allylated glutamic acid 124 by metathesis or Heck reaction 
seemed easiest, we decided to use this scaffold to build a kainate/AMPA PCL. Employing the 
same set of Jeffery-modified Heck conditions as for the kainate-based PCL 107,[146a] we 
reacted ester 129 and 1-(4-iodophneyl)-2-phenyldiazene to yield diazobenzene 130 in 90% as 
a single diastereomer (Scheme 18a). Encouraged by these results, we tried the same protocol 
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for the synthesis of a precursor to 4-GluAzo (25) and indeed obtained 133 in significantly 
higher yields than the protocol used previously (Scheme 19b).[86b] 
 
	  
Scheme 18. a) Synthesis of protected 3-GluAzo (130) and its saponification. b) Efficient synthesis of 
(4R)-substituted pyroglutamate 133, a key-intermediate in the synthesis of 4-GluAzo (25). 
 
Saponification of the ester with lithium hydroxide in THF/water yielded the corresponding 
diacid 131, which was subjected to a number of methods for the deprotection of Boc-groups. 
Unfortunately, Brønsted- and Lewis-acidic conditions (TFA/CH2Cl2, HCl/EtOAc, HCl/1,4-
dioxane, FA/CH2Cl2, TMSOTf/CH2Cl2, TMSI/CH2Cl2, NaI/acetone) lead to decomposition – 
presumably due to protonation/alkylation of the sensitive styrene double bond (Scheme 17, 
left). Attempts to deprotect diacid 131 under pyrolytic conditions (140 ºC, 10-3 mBar) yielded 
the corresponding pyroglutamate. Basic conditions (1 M aqueous KOH) on the other hand 
yielded a product, which showed a high-resolution mass in accordance with the desired 
structure of 3-GluAzo (Scheme 19).  
 
	  
Scheme 19. Reaction pathway leading to decomposition of diacid 131 under Lewis/Brønsted acidic 
conditions and the attempted deprotection using aqueous KOH.  
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However, the NMR spectra indicated the absence of the two vinylic protons. Despite the low 
amounts of material obtained, a detailed analysis of the obtained 2D-spectra seems to suggest 
a rearrangement to pyrrolidine 136 – an unambiguous assignment was however not possible. 
Possibly, the formation of pyrrolidine 136 might proceed via a nucleophilic attack of the α-
nitrogen to the vinyl group, forming a stabilized benzylic anion, which is reprotonated to yield 
136 (Scheme 20b). 
 
 
Scheme 20. a) Putative structure of 136 with. b) Proposed mechanism leading to its formation starting 
from diacid 131. 	  
 While we could not deprotect 131 to yield 3-GluAzo (135), we instead assessed the 
activity of its rearranged product 136 in mouse layer 2/3 neurons. Unfortunately, 136 did not 
show any notable effects, which is reasonable given that it deviates strongly from the 
substitution pattern of known iGluR agonists. 
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9) Pharmacology of Metabotropic Glutamate Receptors: A Structural Perspective 
 
Metabotropic glutamate receptors (mGluRs) belong to family C (mGluR/pheromone) of G-
protein coupled receptors (GPCRs), the largest group of genes in the human genome. They 
are expressed in- and outside the central nervous system and are associated with a broad 
spectrum of physiological processes (for the special role of mGluR6 in ON-bipolar cells see 
Chapter 5). Compared to e.g. ion channels however, the action of mGluRs is subtler, as they 
provide means for the modulation of cellular processes using second-messengers. 
Accordingly, mGluRs have become the target of therapeutic research for the treatment of 
Alzheimer’s and Parkinson’s disease, anxiety and schizophrenia.[161] Even though the 
structural information available from crystal structures of mGluR ligand binding domains is 
not as rich, as for example for iGluRs (cf. Table 1), the structure-activity relationships 
obtained from extensive screening efforts have yielded numerous compounds for the selective 
modulation of mGluR activity. A full mGluR structure has regrettably not been published yet. 
Nevertheless, the X-ray data present provides invaluable information and explanation for 
agonism or antagonism of compounds and the design of new ligands of mGluRs (Table 2). 
 
Table 2. X-Ray structures of mGluR-LBDs. Entries marked with an * have not been published yet. 
Type PDB code Ligand(s) Functional  Mutant(s) Citation 
      mGluR1 1ISR L-glutmate (1), Gd3+ a - [162] 
mGluR1 3KS9 LY341495 (146) ant - * 
mGluR1 1ISS MCG ant - [162] 
mGluR1 1EWK L-glutamate (1) a (dimer) [163] 
mGluR1 1EWT APO - - [163] 
mGluR1 1EWV APO - - [163] 
mGluR3 2E4U L-glutamate (1) a - [164] 
mGluR3 2E4V DCG-IV a - [164] 
mGluR3 2E4W (1S,4S)-ACPD a - [164] 
mGluR3 2E4X (1S,4R)-ACPD (145) a - [164] 
mGluR3 2E4Y (2R,4R)-APDC (172) - - [164] 
mGluR3 3SM9 LY341495 (146) ant - * 
mGluR5 3LMK L-glutamate (1) a - * 
mGluR7 2E4Z MES - - [164] 
mGluR7 3MQ4 LY341495 (146) ant - * 
 
 
The neuromodulatory role of mGluRs and the underlying mechanisms that ultimately lead to 
the modulation of synaptic transmission will be in the focus of this chapter.  
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a) Structure and Function of mGluRs 
As a member of class C GPCRs, metabotropic glutamate receptors belong to the superfamily 
of seven transmembrane receptors (7TM). As such, they are integral membrane proteins and 
feature the canonical seven transmembrane helices (TM1-7). Unlike family A members, 
mGluRs have a large extracellular N-terminal domain, which forms the binding site of 
endogenous ligands. Due to its structure, this part of mGluRs is often referred to as the venus 
flytrap domain (VFD), which is comparable to the clamshell of iGluRs. Like the latter, the 
VFD performs a ~ 31 º movement upon binding of glutamate. This conformational change is 
then relayed to the intracellular parts of the receptor by the cysteine-rich domains (CRDs). 
There are nine important cysteins in the CRD, eight of which are linked by disulfide bonds. 
The ninth C is connected to the venus flytrap domain and has been shown to be crucial for 
intracellular signaling.[165] The transmembrane helices (TM1-7) have been found to be the site 
of mGluR modulation by kinases, as well as positive and negative modulators (PAMs and 
NAMs; Fig. 28a).[5] The intracellular loops formed by TM1-7 are responsible for binding of 
the respective G-proteins. The second intracellular loop in particular has been found to confer 
G-protein coupling specificity (vide supra).[5] Last but not least, the C-terminus of mGluRs 
has been shown to interact with multiple proteins and thus regulate mGluR signaling.[5] 
 
	  
Figure 28. a) Schematic structure of an mGluR including the venus-flytrap (VFD), the cysteine-rich 
(CRD) and the seven transmembrane domains (TM1-7). b) Phylogenetic tree of the eight mGluRs. 
c) Mode of action of a functional mGluR dimer. 	    
Pharmacology of Metabotropic Glutamate Receptors: A Structural Perspective 
 
71 
The metabotropic glutamate receptors have been organized in Group I (mGluR 1 and 5), 
Group II (mGluR2 and 3) and Group III (mGluR4, 6, 7 and 8) according to similarities in 
their amino acid sequence, signaling properties and pharmacology (Fig. 28b). 
Functional metabotropic glutamate receptors are constitutive dimers, which are held 
together by both covalent and non-covalent bonds in the VFD, hydrophobic interactions of the 
TMs and possibly interactions of the C-termini (Fig. 28c).[166] Like in iGluRs, the 
predisposition of the ligand binding domains to dimerize is retained in the crystallization 
constructs, thus providing direct evidence for the functional importance of this association. 
Due to this, open-open, open-closed and closed-closed crystal structures have been obtained 
both in the presence and the absence of L-glutamate (1). This indicates an interesting 
functional explanation for the basal activity of mGluRs and suggests a mere stabilization 
effect of 1 in this equilibrium of states.[5] Most interestingly, it has been found that already 
one molecule of L-glutamate is enough to result in activation of some mGluRs (vide 
infra).[167] 
 
b) Receptor Activation and Intracellular Response 
Much like in iGluRs, binding of glutamate to the VFD of metabotropic glutamate receptors 
causes a convergence of the two lobes, which form the ligand-binding domain (LBD, 
Scheme 21). 
 
	  
Scheme 21. mGluR activation-cycle and the chemic structures of GDP (138) and GTP (137).  
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This conformational change is then relayed to the intracellular loops of the receptor via the 
CRD. There, a G-protein complex consisting of a Gα, a Gβ and a Gγ subunit is bound. In the 
receptor’s inactive state, the Gα binds to guanosine diphosphate (GDP, 138). Upon the action 
of glutamate, the G-protein’s Gα serves as a GDP exchange factor (GEF), promoting an 
exchange of GDP for guanosine triphosphate (GTP, 137) and concomitant dissociation of the 
active Gα from the Gβ,γ subunits. The individual subunits can then activate other effector 
molecules (vide supra) and thus trigger different cellular responses. Ultimately, the Gα is 
hydrolyzed and a new (inactive) G-protein complex is formed, which again binds to the 
mGluR (Scheme 21).[168] 
There are in general two Gα proteins by which the activity of mGluRs is coupled to 
intracellular processes: Gαi/o, which inhibits adenynyl cylcases and thus the production of 
cyclic adenosine monophosphate (cAMP, 140), and Gαq promoting the cleavage of 
phosphatidylinositol-4,5-biphospahte (PIP2, 141) into the second messengers diacyl glycerol 
(DAG, 142) and inositol-1,4,5-triphosphate (IP3, 143) by phospholipase C (Scheme 22). 
 
	  
Scheme 22. Production of cAMP (140) from adenosine triphosphate (ATP, 139) by action of an 
adenynyl cliclase. b) Cleavage of PIP2 (141) into DAG (142) and IP3 (143) by PLC. The DAG shown 
bears the most common acyl residues of diacyl glycerols, stearic acid and arachidonic acid.[169] 
 
For Group I mGluRs, the Gαq pathway is predominant. Therefore, their activation results in 
activation of PLC and by means of IP3 (143) ultimately in the release of Ca2+ from internal 
storages. Together with the DAG (142) resulting from cleavage of PIP2 (141), this activates 
protein kinase C (PKC). Most interestingly it was found that mGluR1 can modulate the 
function of L-type calcium channels in cerebellar neurons by an unknown Gα mechanism. At 
the same time it can be activated by Ca2+ directly, and it has been shown that mGluR5 can 
inhibit K+ channels and thus increase neuronal excitability.[3, 5] 
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Group II and Group III mGluRs couple to Gαi/o, thus inhibiting adenynyl cyclase. 
Conversely, Group II metabotropic glutamate receptors may potentiate cAMP formation by 
modulation of other Gs-coupled receptors via their respective Gβγ subunits.[3] Interestingly, 
this second signaling pathway seems to be the predominant mode of action of type II and III 
mGluRs, as the inhibition of cAMP production seems to be less pronounced. mGluR7 for 
example can inhibit P/Q-type Ca2+ channels through its Gβγ subunit after displacement of the 
latter by Ca2+-loaded calmoduline. Additionally, both Group II and III mGluRs can activate 
G-protein coupled inward rectifying potassium channels (GIRKs) by action of their Gβγ 
proteins. Thus mGluRs can indirectly hyperpolarize neurons.[3] 
By a combination of all of these signaling pathways, metabotropic glutamate receptor 
can modulate neuronal excitability by controlling both Ca2+ and K+ conductances. Moreover, 
they are involved in long-term depression and potentiation (LTD and LTP) by modulation of 
the fast acting iGluRs and they can induce slow excitatory synaptic responses via Na+/Ca2+ 
exchangers and TRPC channels. Since a full account if this matter cannot be given in this 
short summary, the reader may be referred to some excellent books for a more detailed 
discussion.[3, 5] 
 
c) Structural Determinants of Receptor Activation 
As stated earlier, the general mechanism of mGluR activation by L-glutamate (1) can be 
compared to the one found in iGluR, as the degree of VFT closure can be correlated to the 
receptor activity and thus to the ligand’s function (Fig. 29). 
 
	  
Figure 29. a) X-ray structure of L-glutamate (1) in mGluR1 (pdb code 1ISR) with the principal binding 
residues shown as sticks. b) Comparison of mGluR1 VFD-closure from an alignment of antagonist- 
(red), apo (yellow), and agonist-bound structures (green).  
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Like for the clamshell of iGluRs, orthosteric agonists stabilize the venus flytrap in a closed 
conformation and orthosteric antagonists pry it open by exerting steric bulk (cf. Fig. 29b). 
Unlike in iGluRs however, occupancy of a single mGluR monomer is enough to promote 
partial receptor activation.[167] The mode of action of both positive and negative modulators 
cannot be explained as easily. Nevertheless, it is important to note that some positive 
modulators bind at the TMs and can act as agonists when the VFD is deleted, thus suggesting 
a conformational effect, which is impaired in the presence of the extracellular domains.[170] 
 The orthosteric ligand-binding site is very well conserved between the mGluRs. The 
conserved residues interact with the α-carboxy and the α-amino group of L-glutamate 
(Fig. 30a). Residues interacting with the sidechain of 1 are however less preserved. Thus they 
provide an explanation for the observed subtype selectivity of different ligands. Moreover, the 
receptor-bound conformation of L-glutamate (1) differs greatly from the one found in crystal 
structures of ionotropic glutamate receptors. While the latter prefer the so-called “folded 
conformation”, mGluRs bind glutamate in another low energy state, the “extended 
conformation” (Fig. 30b).[163] 
 
	  
Figure 30. a) Illustration of the hydrogen bonds formed by the five principal binding residues in 
mGluR1 as generated by PoseView.[171] b) Comparison of the binding-modes of L-glutamate (1) in 
iGluRs preferring the folded (top) and mGluRs preferring the extended conformation (lower). 
 
This notion is important, as the lowest energy conformations of 4-alkylated glutamate 
analogues differ depending on the configuration at C-4. While for 4-L-configured molecules 
the folded arrangement is favored, a 4-D-substitution results in the extended form dominating, 
thus avoiding a steric clash of the sidechain’s primary CH2 and the α-NH2 group. This offers 
an interesting stereochemical switch, by which agonists or antagonists derived from L-
glutamic acid can be targeted at either iGluRs or mGluRs (cf. chapter 6).  
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d) Structures of Orthosteric Agonists, Antagonists, positive and negative Modulators 
and Allosteric Agonist 
In general, orthosteric agonists of metabotropic glutamate receptors are L-glutamate 
analogues, which may be conformationally constrained. Antagonists are α-amino acids that 
bear bulky groups, which prevent a closure of the VFD. For all agonists crystallized, the 
aforementioned extended conformation is observed. This section will provide an overview of 
orthosteric agonists, antagonists and modulators of Group I-III metabotropic glutamate 
receptors. It however does not aim at being comprehensive, but rather to illustrate the 
structural wealth of mGluR ligands. For more detailed analysis of mGluR pharmacology the 
reader may be referred to excellent reviews.[161, 172] 
 Besides of the principal ligand – L-glutamic acid (1) – (1S,3R)-ACPD (145) does not 
discriminate between the different metabotropic glutamate receptors, too. Most interestingly, 
the conformational restriction in 145 allows the molecule to adopt a conformation perfectly 
matching the one found in the crystal structures of mGluRs containing L-glutamate. The (3S)-
isomer of 145 has been crystallized, too, and the comparison of the respective structures has 
yielded valuable information on the binding determinants of subtype-selective mGluR 
agonists (Fig. 31a).[173] Despite not being selective (activity in Group II & III),[172] LY341495 
(146) can be regarded as the prototypical mGluR antagonist, beautifully illustrating the “foot 
in the door” mechanism. In 146 the α-xanthene methyl moiety prevents an approach of the 
two VFD lobes, almost like a car-jack jammed in between the LBD hemispheres. Thus, VFD-
closure and subsequently receptor activation are prevented.[174] It should be noted however, 
that the reason for the antagonism of 146 at mGluRs is not the alkylation of the α-carbon, but 
rather the steric bulk of the substituent, as molecules substituted with smaller alkyl chains 
(e.g. methyl) at C-1 can be highly selective Group III agonists (vide infra). 
 
	  
Figure 31. a) Nonselective mGluR agonists. b) The non-discriminating antagonist LY341495 (146). 	  
The first selective mGluR agonist reported was L-quisqualic acid (14), a known and potent 
iGluR agonist. In general, both orthosteric agonists and antagonist show the α-amino acid 
motif and a hydrogen-bond acceptor is located in an appropriate distance to mimic the ω-
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carboxy group of (S)-glutamic acid (1) in the extended conformation (Fig. 32a,b). However, 
there are such intriguing structures such as the agonist trans-azetidine-2,4-dicarboxylic acid 
(t-ADA, 149) and the cubane-containing antagonist (S)-ACUDA (152).[175] Functionally, 
orthosteric antagonists act by preventing VFD-closure by exerting steric bulk. 
 The correlation between the structures of positive and negative allosteric modulators 
(PAMs and NAMs) and their function is unfortunately less obvious – if at all present. A 
common motif of these molecules however is the presence of large hydrophobic (aromatic) 
moieties, which are presumably interact with the TMs of metabotropic glutamate receptors.[5] 
Despite the lack of a general structure activity concept, a detailed analysis of individual 
PAMs and NAMs has yielded valuable information on the mechanism of receptor activation 
(Fig. 32c,d).[5] 
 
	  
Figure 32. Group I-preferring a) agonists, b) antagonists, c) positive modulators and d) negative 
modulators. Molecules marked with an * have not yet been crystallized with a receptor. 	  
Among the negative allosteric modulators, there are such interesting structures as the 
chromene-derivative CPCCOEt (161) and the azobenzene SIB1757 (166). Unfortunately, 
there is no information whether 166 is photochromic (i.e. photoswitchable).[176]  
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 Agonists with a preference for Group II mGluRs are conformationally highly 
restricted. LY354740 (170) and LY379268 (171) feature a (oxa) bicyclo[3.1.0]hexane motif 
and in L-CCG-I (173) C-3 and C-4 have been bridged by a cyclopropane (Fig. 33a).[177] Both 
PAM LY487379 (174) and the biphenyl-containing BINA (175) are highly selective for 
mGluR2, yet again there does not seem to be an obvious structure-activity relationship 
(Fig. 33b).[178] 
 
	  
Figure 33. Group II-preferring a) agonists and b) positive modulators. Molecules marked with an * 
have not been crystallized yet. 
 
 Group III-preferring agonists (Fig, 34a) include L-AP4 (176) and its cyclic and 
phosphate analogues Z-cyclopentyl-AP4 (177) and MAP4 (178).[179] Most interestingly L-
AP5, a homolog of 176, which bears an additional CH2 group, is a selective NMDA 
antagonist. [9] Then again, the elongated AMPA-derivative, (S)-homo-AMPA (181),[180] is a 
selective mGluR6 agonist, indicating an intriguing connection to iGluR pharmacology.[9] 
 
	  
Figure 34. Group III-preferring a) agonists, b) allosteric agonists, c) positive modulators and 
d) negative modulators. Molecules marked with an * have not yet been crystallized with a receptor. 
 
Most interestingly, there is an allosteric agonist, the N,N’-dibenzhydryl-1,2-diamine AMN082 
(182, Fig. 34b), which selectively activates mGluR7. Despite the lack of information on its 
allosteric binding site, it has been shown to induce mGluR7-dependant stress-hormone 
release.[181] Unfortunately, none of these Group III-preferring molecules including the PAMs 
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and NAMs (Fig. 34c,d) have been crystallized with their respective targets. Therefore, a 
structure-based analysis of their mode of action remains complicated. 
 
e) Résumé 
In summary, the information that can be gained from X-ray structures of metabotropic 
glutamate receptor VFDs is rather limited when compared to the 150 structures of iGluR 
ligand-binding domains. At the same time however, the amount of information available from 
structure-activity relationship screenings is enormous and surely reflects the importance of 
mGluRs for both academic and pharmacological research. As metabotropic glutamate 
receptors play an important modulatory role in synaptic transmission, it is no wonder that 
enormous effort have been taken to find both positive and negative modulators, which can be 
used in the treatment of various neuronal disorders. Given the explanatory power of crystal 
structures, it is to be expected that the structural collections will be expanded and they will for 
sure – at some point – include full-fledged mGluRs, as other 7TM receptors such as rhodopsin 
and GABAB receptors have already been crystallized, too.[182] 
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10) A Photoswitched Tethered Ligand of mGluRs 
 
Given the success of our group controlling both endogenous and genetically modified iGluRs 
both in vitro and in vivo, we were highly interested in exploring the option of applying the 
PCL/PTL concept to metabotropic glutamate receptors, too. As targets, the group II mGluRs 
mGluR2 and mGluR3 were selected because of their importance in memory formation and for 
being major drug targets for neuropsychiatric disorders. By comparing the binding mode of L-
glutamate (1) in mGluRs (cf. Chapter 5) and by homology modeling of mGluR2 and mGluR3 
(vide infra) we anticipated, that we could not use the same molecules as previously in GluK2 
(i.e. MAG-0, MAG-1), as they had the “wrong” configuration at C-4 (Figure 35a,b). Initial 
experiments had confirmed our hypothesis that – unlike for iGluRs – we would need D-
configured molecules like 187 (Figure 35c) in order to photosensitize mGluRs using the PTL 
concept.[183] To us, this stereochemical switch (i.e. L to D) was a stroke of luck, since we could 
use many of the strategies that had been used to synthesize LMAGs, too.[86a] 
 
	  
Figure 35. a) L- or D-configured glutamic acid analogues. b) mGluR3 (pdb 2E4U) as a model receptor 
of L- or D-substituted glutamate analogues. c) The prototype of DMAG-n 187 (n = 0,1,2). 
 
With the biological and the synthetic target identified, we were now faced with the 
challenge of synthesizing DMAGs (187) in both a diastereoselective and high-yielding way, 
since we would need multiple 100 mg for biological testing in vitro and in vivo. The 
following chapter therefore reports our considerations to the synthesis of these 4-D-substituted 
glutamate derivatives.  
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a) Diastereoselective Synthesis of a PTL for mGLuR2 
 
Owing to the high interest in 4-alkylated glutamic acids as selective ligands for ionotropic 
glutamate receptors and EAAT inhibitors,[184] the most commonly used strategy for their 
synthesis is the alkylation of pyroglutamic acid (188). Alternatives include enzyme mediated 
transamination to ketone 189,[184-185] hydrogenation of aldol-condensation products like 190 
using Adam’s catalyst,[186] or direct alkylation of glutamic acid 1.[187] Many of them however 
either suffer from low yields or diastereoselectivity, or could not be applied to our envisioned 
synthesis since they are not compatible with the chemical functionalities of the target 
molecule (Scheme 23). 
 
	  
Scheme 23. Synthesis of 4-substituted glutamic acid analogues from different precursors. 
 
We were therefore pleased to find, that protocols for the direct alkylation of N-Boc 
glutamic acid dimethyl ester (191) reported by Hanessian and coworkers promised high 
stereoselectivity and high yields for a variety of electrophiles (Scheme 24a).[188] Moreover, 
the only observed diastereomers were all D-configured, as was required for our synthesis of a 
PCL for mGluR2. This high selectivity can be rationalized by the transition state shown in 
Scheme 24b. It involves an intramolecular coordination of the dianion generated from N-Boc 
glutamic acid dimethyl ester (191) by a lithium cation and alkylation from the 
thermodynamically most favored conformations. In both cases, electrophiles only seem to 
attack from the Si-face (Scheme 24b).[188] 
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Scheme 24. a) Direct alkylation of N-Boc glutamic acid dimethyl ester (191) proceeds via a dianion. 
b) Transition state of the alkylation. The attack of the electrophile exclusively happens from the Si-face 
of the ester enolate. 
 
The representative synthesis of DMAG-0 (187, n = 0) started from L-glutamic acid (1), 
which was protected by standard protocols.[189] Using the methodology developed by 
Hanessian and coworkers,[188] diester 191 was alkylated in the 4-position using lithium 
hexamethyldisilazide and an excess of allyl bromide to yield D-allylated glutamate 192 as a 
single diastereomer in good yields. Subsequent extension of the alkene chain using a 
metathesis reaction with acrylic acid gave enoate 193, which then had to be selectively 
reduced. Unfortunately, we could not use the metathesis catalyst Grubbs II as the 
hydrogenation catalyst as described in some protocols.[190] Hence, resorting to palladium on 
charcoal under an H2-atmosphere, we obtained acid 194 in very good yields on a gram scale 
over two steps, which served as a key intermediate in our synthesis of PTLs for mGluR2 
(Scheme 25). 
 
	  
Scheme 25. Diastereoselective synthesis of key-intermediate 194 from L-glutamic acid (1). 
 
With 194 in hand, the following steps were modeled after the initial LMAG-synthesis.[86a] 
However, the known procedures could be improved to provide a higher-yielding access to 
PTLs for metabotropic glutamate receptors. 
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Starting from acid 194, we introduced the photoswitchable unit, 4,4’-azo dianiline, by 
an amide coupling. Interestingly, HBTU proved superior to other coupling agents like CDI, 
EDCI, PYBOP or Ghosez’s reagent.[191] Another amide formation using Fmoc glycine, which 
was activated as the acid chloride using oxalyl chloride and catalytic amounts of DMF, gave 
the corresponding fluorenyl carbamate-protected bisamide, which was deprotected using 
piperidine in DMF to yield the primary amine 196 (Scheme 26). Other, gentler activation 
methods (HBTU, CDI, EDCI, PYBOB) did not yield any coupling product, probably due to 
the low nucleophilicity of the anilinic amino function. 
 
	  
Scheme 26. Representative synthesis of DMAG-0 precursor 196: Coupling to the photoswitch 4,4’-
azo dianiline and installation of the terminal glycine moiety. 
 
Dimethyl ester 196 was subsequently saponified using lithium hydroxide in water/THF to 
yield diacid 197 in good yields. For the installation of the maleimide functionality, we used a 
slightly modified protocol than the one used in the synthesis of L-configured MAGs.[86a] 
Additionally, we found, that in order to obtain high yields the N-methoxycarbonyl maleimide 
reagent had to be purified just before use by column chromatography. Finally, treatment of 
the obtained cabamate with HCl-saturated ethyl acetate gave DMAG-0 (198) in very good 
yields over two steps as its HCl-salt (Scheme 27). 
 
	  
Scheme 27. Representative synthesis of DMAG-0: Saponification, maleimide formation and global 
deprotection yields DMAG-0 (198) as its HCl-salt after deprotection.  
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Using this scalable and efficient route, we obtained tether-models DTM-0 (199) and  
DTM-1 (200), which lack the photoswitch and bear no or one glycine unit respectively. 
Additionally, we synthesized DMAG-1 (198), which has an additional glycine spacer and 
which had previously been synthesized using a different route (Fig. 36).[86a] 
 
	  
Figure 36. a) Tether-models DTM-0 (199) and DTM-1 (200). b) PTLs DMAG-0 (198) and  
DMAG-1 (201) obtained as their HCl-salts using a novel, diastereoselective and scalable route. 
 
 With both the tether-models and the 4-D-substituted PTLs synthesized, we sent the 
molecules to our collaboration partners in the Group of Ehud Isacoff, UC Berkeley, for 
biological evaluation. The results of their findings are summarized in the following section 
and have been submitted for publication. 
 
Note: The numbering, the outline of figures and schemes, and the citations of the original 
manuscript have been adjusted to fit the format of this thesis. 
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b) Optical Control of a Metabotropic Glutamate Receptor 
 
Joshua Levitz, Carlos Pantoja, Benjamin Gaub, Harald Janovjak, Brian Kane, Philipp 
Stawski, Dirk Trauner and Ehud Y. Isacoff 
 
(This work was submitted for publication in 2012) 
Summary 
 We have developed an approach to elucidate the function of GPCRs by chemically re-
engineering them to be sensitive to light. The class C glutamate-gated GPCRs, mGluR2, 
mGluR3 and mGluR6, which couple to Gi/o, were derivatized with photoswitchable ligands 
to generate light-agonized and light-antagonized receptors. The light agonized “LimGluR2” 
and “LimGluR3” respond to glutamate and to light in the same way, desensitize modestly and 
slowly and recover completely. The photoswitches are bistable, enabling activation by a brief 
light pulse to be sustained in the dark before being switched off by longer wavelength light 
pulse. Light-driven deactivation is fast and supports multiple reproducible rounds of on/off 
switching. Optical activation of LimGluR2 gates two of the primary functions of mGluR2: 
suppression of neuronal firing and inhibition of neurotransmitter release. Photo-antagonism 
relieves inhibitory tone during spontaneous activity. These light-gated mGluRs pave the way 
for determining the function of mGluRs and their heterodimeric combinations in synaptic 
plasticity, memory and disease. 
 
Introduction 
 The ability to turn protein function on an off with light provides the opportunity to 
reversibly manipulate signaling in living cells with a high spatiotemporal precision that is not 
achievable using traditional pharmacological or genetic approaches. Light-gated ion channels 
and pumps can be used to elicit strong depolarizing and hyperpolarizing photocurrents.[97d, 192] 
Complementary to direct optical control of neuronal firing are efforts to remote control 
modulatory signaling proteins. Of special interest are G-protein coupled receptors (GPCRs), 
the largest family of membrane signaling proteins. These receptors respond to a wide-array of 
stimuli and contain a signature seven transmembrane domain that couples to heterotrimeric G-
proteins, including the Gq, Gs, Gt, and Gi/o.[193] These pathways exert different effects, but 
primarily play roles in controlling second messenger levels and regulating other signaling 
proteins, including ion channels and kinases. Due to their ubiquity and importance in many 
diseases, GPCRs are the most explored drug targets in all of biology. Despite this, the specific 
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biochemical, physiological, and behavioral roles of many GPCRs are not well understood and 
make this field ripe for the application of new tools for high-precision probing. 
Engineered GPCRs that respond to non-native ligands—the so-called RASSLs and 
DREADDs—have been used to orthogonally activate G protein pathways in vitro[150a] and in 
vivo.[194] Because these receptors lack the spatiotemporal precision of optical manipulation, 
interest has remained in the development of light-activated GPCRs. Until the present, the 
effort has centered on the naturally light-sensitive rhodopsin[195] and melanopsin [196] and 
chimeras that combine the transmembrane portions of rhodopsin with the cytoplasmic loops 
of adrenergic or serotonergic receptors to couple to other G-proteins [6b, 197] The rat rhodopsin 
RO4 has been used to couple via Gi/o to G-protein activated inward rectifier (GIRK) channels 
in HEK293 cells and cultured hippocampal neurons, and thereby to control excitability as 
well as rhythmic activity in chick spinal cord[195a] and mouse cerebellum.[198] Chimeras 
between bovine rhodopsin and either the human α1 or β2 adrenergic receptor have been shown 
to light-activate Gq and Gs.[197a] These “optoXRs” have been used in vivo to modulate activity 
in the nucleus accumbens and thereby control reward-related behavior in mice.[6b] Most 
recently, a chimera between RO4 and the C- terminus of the 5-HT1A receptor was shown to 
mimic serotonergic signaling in the dorsal raphe nuclei.[197b] 
 A major advantage of vertebrate opsin-based GPCRs is their use of the naturally 
bioavailable retinal as the chromophore. However, there are two potential disadvantages. 
First, unlike the microbial opsins, in which retinal is permanently bound, the isomerized trans-
retinal dissociates from rhodopsin and must be replaced by fresh cis-retinal.[199] In 
photoreceptor cells fresh cis-retinal is delivered efficiently from the retinal pigment 
epithelium and under physiological conditions only a very small fraction of rhodopsins are 
photo-bleached at any one time, thus assuring a large population of unbleached rhodopsin.[200] 
However, in the rest of the nervous system the concentration of cis-retinal is lower and the 
replenishment of bleached retinal may be slower. Moreover, the deactivation of rhodopsin is 
slow in the absence of the photoreceptor cell-specific enzymatic pathway. 
We report here an alternative approach to engineering light gating into GPCRs in which we 
use photoswitchable tethered ligands (PTLs). The attraction of this approach is that it provides 
optical control over the native receptor, so that in addition to providing heterologous control 
of G protein signaling, it provides the unique possibility for investigating the normal function 
of that receptor. The PTL approach has been used to light-block K+ channels and light-
activate ionotropic glutamate receptors,[86a, 97j, 201] providing for fast bidirectional 
photoswitching, bistability, and modularity.[202] 
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We targeted the metabotropic glutamate receptors (mGluRs), class C GPCRs that, like 
ionotropic glutamate receptors, are allosterically regulated by glutamate binding to a large 
extracellular clamshell ligand binding domain (LBD).[161] The LBDs form back-to-back 
homo- or hetero-dimers whose glutamate-induced rearrangement is propagated via a cysteine-
rich domain to a 7- transmembrane domain whose cytoplasmic loops interact with G 
proteins.[163, 173, 203] Other GPCRs of this class include T1R taste receptors, vomeronasal 
pheromone receptors, GABAB receptors, and the calcium receptor.[203] The mGluRs are 
divided into three groups based on sequence homology.[161] We focused initially on the group 
II mGluRs, mGluR2 and 3, which couple to the Gi/o pathway to inhibit adenylyl cyclase,[204] 
and which also activate GIRK channels, thereby reducing excitability, and inhibit voltage-
gated calcium channels, thereby inhibiting neurotransmitter release.[205] Presynaptic group II 
mGluRs also play roles in long term depression and potentiation of synaptic transmission in 
multiple brain regions including the hippocampus,[206] nucleus accumbens,[207] striatum,[208] 
and amygdala.[209] Genetic knock-out and pharmacological studies have implicated mGluR2 
and 3 in spatial memory,[210] motor coordination,[211] and other aspects of cognition.[212] 
Because of these important physiological roles, group II mGluRs are major drug targets for 
neuropsychiatric disorders including anxiety, depression, and schizophrenia.[213] We extended 
our engineering to the Group III mGluR, mGluR6. Members of this family also couple to the 
Gi/o pathway and have been implicated in similar cellular functions. But they display different 
expression profiles, subcellular targeting and regulation via PDZ ligands, kinases, and 
Ca2+/calmodulin. 
We used a combination of structural analysis and novel test compounds to develop PTLs with 
appropriate stereochemistry, length and molecular composition and a powerful but simple and 
fast battery of Monte-Carlo simulations to predict appropriate cysteine attachment sites on the 
LBD. The approach was successful and we report examples of both photo-agonism and 
photo-antagonism. The photo-agonism of mGluR2 in neurons evokes rapid optical activation 
and deactivation, as well as bistable photo-control, can be used to control excitability and pre-
synaptic inhibition in cultured neurons, and also works in intact brain slices. In vivo, mGluR2 
photo-agonism can be used to reversibly and repeatedly modulate escape behavior in larval 
zebra fish. Furthermore, we demonstrate that this approach may be generalized by 
engineering agonistic photocontrol of the group II mGluR, mGluR3, and antagonistic 
photocontrol of the group III mGluR, mGluR6. The introduction of photosensitivity into 
native GPCRs provides the means for probing their biological functions at a level of precision 
not previously available. Optical control of mGluRs, one of the largest families of GPCRs that 
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respond to a single neurotransmitter, and one of the brains major neurotransmitters at that, 
paves the way for determining the function of each receptor type and the many heteromeric 
combinations that they make in the multiple neuron types and brain regions where they are 
expressed.[214] 
 
Experimental Procedures Chemical Synthesis 
The chemical synthesis of DMAG-0, DMAG-1 and D-tether models was carried out as 
described in the Supplementary Information. The synthesis of L-tether model has been 
described previously.[86a] Homology modeling and Monte-Carlo simulations to select MAG 
attachment sites are described in Supplemental Information. 
 
Molecular Biology and Gene Expression in Cultured Cells 
Mutations were introduced into plasmids using the QuickChange mutagenesis kit (Agilent) 
and transfection was performed using Lipofectamine 2000 (Invitrogen) and the calcium 
phosphate method for HEK 293 cells and neurons, respectively. See Supplementary 
Information for details. 
 
Cultured Cell Electrophysiology 
HEK 293, HEK 293T, and Dissociated Neuron whole cell patch clamp electrophysiology 
coupled with wavelength-specific illumination was performed using standard techniques. See 
Supplementary Information for details. 
 
Hippocampal Slice Gene Expression and Electrophysiology 
Hippocampi were obtained from postnatal Sprague-Dawley rats (postnatal days 6 and 7) and 
400 µm slices were prepared, cultured, and electrophysiology was performed as previously 
described (Janovjak et al., 2010), with minor variations. See Supplementary Information for 
details. 
 
Zebrafish Transgenesis 
Expression of mGluR2-L300C was targeted to neurons using the UAS/GAL4 system. See 
Supplementary Information for details. 
 
Zebrafish Behavioral Assay 
Swim and escape responses were elicited using an 8 Ohm mini-speaker (Radioshack) and 
images were captured using a behavioral camera (IDS, USB 2 uEye).[119]  
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Statistics and Data Analysis 
Data was analyzed using Clampfit (Axon Instruments) and Origin (OriginLab) software. 
Statistical analysis was performed using Microsoft Excel. All values reported are mean ± 
s.e.m. 
 
Results 
 
Tether Model Pharmacology and Synthesis of Photoswitches 
 To design photocontrol of mGluR2, we first inspected the available crystal structures of 
mGluR clamshells in their open and closed forms, which show that glutamate is bound in a 
highly conserved conformation. Using a homology model of mGluR2 based on the closed, 
glutamate-bound structure of mGluR3 (PDB ID: 2E4U) we asked if there is an access channel 
by which a PTL could reach a thiol- reactive end to the lip of the LBD for cysteine attachment 
while its glutamate end is bound in the ligand binding site. The model reveals such an access 
channel (Fig. S1A) that may provide a route to the 4’ carbon of glutamate, which was the site 
of attachment for the linker in previously described MAG PTLs. It was also apparent that 
substituents attached to the 4’-position of glutamate with D-stereochemistry will point to the 
solvent-exposed side of the clamshell (Fig. S1B, C) and thus, this configuration seemed best 
suited for tether attachment. This observation is consistent with pharmacological studies 
indicating that 4’ substituted glutamate analogues with D stereochemistry produce more 
potent activation of mGluR2.[215] To further test what types of molecules may be used to 
control mGluR2, we tested, as a free ligand, L-Tether-1 (previously referred to as “tether 
model”).[86a] This compound contains one ring of the azobenzene, a linker and the glutamate 
moiety and thus mimics half of MAG (Fig. 37A). Wild type rat mGluR2 and GIRK1 were co-
expressed in HEK293 cells. Whole-cell voltage clamp recordings showed large inward 
currents in response to glutamate but no response to 1-3 mM L-Tether-1 and no effect of L-
Tether-1 on the glutamate response, indicating lack of both agonism and antagonism. We next 
examined compounds with 4’ D-stereochemistry and either one or two glycine linkers 
connecting the glutamate group and the benzene ring (D-Tether-0 and D-Tether-1; Fig. S1A). 
1 mM D-Tether-0 activated mGluR2 currents to 26 ± 5% (n=6; Fig. S1D) of the size of 
currents activated by saturating (1 mM) glutamate. 1 mM D-Tether-1 showed no activation but 
reduced the currents evoked by 1 mM glutamate by 55±1% (n=4; Fig. S1E). These tether 
models confirmed our stereochemical predictions and provided the impetus for synthesizing 
DMAG-0 and DMAG-1 (Fig. 37B).  
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Figure 37. Design of photoswitches for light-control of mGluR2. (A) Chemical structure of tether 
models including previously described L-Tether-1 and new 4’ D versions with two different linker 
lengths (D-Tether-0 and D-Tether-1) (B) Structure of DMAG molecules. 380 nm light maximally 
isomerizes to the cis state, whereas 500 nm light isomerizes to the trans state. Spontaneous thermal 
relaxation from cis to trans occurs over tens of minutes at room temperature. (C) Schematic of light-
induced agonism. mGluRs contain a ligand-binding clamshell domain (LBD; grey) that is coupled to a 
7-transmembrane domain (TMD; green) by a cysteine rich domain (CRD, dark blue). Agonist binding 
to the LBD initiates clamshell closure, which rearranges a dimer interface with a partner LBD of a 
second subunit and transmits a conformational change via the TMD to the cytoplasmic domain, 
thereby activating G-proteins. Under 380 nm illumination DMAG enters the cis state and reorients the 
glutamate moiety into the ligand binding site to drive clamshell closure and activate G protein and 
downstream signaling. (D) Schematic of 380 nm-induced antagonism. Glutamate (dark orange circles) 
is shown in the bound, activated state of mGluR2. Upon photoisomerization the glutamate end of MAG 
enters the binding site and prevents clamshell closure, thus deactivating the receptor. 
 
Monte Carlo Simulations of DMAG-0 Reach 
 In order to rationally design light-gated versions of mGluR2, we used Monte Carlo 
simulations to identify geometrically appropriate cysteine-attachment points for the 
conjugation of DMAG-0. First we built a homology model of mGluR2 in the open, glutamate-
bound state using the mGluR1 open, glutamate- bound crystal structure (PDB ID 1EWK) as a 
template. We then generated molecular models of DMAG-0 with geometries of cis- and trans- 
azobenzene based on earlier experimentally determined coordinates that were validated 
computationally.[216] After manually positioning the glutamate-group of DMAG-0 in the 
binding pocket, the Monte-Carlo multiple minimum (MCMM) algorithm [217] was used to 
search the space accessible to DMAG-0 with single-bond rotations as degrees of freedom. 
Twenty thousand orientations/structures were generated by MCMM and for each the distance 
from the cysteine-reactive maleimide (Mal) group of MAG to every residue on the surface of 
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the LBD was measured automatically. Simulations were performed for both cis- and trans-
conformations of DMAG-0 (Figure 38A shows a superposition of 20 conformations of 
DMAG-0 bound to the LBD of mGluR2 from the cis simulation.) The conformational search 
identified eight clusters of 3-8 residues that were significantly populated by the Mal-group of 
DMAG-0 (Figure 38B). Notably, the region between residues 299 and 305 contained multiple 
residues with high frequencies, as well as substantially higher scores for cis than for trans, 
indicating that such sites may allow for selective activation of mGluR2 in the cis state. 
 
	  
Figure 38. Monte Carlo simulations and cysteine-scanning of mGluR2 ligand-binding domain.  
(A) cis-DMAG-0 (red stick depiction) with glutamate end bound in LBD (gray surface depiction) is 
shown in 20 superposed conformations calculated by Monte Carlo simulation using homology model 
of the mGluR2 LBD in the open, glutamate-bound conformation. (B) Results of DMAG-0 simulations 
for cis and trans conformations. Lines indicate the frequency with which the maleimide end of MAG 
approaches within 6 Å of the Ca of a particular residue in the cis state (purple) and trans state (green). 
(C) Open homology model of mGluR2 LBD showing native side chains of 7 residues individually 
substituted to cysteine. (D) Results of photoswitching of DMAG-0 and DMAG-1 attached at each of the 
seven positions. “x” indicates no photoresponse. Agonistic and antagonistic effects are quantified 
(mean + s.e.m.) relative to response to 1 mm glutamate. Data from >2 different coverslips for all 
conditions tested. 
 
The Monte Carlo simulations reveal amino acids whose Cα positions are near the maleimide. 
We selected a subset of seven residues with orientations favorable (not pointing into the core 
of the protein) for the maleimide end of MAG to conjugate and for its glutamate end to enter 
the ligand-binding site without steric clashes. Seven candidate sites were identified: Q42, 
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D146, E373 and S376 in the upper lobe of the LBD, L300 and S302 on the lower lobe, and 
D215 at the hinge (Fig. 38C). Each site was individually substituted with cysteine and co-
expressed with GIRK1 in HEK293 cells. 
 
Photo-Antagonism by DMAG-1: LimGluR2-block 
 We focused initially on two MAG attachment sites, L300C and S302C, because of their 
high scores in the Monte Carlo simulations and their large photo-effects in initial experiments 
(Fig. 38B, D). Cells expressing either variant were labeled with either DMAG-0 or DMAG-1 
(50-100 µM) for 30-60 minutes, patch- clamped in the whole cell configuration and alternately 
challenged with 380 nm light to isomerize the photoswitch to cis and 500 nm light to 
isomerize to trans. This was done in the absence of glutamate to determine if there was photo-
agonism or in the presence of glutamate to determine if there was photo-antagonism. 
 Following labeling at S302C and L300C with DMAG-1 we found that illumination at 
380 and 500 nm had no effect on the current (Fig. 3A, S2A). However, in the presence of L-
glutamate, 380 nm light induced a marked decrease in the current that was reversed by 
illumination at 500 nm (Fig. 3A, S2A). Repeated switching between 380 and 500 nm light 
toggled the glutamate-induced current between high and low levels. The percentage photo-
antagonism was 21 ±2% (n = 7) for DMAG-1 at L300C and 53 ± 4% (n = 5) at S302C in 
1 mM glutamate. At concentrations greater than 1mM, photoantagonism was decreased 
(Fig. S2B), indicating a competitive mechanism. Due to the large potency of the 302C 
substitution in combination with DMAG-1 in photo-antagonism of mGluR2, we term this tool 
“LimGluR2-block”. Of the seven attachment sites that were selected for study, four (including 
L300C and S302C) showed photo-antagonism with DMAG-1 (Figure 2C, D). These results 
are consistent with the antagonism of the D- Tether-1 compound, observed above. 
 
Photo-Agonism by DMAG-0: LimGluR2 
We next turned to the version of MAG that was based on the agonist D-Tether-0, namely 
DMAG-0. Of the seven sites that we examined, only two had a photo-response to DMAG-0: 
L300C showed robust photo-agonism (Fig. 39B) and S373C had weak photo-antagonism 
(Fig. 39D). We focused on the L300C/DMAG-0 combination because of the utility of photo-
activation, and refer to it henceforth as “LimGluR2”. Voltage ramps confirmed that the light-
activation of LimGluR2 at 380 nm was due to the opening of the same inward-rectifying 
potassium conductance as was activated by glutamate (Fig. S3A). The photo-activation of 
LimGluR2 by 380 nm light yielded currents about half as large as those evoked by saturating 
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glutamate (48 ± 4% compared to 1 mM glutamate, n = 10; Fig. 39C). Illumination at 500 nm 
terminated the activation of the GIRK1 channels as rapidly as they were activated by 380 nm 
light (Fig. 39B, C). 
 
	  
Figure 39. Photo-antagonism of mGluR2 and mGluR6 and photo-agonism of mGluR2 and mGluR3. 
(A-F) Effects of photoswitching DMAG0 and DMAG1 on the activation of GIRK1 current in HEK293 
cells. (A) When DMAG-1 is attached to S302C (“LimGluR2-block”) light has no effect in the absence of 
glutamate, but 380 nm light evokes photo-antagonism in the presence of glutamate. Black bars 
indicate application of 1 mm L-glutamate. Green bars indicate illumination with 500 nm light and purple 
bars indicate 380 nm light. (B, C) When DMAG-0 is attached to L300C 380 nm light evokes GIRK1 
current on its own. GIRK1 current trace shows sustained response in the dark following a brief 
illumination at 380 nm (B). The current remains activated until deactivation is initiated by 500 nm light. 
No photo- antagonism is seen in the presence of glutamate, indicating that DMAG-0 is not a partial 
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agonist of mGluR2- L300C (C). (D) GIRK1 current evoked by repetitive rounds of photo-activation and 
photo- deactivation of mGluR2-L300C-DMAG-0 (“LimGluR2”) by pulses of 380 nm and 500 nm light, 
respectively. (E) When DMAG-0 is attached to mGluR3-Q306C (“LimGluR3”) robust 380 nm-induced 
antagonism is seen. Similar to LimGluR2, no photo-antagonism was seen in the presence of 
glutamate. (F) When DMAG-0 is attached to mGluR6-K306C (“LimGluR6-block”) robust 380 nm-
induced photoantagonism is seen, indicating that the PTL approach can be extended to group III 
mGluRs. 
 
An advantageous property of azobenzene photoswitches is their bistability, which makes it 
possible to produce persistent occupancy in the dark of the activating cis state following a 
photo-isomerizing light pulse.[97d, 218] Indeed, we found that a brief (1 s) activating light pulse 
at 380 nm, which was long-enough for the azobenzene to reach the photostationary state, 
evoked a period of GIRK activation that persisted for tens of seconds in the dark, and which 
could be rapidly turned off by illumination with 500 nm light (Fig. 39B). During this bout of 
protracted activation in the dark the current declined by ~10-20%, a decline that was similar 
to what was seen under continuous illumination of LimGluR2 at 380 nm, as well as in 
response to extended application of glutamate. 
 Notably, no antagonism of the glutamate response was induced by illumination at 
380 nm (Fig. 4C, S3C). This suggests that the lack of full activation by DMAG-0 attached to 
L300C is not due to partial agonism by cis-DMAG-0, but to incomplete occupancy of the cis 
state at 380 nm[218] and, possibly, to incomplete labeling of the engineered cysteine. 
Application of glutamate following initiation of illumination at 380 nm increased the inward 
current above the level induced by light alone (Fig. S3B). This result further indicates that 
MAG does not lock the LBD in a partially activated conformation, but rather functions as a 
full agonist in a fraction of subunits. 
 Repeated bouts of photoswitching of LimGluR2 yielded multiple rounds of photo-
activation of GIRK1 channels without decline of the response (Fig. 39D). The reproducibility 
of the optical activation of LimGluR2 is consistent with the lack of GRK-dependent 
desensitization of mGluR2.[219] Having observed that LimGluR2 can be rapidly turned on and 
off with light and repeatedly activated in a reproducible manner, we asked how it compares 
with the earlier light-gated GPCRs which are made either of rhodopsin or of rhodopsin 
chimeras. To address this, we tested the critical light-gated component of all of the prior 
GPCRs: rhodopsin. Rat rhodopsin, RO4, which also couples to GIRK1 channels,[195a] was 
expressed in HEK293 cells and the cells were incubated for prolonged times (40 minutes) in 
1 µM 11-cis retinal in the dark. Illumination of cells co-expressing RO4 and GIRK1 with 490 
nm light activated large inward GIRK currents (Fig. S4A) that were similar in amplitude and 
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rise time to those evoked by optical activation of LimGluR2 (Fig. S4B). However, the GIRK1 
deactivation kinetics of RO4 upon light off were much slower than the deactivation kinetics 
during light-driven deactivation of LimGluR2 (Fig. S4A-C). Due to the slow deactivation 
kinetics of RO4, repeated optical stimulation was limited to intervals of 90 s (Fig. S4D). Even 
at this long interval (6-times longer than the one which produced reproducible photo-
activation of LimGluR2) the RO4-mediated responses declined significantly from pulse to 
pulse (Fig. S4D,F). In contrast, LimGluR2 photo- responses were stable in amplitude (Fig. 
39D, S4E,F). 
 
Generalization of Photocontrol to mGluR3 and mGluR6 
 To test if the PTL approach could be generalized to optically control other mGluRs, we 
tested cysteine substitutions in, mGluR3, a second group II mGluR member, and mGluR6, a 
member of group III mGluRs, at residues that are homologous to L300 and S302 of mGluR2 
(Fig S5A). Optical control of mGluR3 is attractive because of the lack of agonists and 
antagonists that differentiate between mGluR2 and 3, while mGluR6 is an important target for 
photocontrol because of its central role in synaptic transmission from photoreceptors to ON 
bipolar cells in the retina. Figure S5B, C and D summarizes the results of the mutational 
screens of mGluR2, mGluR3 and mGluR6. Interestingly, photoswitching of DMAG-0 or 
DMAG-1 anchored at sites of mGluR3 and mGluR6 that are homologous to mGluR2’s L300 
and S302 yielded similar effects in mGluR3 and different effects in mGluR6, where only 
photo- antagonism was observed, providing a readout of the degree of geometric similarity 
near the LBD binding pocket. 
 Conjugation of mGluR3 Q306C (the homolog of mGluR2-L300C) with DMAG-0 
produced strong photo-agonism (“LimGluR3”) under 380 nm light in HEK293T cells co-
transfected with GIRK1 (Fig. 39E). The photocurrents were 74 ± 12 % (n = 6 cells) the 
amplitude of 1 mM glutamate evoked currents, indicating that LimGluR3 is even more robust 
than LimGluR2. Conjugation of mGluR6-K306C (the homolog of mGluR2-L300C) with 
DMAG-0 produced a robust photo-antagonism under 380 nm light (Fig. 39F). The percentage 
photo-antagonism was 40 ± 3 % (n = 5 cells) for DMAG-0 at mGluR6-K306C in 1 mM 
glutamate. We term this tool “LimGluR6-block”. 
 The ability of optical stimulation of LimGluR2 and 3 to evoke large GIRK1 currents, 
that persist in the dark, but which can be rapidly deactivated by light and which, moreover, 
can be sculpted by alternating light pulses into trains of reproducible effector activation and 
deactivation represent important advantages over previous light-gated GPCRs based on 
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rhodopsin with loops from ligand-gated GPCRs, since, outside of photoreceptor cells, 
rhodopsin deactivates slowly and does not recover completely. An additional advantage is 
that, functionally, LimGluR2 is a native receptor (altered only by a cysteine mutation and 
conjugation with DMAG-0, which does not alter sensitivity to standard mGluR 
pharmacological agonists and antagonists; Fig. S3D,E,F) and so could make it possible to 
optically stimulate native mGluR2 targets with light. We next tested this possibility in 
neurons. 
 
Optical Control of Excitability in Hippocampal Neurons 
 We examined the ability of LimGluR2 to optically activate the native downstream 
targets of mGluR2 in cultured hippocampal neurons. These include GIRK channels in the cell 
body[220] and voltage-gated calcium channels in the presynaptic nerve terminal.[221] Indeed, we 
found that the cysteine-substituted mGluR2-L300C, tagged with eGFP at the C- terminus, is 
distributed throughout the soma and many fine processes of the neuron (Fig. 40B). 
 We first tested the expectation that activation by LimGluR2 of cell body GIRK channels 
would decrease excitability (Fig. 40A). In high extracellular potassium (60 mM) and under 
voltage clamp, illumination with 380 nm light evoked large inward currents that were 
deactivated by 500 nm light (Fig. S6A). Interestingly, even though photoswitching was done 
at the same light intensity in the two cell types (0.4 mW/mm2 at 380 nm), the photo-activation 
rate was ~5-fold faster in neurons than in the HEK293 cells (respectively, the single 
exponential fits were: τ = 1.03 ± 0.06 s, n = 5, versus 5.69 ± 0.69, n = 8; unpaired, 1-tailed t-
test, p = 0.004). This is consistent with previous observations of faster activation of GIRK 
channels by native GiPCRs in cultured neurons compared to heterologously expressed 
receptors in HEK293 cells that are co-transfected with GIRK.[222] The observation suggests 
that LimGluR2 assembles into the native G-protein signaling machinery of neurons. 
 To test the ability of LimGluR2 to modulate neuronal excitability via GIRK channel 
activation, we performed current clamp experiments. Neurons expressing LimGluR2 were 
labeled with DMAG-0 and given 2 s depolarizing current injections, in 10 pA increments, 
under current clamp. This was done during alternating illumination with 380 nm and 500 nm 
light. Photo-activation of LimGluR2 at 380 nm greatly decreased the number of action 
potentials fired evoked by each level of depolarization (Fig. 40C,D). This optical inhibition 
was highly reversible and repeatable (Fig. 40C and G; Fig S6B). The photo-currents were big 
enough to evoke a reversible 5-15 mV hyperpolarization at the resting potential (Fig. 40E) 
and, in accordance with the bistability of the system, the hyperpolarization and silencing 
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persisted for tens of seconds in the dark after activation of LimGluR2 by a brief 380 nm light 
pulse (Fig. 40E,F). 
	  
Figure 40. LimGluR2 hyperpolarizes and reduces excitability in cultured hippocampal neurons.  
(A) Schematic showing LimGluR2 mediated control of excitability via GIRK channels. Note: Light is 
applied to entire field of view. (B) LimGluR2-eGFP is widely distributed in cultured hippocampal 
neuron. Scale = 50 µm. (C) Representative cell shows trains of spikes elicited by depolarizing current 
steps (gray traces) when LimGluR2 is off (500 nm illumination, green bar) are reversibly suppressed 
by activation of LimGluR2 (380 nm illumination, violet bar). (D) Summary of current step experiments 
shown in (C) for 8 cells. Bars indicate number of spikes in response to 2 s current injections under 380 
nm (violet bar) or 500 nm (green bar) light. Star indicates statistical significance (paired, 1-tailed t-test, 
p = 0.009, 0.004, and 0.009, respectively, for currents of 10, 20, and 30 pA). (E, F) Representative 
cells show bistability of LimGluR2. (E) Hyperpolarization from resting-potential in representative cell in 
the response to brief (1 s) LimGluR2 activation by 380 nm light (violet bar) persists for tens of seconds 
in the dark before LimGluR2 deactivation by 500 nm light (green bar). (F) The persistent activation in 
the dark effectively suppresses spikes. LimGluR2 activation induced an average hyperpolarization of 8 
± 4 mV (n=15) from resting potentials ranging from -40 to -60 mV. (G) Representative trace shows 
repeatable spike silencing by photocontrol of LimGluR2.  
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We next tested if photo-antagonism by “LimGluR2-block” could alter spike-firing patterns. In 
regions with high transfection efficiency (>1 transfected neuron per field of view) optical 
antagonism of mGluR2 with 380 nm light resulted in an increased firing frequency that was 
reversed by 500 nm light (Fig. S6C,D). This experiment demonstrates that LimGluR2-block 
is a robust enough tool to alter neuronal signaling properties despite incomplete antagonism. 
This result indicates that under basal signaling conditions there is sufficient inhibitory tone 
produced by glutamate binding to mGluR2 to suppress spike firing. 
 
Optical Control of Synaptic Transmission and Short Term Plasticity in Hippocampal 
Autapses 
 Group II metabotropic glutamate receptors are known to traffic to presynaptic terminals 
and play inhibitory roles in synaptic transmission and plasticity.[161] We asked whether 
LimGluR2 would provide for optical control of neurotransmitter release (Fig. 41A). We 
expressed mGluR2-L300C in low-density hippocampal cultures in which there are so few 
neurons that each neuron forms synapses onto itself (autapses). Cells were patch-clamped in 
the whole cell mode and we recorded postsynaptic currents elicited by brief depolarization 
steps, which elicited single action potentials. Excitatory post-synaptic currents (EPSCs) were 
detected in some cells (Fig. 5B) and inhibitory post- synaptic currents (IPSCs) were detected 
in others (Fig. 41C). EPSCs and IPSCs were identified based on the kinetics of decay with 
EPSCs approximately ten times faster than IPSCs (~5 ms vs. 50 ms), as has been described 
previously.[223] Activation of LimGluR2 by illumination at 380 nm rapidly and reversibly 
inhibited both the EPSCs (41 ± 5%, n =8) and IPSCs (36 ± 3%, n = 4) (Fig. 41B and C). 
Furthermore, LimGluR2 could be used to optically inhibit EPSC amplitude repeatedly 
(Fig. S6D). 
 In contrast to the potent inhibition by LimGluR2, there was no optical inhibition in 
either cells tranfected with GFP instead of LimGluR2 or cells transfected with LimGluR2 but 
not labeled with DMAG-0 (Fig. 5D). Moreover, there was no change in baseline PSC 
amplitude in labeled and transfected (LimGluR2) cells compared to GFP-transfected or 
unlabeled cells (223 ± 64 pA ; n = 12 vs. 262 ± 68 pA; n=5 vs. 232 ± 91 pA; n = 5), indicating 
that expression of LimGluR2 does not produce a long-term homeostatic change in synaptic 
strength. In addition, the optical inhibition of transmission by LimGluR2 produced no change 
in PSC decay time (Fig. S7A), time to peak (Fig. S7B) or jitter (S.E.M of time to peak), 
leaving the post- synaptic currents unchanged in shape (Fig. S7C). 
 To test if the LimGluR2-mediated optical inhibition of transmission proceeds through a 
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pre-synaptic mechanism, we performed paired pulse experiments. The optical inhibition of 
transmission by illumination with 380 nm light was associated with a substantial increase in 
the relative size of the EPSC evoked by the second pulse (Fig. 41E).  
 
	  
Figure 41. Optical activation of LimGluR2 reversibly decreases excitatory and inhibitory post-synaptic 
currents and increases paired pulse facilitation at hippocampal autapses. (A) Schematic shows optical 
control of neurotransmitter release via LimGluR2 triggered G-protein suppression of opening of a 
presynaptic voltage-gated calcium channel (VGCC). (B, C) Representative autaptic excitatory (B) and 
inhibitory (C) post synaptic currents elicited by short (2 ms) depolarizing steps are decreased in 
amplitude by LimGluR2 activation by 380 nm light (violet traces) compared to deactivation by 500 nm 
light (green traces. (D) Pooled inhibition of EPSCs and IPSCs by optical activation of LimGluR2 
compared to controls in which mGluR2 (L300C) was expressed but not labeled with DMAG-0 and 
where mGluR2 was not expressed. Values in parentheses denote number of cells tested. (E) 
Representative single sweeps of paired pulse recordings (50 ms inter-stimulus interval) of EPSCs 
under 500 nm light (green bar) followed by 380 nm light (violet bar). (F) Summary of paired pulse ratio 
(PPR) values for representative cell. 380 nm light (violet bar) significantly increased the PPR 
compared to 500 nm light (green bar) (n=10 sweeps/condition; paired, 1-tailed t-test, p = 0.008). (G) 
Plot of average PPRs measured for 5 autaptic cells under 500 nm light (green symbols) and 380 nm 
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light (violet symbols). (H) Representative EPSC amplitudes from a cell showing repeatable, bistable 
optical inhibition of an excitatory autapse. Illumination at 500 nm to deactivate LimGluR2 is followed by 
brief (1 s) illumination at 380 nm (violet arrows) followed by a period of darkness until illumination at 
500 nm to deactivate LimGluR2 was resumed. Inserts (i), (ii), and (iii) show EPSCs from indicated 
times. 
 
This increase in paired pulse ratio was significant (Fig. 41F and G; paired, 1-tailed t test, p = 
0.01). This indicates that activation of LimGluR2 inhibits postsynaptic currents by decreasing 
release probability and, thereby, increasing facilitation. This is exactly the mechanism by 
which native mGluR2 acts presynaptically via inhibition of N and P/Q type voltage-gated 
calcium channels, as has been observed for native group II mGluRs at the calyx of Held[221b] 
and for heterologously expressed receptors and channels in HEK293 cells.[224] Notably, the 
paired pulse ratio in LimGluR2 positive cells was the same as that in GFP-transfected cells 
(respectively 1.5 ± 0.1, n = 5 vs. 1.4 ± 0.3, n = 4), indicating that expression and labeling of 
LimGluR2 does not alter the basal release. 
 Finally, we tested the ability of LimGluR2 to produce multiple rounds of inhibition of 
transmission and recovery and for the inhibition to outlast the activating light pulse due to the 
bistable nature of the photoswitch. Illumination at 380 nm reversibly and reproducibly 
inhibited EPSC amplitude (Fig. 41H and S7E). Brief photo-activation produced sustained 
inhibition of synaptic transmission that persisted in the dark for minutes, but which could be 
rapidly reversed by illumination at 500 nm. These experiments show that LimGluR2 provides 
a powerful means for the optical control of presynaptic inhibition of neurotransmitter release. 
Optical Control of Neuronal Excitability in Hippocampal Slices 
 To examine applicability in intact tissue, we tested LimGluR2 in cultured hippocampal 
slices. Slices prepared from P6-P8 rats were transfected with LimGluR2 (mGluR2-L300C) 
and td-Tomato (as a transfection marker) by Biolistic gene transfer. Expression was seen in 
scattered cells located throughout the hippocampus. Slices were incubated with DMAG-0 and 
whole cell patch-clamp recordings were performed on cells two or three layers below the 
surface of the slice. At resting potential (between -45 mV and -65 mV) LimGluR2 activation 
by illumination at 390 nm induced a small (3-8 mV), reversible hyperpolarization (Fig. 42A). 
In response to depolarizing current injections, illumination at 390 nm reproducibly decreased 
action potential firing rate (Fig. 42B, C), as was seen in the dissociated cultured neurons 
(Fig. 40C, D). Illumination with 500 nm light restored firing frequency to levels seen before 
LimGluR2 activation. In addition, LimGluR2 activation was able to decrease spontaneous 
spike firing (Fig. 42D) in a bistable, rapidly reversible and reproducible manner, with similar 
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efficacy to the photo- control of dissociated cultured neurons. Importantly, LimGluR2 
expression and DMAG-0 labeling did not adversely affect neurons, leaving the average 
resting membrane potential unaltered (Fig. S8A).  
 
	  
Figure 42. LimGluR2-mediated control of neuronal excitability in hippocampal slice.  
(A) Hyperpolarization is triggered by illumination at 390 nm (violet bar) and reversed by illumination at 
500 nm (green bar) in a representative cell. (B) Representative cell recorded in whole-cell patch in 
cultured hippocampal slice shows spike firing in response to 1s, 200 pA depolarizing current injections 
during 500 nm (green bars) or 380 nm (violet bar) illumination. LimGluR2 activation reversibly 
decreases the number of spikes. (C) Summary of optical control of spike firing in response to current 
steps in LimGluR2-positive neurons (n = 6 cells). Star indicates statistical significance (paired, 1-tailed 
t-test, p = 0.024). (D) Representative trace showing reversible, bistable silencing of spontaneous 
activity by LimGluR2. 
 
Also, no photo-effects were observed with DMAG-0 but in absence of mGluR2-300C 
(S8B,D) or with mGluR2-300C but in absence of DMAG-0 (S8C), indicating that 
orthogonality is maintained in slices. These results indicate that expression, labeling, and 
optical activation of LimGluR2 are attainable in intact tissue, providing a powerful means to 
probe the role of G-protein signaling in general, and mGluRs in particular, in the native 
preparation. We next turned to in vivo experiments to determine if global LimGluR2 
activation in neurons could alter behavior. 
 
Optical Control of Zebrafish Behavior 
 We evaluated if LimGluR2 activation affected the zebrafish escape response. The 
escape response in zebrafish is a well-characterized behavior in teleost fish that is similar to 
the mammalian startle.[225] The mammalian acoustic startle response is mediated by eighth 
A Photoswitched Tethered Ligand of mGluRs 
 
101 
cranial nerve inputs to circuits in the lower brainstem that process auditory inputs to provide a 
behavioral output thought to involve activity of giant reticulospinal neurons of the caudal 
pontine reticular nucleus. The homologous circuit in teleost fish also receives inputs from the 
eighth cranial nerve, converging onto three pair of giant reticulospinal neurons. Mauthner 
cells are the largest of these reticulospinal neurons involved in startle and seem to play a 
predominant role. Excitatory afferent inputs initiated by startle stimuli converge directly onto 
the Mauthner cells, but also provide feed-forward electrical inputs to glycinergic interneurons 
that inhibit Mauthner firing bilaterally. Experiments with graded stimuli, similar to the 
sound/vibration stimulus protocol described in the present study, have revealed that at lower 
stimulus intensities the feed-forward inhibition dominates and that at higher stimulus intensity 
excitatory inputs overcome the inhibition to induce firing of Mauthner cells and escape 
behavior.[226] 
 We generated transgenic zebrafish (Danio Rerio) in which LimGluR2(L300C) 
expression is driven by repeats of the GAL4 Upstream Activating Sequence (UAS). We 
crossed UAS:LimGluR2 zebrafish to HuC:GAL4;UAS:Kaede fish to generate 
HuC:Gal4;UAS:Kaede;UAS:LimGluR2 zebrafish. The HuC promoter drives pan-neuronal 
expression of Gal4 and consequently of LimGluR2. The UAS:Kaede transgene is used as a 
fluorescent marker for HuC:Gal4 transgene presence. LimGluR2-expressing zebrafish 5 days 
post-fertilization (dpf) that were exposed to DMAG-0 for 45 minutes and recovered for 1 hour 
in the dark were healthy, responsive to touch and indistinguishable from untreated zebrafish 
or from fish treated with DMAG-0 that did not contain the UAS:LimGluR2 transgene. 
 Fish at 5 dpf were individually mounted in a glass-well petri dish with the head 
embedded in agar and subjected to sound/vibration stimuli (900 Hz, 120 ms) ranging from 
low energy to high energy (0.1 mVpp- 10 mVpp, 0.5 mVpp increments), administered by a 
mini-speaker inserted between the dish and a glass slide set on a microscope stage. At lower 
energy levels the sound/vibration stimulus induced forward swims, while higher energy levels 
elicited escape responses with the typical C-bend.[227] LimGluR2 was photo-controlled by 
patterned illumination applied caudal to the eyes. To activate LimGluR2 we illuminated the 
fish with 380 nm light for 400 ms and to deactivate it we applied 510 nm light for 1s. When 
fish were subjected to sub-threshold sound/vibration stimuli that did not induce forward 
swims or escape responses in the dark, activation of LimGluR2 increased the probability of an 
escape response (Fig. 43C,D). This effect was reversed by 510 nm light and could be toggled 
back and forth multiple times by repeatedly turning activating and deactivating LimGluR2 
(Fig. 43C). The behavior of fish expressing LimGluR2 but not labeled with DMAG-0 was not 
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altered by light (Fig. 43D). This result establishes that LimGluR2 can be used to study G 
protein signaling in intact neural circuits in vivo. 
 
	  
Figure 43. Photo-agonism of LimGluR2 increases escape response probability in zebrasfish. (A, B) 
UAS- GFP imaging shows pan-neuronal expression in HUC-GAL4 driver line. (C) Representative fish 
showing reversible modulation of escape response probability. Each data point represents the escape 
probability during a period of ten trials. Violet and Green points represent trials after illumination at 510 
and 380 nm, respectively. (D) Summary of LimGluR2-mediation of escape response. Green bars 
indicate illumination with 510 nm light and purple bars indicate 380 nm light. Stars indicate statistical 
significance (p = 0.007 for comparison of 510 nm vs. 380 nm illumination for MAG-labeled fish with 1-
tailed paired T-Test and p=0.03 for comparison of MAG-labeled and unlabeled fish with 1 tailed 
unpaired T-Test). 
 
Discussion 
 We present the rational design and synthesis of new tethered glutamate photoswitches 
(DMAGs) and their protein attachment sites in the native vertebrate glutamate GPCRs, the 
mGluRs, which endows these receptors with the ability to be gated by light. The approach 
works to produce photo-agonism in mGluR2 and mGluR3 or photo-antagonism of mGluR2 
and mGluR6. The design was based on the X-ray structures of mGluR LBDs and on 
experiments with synthetic ligands that model a portion of the MAG photoswitch (the “tether 
models”), which indicated that, unlike the requirement for L-stereochemistry at the 4’-position 
of MAG in the light gating the iGluR6 channel,[86a] mGluR2 requires D-stereochemistry at the 
4’-position. This led us to synthesize a new pair of MAGs: DMAG-0 and DMAG-1. To 
determine the amino acid side chains within reach of DMAG, we used a simple and novel 
Monte Carlo simulation in which the glutamate end of MAG resided in the binding pocket 
and its maleimide end was free to move in the cis and trans states of the azobenzene, 
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providing a guide for where to place cysteine attachment sites for the MAG. Of seven 
attachment sites that were selected for study, four showed photo-responses with DMAG-1 and 
two showed photo-responses with DMAG-0, considerably accelerating the engineering 
process. The attraction of this approach is that only two Monte Carlo simulations are needed 
(one for cis and one for trans) to predict all of the appropriate attachment sites for a particular 
PTL-receptor pair – something only requiring a few days of computation on a single 
processor. 
 We show that, despite their limited homology (66% identity between mGluR2 and 
mGluR3 and 44% identity between mGluR2 and mGluR6), photo-control can be generalized 
within the mGluR family from mGluR2 to the other Group II member mGluR3 and the Group 
III member mGluR6, with the same D stereoisomer linkage to the glutamate of MAG being 
required. Differences in photo-switching with a particular MAG at homologous sites of these 
three mGluRs provides reveals differences between their LBDs. 
 The photo-agonism with DMAG-0 at position L300C of mGluR2, LimGluR2, which we 
developed first, became the principle chemical-optogenetic tool employed in this study, but 
LimGluR3 has even stronger photo-agonism. In comparison with rhodopsin, which is the 
basis of most of the prior light-gated GPCRs that could be used for heterologous control, and 
which returns to its resting state after a light pulse in a light-independent and slow manner, 
LimGluR2 can be actively toggled both on and off, yielding faster kinetics. Moreover, 
LimGluR2 permits repetitive stimulation at high rates without decline, whereas rhodopsin 
declines substantially in potency even at much lower repetition rates. In addition, rhodopsin 
requires constant illumination to be activated, which increases the chance of tissue damage 
and can act as a confounding variable for behavioral studies, while LimGluR2 is bistable, 
eliminating the need for constant illumination. Most importantly, optical control of native 
GPCRs provides a unique opportunity to examine their biological roles. A powerful 
complement to photo-agonism for such an effort is the photo-antagonism that we demonstrate 
for mGluR2 and mGluR6. 
 Two of the mechanisms by which mGluR2 regulates neuronal activity are shown to be 
accessible to optical control using LimGluR2 in hippocampal neurons. First, LimGluR2 
photo-activation of somato-dendritic GIRK channels suppresses excitability. This suppression 
can be turned on and off repeatedly and reproducibly for many illumination cycles and can be 
maintained for extended periods in the dark until it is rapidly toggled off by illumination at 
the longer wavelength. Alternatively, LimGluR2-block photo-antagonism induced an increase 
in firing frequency indicating that basal activity of mGluR2 plays a role in regulating network 
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activity. Second, optical activation of presynaptic LimGluR2 provides a robust means of 
inhibiting neurotransmitter release. Here the bistability and repeatability of LimGluR2 
signaling make it possible to flexibly control synaptic transmission over a wide range of time 
scales. Moreover, given the importance of group II and III mGluRs in long term plasticity, 
photo-agonism and photo- antagonism should make it possible to determine the precise spatial 
(i.e. pre- vs. post-synaptic; synaptic vs. peri-synaptic) and temporal properties of signaling by 
individual receptors to mediate lasting changes in synaptic strength. When coupled with 
genetic targeting, LimGluRs will allow for the dissection of the functions of mGluRs in 
specific cell-types, including both neurons and glia, and in different brain regions to define 
their roles in circuit function and behavior. Currently, such experiments are not possible 
because in many systems the same mGluRs are expressed in multiple cell types, and may not 
be distinguished pharmacologically. 
 We demonstrate the utility of LimGluR2 for photo-manipulation of vertebrate behavior 
via the reversible modulation of the escape response, a widely-studied behavior that is 
intriguingly similar in architecture and pharmacological regulation[227-228] to the mammalian 
startle response.[229] LimGluR2 was activated in an area that covers the hindbrain circuits that 
control the escape response and the spinal cord. Activation of LimGluR2 decreased the 
threshold of the escape response. Conceivably, mGluR2 activation decreases synaptic 
transmission through pre-synaptic mechanisms that affect inhibitory neurons 
disproportionately when compared to the effect in excitatory neurons. This effect could be 
due to cell-specific differences in receptor expression or coupling of LimGluR2 to 
downstream effectors. Interestingly, group II mGluRs are widely expressed in the brain of 
teleost fish,[230] raising the possibility that the behavioral effects that we observed are 
naturally regulated by these receptors. Future experiments can use a combination of genetic 
targeting with cell-type specific GAL4 enhancer-trap lines, finely targeted illumination and 
both photo-agonism and antagonism to address this possibility. 
 Importantly, LimGluR2 transgenic expression and labeling with DMAG-0 was found to 
be non-toxic and to not affect behavior in the absence of receptor activation. The bistability 
afforded by our optical switch allowed us to toggle receptor activity in intact animals using 
brief pulses of light, where behavior was then assessed over an extended time in the dark, 
avoiding both photo-toxicity and a potential behavioral confound of light. 
 While there are major similarities between GPCRs, which couple to the same pathways, 
such as the Gi/o or Gq pathways, downstream, non-canonical effectors and regulators are 
known to be specific to individual receptors. For instance, within the mGluR family different 
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receptors, which couple to the same G-protein pathway, nevertheless couple to different 
effectors in a cell-dependent manner[16, 161, 224] and this specificity can be complicated by 
diverse forms of hetero-dimerization with other family members that respond to the same 
transmitter, but also with GCPRs from other families which respond to distinct ligands.[214, 231] 
Furthermore, regulation in the form of subcellular localization, post-translational 
modification, and desensitization can be widely different among GPCRs in the same 
family.[193, 232] Thus, LimGluRs provide a novel, high precision way to probe the role of 
specific mGluR signaling in different cell types. Since LimGluR2 maintains close to native 
ligand sensitivity, knock-in mice with a single point mutation to introduce a cysteine anchor 
at position 300 should allow for high resolution, specific orthogonal photo-agonism or photo-
antagonism while maintaining the receptor’s native function. Given the lack of specificity of 
pharmacological agonists within the group II mGluRs, this would provide a new way to 
specifically probe the receptor’s function in anxiety, depression, and schizophrenia, for which 
they are major drug targets.[213] 
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I.2 Toward an Orthogonal Receptor-Ligand Pair based on iGluRs 
 
Nature has endowed animals and plants with highly sophisticated means to both sense 
chemicals in their environment and to use them for transmission of information for their own 
purposes. From pheromones in yeast to neurotransmitters in humans, specialized receptors 
bind these chemicals and relay the information via intracellular processes. There are two 
general mechanisms for the transduction of signals though the plasma membrane: via 
stimulus-gated channels (i.e. the ionotropic pathway) or stimulus-actuated proteins (i.e. the 
metabotropic pathway). In both cases, the cell responds to an extracellular signaling molecule 
and creates a response that can be anything from a change in membrane potential (if for 
example a channel is activated), release of second messengers, changes in transcription, 
changes in growth, apoptosis, etc. It is therefore with no surprise, that this enormous 
complexity has both fascinated and challenged scientist to unravel the different pathways 
associated with biological signaling. Among methods such as knock-out, development of 
selective drugs to silence or activate certain biological circuits or introduction of exogenous 
proteins, building entirely new signaling pathways has become one of the most powerful 
approaches. Such attempts can include both the manipulation of messenger molecules (by 
chemical) as well as their receptors and the associated ways of signaling (by biological 
means) and have therefore become a prime example of chemical biology. 
 The investigation of glutamate receptors (both ionotropic and metabotropic) has for 
long been governed by the search for more selective agonists, antagonists or modulators and 
has therefore been a domain of pharmacology. With the option of photocontrol of mGluRs 
and iGluRs, our group has introduced a completely new way of dissecting the glutamatergic 
circuitry.[97h] Thus, the PCL/PTL concept shifts the research of glutamate receptors into the 
realm of optochemical genetics. Even though our approach has been highly successful,[97d, 97h, 
97i] harnessing the spatiotemporal control of light is not enough to prevent a problem, which 
reminds of the observer effect in physics. By introduction of our photochromic molecules or 
the genetically modified receptors for the covalent attachment of PTLs, the response of 
glutamatergic networks to their native neurotransmitter, i.e. L-glutamate, is inevitably 
changed. Since LiGluR will hetero-tetramerize with its natural congener GluK2, introduction 
of the PTL-conjugate into a neuron will change the synaptic landscape of glutamate receptors. 
Even though soluble, photochromic ligands (PCLs) lack the problem of introducing 
genetically modified receptors, they will for sure create an unwanted response by residual 
activity outside of the area of interest, thus perturbing the natural glutamatergic circuitry. 
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 Faced with this dilemma, we decided to investigate ways of creating an iGluR-based 
orthogonal receptor-ligand system, which does not interfere with the native synaptic 
landscape. This would both include orthogonality in tetramerization (i.e. no tetramer 
formation between native and artificial receptors) as well as in ligand specificity (i.e. no 
activation by L-glutamate (1) and in turn no activation of natural iGluRs by the artificial 
ligand). Such reengineering of native receptors into an orthogonal receptor is admittedly no 
entirely new concept (vide supra). There are, however, only a few rather recent cases that 
have yielded fully orthogonal receptor-ligand systems. The most relevant publications, which 
have inspired this work, will be showcased in the following section. 
 
1) Orthogonal Receptors: State of the Art 
The gene family of G-protein coupled receptors (GPCRS) is by far the biggest target 
for pharmaceutical discovery.[233] They activate a variety of G-protein pathways (Gi, Gs, Gq) 
and regulate many biological responses.[168] It is due to this importance, that GPCRs have 
become the target of reengineering to induce and modulate signal-transduction both in vivo 
and in vitro. Even though there is some confusion about the name of such artificial receptors, 
designer receptors exclusively activated by designer dugs (DREADs)[234] and receptors 
activated solely by synthetic ligands (RASSLs)[235] are (more or less) orthogonal receptor-
ligand pairs developed by the clever combination of chemical and biological approaches. 
Since the development of a β-adrenergic receptor by Strader and coworkers, which 
ceases to respond to its natural ligand and instead can be activated by artificial molecules due 
to a single-point mutation,[236] RASSLs and DREADs have been evolved on the basis of 
human κ-opioid, 5HT4, melanocortin 4, M3 and M4 muscarinic, α2-adrenergic and rat 
muscarinic M3 receptors. Initially, existing drugs, which had been developed by the 
pharmaceutical industry for different purposes, were used to activate these artificial receptors. 
Accordingly, these systems suffered from immense background due to the nonselective 
binding of their chemical actuators unless their “natural targets” had been knocked out.[150a] 
Armbruster and coworkers found an elegant solution to this problem by means of combining a 
pharmacologically inert chemical, clozapine-N-oxide (CNO, 202), with directed evolution of 
the parent receptor to only allow binding of 202 instead of its endogenous ligand (Scheme 
28).[234] Due to the high similarity of all GPCRs as members of the seven transmembrane 
receptors (7TMRs), this general concept should be applicable to almost all members of the 
family and existing RASSLs/DREADs can indeed be coupled to different G-proteins by 
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substitution of intracellular domains, making this work a milestone in the development of 
orthogonal G-protein coupled receptors.[237] 
 
	  
Scheme 28. General concept of modern RASSLs/DREADs based on the human muscarinic 
acetylcholine receptor M3 (hM3), its native ligand acetylcholine (ACH, 203) and the pharmacologically 
inert ligand CNO (202) acting on a DREAD. 
 
 A different approach toward the orthogonal control of mammalian signal transduction 
pathways is the introduction of xenoreceptors or channels, which can interface to or influence 
the endogenous signaling cascades. An example for a receptor interfacing to the G-protein 
pathway is the drosophila allatostatin receptor (AR). Allatostatins are neuropeptide hormones, 
which inhibit the generation of the juvenile hormone and reduce food intake in drosophila and 
other insects or crustaceans.[238] In mammals, there is no natural target for the allatostatins and 
hence their receptor, a GPCR, has been used to inactivate neurons in rats, ferrets and 
monkeys. Its mode of action involves the activation of G-protein coupled inward rectifying 
potassium channels (GIRKs) by the βγ-subunit of AR’s associated G-protein. Due to this 
hyperpolarization, the allatostatin/AR/GIRK system effectively reduces neuronal excitability 
and can be used to dissect neuronal networks.[239] 
 A more direct way of controlling the excitability of cells using ion channels was yet 
again discovered in C. elegans. Glutamate-gated chloride channels (GluCl) from these 
nematodes were found to be sensitive to avermectins, anthelmintic and insecticidal macrolides 
isolated from fermentation broths of the actinomycete S. avermitiis (Fig. 44).[240] Owing to the 
high affinity of these GluCls to the semisynthetic macrolide ivermectin (a 9:1 mixture of 204 
and 205), they can be used to effectively silence neurons due to their Cl–-conductance induced 
by low nanomolar concentrations (5 nM) of 204 and 205.[241]  
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Figure 44. Ivermectin macrolides H2B1a (204) and H2B1b (205). 
 
Even though this system seems to be fully orthogonal, ivermectin is known to have different 
effects on GABA, P2X2 and neuronal AChRs.[242] Therefore, side-effects can not be excluded 
in long-time experiments, even though the most probable, i.e. GABA-potentiation, was not 
found by Lester and coworkers (at 5 nM ivermectin).[241] 
 Wulff et al. have reported a different approach for orthogonal control of neuronal 
excitability by ion channels, which uses engineered γ-amino butyric acid receptors 
(GABAARs).[243] In the latter, the γ2-subunit confers sensitivity to the artificial drug zolpidem 
(206), which is a competitive agonist to GABA. If however, phenylalanine F77 of γ2 is 
mutated to isoleucine (F77I), the resulting GABAARs which incorporate γ2-F77I become 
unresponsive to 206. In a tour de force of biological methods, the authors created transgenic 
mice, in which the natural, zolpidem-sensitive subunit had been replaced by an insensitive 
version. They then used Cre-recombinase-catalyzed site-specific recombination to restore 
sensitivity to zolpidem (206) in purkinje cells and thus silence them (Scheme 29). 
 
	  
Scheme 29. Schematic of engineered GABAA receptors for the modulation of specific neuronal cell 
types by the zolpidem-sensitive subunit γ2.  
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Most remarkably, the authors demonstrate that hyperpolarization of named neurons results in 
immediate motor-deficits of the animals expressing the γ2-F77 subunit.[243] 
Surprisingly, it was only very recently that an orthogonal neuron-activating receptor-
ligand system was reported. In a seminal work, Sternson and coworkers designed ligand-
binding domains (LBDs) of nicotinic acetylcholine receptors (nAChRs) that are activated by 
an artificial, otherwise pharmacologically inactive quinuclidine-derived ligand 89S (207). 
Highlighting the high variability of their approach, the authors showed that the 89S-sensitive 
LBD could be fused to ion pore domains (IPD) of GABAA, glycine and 5HT3 receptors, 
thereby creating both depolarizing cation channels (5HT3) and hyperpolarizing anion channels 
(GABAA, glycine receptor). This was possible, because the α7-LBD behaves like an isolated 
component, which can be fused to IPDs of other pentameric ligand-gated channels to change 
characteristics such as ion selectivity or conductance (Scheme 30).[244] 
 
	  
Scheme 30. a) Mode of action of an endogenous, acetylcholine-gated nAChR. b) Schematic design of 
orthogonal de- and hyperpolarizing ion channels based on a common ligand-binding domain (LBD*), 
which binds the quinuclidine-derived molecule 89S (207), and two different ion pore domains (IPD and 
IPD*).  
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This work highlights the power of combining extensive biological screening (for suitable 
mutations) and prudent chemical synthesis (by understanding the molecular mechanism 
underlying the binding of quinuclidine-agonists). 
 In a way, Sternson’s methodology is related to a technique introduced by Shokat, 
commonly known as “bump-hole approach”. It refers to altering an enzyme’s ligand/cofactor 
specificity by chemically introducing steric bulk on the ligand (“bump”), which can only be 
accommodated by a modified protein. This is achieved by reducing the size of residues 
flanking the binding-site by a point mutation (“hole”). Shokat and coworkers used this 
technique to map the target specificity of tyrosine kinases, which otherwise would have been 
difficult to do, owing to redundancy of phosphorylating enzymes. They created a mutant 
kinase (I338G), which had a low affinity for adenosine triphosphate (ATP, 139), but can bind 
the non-natural analogue 208 (Scheme 31).[245] 
 
 
Scheme 31. Schematic of the “bump-hole approach” of rous sarcoma tyrosine kinase (v-Src). a) A 
wild-type kinase and natural ATP (139). b) Mutant kinase with a “hole” and ATP analogue ATP* (208) 
with a sterically demanding pyrrolidine ring, i.e. the “bump”. 
 
The authors show, that this approach not only can be used to create kinases sensitive to ATP-
analogues, but also can be engineered to be sensitive toward inhibitors, that do not block the 
wild-type enzyme. Using this methodology, kinases inducing pre-mitotic cell cycle arrest 
could be identified in yeast.[246] 
 Inspired by this work, we decided to first base our design of an orthogonal, ionotropic 
receptor (iXR) on a rational selection of both parent iGluRs and mutations. Our progress 
toward such an iXR is outlined in the next section.  
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2) Receptor Design 
Judging from the available literature on the design of orthogonal receptor-ligand pairs, we 
were now faced with a set of three separate problems: 1. Find a drug that is pharmacologically 
inactive but activates a mutant iGluR, 2. Design an iGluR mutant, which does not respond to 
glutamate (or which has a significantly decrease affinity for its natural ligand), but does bind 
the designer ligand, and 3. Prevent cross-tetramerization of mutant and wild-type receptors. 
 Thankfully, the latter problem can be addressed by exploiting the underling 
mechanisms of glutamate-receptor tetramerization. In general, it is accepted that iGluRs form 
so called “dimer of dimers”, i.e. GluR-monomers first form dimers of their own kind and then 
dimerize with another dimer of the same or another GluR-type to form the functional receptor 
(Scheme 32a).[247] Stern-Bach and coworkers were able to show that such dimerization, or 
tetramerization events respectively, are initiated by interaction of the N-terminal domains 
(NTDs) and then further strengthened by interactions of the ligand-binding (LBDs) and 
transmembrane domains (TMDs). By creating chimeras with different NTDs they were able 
to explore the different requirements for functional tetramerization and (as a side-effect) 
create iGluRs that exclusively assemble with their own kind (Scheme 32b).[248] 
 
	  
Scheme 32. a) Tetramerization of iGluRs according to the dimer of dimer model. b) Chimeras 
resulting from fusing GluA3 NTDs to GluK2 LBD and TMD, which only co-assemble with themselves. 
 
Using this technique, we were sure to suppress hetero-tetramerization of our envisioned 
constructs and we gratefully received a chimeric construct of a GluA3 NTD fused to the 
GluK2 LBD and TMD from Y. Stern-Bach to be used as a template. For the initial screen of 
suitable mutations within the ligand-binding domain however, we decided to use unaltered 
GluK2 constructs and to introduce the found mutations into the NTD3-R6 receptor later on.  
Toward an Orthogonal Receptor-Ligand Pair based on iGluRs 
113 
3) Rational Mutation Approach 
The ligand-binding domain of iGluRs forms highly specialized hydrogen bonds involving 
both amino acid residues and hydrate water molecules to stabilize L-glutamate in its preferred 
“bent” conformation. Said interactions are crucial for the efficient binding, LBD-closure, 
inter-domain stabilization and thus receptor activation.[5] It is therefore not surprising, that 
only a handful of mutations involving the principal binding residues are known, which do not 
completely abolish iGluR-response or expression.[78] It has been suggested that this is part of 
a quality check mechanism for functional iGluR subunits.[79-80] E738D for example seems to 
be tolerated in GluK2, the EC50 for glutamate however is significantly shifted from 191 µM to 
52 mM.[79] This can in part be attributed to a massive disruption of the H-bonding network 
that both binds L-glutamate and stabilizes the S1-S2 domains in a closed conformation 
(Fig. 45). 
 
	  
Figure 45. Hydrogen-bonds (omitting the water molecules) in the GluK2 LBD (pdb code 1S7Y) 
generated by PoseView.[249] a) Wild-type LBD. b) E738D mutation. 
 
Despite these massive changes in the LBD, Fleck and coworkers have shown that GluK2 
E738D is still a functional receptor, which does traffic normally to the cell’s surface.[79] 
Together with the marked loss of affinity for glutamate, we selected this mutation as a perfect 
candidate for a “bump-hole” approach, since already two of our three requirements (vide 
supra) toward an orthogonal ionotropic receptor were met by the E738D variant of GluK2. 
We felt, that the third criterion, i.e. a ligand capable of activating the mutant channel with 
enhanced efficacy could be developed once enough structure-activity relationship (SAR) data 
had been collected. 
 Judging from the literature, we concluded that the iGluR LBD had indeed been 
evolved to bind amino-acid like molecules and therefore looked out for further, non-invasive 
mutations, which would not involve the principle binding residues (other than E738D) and 
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therefore most likely would result in fully functional and trafficked receptors. A highly 
conserved, nonpolar residue flanking the ligand-binding cavity in kainate-, NMDA- and 
AMPA-type glutamate receptors caught our eye (Fig. 46). 
 
	  
Figure 46. X-Ray structures of L-glutamate in the LBDs of a) GluA2 (pdb code 1FTJ), b) GluK2 (pdb 
code 1S7Y) and GluN2a (pdb code 2A5S) with the principal binding residues shown as sticks and the 
putative site of mutation highlighted in red. 
 
In all glutamate-binding domains of iGluRs, a leucine or valine residue occupies this 
functional position (alignment not shown; positions L671, V685 and V685 in GluA2, GluK2 
and GluN2a respectively). Functional analysis of V685A, V685L and V685F GluN2A 
mutants by Bräuner-Osborne and coworkers revealed that not only are named mutations 
tolerated, they also distinctly shift the EC50 of glutamate – for both the sterically more 
(V685L, V685F) and less demanding (V685A) variants.[250] The related mutation of leucine 
671 to threonine (L671T) was reported by Armstrong, Mayer and Gouaux in the AMPA 
receptor GluA2. Most notably, not only did this modification shift the efficacy of glutamate 
by a factor of almost 9 (from 21 µM to 177 µM), it also inverted the relative potencies of 
kainate and AMPA, making kainic acid (17) a partial agonist with 24% efficacy compared to 
glutamate (up from 2%) and an EC50 of 65 µM (down from 174 µM).[26] Encouraged by these 
findings, we planned to use mutations of residues L671 and V685 respectively to create a 
“hole” in the LBD which could then be occupied by for example sterically demanding 4-
substituted glutamic acid or kainic acid derivatives bearing additional substituents on the 
isopropylene moiety. 
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a) GluK2 E738D L439C (“FliGluR”) 
The first mutation we assessed as a candidate for an orthogonal receptor based on GluK2 was 
E738D, which had been reported by Fleck and coworkers.[79] With this mutant we were sure 
to tackle the problem of reduced affinity for L-glutamate while still having reasonable surface 
expression. Since we were interested on how E738D influences the receptor properties, we 
decided to introduce named modification in one of our LiGluR constructs bearing a C-
terminal GFP-tag and a WPRE element for enhanced expression. [86a, 251] The exchange of 
glutamate 738 for an aspartate was realized using single point mutagenesis and we termed the 
new construct (i.e. GluK2•GFP E738D L439C + WPRE) “FliGluR” acknowledging the work 
of Fleck et al. First we expressed the corresponding plasmid in HEK293T cells and 
determined the EC50 of L-glutamate with the desensitization of the receptors blocked by 
concanavaline A (ConA).[252] In accordance with the literature we observed a left-shifted half-
maximal concentration of 11 mM, as ConA is known to render agonists more potent 
(Fig. 47).[252] Even though their affinity toward the receptor had been shifted to the high 
micromolar range (data not shown), we could estimate the EC50 values of the known GluK2 
agonists quisqualate (14) and kainic acid (17) to still be lower than the one of  
L-glutamate (1).[253] 
 
	  
Figure 47. a) Dose-response curve of L-glutamate (1) in ConA-treated HEK293T cells expressing 
FliGluR (n = 9; mean ± SEM) relative to saturating glutamate (50 mM). b) Two full agonists of FliGluR 
(ConA-treated): quisqualic acid (14) and kainic (17). 
 
 Amazed by these results, we asked whether FliGluR could already be used as a 
orthogonal photoswitchable receptor, since it did not show any activation by the maximal L-
glutamate concentrations observed in synapses of >1 mM.[254] Hence, we expressed FliGluR in 
HEK293T cells and labeled the construct with MAG-0 (209) or MAG-1 (24) according to 
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established procedures.[86a] The results of our photoswitching experiments are summarized in 
Scheme 33. 
 
 
Scheme 33. a) Photoswitching of FliGluR with MAG-1 (24) with partial co-administration of 50 mM L-
glutamate. b) Structure and schematic light-induced isomerization of MAG-0 (209). c) Photoswitching 
of LiGluR with MAG-0 and partial co-administration of 300 µM L-glutamate. d) Photoswitching of 
FliGluR with partial co-administration of 50 mM L-glutamate. 
 
We were pleased to find, that the FliGluR-MAG-1 conjugate did indeed show photocurrents 
upon switching from 500 nm to 380 nm of light (Scheme 33a), albeit only with low efficiency 
(10.5 ± 0.5% photocurrent; n = 4). We therefore decided to compare the performance of 
LiGluR to its mutant with the strongest PTL MAG-0 (209; Scheme 33b,c) attached.[97g] 
 In our hands, the LiGluR-MAG-0 system performed well with 29 ± 3% photo-
switching (n = 5). Most interestingly, we observed an excess-current of 9.4 ± 0.9% (n = 4) 
when changing from 500 nm to 380 nm of light while co-administering 300 µM L-glutamate 
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(Scheme 33c). For FliGluR however, there was hardly any photocurrent (1.8 ± 0.2%, n = 3) 
and upon co-administration of 50 mM glutamate, MAG-0 (209) acted as a photoswitchable 
antagonist (18.5 ± 0.4% reduction of current, n = 3). Moreover, FliGluR showed a 
significantly slower response both to glutamate and to switching with light (Scheme 33d). 
This seems to indicate, that by mutation of E738 to aspartate, both MAG-0 (209) and  
MAG-1 (24) had been rendered weaker agonists than L-glutamate (1). 
 Since it had been shown that labeling of LiGluR proceeds with higher efficiency when 
pre-irradiating the MAG-containing solution with 380 nm of light,[255] we tried to attach 
MAG-0 to FliGluR using the highest concentration soluble in water and irradiated it for 30 s. 
Aimingt an affinity-based labeling process, we were disappointed to find that there was no 
increase in photocurrent (data not shown). Yet, when perfusing with 50 mM L-glutamate and 
switching from 500 nm to 380 nm of light, we observed an excess-current like in LiGluR for 
some cells, thus indicating indeed a labeling-dependent effect. Moreover, we realized that 
there seemed to be a cooperative effect of L-glutamate (1) and MAG-0 (209) for some 
concentrations, as the change in current did vary relative to the concentration of 1 (see wash 
out in Scheme 33d). Eventually however, our results were inconclusive since we could not 
further improve the rate of labeling due to the limited solubility of the PTL in water. We 
therefore decided to abandon the option of controlling our GluK2 E738D construct with light 
and rather focus on exploring its pharmacological profile. 
 Accordingly, we screened for lead structures for a selective activation of FliGluR in 
order to create an orthogonal receptor-ligand system capable of sustained stimulation by 
administration of a drug. To this end, we assembled a small library of commercially available 
compounds. Since iGluRs have evolved from simpler congeners binding not only to L-
glutamate (1), but a variety of different amino acids,[68] we first selected molecules 
resembling amino acids and derivatives thereof for our screening (Fig. 48a). In addition, we 
decided to synthesize a few molecules, which could fill the space opened up by mutation of 
glutamate 738 to aspartate (Fig. 48b). Accordingly we selected 2-(aminomethyl)pentanedioic 
acid (228) as a carbon-, and hydrazine-derivatives 229 and 230 as nitrogen-extended versions 
of L-glutamate (1) and kainic acid (17) respectively. 
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Figure 48. a) Commercially available ligands to be screened for activity in FliGluR. b) Envisioned 
ligands to be synthesized for the bump-hole approach with GluK2 E738D. 
 
The synthesis of racemic β-amino acid 228 was carried out in a simple four-step 
sequence. Dimerization of tert.-butyl acrylate (231) by Baylis-Hillman reaction furnished 2-
methylene pentanedioate 232 according to known protocols (Scheme 34).[256] For the 
succeeding hetero Michael addition of dibenzylamine we screened a variety of conditions 
including catalytic amounts of CeCl3•NaI on silica, otherwise known to carry out the desired 
transformation in good yields.[257] After some experimentation however, we found that 
deprotonation with n-butyllithium[258] and concomitant addition of the resulting lithium amide 
to Michael-System 232 yielded the protected β-amino acid 233 in good yields. For a 
resolution of the enantiomers, we also tried an addition of (R)-N-benzyl-α-
methylbenzylamine (234) as a chiral auxiliary group after deprotonation to the lithium amide. 
For a first evaluation of the properties of 228 however, we decided to use racemic material 
and therefore did not separate the diastereomers. As the final step of the synthesis, 
deprotection by hydrogenolysis and acid-mediated cleavage of the tert.-butyl esters gave 
racemic β-amino acid 228 as a colorless, hygroscopic solid in good yields over two 
steps (Scheme 34). 
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Scheme 34. a) Synthesis of the protected β-amino acids 223 and 235. b) Deprotection of 233. 
 
 The synthesis of the hydrazine derivatives 229 and 230 proved to be considerably 
more challenging. Since especially for the kainic acid derivative 230 a modified total 
synthesis was hardly practical, we were pleased to find an approach reported by Collet and 
coworkers using the electron-poor oxaziridines 241 and 242 as electrophilic amination 
reagents (Scheme 35a).[259] Unfortunately, we could not obtained the Boc-protected 
hydrazines in reproducible yields using the oxaziridines as an electrophilic nitrogen source. A 
racemic approach toward 229 from dimethyl glutarate, which was deprotonated using 
KHMDS and addition of the resulting potassium enolate to di-tert-butyl azodicarboxylate 
(DTAD), finally yielded the protected α-hydrazino acid (±)-244 in 32% (Scheme 35b). 
 
	  
Scheme 35. a) Attempted electrophilic amination of glutamic and kainic acid derivatives 237 and 239. 
b) Attempted synthesis of racemic hydrazine derivative (±)-229. 
 
Deprotection of (±)-244 using lithium hydroxide followed by TFA or HCl did not yield the 
expected N-aminated amino acid (±)-229. We screened other methods of deprotection, but 
could not identify the problem. Although we found spectroscopic hints (HRSM, NMR) that 
we had indeed synthesized hydrazino acid (±)-229, we could not obtain it in pure form. 
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Despite this, we were now ready to screen the small set of ligands shown in Figure 48 
for. To this end, we expressed the FliGluR construct in HEK293T cells and analyzed its 
response to the various compounds (1 mM) relative to saturating L-glutamate (50 mM) by 
whole cell patch-clamp electrophysiology. Disappointingly, we did not find any significant 
activation of the receptor by any of the molecules screened (data not shown). Therefore, we 
decided to further analyze the properties of this mutated GluK2 LBD. 
 In collaboration with Gisbert Schneider (ETH Zürich) we studied the behavior of both 
the wild type (wt) and mutated ligand-binding domains using molecular dynamics (MD). To 
this end, we correlated the stability of both LBDs to their pocket size (Fig. 49). 
 
	  
Figure 49. a) Molecular dynamics simulation of the GluK2 LB (pdb code 1S7Y). b) Molecular 
dynamics simulation of the FliGluR LBD (derived from pdb code 1S7Y). 
 
We found that the mutated LBD in fact has a high probability of residing in open, i.e. high-
volume conformations, whereas the wild type seems to stay in its closed state for a longer 
period of time. Taking into account previous reports by Kurnikova et al.,[260] which seem to 
indicate a disruption of ligand recognition and orientation by E738D, we concluded that in 
order to come forth with an orthogonal receptor-ligand pair for the FliGluR construct, we 
might either have to resort to in silico docking methods, or a high-throughput screen of bigger 
libraries (vide infra). Accordingly we decided to shift the focus away from E738D in favor of 
mutations of the nonpolar residues L671 and V685 in GluA2 and GluK2 respectively.  
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b) “Bump-Hole” Approach 
Since we did not obtain any SAR information from the experiments with FliGluR and our 
small ligand set, we next evaluated the potential of GluA2 L671 and GluK2 V685 mutants to 
be used as potential iGluR-based orthogonal receptors. To directly address the most drastic 
alterations of the wild-type receptors, i.e. leucine or valine to glycine or serine, resulting in 
the biggest “holes”, we introduced named changes in GluA2 and GluK2 using single point 
mutagenesis.[119] Plasmids coding for GluA2 L671G, L671S and GluK2 V685G respectively 
were expressed in HEK293T cells and their response to L-glutamate (1) was determined by 
whole cell patch-clamp electrophysiology. While for the GluK2 mutants we did not observe 
any currents – probably due to incorrect folding of the protein – the affinity toward 1 had 
indeed been decreased substantially in the modified AMPA-type receptors (Fig. 50). 
 
	  
Figure 50. Dose-response curves of L-glutamate (1) in GluA2 L671S (red), GluA2 L671G (green; n = 
5; data ± SEM) and “wt” GluA2 L504Y receptors (blue; n = 8; data ± SEM) relative to saturating 
glutamate (see graphs). In all three cases, the desensitization was blocked by the L504Y mutation. 
 
In comparison to their “natural” congener (EC50 = 35 µM), GluA2 L671S and L671G mutants 
had EC50 values of 255 µM and 914 µM respectively. To address whether mutations of leucine 
671 to either glycine or serine had also influenced the ligand-specificity in comparison to the 
parent AMPA receptor, we determined the efficacy of kainic acid (17) in GluA2 L671G. As 
expected, we found a substantially increased activity of 17 in case of the L671G mutant 
(61 ± 5% efficacy). For this alterations of the GluA2 LBD, our data even exceeds the trend 
reported by Gouaux et al. for the related L671T mutation,[26] thus indicating a strong shift 
toward preference of kainic acid (Fig. 51). 
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Figure 51. Relative potency of kainic acid (2 mM) in wild-type GluA2 (solid) and GluA2 L671G 
(dashed; n = 5, data ± SEM) to L-glutamate (1 mM and 4 mM). The desensitization of receptors was 
blocked by the L504Y mutation. 
 
 With this data in hand, we concluded that mutation of the nonpolar residues L671 had 
indeed created strong candidates for a bump-hole approach toward an orthogonal receptor-
ligand pair. Moreover, we were interested whether the receptors might now accept different 
substrates as their wild-type counterparts. As our group had previously tried to design a 
photoswitchable tethered receptor-ligand system based on GluA2, we screened the GluA2 
L671G mutation for activation by MAG-type molecules. While lacking proper tether-models, 
we directly used MAG-0 (209) as a potential agonist. We were pleased to find, that unlike for 
the wild-type, the exchange of a leucine for glycine had indeed rendered 209 an agonist of 
AMPA-type receptors bearing the L671G mutation (Fig. 52). 
 
	  
Figure 52. Exemplary voltage-clamp recording of GluA2 L504Y L671G (holding potential -70 mV).  
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Much to our delight, MAG-0 (209) showed 74 ± 5% (n = 3) depolarization at 100 µM. At the 
same concentration, L-glutamate (1) only showed 14 ± 3% (n = 5) current. Not only is this the 
first time we have found a molecule, which is more efficacious than the native ligand L-
glutamate (1), but at the same time, the L671G mutation offered the opportunity to design a 
PTL-receptor system based on GluA2, since it had apparently created an exit tunnel for 4-L-
alkylated glutamate analogues like 209 (Fig. 53). 
 
	  
Figure 53. Comparison of the GluK2 and GluA2 LBDs. a) GluK2 wt (pdb code 1S7Y). b) GluA2 wt 
(pdb code 1FTJ). c) GluA2 L671G (based on pdb code 1FTJ). The presence and position of the exit 
tunnel is indicated by a red arrow. 
 
To test our hypothesis that GluA2 L671G might be used in conjugation with MAG-0, we 
introduced the homologous cysteine mutation as used in LiGluR (L439C) in our receptor. 
Changing leucine 422 into a cysteine however, did not yield a viable construct, since we 
could not observe any glutamate-induced currents in HEK293T cells transfected with GluA2 
L422C L504Y L671G. Possibly, the third mutation prevents proper folding of the iGluR 
monomers. In future experiments, we will therefore independently address different mutations 
for the covalent attachment of a photoswitch using the maleimide-Michael approach and 
combine them with our kainate-type AMPA receptor GluA2 L671G. 
 With respect to our goal of creating an orthogonal receptor-ligand pair using named 
receptor, we will synthesize molecules derived from LTM-0 (245), which can fill the hole 
generated by the L671G mutation more efficiently than MAG-0 (209), or its tether-model 
245. Initial docking experiments suggest that derivatives like 246, 247 bearing an additional 
alkyl substituent in the 4- or in the 6-position should be very promising (Scheme 36).  
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Scheme 36. Envisioned orthogonal ligands derived from tether-model LTM-0 (245). 
 
Since the two substitutions of L671 presented above had resulted in a substantially 
altered ligand-specificity and decreased affinity toward the native neurotransmitter L-
glutamate (1), it was time to screen for more possible bioorthogonal ligands. Judging from our 
experience with small libraries (vide supra) and comparing our advances to the ones of 
Armbruster, Conklin and Sternson,[150a, 234, 244] we however concluded, that for the 
development of an iXR we would need efficient means for both the screening of compounds 
and mutations. This, we felt, could not be realized by manual patch-clamp electrophysiology. 
Accordingly, we decided to develop means to help us identify suitable receptor-ligand 
combinations. Ideally, such methods would be amenable to high-throughput, i.e. automated 
processing and might allow for both unguided mutation of receptors by random mutagenesis 
and improvement of rationally designed mutants by e.g. directed evolution at the same time. 
The following chapter summarizes our progress toward such a screening system. 
 
4) Yeast Assay for Glutamate Receptor Activity (YAGA) 
Challenged with the problem of rationally selecting potential ligands for our mutated iGluRs, 
we felt that in the absence of sufficient structure-activity relationship data, high-throughput 
screening might be better suited to come forth with lead structures, which could then be used 
to optimize receptor-ligand interactions. Unfortunately, we did not find any literature 
precedence describing such a method in ionotropic glutamate receptors. Even though we 
experimented with fluorescence-based assays similar to those used by Sternson and 
coworkers,[244] this did not yield reliable data. 
We therefore felt that a yeast-based system similar to the one used to improve 
RASSLS/DREADS,[237] would be ideal for our purposes. Moreover, directed evolution might 
be used to improve any found iXR-ligand combinations. Unfortunately, unlike for the human 
muscarinic M3 receptor, there is no biochemical method of coupling iGluR-activity to yeast 
growth via the pheromonic signaling pathway.[261] We therefore devised a strategy to relay the 
information of LBD-closure to a signal enhancing growth in S. cerevisiae. 
In collaboration with Harald Janovjak (IST Austria, Wien) we designed a yeast screen, 
which employs a method developed by Reuveny et al. for the investigation of Gβγ-dependent 
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activation of inward rectifying potassium channels (IRKs).[262] Using a yeast strain 
(SGY1528) lacking both low and high affinity potassium transporters (Δtrk1, Δtrk2),[263] they 
screened for mutant IRKs not requiring interaction with a Gβγ unit. Such channels allow K+ 
ions to pass the cell membrane and thus alleviate the potassium-starved yeasts’ growth deficit. 
We envisioned using the same approach, but intended to replace the inward rectifying K+ 
channels by ionotropic glutamate receptors to supply the K+-deficient yeast with potassium 
ions. Unlike IRKs however, modern iGluRs hardly discriminate between monovalent ions, 
since they lack the typical TXVGYG filter sequence found in K+ channels.[264] The selectivity 
of sodium over potassium in GluA2 for example is PNa/PK = 0.67,[68] where P is the 
permeability for the respective ions. In GluR0 and other bacterial glutamate receptors, an 
enhanced discrimination between sodium and potassium ions is observed (PNa/PK = 0.01 for 
GluR0).[68] Together with similarities to K+ channels in the pore topology,[265] this supports 
the idea that there might be an evolutionary link between iGluRs and potassium channels. 
Recently, an ionotropic glutamate receptor bearing both the TXVGYG-motif and the domain 
architecture of modern iGluRs, thus resembling a “missing link” between the two channels, 
has been described.[266] 
 Our yeast assay for glutamate receptor activity (YAGA) can be divided into seven 
individual steps (Scheme 37) starting from cDNA for the expression of selected iGluRs in 
yeasts: (1.) A library of mutant iGluRs is generated either by rational design (vide supra) or 
using error-prone PCR.[267]  
 
 
Scheme 37. Conceptual scheme showing the rescue of K+-starved yeast by functional expression of 
ionotropic glutamate receptors and the application to the directed evolution of an iXR.  
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(2.) Yeasts lacking potassium transporters (SGY1528)[263] are transfected with the DNA 
library. (3.) The auxotrophic yeasts are grown on K+-poor media to select for those 
functionally expressing the mutant iGluRs. The medium can be supplemented with selected 
drugs to be screened as putative agonists of the iXRs. (4.) Colonies, which are rescued by the 
action of functional receptors are picked and screened for proper growth properties in liquid 
culture. (5.) The cDNA of the best candidates is isolated and can be subjected to (6.) another 
round of directed evolution or (7.) may be functionally characterized using electrophysiology. 
 To set up a library of iGluRs for expression in yeasts, we selected GluA2 and GluK2 
as the parent receptors and cloned them into a vector under the control of a pMet promoter, so 
we could later suppress the protein expression by supplementing L-methionine to the growth 
medium.[268] We decided to use the modern ionotropic glutamate receptors GluA2 and GluK2 
(r. norvegicus) as a template and chose the respective R-variants at their Q/R editing site, thus 
preventing the potentially toxic influx of calcium ions into the yeast by rendering the pore 
impermeable to Ca2+ ions.[269] While by using GluR0 we would have had the benefit of K+-
selectivity too,[68] we reasoned that the pharmacological characterization of GluA2 and GluK2 
is far more developed and should help us to select potential agonists for the iXRs. In order to 
ensure prolonged activation of the receptors by the action of either glutamate or any other 
drug supplemented to the yeast, we blocked the desensitization of the receptors with the 
L504Y mutation in GluA2 and with K531G and D776K respectively in GluK2.[78, 270] Thus, 
we would not have to rely on the metabolic stability of cyclothiazide or concanavaline A.[252] 
Additionally, we designed plasmids bearing both vertebrate and yeast Kozak consensus 
sequences in order to study the influence of different expression levels of the iGluRs.[271] The 
necessary alterations of the ionotropic glutamate receptors (Q/R site, non-desensitizing 
mutations, Kozak sequence) were carried out using standard techniques,[119] to yield a set of 
cDNAs, which is summarized in Table 3. 
 
Table 3. Summary of the generated pMet cDNA library coding for iGluRs. 
Name Parent iGluR Q/R Kozak Non-desensitizing mutation 
A1.1 GluA2 R TAGACCATG L504Y 
A2.1 GluA2 R AAAAAAATG L504Y 
K1.1 GluK2 R TAGACCATG K531G 
K2.1 GluK2 R AAAAAAATG K531G 
K1.2 GluK2 R TAGACCATG D776K 
K2.2 GluK2 R AAAAAAATG D776K 
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 With the first collection of plasmids for the expression of iGluRs in yeast in hand, we 
turned to our collaboration partners in the group of Katja Strässer (LMU Munich) to evaluate 
the ability of the different constructs to rescue the SGY1528 strain (gracious gift from Eitan 
Reuveny) on low K+ media. The yeasts were transfected with the respective constructs and 
grown with varying amounts of L-glutamate (1) and K+ (Fig. 54). 
 
	  
Figure 54. Dotspot assay of yeasts (SGY1528) expressing iGluRs. The colonies were grown under 
different conditions as indicated (IRK = inward rectifying potassium channel not requiring activation by 
a Gβγ  dimer).[262] 
 
We found that the strain used (SGY1528) did indeed show the expected behavior of inhibited 
growth on low K+ media and could either be rescued by supplementing KCl (100 mM), or 
expression of the mutant IRK developed by Reuveny and coworkers.[262] Much to our delight, 
one of our constructs, K2.2 (i.e. GluK2R D776K), did also show the same ability, however 
with slightly diminished potency. As can be seen in Figure 54, the yeasts were able to grow in 
the presence of 1 mM, 5 mM and 10 mM glutamate (concentrations at or well beyond the 
saturation-limit), while without the supplement there was no growth (not shown).[119] Most 
importantly, this effect was mitigated in the presence of 1 mM L-methionine, indicating a 
correlation of protein expression to the enhanced growth rate. The persistent growth of IRK-
expressing yeast can be attributed to residual protein concentrations, as reported in the 
original paper by Reuveny et al.[262] Unfortunately the effect of K2.2-expression was not as 
profound as the one for the potassium channel, this however may be attributed to their relative 
sizes. Glutamate receptor monomers with their ca. 900 amino acids are considerably more 
complex than IRKs, which generally have a size of about 550 amino acids. 
 Despite this difference, we decided to analyze the growth properties of yeasts 
expressing the kainate receptor K2.2 in liquid media. By doing this, we sought to investigate 
the effect of other kainate-type agonists (e.g. kainic acid) or antagonists (e.g. CNQX) more 
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easily than by using plate-cultured yeasts. Accordingly, we grew K2.2-transfected yeasts 
(SGY1528) in liquid culture and measured their time-dependent growth in 96-well plates. A 
summary of these statistics is shown in Figure 55. 
 
 
Figure 55. Liquid culture of SGY1528 yeasts expressing the different iGluR constructs (additives and 
concentrations as indicated). 
 
As expected, all yeasts grow well at 100 mM KCl (Fig. 55a) and only the IRK-construct 
rescues the growth-deficient strain (SGY1528) at a KCl concentration of 2 mM (Fig. 55b). 
While 1 mM of L-glutamate (1) is commonly considered to be saturating at modern iGluRs, 
we reasoned that due to the yeast cell wall, there might be a concentration gradient of 
glutamate and we would have to increase its concentration. Accordingly, we used 10 mM L-
glutamate (1) and were please to find, that the also kainate receptor K2.2 promotes an 
enhanced growth as compared to the other constructs (Fig. 55c). Moreover, we verified that 
this is indeed a pharmacologically significant effect, since AMPA (albeit at a lower 
concentration) is not able to activate the kainate-type receptor construct (Fig. 55d). Given the 
relative permeability of iGluRs for potassium over sodium (approx. 3:2), it is reasonable to 
expect a diminished growth when compared to the inward-rectifying potassium channel 
(IRK). We will therefore explore options to enhance the K+-selectivity of our iGluR 
constructs by e.g. expressing GluR0 or the artificial, potassium-selective glutamate receptor 
HyLighter.[68, 97d] Nonetheless, the growth obtained from K2.2 in the presence of 10 mM L-
glutamate (1) is already enough to be used as a screening platform for mutations toward an 
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orthogonal receptor-ligand pair and we will report our progress toward such an iXR in due 
course. 
 
5. Conclusions and Outlook 
In summary we have developed several approaches toward an orthogonal receptor-ligand 
system based on ionotropic glutamate receptors. Our attempts to rationally design mutations 
that can alter iGluR-specificity have so far yielded receptors, which show a highly reduced 
affinity toward L-glutamate. At the same time, we have shown that some of our modified 
iGluRs can be controlled using the photoswitched tethered ligand (PTL) approach. 
Additionally, we have created modified AMPA receptors, which show a marked increase in 
affinity toward kainate-type ligands. One of them efficiently functions as a “MAG”-receptor, 
i.e. it has a higher affinity for MAG-0 (209) than for its endogenous ligand L-glutamate (1). 
We hope to use these constructs to design a PTL-receptor system of GluAs, which would be 
highly interesting for the neurobiological community, as AMPARs are responsible for the 
major part of the excitatory neurotransmission at glutamatergic synapses. Therefore, a light-
gated, tethered AMPA receptor (“LiGluA”) would be a great addition to our portfolio of 
optogenetic tools. 
 In a complementary approach toward an orthogonal receptor-ligand pair, we have 
designed a yeast assay for glutamate receptor activity (“YAGA”), which allows for the 
screening of both ligands and modified receptors. We plan to use this system, which is based 
on the conditional rescue of a yeast strain lacking both low- and high-affinity potassium 
transporters (SGY1528), for a directed evolution of ionotropic glutamate receptors toward a 
designer receptor-ligand pair. Thus we seek to provide an orthogonal toolset for the dissection 
of neural networks. 
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II. Toward the Total Synthesis of Herquline A & B  
 
Philipp Stawski, Giulio Volpin and Dirk Trauner 
 
While arguably the most glorious field of organic chemistry, total synthesis is at the 
same time the most controversial. Starting with Wöhler’s synthesis of urea,[272] the era of total 
synthesis has yielded such epochal achievements as Woodward and Eschenmoser’s 1973 
synthesis of cobyric acid and the synthesis of prostaglandins F2α and E2 by Corey in 1969.[273] 
While those and related endeavors have surely both promoted the development of synthetic 
strategies and our understanding of natural product chemistry, it is questionable, whether the 
current direction toward more and more complex targets, such as maitotoxin,[274] will have the 
same effect, or whether this will finally mark total synthesis as a science conducted in an 
ivory tower. Regardless of such arguments however, we believe that total synthesis is mainly 
– and has ever been – a highly successful method of training organic chemist in a variety of 
techniques, which would otherwise be difficult to combine. Accordingly, we regard the total 
synthesis of natural products as a field, in which students can both explore and push the 
boundaries of chemical synthesis and, more importantly, of their own knowledge and skills. 
The following chapters describe our attempts toward the synthesis of such two small, yet 
challenging natural products, herquline A and B. 
 
Note: This work was conducted partially in collaboration with Giulio Volpin (planning and 
supervision of G.V.’s master thesis by P.S.).[275] 
 
1) The Herquline Alkaloids 
The herquline alkaloids A and B were isolated in 1979 and 1996 by Omura and coworkers 
from the penicillium strain FG-3772, a soil isolate.[276] It was immediately clear, that 
herquline A (248) and B (249) did not match any structure previously extracted from this 
fungus (Fig. 56). However, it was not before a crystal structure of 248 was obtained by 
Matsumoto and coworkers,[277] that the molecular architecture of both alkaloids could be 
determined unambiguously. Herquline A and B (248, 249) bear a piperazine ring and in 
herquline B (249) there are also two cyclohexenones present. In addition to that, there is a 
pyrrolidine ring incorporated in 248, making it a pentacyclic system. Unfortunately, the 2-
dimensional drawings of both herquline A and B do not adequately represent their strained 
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nature. As can be seen from the X-ray structure of 248, all the rings appear to be distorted and 
the piperazine ring resides in a boat conformation (Fig. 56). 
 
	  
Figure 56. The chemical structures of herquline A and B (248 and 249 respectively), the X-ray 
structure of 248•HBr and a scanning electron micrograph of the penicillium strain FG-372.[277] 
 
Since the chemical synthesis of these structural features promised to be challenging, we 
selected the herqulines as a target of our total synthesis program. 
 Biosynthetically, it is believed that both 248 and 249 stem from two molecules of L-
tyrosine (250), which undergo cyclization to form a diketopiperazine (Scheme 38). Omura 
and coworkers have presented evidence for this, since supplementing 250 to the fermentation 
broth increased the amount of herquline alkaloids isolated. Unfortunately, they did not 
conduct a labeling study to unambiguously prove the incorporation of the aromatic amino 
acid in herquline A and B. Despite this, Omura’s biosynthetic proposal seems reasonable, as it 
links the herquline alkaloids to the known class of dityrosine alkaloids. This class of natural 
products is known to undergo phenoloxidative couplings, yielding either C-O- or C-C- 
coupled products such as piperazinomycin or mycocyclosin (vide infra).[278] 
 
	  
Scheme 38. Omura’s proposed biosynthesis of herquline A and B (248, 249).  
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It is unclear, at which stage of the biosynthesis the diketopiperazine is reduced to the 
piperazine. However, it can be assumed, that following coupling and dearomatization, the 
proposed aza-Michael addition of the piperazine nitrogen in 254 will proceed more easily, if 
the reduction happens earlier in the synthesis (Scheme 28). It is important to note, that the 
hypothetic C2-symmetric intermediate 255 might serve as a substrate for the aforementioned 
hetero-Michael addition, too. This would however require an additional double-bond 
migration after formation of the pyrrolidine ring. To complete the biosynthetic proposal, 
methylation of the secondary amine 256 would yield herquline A (248). This might then serve 
as a precursor to herquline B (249) via an E2 elimination, yielding the triple-substituted 
double bond rather than reforming the Michael-system (Scheme 38). 
So far, there has been only one report on the attempted total synthesis of the herquline 
alkaloids by Norioshi and coworkers.[279] The authors constructed the 12-membered ring of 
herquline B (249) by an efficient intramolecular coupling of an iodotyrosine-derived 
diketopiperazine 257, which was protected as the bis-imido ether 258 (Scheme 39a).[279] 
 
	  
Scheme 39. a) Reported progress toward the herquline alkaloids by Norioshi et al. b) Key-step in the 
total synthesis of mycocyclosine (262). c) Key-step in the synthesis of piperazonomycin (265). 	  
Most notably, only carbonate 258 could be coupled to give the cyclic product, while both the 
free phenol and the diketopiperazine could not. Despite this, there has been no further report 
on the progress of their total synthesis so far. The recently published total synthesis of the 
related natural product mycocyclosine (262) by Hutton and coworkers,[280] which used an 
elegant borylation-Suzuki Miaura coupling sequence, does not report any similar constraints 
(Scheme 39b), Boger et al. state, that during their synthesis of piperazinomycin (265), they 
could only promote the ring-closure – using a modified Ullman-coupling – when the 
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piperazine moiety was still at the keto-piperazine stage (Scheme 39c).[281] This seems to 
indicate a strong dependency of this type of reactions on the conformation of the piperazine 
ring. The present reports suggest an increased preference of boat-like structures with an axial 
position of substituents, when there is still an sp2-center present in the piperazine ring (i.e. 
diketopiperazine or bis-imido ether stage).[282] Any synthetic plan involving formation of a 
piperazine-briding macrocycle, therefore has to account for these conformational 
requirements. 
 
2) Retrosynthesis 
Structurally, the herqulines (248, 249) belong to the class of piperazine alkaloids. Arguably, 
their structural attraction is due to their tetracyclic and pentacyclic cores, which make up a 
compact arrangement of four contiguous and two isolated stereocenters. Both molecules share 
the bi(cyclohexenedione) motif. Given the pKA of ketones, the α-stereocenters adjacent to 
those carbonyl groups can be considered to be under thermodynamic control, as they would 
otherwise epimerize under the isolation conditions. The other two stereocenters in the 
piperazine ring bear a configuration, which is in agreement with the proposed biosynthetic 
origin from L-tyrosine.[277] In herquline A (248), the octahydro-1H-indole, or dodecahydro-
pyrazino[1,2-a]indole moieties (Fig. 57) are challenging, since they form a highly strained, 
cage-like structure (cf. X-ray, Fig. 56). It is important to note (vide infra), that to 
accommodate these conformational constraints, the piperazine ring reside in the 
thermodynamically unfavorable boat-conformation. 
 
	  
Figure 57. The structural features of the herquline alkaloids (the respective motifs are shown in bold). 	  
Taking into account the strained nature of herquline A and B, we decided not to access the 
herqulines via the octahydro-1H-indole, or dodecahydro-pyrazino[1,2-a]indole motifs. We 
rather decided to approach 248 and 249 as a bi(cyclohexenedione)-bridged piperazine. This 
would allow us to access the two natural products via the formation of a 12-membered ring, 
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rather than having to synthesize the [6.5.6] system first and then the nine-membered ring, as 
we were convinced, that such a reaction would suffer from the increase ring-strain of this 
smaller carbocycle.[283] 
 Our retrosynthetic analysis is based on the insight, that the C2-symmetric diketone 255 
might be a valid biosynthetic precursor to both herquline alkaloids (cf. Scheme 38). 
Assuming, that herquline B (249) is formed from herquline A (248) in an E2-type elimination, 
the latter can be synthesized by methylation of the secondary amine 256 (Scheme 40). We 
suggest, that a double-bond isomerization of the conjugated double-bond of the resulting α,β-
unsaturated enone 257 can be achieved under acidic or basic conditions, since the un-
conjugated double-bond is of the same order of substitution (triple-substituted) and 
corresponds to the constitution as found in the natural product. 
 
	  
Scheme 40. Retrosynthesis part I: from the herquline alkaloids to the C2-symmetric precursors 255 
and 258. (MVK = methylvinyl ketone). 
 
The herquline A core-structure is formed by an aza-Michael addition of either of the two 
nitrogen atoms in the C2-symmetric dienone 255. To avoid any addition preceding this step, 
we envision masking the piperazine with Boc groups. As a key step of the synthesis, we 
envision a novel and challenging intramolecular reductive coupling of the bis(α-iodo ketone) 
259, since this is an established method for the synthesis of bi(cyclohexenediones) 
intermolecularly.[284] For an intramolecular process however, we reasoned that introducing the 
more flexible cyclohexenones should compensate for the aforementioned conformational 
requirements of strategies involving macrocyclizations to a bridged piperazine. This general 
approach, which has recently been successfully been applied by Baran et al. in the total 
synthesis of the macrocyclophane haouamine A,[285] and by our group in the total synthesis of 
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the assigned structure of haouamine B,[286] is based on the fact, that there are only three sp2 
centers in a cyclohexenone as compared to six in a benzene ring. It is for this reason, tht the 
alkylative ring-closure to 264 only worked on the cyclohexenone- and not on the biaryl-stage 
(Scheme 41). 
 
	  
Scheme 41. Synthesis of the assigned structure of haouamine B peracetate (264) from a 
cyclohexenaone precursor via alkylation. 
 
For our proposed retrosynthesis, iodoenone 259 can be accessed from dialdehyde 262, 
after a diastereoselective addition of methylvinyl ketone (MVK), followed by a double-
Robinson annulation and iodination of the resulting dienone 260. We found, that dialdehyde 
262 can be traced back to the corresponding diol 266 and thus to the diamino diol 267 after 
selective protection of the piperazine nitrogens using a carbamate protecting group 
(Scheme 42). 
 
	  
Scheme 42. Retrosynthesis part II: reduction-oxidation and condensation-hydrolysis sequences 
connecting the C2-symmetric dialdehyde 262 to (S)-pyroglutamic acid (188). 
 
As the reduction of diketopiperazines is an obvious, and for that reason well documented 
approach for the synthesis of piperazines, 267 can be traced back to lactam 268 by reduction 
using e.g. lithium aluminium hydride. Much to our delight we found, that 268 is a literature-
known compound, which can be synthesized from (S)-pyroglutamic acid (188) in just two 
steps.[287] 
 We were, of course, fascinated by the idea, that we could link both herquline alkaloids 
to (S)-pyroglutamate (188), as this would be a nice connection to the chemical biology work 
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discussed in previous chapters. Before reporting our progress toward herquline A and B 
however, we will briefly summarize the use of L-pyroglutamic acid (188) and L-glutamate (1) 
in the total synthesis of natural products. 
 
3) L-Glutamate and L-Pyroglutamate in Total Synthesis 
The 21 proteinogenic L-amino acids are ideal substrates for ex-chiral pool approaches, as they 
do not only provide a stereocenter, but many different functionalities, which can be exploited 
in the total synthesis of natural products. Among those readily available amino acids, this 
chapter will focus on the use of (S)-glutamate (1) and (S)-pyroglutamic acid (188) in total 
synthesis. (Bio)synthetically, 188 is obtained from L-glutamic acid (1) by condensation. The 
biosynthesis of 1 itself is highly interesting, as it connects to the Krebs-cycle and hence to 
energy production of the cell. (S)-glutamate (1) is synthesized by transamination to α-
ketoglutarate, which is a key-intermediate of glycolysis. As such, 1 can be considered as one 
of the main biosynthetic storages of nitrogen. Moreover, the biochemical role of L-glutamate 
(1) is not only limited to serving as a precursor for the synthesis of other amino acids, the 
synthesis of peptides and the use as neurotransmitter, it is also the cofactor of 
monooxygenases in its deaminated form (i.e. α-ketoglutarate) and thus plays a major role in 
the oxidative processing of other metabolites.[288] 
 The use of (S)-glutamic acid (1) and L-pyro-glutamate (188) in total synthesis is 
widespread. In addition to serving as a starting material for the preparation of chiral 
auxiliaries,[289] there are more than 28 syntheses of or toward natural products incorporating 
those two forms of glutamate in their carbon skeleton (i.e. no simple glutamic amides).[290] A 
selection of those, which retain the amino-function, are depicted in Figure 58. The structures 
feature a variety of different natural product classes, among them rather small molecules like 
acivicin (283) synthesized by Silverman and coworkers,[290d] and such enormous hexapeptide 
alkaloids like the dimeric chloptosin (274) prepared by the Ley group.[290k] For a detailed 
discussion of their synthesis the reader may be referred to the original manuscripts.[290b-d, 290g, 
290k, 290m, 290o, 290q-v, 290x, 290aa] Despite this diversity, all molecules shown in Figure 58 retain the 
α-amino stereocenter present in 1 or 188, even though the respective syntheses have been 
realized using quite different chemical synthons (vide infra).  
Toward the Total Synthesis of Herquline A and B 
138 
	  
Figure 58. Natural products synthesized from either L-pyroglutamate (1) or L-glutamic acid (188) 
where the amino group has been converted to another function. The carbons corresponding to the 
precursor are shown in bold. The α-amino carbon has been marked with an α. 	  
At the same time, there are several syntheses incorporating the glutamate carbon 
skeleton, but not the amino-function. Thus, L-glutamate does not only serve as a chiral 
building block for alkaloids such as indolactam V (272), porothramycin B (275) or martinellic 
acid (282), but also for polyketide and terpenoid natural products such as 13,4-threo 
desicomacin (286) and eldanolide (288) (Fig. 59).[290l, 290p, 290q, 290s, 290t] To this end, the α-
amino group has been converted into another functionality in those molecules. In most of 
them, like e.g. the indolizidine alkaloid (+)-swainsonine (289) or the spiroketal (+)-calyculin 
A (285), it has been transformed into an oxygen-bearing stereocenter using diazotization or 
similar substitution strategies resulting in a deamination (vide infra).[290j, 290ab] In other 
molecules like reblastin (287), isoaltholacton (290) and (+)-quebrachamine (291),[290a, 290w, 
290y] the glutamic descent is hardly recognizable any more. Especially in 291 since the α-
stereocenter has been lost completely after serving as a template for the diastereoselective 
alkylation in the ω-position. This is a very powerful approach, since depending on whether 
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the alkylation is performed on L-glutamic acid (1) or (S)-pyroglutamate (188), different 
diastereoselectivities can be obtained (cf. chapter I.7). 
 
	  
Figure 59. Natural products synthesized from either L-pyroglutamate (1) or L-glutamic acid (188) 
where the amino group has been converted to another function. The carbons corresponding to 1 are 
shown in bold. The α-amino carbon has been marked with an α. 
 
 While a detailed analysis of the methods used to synthesize the molecules shown in 
Figures 58 and 59 would go beyond the scope of this work, we will rather focus on the key 
transformations performed on both L-glutamic (1) and L-pyroglutamic acid (188). As 
mentioned earlier, diastereoselective alkylation of C-4 is one of the most commonly used 
reactions in glutamate chemistry (Scheme 43 A, D).e.g.[84, 188] Selective manipulation of either 
carboxyl groups (Scheme 43 C, E, H, J) are non the less important and provide a variety of 
functional handles, which can be further elaborated.e.g. [290b, 290h, 290k, 290o, 291] Among the most 
interesting transformations of glutamates however are reactions introducing substituents in the 
3-position. This can be realized either by selective chlorination and displacement of the 
halogen (Scheme 43 B),e.g. [290d] or by dehydrogenation to the enone and subsequent Michael 
addition of nucleophiles.e.g. [292] Reactions of such α,β-unsaturated systems with 1,3-dipoles or 
dienes, yield 3,4-syn-disusbtitued glutamate analogues.e.g. [293] Such glutamic enones can also 
be subjected to dihydroxylations, giving 3,4-dihydroxy pyrrolidones (Scheme 43 F).e.g. [294] 
Another key-transformation involves exchange of the α-stereocenter nitrogen for an oxygen. 
This can be realized either by lactonization after diazotization and intramolecular substitution 
under double inversion, or by formation of a terminal epoxide (Scheme 43 G, I). e.g. [290a, 290l]  
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Scheme 43. Typical synthetic transformations of L-glutamic (1) or L-pyroglutamic acid (188). Only key-
modifications are shown, protecting group and other modifications have been omitted for clarity. 
 
In summary, L-glutamate (1) and L-pyroglutamate (188) can be regarded as versatile building 
blocks for the total synthesis of many different natural product classes. They allow for a 
variety of chemical transformations and the introduction of both carbon- and heteroatom-
substituted stereocenters at any of the three central carbon atoms.  
 
4) Toward the Total Synthesis of Herquline A and B 
Owing to its high versatility, we were positive that (S)-pyroglutamic acid (188) would prove 
as a good starting material for our envisioned synthesis of herquline A and B (248, 249. It 
commenced with the transformation of 188 into the glutamic diketopiperazine 268 using a 
procedure reported by Parrish and Mathias (Scheme 44a).[287] Unfortunately, initial studies 
had shown, that a direct reduction of 268 to the amino alcohol 267 using LiAlH4 or BH3•THF 
was not possible.[275] The main reason for this was the low solubility of diketopiperazine 268 
in organic solvents except for DMF or DMSO (Scheme 44b). 
 
	  
Scheme 44. a) Formation of glutamic diketopiperazine 268 from (S)-pyroglutamic acid (188). 
b) Attempted direct reduction of 268 to aminoalcohol 267.  
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We therefore decided to investigate a stepwise protocol for reduction of glutamic 
diketopiperazine 268. To this end, we first formed the dimethyl ester 292 in order to improve 
the solubility. After intensive experimentation,[275] we found that the esterification worked 
best under conditions using CBr4 as a catalyst (Scheme 45).[295] 
 
	  
Scheme 45. a) Esterification of diacid 268 using CBr4 as catalyst. 	  
Since diketopiperazines are known for their low solubility, we decided to first reduce the 
lactam carboxyl groups while leaving the esters untouched. To this end, we converted 292 
into dithioketopiperazine 294 in good yields using Lawesson’s reagent (293, Scheme 46a). 
However, desulfurization using Raney-Nickel[296] did not yield the desired piperazine 
dimethyl ester, but the piperazine bislactam 295, which resulted from an intramolecular attack 
of the intermediary formed secondary amine (Scheme 46b).  
 
 
Scheme 46. a) Thionylation of diketopiperazine 292 using Lawesson’s reagent. b) Dethionylation 
attempt leading to bislactam 295. c) Dethionylation and in situ protection yields the Boc-protected 
piperazine 296. 
 
Attempts to protect the free piperazine with Boc-anhydride in situ did unfortunately not yield 
the clean carbamate 296. Instead, we isolated a mixture of products, which contained 296 as 
indicated by HRMS and NMR along with a chromatographically and spectroscopically very 
similar molecule – probably a diastereomer of 296 resulting from epimerization during the 
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desulfurization (Scheme 46c). Due to these problems, we decided to not follow up on this 
route  
 Since our two-step approach toward the reduction of the diketopiperazine was 
unsuccessful, we again focused on a one-pot reduction. Based on our initial studies,[275] we 
first reduced ester 292, which showed an improved solubility in THF as compared to diacid 
268. After considerable optimization of the reaction conditions, we obtained diol 266 in 
acceptable yield upon reduction using lithium aluminium hydride and chemoselective 
protection of the piperazine as di(tert.-butyl) carbamate. Oxidation-state adjustment under 
Swern conditions then yielded the piperazine dialdehyde 262 in 86% (Scheme 47).[297] 
 
	  
Scheme 47. Reduction of glutamic diketopiperazine dimethyl ester 292 and oxidation of the primary 
alcohol under Swern-conditions to dialdehyde 262. 
 
With 262 in hands, we now had to form keto-aldehyde 261 in a diastereoselective manner, as 
this should set the stereocenter at the cyclohexenone (Table 4). To this end, we screened a 
variety of reagents and organocatalysts known to promote an addition of MVK α to primary 
aldehydes. Trimethylsilyl diethylamide gave kateoaldehyde 261 in good yields and – as 
expected – without any apparent stereoinduction (Table 4, entry 1).[298] Screening several 
organocatalysts, we found that both enantiomers of 2-(methoxydiphenylmethyl) 
pyrrolidine (297) did yield the desired product in acceptable yields (Table 4, entries 2 and 3). 
While with (S)-297 we obtained an encouraging 1 : 2.7 mixture of diastereomers, its 
enantiomer, (R)-297, did only give a low 1.7 : 1 ratio (mismatched case). Unfortunately, the 
meso-compound could not be differentiated from the C2-symmetric products and the absolute 
configuration of the different isomers could not be assigned. However, by comparison to 
products obtained by others,[299] it is reasonable to assume that (R)-297 does in fact yield the 
configuration matching the one of herquline A and B. In contrast to the 2-
(methoxydihphenylmethyl) pyrrolidines, neither Jørgensen’s nor MacMillan’s 1st gen. catalyst 
(298, 299) did yield the product in detectable yields (Table 4, entries 4 and 5). 
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Table 4. Reaction conditions for the organocatalytic addition of MVK to dialdehyde 262. 
	  	  
Entry Catalyst/Reagent Conditions Yield d.r. 
     
1 TMSNEt2 MeCN, reflux
[298] 74% 1 : 2 : 1 
2 (S)-297 
ethyl-3,4-dihydroxybenzoate, 
MVK (neat), 4 ºC[299a, 300] 
51% “1 : 2.7” 
3 (R)-297 
ethyl-3,4-dihydroxybenzoate, 
MVK (neat), 4 ºC[299a, 300] 
44% “1.7 : 1” 
4 298 MVK (neat), RT[301] - - 
5 299 TFA, MVK (neat), RT[301] - - 
 
With the keto-aldehyde 261 synthesized as both stochastic and enriched 
diastereomeric mixtures, we turned our attention to the upcoming Robinson annulation, which 
should form the two six-membered rings of the natural products and retain the stereocenter 
introduced in the previous step. A literature survey on the condensation of α-branched 
aldehydes to 2-cyclohexenones substituted solely in the 4-position was unfortunately not very 
encouraging. There are only a handful of methods, which are compatible to Boc-protecting 
groups and which have been used for the stereoselective synthesis of enones with a 
stereocenter at C-4. While we tested the reagent systems introduced by Baran/Chakraborti and 
Nicolaou/Srihari alongside other methods (Table 5). Most notably, the recently published use 
of (S)-1-(pyrrolidin-2-ylmethyl)pyrrolidine•TFA as an organocatalysts for the Robinson 
annulation of keto-aldehydes to 4-substituted cyclohexenones, did not retain the 
stereoinformation in 261 (Table 5, entry 13). Much to our surprise, only the reagent-system of 
tetra-n.-butyl ammonium hydroxide together with potassium hydroxide in THF/Et2O as 
introduced by Nicolaou and Srihari, did promote the desired transformation in acceptable 
yields (Table 5, entries 5-9). We found, that there was a strong connection between the 
concentration of the reaction and the yields obtained. This seems to suggest that there is a 
substantial amount of inter- instead of intra-molecular condensation when using too high 
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concentrations. High dilution did eliminate the problem, yet – due to the low reagent 
concentrations – the reaction times increased to up to three days (Table 5, entry 7). 
 
Table 5. Reaction conditions for the Robinson annulation of 261 to enone 260. 
	  	  
Entry Conditions Comment d.r. 
    
1 LiOH, MeOH, RT[302] decomp. - 
2 LiOH, i-PrOH, RT[299a] decomp. - 
3 LiOH, CF3CH2OH, RT decomp. - 
4 LiOH, (CF3)2CHOH, RT traces n.d. 
5 (n-Bu)4NOH, KOH, THF/Et2O, Δ, c = 63 mM[299b, 303] traces - 
6 (n-Bu)4NOH, KOH, THF/Et2O, Δ, c = 10 mM 48% 1 : 2 : 1 
7 (n-Bu)4NOH, KOH, THF/Et2O, Δ, c = 3 mM, 3 d 57% 1 : 2 : 1 
8 cf. entry 6, but d.r. (s.m.) = “1.7 : 1”  1 : 2 : 1 
9 cf. entry 6, but d.r. (s.m.) = “1 : 3.1”  1 : 2 : 1 
10 pTsOH[304] n.r. - 
11 Na2SO4, THF, RT traces n.d. 
12 MgSO4, THF, RT [301] decomp. - 
13 (S)-1-(pyrrolidin-2-ylmethyl)pyrrolidine•TFA, RT 45% 1 : 2 : 1 
 
decomp. = decomposition, n.d. = not determined, n.r. = no reaction, s.m. = starting meterial 
 
While we finally obtained enone 261 in reproducible yields, we found that there was a 
substantial loss of diastereomeric purity under the conditions used. Regardless of the 
diastereomeric excess of the keto-aldehydes 262, we always obtained a 1:2:1 mixture of the 
three possible diastereomeric enones. While they could be discriminated by NMR, we could 
not separate the meso and the two C2-symmetric compounds at this stage. Despite varying 
reaction parameters such as concentration, time and temperature, all our attempts to retain the 
diastereomeric excess introduced in the previous step failed. It is to assume, that our substrate 
for the Robinson annulation, 261, is exceptionally prone to deprotonation α to the aldehyde. 
While a more in-depth screening of reaction parameters might yield conditions, which 
preserve the stereoinformation at C-4, none of the conditions screened resulted in a 
diastereospecific formation of 260.  
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Accordingly, we decided to continue our work with the stochastic mixture to then later 
separate the individual isomers, so we could determine their potential use as coupling 
substrates in the upcoming key-step individually. 
 The mixture of diastereomeric enones was subsequently iodinated using I2 in 
pyridine/CH2Cl2,[299a] to yield the α-iodo enones 259a-c, which could be separated by HPLC 
(Scheme 48). Unfortunately, the absolute configuration of neither of the two C2-symmetric 
iodides 259a and 259c could be assigned. 
 
	  
Scheme 48. Formation of the three diastereomeric α-iodo enones 259a-c. 
 
With our key-intermediates 259a-c synthesized, we were now ready to explore 
reaction conditions for the envisioned intramolecular reductive cyclization. However, as we 
had decided to reduce the diketopiperazine early in the synthesis, we were lacking factors 
inducing a conformational bias toward a boat-like structure. Moreover, an obtained crystal 
structure of the parent diol 266[275] seems to suggest a preferred equatorial position of the 
substituents. Most interestingly, the central heterocycle does not reside in a chair or in a boat, 
but in a twist-boat conformation (Scheme 29a). While this is usually considered a high-energy 
conformation, effects of the crystal lattice, which most notably deviates from the C2-
symmetry, might help stabilize it. 
 
	  
Scheme 49. a) X-ray structure of diol 266. b) Conformational analysis of the 266. 	  
Assuming that the solid-state structure captures the true conformation of diol 266 in solution – 
and by that analogy of the α-iodo enones 259a-c, too –twist-boat 266a would have to 
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equilibrate to the boat conformer 266b for an efficient coupling as envisioned in our total 
synthesis. After all, this corresponds to the conformation of the piperazine ring as found in 
herquline A and B (248, 249). While this might be considered a potential pitfall in our 
synthetic strategy, we were still positive that the key-step coupling could be carried out at the 
piperazine oxidation stage, since we had considerably increased the conformational freedom 
of our coupling substrate due to the 4-substituted cyclohexenones (vide supra). 
 Accordingly, we went forth to evaluate several conditions, which seemed promising 
for the desired intramolecular reductive macrocyclization. To rule out any influence of the  
C-4 stereocenters at the enones, we tried the different methods on each isomer separately. 
While there was no obvious difference in their reactivity by TLC and LC-MS, products could 
not always be isolated for each isomer, since both isolation and purification proved 
challenging. The conditions, to which the α-iodo enones 259a-c were subjected, are 
summarized in Table 6. 
 
Table 6. Reaction conditions screened for the intramolecular coupling of 259a-c. 
	  	  	  
Entry Conditions Comments 
   
1 Ni(PPh3)2Cl2, Zn, PPh3, NaH, MePh, 90 ºC[284a] decomp. 
2 Ni(PPh3)2Cl2, Zn, PPh3, NaH, THF, 90 ºC  decomp. 
3 Ni(PPh3)2Cl2, Zn, PPh3, THF, RT dehalogenation 
4 Ni(PPh3)2Cl2, Zn, PPh3, DMF, 55 ºC 306 (5%) 
5 Ni(COD)2, THF, -78 ºC to RT[305] complex mixture 
6 Ni(COD)2, THF, -78 ºC to reflux complex mixture 
6 Ni(COD)2, PPh3, DMF, RT to 120 ºC complex mixture 
7 Ni(PPh3)4, DMF, 0 ºC to RT complex mixture 
8 Ni(PPh3)4, DMF, 0ºC to 90 ºC complex mixture 
9 Ni(COD)2, dppp, DMF, RT to 130 ºC complex mixture 
10 Ni(COD)2, P(n-Bu)3, DMF, RT to 40 ºC complex mixture 
11 Ni(COD)2, P(n-Bu)3, THF; -78 ºC to RT; c = 4 mM 
305, 
306 (5%) 
12 like entry 10; addition of 259a-c by syringe pump (2 h) 
305 (16%), 
306 
14 In, LiCl, Pd/C[284b] complex mixture 
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15 Cu, DMF, 130 ºC decomp. 
16 Cu (activated), RT to 130 ºC decomp. 
17 Cu, neat, 140 ºC sealed tube decomp. 
18 CuTC, NMP, RT to 130 ºC[306] decomp. 
19 Me6Sn2 (1.1 eq), Pd(PPh3)4, THF, 50 ºC[307] dehalogenation 
20 n-Bu6Sn2, Pd(PPh3)4, THF; 50 ºC 
dehalogenation;
complex mixture 
21 Me6Sn2, Pd(PPh3)4, THF; workup; PEPPSI-iPr  decomp. 
22 (BPin)2, Pd(dppf)Cl2, KOAc, DMSO, 80 ºC[308] decomp. 
23 309, CuCl, DMF, 70 ºC[309] 306 (24%). 
reagents and conditions as indicated; decomp = decomposition 
 
Unfortunately, we were not able to isolate the desired product 258 in any of the reactions. 
When using simpler substrates like 300 however, we obtained the α,α’-coupled product 301 
in yields very close to those published (Scheme 50a).[284a] To assess, whether this is due to 
conformational problems during the formation of the 12-membered ring, we prepared a model 
α-iodo enone 303, which resembles a monomeric version of piperzines 259a-c and which was 
readily available from enone 302 prepared for an alternative approach toward the herqulines 
previously.[275] Much to our surprise, the model did not yield any bis(cyclohexenone) product 
304 when subjected to Ni(PPh3)4/Zn/NaH, but decomposed under the reaction conditions 
(Scheme 50b). 
 
	  
Scheme 50. a) Coupling of the simple α-iodo enone 300 in good yields. b) Attempted coupling of 
model enone 303 derived from L-glutamic acid (1). 	  
Assuming that the hemi-aminal is stable under these coupling conditions, we reasoned that 
there might be a general problem with the reaction intermediates and some of the 
functionalities in both model system and piperazine dione (vide infra), as it has been 
suggested that Ni-mediated biaryl-couplings might proceed via radical intermediates.[310] 
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 Even though the other nickel-based methods mainly lead to proto-dehalogenation 
(Table 6, entry 3), we were amazed by the side-products we obtained using high dilution 
conditions and Ni(COD)2/PBu3 in stoichiometric amounts (Table 6, entries 11 and 12). In 
addition to the iodinated and deiodinated dimers 305 and 307, we found the 24-membered 
macrocycle 306 and even the 36-membered trimer 308 – the latter could however only by 
characterized by HRMS since it was a minor constituent of the reaction mixture (Fig. 60). 
 
	  
Figure 60. Dimers 304-307 and trimer 308 isolated from the coupling reactions. 
 
This seemed to suggest that there is in fact a reaction pathway available leading to α,α’-
coupled dienones. Yet, increasing the dilution factor by employing pseudo-high-dilution 
conditions (addition of iodides 259a-c by a syringe pump) did not produce any detectable 
amounts of the desired product 258, nor did it increase the amount of dimers isolated. It 
instead seemed to enhance the rate of proto-dehalogenation. Because of these problems and 
since it has been speculated, that nickel-based biaryl couplings might proceed via radical 
intermediates,[310] we wanted to explore alternative metals to promote the coupling. 
 Accordingly, we evaluated a number of conditions used in both the coupling of α-iodo 
enones and aryl iodides. Most notably, a method, which was developed by Lee et al. and 
which had been shown to promote a reductive C-C bond formation of the simple iodoenone 
300 (cf. Scheme 50a) using a two metal reagent system of indium and palladium,[284b] did yet 
again not yield any product but a complex mixture (Table 6, entry 14). Unfortunately so did 
classical Ullman-type conditions (Table 6, entries 15-17) and copper(I)-thiophene-2-
carboxylate (CuTC, Table 6, entry 18), probably due to the harsh reaction conditions required 
according to the literature. 
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 Since all our approaches toward the macrocycle 258 using one-step procedures had 
been unsuccessful, we decided to explore the option of two-step protocols. However, neither a 
borylation-Suzuki-Miaura coupling sequence nor Stille-Kelly conditions, where the active 
vinyl-metal species is formed in situ, did provide us with any product.[307-308] In the latter case 
however, we could identify both the mono- and the distannylated dienone as products of the 
reaction. To exploit this finding, we synthesized distannane 309 on purpose (Scheme 51a) and 
explored its potential oxidative dimerization using copper(I) or (II) salts. This relatively 
underdeveloped method is believed to proceed via a transmetallation to a dicopper species, 
which then first disproportinates to give a copper(II) intermediate. Reductive elimination 
furnishes the C-C bond in the end (Scheme 51b).[311] Yet again, the attempted intramolecular 
coupling of distannane 309 using copper(I) chloride did not yield the desired twelve-
membered carbocycle 258 but again the 24-membered C2-symmetric dimer 306 (Table 6, 
entry 23). 
 
	  
Scheme 51. a) Attempted two-step cyclization via the distannane 309. b) Proposed mechanism for the 
Cu(I)-mediated C-C bond formation from distannanes. 
 
Having screened a variety of different coupling conditions without success, we felt 
that we had to reconsider our initial ideas on the reactivity and the conformational 
arrangement of α-iodo enones 259a-c. The fact that we observed inter- instead of 
intramolecular coupling even at high dilution suggests, that there is no general incompatibility 
of the reagents and the starting material. We reasoned that there rather might be a 
conformational problem, such as that a 13-membered, metal-bridged intermediate cannot be 
formed or is less reactive than other possible reaction pathways. In further studies we will 
seek to overcome this problem by enforcing more reactive conformations (vide supra). 
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5) Resumé 
In summary we have developed a scalable route to advanced piperazine precursors for the 
total synthesis of herquline A and B (248, 249), two tyrosine-derived alkaloids isolated from a 
broth of penicillium herquei. Our synthesis starts from the readily available starting material 
L-pyroglutamic acid (188), which serves as a chiral precursor and sets the two stereocenters at 
the piperazine core. Further key-transformations involve formation of the piperazine ring by 
reduction of a diketopiperazine and an organocatalytic addition of MVK to aldehyde 262. The 
following installation of the two cyclohexenones in 260 by a double Robinson annulation can 
– in principle – be developed into a diastereoselective process (Scheme 52). 
 
	  
Scheme 52. Summary of the accomplished goals toward the herquline alkaloids. 
 
While we obtained the coupling precursors 259a-c from dienones 260 in very good yield, we 
have yet to assign the absolute configuration of the obtained C2-symmetric α-iodo 
diastereomers. So far our attempts to intramolecularly couple the vinyl iodides have not 
yielded any twelve-membered macrocycles. Instead we have isolated the linear and cyclic 
dimers 305 and 306. This seems to suggest that there is in fact a reaction pathway leading to 
α,α’-coupled dienones, which might be redirected toward the desired products. Our current 
results however indicate that there is a conformational problem preventing the intramolecular 
coupling. Future strategies will therefore have to assess this issue by locking the cyclization 
precursors in an orientation, which facilitates ring closure (vide infra). 
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6) Outlook 
The results of our present coupling strategy seem to suggest that there is a conformational 
problem preventing the formation of the twelve-membered ring in the key intermediate 258 of 
our synthesis. As shifting the conformer-equilibrium toward the boat-geometry by heating did 
not succeed, we will instead investigate chemical options to lock the piperazine in a 
conformation that allows the two iodoenones to interact. 
 To us, there seem to be two general solutions to this problem: 1. tethering of the 
piperazine ring and 2. tethering of the α-iodo enones. For the first option, a literature survey 
suggest that when forming DABCO-like structures by linking the piperazine nitrogens, the 
all-equatorial arrangement 311, which allows the piperazine substituents to minimize their 
steric repulsion, is generally preferred over the axial arrangement 310 (Scheme 53a).[312] 
Accordingly, our future efforts will focus on strategies that involve tethering via the 
cyclohexenone moieties (Scheme 53b,c). 
 
	  
Scheme 53. a) Tethering strategy involving formation of DABCO-like structures. b) Envisioned 
reduction-tethering sequence via the catechol linked di(vinyliodide) 313. c) An alternative, silicon-
based tethering strategy via the dialkoxysilane 315.  
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We therefore seek to diastereoselectively reduce the α-iodoenones to the corresponding 
allylic alcohols 312 using the Corey-Backshi-Shibata catalyst.[313] The hydroxy groups can 
then serve as handles for possible catechol- or silicon-based tethering methods forming 18- or 
17-membered macrocycles respectively (Scheme 53b,c). The key-transformation would then 
involve a macrocyclic ring-closure to the [6.6.7.12] and [6.6.8.12] pentacyclic ring systems 
314 or 316. While these reactions might suffer from transannular ring strain, especially the 
silicon-based method should benefit from the Thorpe-Ingold effect induced by bulky 
substituents on the silicon. Using standard transformations, both coupling products can then 
be converted into the α, α’-coupled dienone 258, which can then be processed further along 
the routes of the original proposal. 
Alternative strategies to the herquline alkaloids might involve a combination of the 
results obtained in this study and the methods used to synthesize other (diketo)piperazine 
alkaloids like mycocyclosin (262) or piperazinomycin (265).[280-281] Hutton and coworkers 
have shown that bis(iodoaryl)diketopiperazines can be coupled efficiently using the 
conditions developed by Lin et al.[280] Accordingly, our revised strategy will involve 
transformation of L-pyroglutamic acid (188) to the diketopiperazine α-iodo dienone 317, 
which can then be coupled intramolecularly. Following this key-step, the enone carbonyls will 
be protected to yield ketal 319. After reduction of the diketopiperazine to the piperazine using 
e.g. LiAlH4,[314] acetal deprotection and concomitant aza-Michael addition will form the 
dodecahydro-pyrazino[1,2-a]indole moiety present in herquline A (Scheme 54). 
 
	  
Scheme 54. An alternative synthetic strategy toward the herquline alkaloids, which combines the 
results of this study and preceeding approaches toward (diketo)piperazine alkaloids. 
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The remaining steps of the synthesis will then involve methylation of 256 and double bond-
isomerization as proposed in the original retrosynthetic analysis. Finally, herquline A (248) 
can be obtained, which we will use to probe its biosynthetic relationship to herquline B (249). 
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1) General Experimental Details and Instrumentation 
Unless stated otherwise, all reactions were carried out under an Argon atmosphere in 
oven-dried glassware. Solvents for extraction and flash column chromatography were 
purchased in technical grade and distilled under reduced pressure prior to use. Flash column 
chromatography was performed using Merck silica gel (SiO2; 40-63µm, 60 Å) or Waters C18 
(C18; 55-105 µm, 125 Å) as the stationary phase with forced flow as reported in [315]. 
Reactions and chromatography fractions were monitored with Merck silica gel 60 F254 or 
Machery-Nagel RP-18W/UV glass plates and visualized using a 254 nm UV lamp and/or by 
treatment with a suitable stain (potassium permanganate, ceric ammonium molybdate, 
ninhydrine, and anisaldehyde) followed by heating. Tetrahydrofuran (THF) and diethyl ether 
(Et2O) were distilled from sodium benzophenone. n-Butyllithium (n-BuLi) was titrated using 
iodine prior to use. All other solvents, as well as starting materials and reagents were obtained 
from commercial sources and used without further purification or were prepared according to 
the procedures cited. 
Unless otherwise specified, proton (1H) and carbon (13C) spectra were recorded at 300 K 
in the solvents indicated. The Varian Mercury spectrometers used were operated at 300 MHz, 
400 MHz and 600 MHz for proton nuclei and 75 MHz, 100 MHz and 150 MHz for carbon 
nuclei. For 1H NMR spectra signals arising from residual non-deuterated solvent were used as 
the internal standard and the solvent shifts reported by Fulmer et al.[316] were used as 
reference. 1H NMR data are denoted as follows: chemical shift (δ) (multiplicity, coupling 
constant(s) J (Hz), relative integral (,assignment)) where multiplicity is defined as: s = singlet; 
d = doublet; t = triplet; q = quartet; m = multiplet; mc = centrosymmetric multiplet; br = 
broad; a = apparent or combinations thereof. For regio-isomeric mixtures fractions of protons 
are reported for integrals to illustrate the ratio of isomers. The assignment of atoms is based 
on suitable 2D-spectra (HSQC, HMBC, COSY, NOESY). The atom numbers do not follow 
IUPAC-conform rules, but are rather based on practical considerations. 
Melting points (mp) were determined with a Stanford Research Systems MPA120 
apparatus and are uncorrected. UV-spectra (UV) were obtained using a Varian Cary 50 Scan 
UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm light path). Infrared 
spectra (ṽ) were recorded on a Perkin-Elmer BXII-FTIR spectrometer equipped with an ATR 
unit. Samples were analyzed as neat materials. A Varian MAT CH7A mass spectrometer was 
used to obtain low- and high-resolution electron impact (EI) mass spectra. Low- and high-
resolution electrospray (ESI) mass spectra were obtained on a Varian MAT 711 MS 
instrument operating in either positive or negative ionization modes.  
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2) A Photochromic Agonist of AMPA Receptors – Synthetic Procedures 
 
Overview: 
 
	  
Supporting Scheme 1. Generalized scheme for the synthesis of ATA-type molecules. 
 
Methyl 3-hydroxyisoxazole-5-carboxylate (90) 
 
Isoxazole 90 was synthesized according to known procedures.[115] The analytical data 
matched those reported previously. 
 
Methyl 3-(allyloxy)isoxazole-5-carboxylate (91) 
 
Allyl ether 91 was synthesized according to known procedures.[116] The analytical data 
matched those reported previously. 
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3-(allyloxy)isoxazole-5-carboxamide (S2) 
 
To ester 91 (9.60 g, 52.4 mmol) was added aqueous ammonia (85 mL, 25% in H2O) at 0 °C 
and the mixture was allowed to warm to room temperature while stirring over the course of 13 
h. The precipitate was collected and dried to yield 8.70 g (98%) of pure amide S2 as a 
colorless solid.  
 
Rf  = 0.27 (CH2Cl2/MeOH/AcOH/H2O = 90:10:2:2). 
 
mp (MeOH/H2O) = 147-148 ºC. 
 
IR (ATR): ṽ = 3364 (m), 3177 (m), 3149 (m), 1687 (s), 1676 (s), 1631 (s), 1615 (s), 1496 (s), 
1453 (s), 1345 (s), 1240 (s), 1104 (s), 970 (s), 932 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 6.62 (s, 1H), 6.07 (ddt, J = 17.2 Hz, J = 10.5 Hz, J = 
5.8 Hz, 1H), 5.44 (adq, J = 17.2 Hz, J = 1.5 Hz, 1H), 5.29 (adq, J = 10.5 Hz, J = 1.2 Hz, 1H), 
4.78 (ddd, J = 5.8 Hz, J = 1.5 Hz, J = 1.2 Hz, 2H) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 172.5, 165.4, 157.8, 133.2, 119.1, 98.3, 71.4 ppm. 
 
HRMS (ESI) Calc. for C7H9N2O3+:  169.0608 [M+H]+ 
Found:    169.0601 [M+H]+. 
 
3-(allyloxy)isoxazole-5-carbonitrile (92) 
 
To a solution of amide S2 (8.50 g, 50.5 mmol) in DMF (100 mL) was added cyanuric chloride 
(9.32 g, 50.5 mmol) in Et2O/DMF (1:2, 60 mL) at 0 °C over 20 min. The resulting mixture 
was allowed to warm to room temperature over the course of 3 h. A colorless precipitate 
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formed and the solution turned yellow. Et2O (250 mL) was added to the reaction mixture and 
the organic phase was washed successively with saturated aqueous NaHCO3 (2 × 150 mL), 
10% aqueous NaCl (1 × 200 mL) and brine (1 × 200 mL). The organic phase was dried over 
Na2SO4, filtered and concentrated. Normal phase flash column chromatography (SiO2; n-
pentane/Et2O = 16:1) yielded 7.12 g (94%) of nitrile 92 as a colorless, volatile liquid. 
 
Rf  = 0.4 (n-Pentane/Et2O = 16:1). 
 
IR (ATR): ṽ = 3144 (w), 2248 (w), 1599 (s), 1502 (s), 1418 (m), 1350 (m), 1245 (w), 1140 
(w), 1034 (w), 989 (w), 928 (w), 811 (w) cm–1. 
 
1H NMR (CD2Cl2, 400 MHz) δ 6.62 (s, 1H), 6.06 (ddt, J = 17.2 Hz, J = 10.5 Hz, J = 5.8 Hz, 
1H), 5.45 (mc, 1H), 5.35 (mc, 1H), 4.80 (ddd, J = 5.7 Hz, J = 1.5 Hz, J = 1.2 Hz, 2H) ppm. 
 
13C NMR (CD2Cl2, 100 MHz) δ 171.3, 143.3, 131.7, 119.8, 108.7, 105.9, 72.0 ppm. 
 
HRMS (EI)  Calc. for C7H7N2O2+:  151.0508 [M+H]+ 
Found:    151.0494 [M+H]+. 
 
tert-butyl 2-(bis(tert-butoxycarbonyl)amino)acrylate (93) 
 
Dehydroalanine 93 was synthesized according to known procedures.[114] The spectroscopic 
data matched those reported previously. 
 
tert-butyl 3-(3-(allyloxy)-5-cyanoisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propa-
noate (94) 
 
To a solution of nitrile 92 (500 mg, 3.33 mmol) in THF (17 mL) was added dropwise 
precooled (-110 ºC) n-BuLi (1.4 mL, 3.50 mmol; 2.5 M in hexanes) in THF (2.5 mL) over 10 
min at -110 ºC with a double tipped needle and the obtained deep red solution was stirred for 
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30 min. A precooled (-110 ºC) solution of tert-butyl 2-(bis(tert-butoxy-
carbonyl)amino)acrylate (93; 1.14 g, 3.33 mmol) in THF (4.5 mL) was added dropwise to the 
reaction and stirring was continued for 2 h. The mixture was quenched by addition of 
precooled HCl in MeOH (4.0 mL, 0.06 M) at −108 ºC. To the obtained pale yellow solution 
was added saturated aqueous NH4Cl (20 mL) and the mixture was allowed to warm to room 
temperature. The biphasic mixture was extracted with EtOAc (4 x 15 mL), dried over MgSO4, 
filtered and concentrated. Purification by normal phase flash column chromatography (SiO2; 
PE/EtOAc = 17:1) gave 1.03 g (61%) of propanoate 94 as a colorless solid.  
 
Rf  = 0.4 (PE/EtOAc = 10:1). 
 
mp (PE/EtOAc) = 73 ºC. 
 
IR (ATR): ṽ = 2980 (w), 2938 (w), 1728 (s), 1697 (s), 1551 (s), 1382 (m), 1367 (s), 1356 (s), 
1143 (s), 1122 (s), 978 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 6.16-5.98 (m, 1H), 5.42 (add, J = 17.2 Hz, J = 1.4 Hz, 1H), 
5.32 (add, J = 10.5 Hz, J = 1.2 Hz, 1H), 4.99 (dd, J = 9.8 Hz, J = 5.0 Hz, 1H), 4.79 (adt, J = 
5.8 Hz, J = 1.3 Hz, 2H), 3.29-3.14 (m, 2H), 1.45 (s, 27 H) ppm. 
 
13C NMR (CDCl3, 75 MHz) δ 169.9, 168.1, 152.3, 141.1, 131.4, 119.8, 117.2, 108.3, 83.6, 
82.4, 71.8, 57.2, 28.1, 28.0, 22.1 ppm. 
 
HRMS (ESI) Calc. for C24H35N3NaO8+: 516.2322 [M+Na]+ 
Found:    516.2317 [M+Na]+. 
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tert-butyl 3-(3-(allyloxy)-5-(2H-tetrazol-5-yl)isoxazol-4-yl)-2-(bis(tert-butoxycarbonyl) 
amino)propanoate (95) 
 
To a solution of nitrile 94 (1.00 g, 2.03 mmol) in DME (20 mL) was added sodium azide (145 
mg, 2.23 mmol) and NEt3•HCl (307 mg, 2.23 mmol). The resulting suspension was stirred for 
68 h at 110 ºC in a sealed tube (external bath temperature). The mixture was cooled to room 
temperature and the solvent removed under reduced pressure. Normal phase flash column 
chromatography (SiO2; CH2Cl2/MeOH/AcOH/H2O = 90:10:0.6:0.6) yielded 984 mg (90%) of 
tetrazole 95 as a colorless solid. 
 
Rf = 0.2 (CH2Cl2/MeOH/AcOH/H2O = 90:10:0.6:0.6). 
 
mp (CH2Cl2/MeOH/AcOH/H2O) = 199 ºC (decomp.). 
 
IR (ATR): ṽ = 2980 (m), 2936 (m), 1777 (m), 1736 (s), 1701 (s), 1506 (m), 1367 (s), 1236 (s), 
1137 (s), 1098 (s) cm-1. 
 
1H NMR (CDCl3, 600 MHz) δ 6.09 (ddt, J = 17.2 Hz, J = 10.6 Hz, J = 5.7 Hz, 1H), 5.46 (dd, 
J = 17.3 Hz, J = 1.40 Hz, 1H), 5.33 (dd, J = 10.5 Hz, J = 1.3 Hz, 1H), 5.17 (dd, J = 7.6 Hz, J 
= 5.9 Hz, 1H), 4.85 (mc, 2H), 3.43 (dd, J = 15.0 Hz, J = 5.7 Hz, 1H), 3.32 (dd, J = 15.0 Hz, 
J = 7.9 Hz, 1H), 1.49 (s, 9H), 1.43 (s, 18H) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 170.7, 170.0, 152.5, 131.8, 119.2, 108.2, 84.2, 83.3, 71.3, 
57.8, 28.1 (2x), 23.0 ppm (2 C obscured). 
 
HRMS (ESI) Calc. for C24H36N6NaO8+: 559.2492 [M+Na]+ 
Found:    559.2488 [M+Na]+. 
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(4-(phenyldiazenyl)phenyl)methanol (S2) 
 
To a solution of 4-aminobenzyl alcohol (2.50 g, 20.3 mmol) in glacial acetic acid (100 mL) 
was added nitrosobenzene (2.39 g, 22.3 mmol) and the mixture was stirred overnight at room 
temperature. The solvent was removed under reduced pressure, the residue taken up in EtOAc 
(100 mL), washed with a saturated aqueous solution of saturated aqueous NaHCO3 (2 x 20 
mL) and brine (1 x 20 mL). The organic phase was dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 4:1 to 3:1) 
yielded 3.65 g (85%) of alcohol S2 as an orange solid. 
 
Rf = 0.4 (PE/EtOAc = 2:1). 
 
mp (PE/EtOAc) = 134 ºC. 
 
UV (DMSO): λmax = 330 nm. 
 
IR (ATR): ṽ = 3293 (br m), 1582 (w), 1442 (m), 1348 (m), 1302 (m), 1150 (m), 1024 (s), 
1008 (s), 850 (s), 830 (s), 762 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 7.95-8.89 (m, 4H), 7.62-7.51 (m, 5H), 4.76 (d, J = 5.8 Hz, 
2H), 4.39 (t, J = 5.8 Hz, 1OH) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 153.5, 152.5, 147.1, 132.0, 130.1, 128.0, 123.5 (2x), 
64.2 ppm. 
 
HRMS (ESI) Calc. for C13H13N2O+: 213.1028 [M+H]+ 
Found:    213.1022 [M+H]+. 
  
N N
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(3-(phenyldiazenyl)phenyl)methanol (S3) 
 
To a solution of 3-aminobenzyl alcohol (2.50 g, 20.3 mmol) in glacial AcOH (100 mL) was 
added nitrosobenzene (2.39 g, 22.3 mmol) and the mixture was stirred overnight at room 
temperature. The solvent was removed under reduced pressure, the residue taken up in EtOAc 
(100 mL) and washed with a saturated aqueous solution of NaHCO3 (2 x 20 mL) and brine 
(1 x 20 mL). The organic phase was dried over MgSO4, filtered and concentrated. Normal 
phase flash column chromatography (SiO2; PE/EtOAc = 4:1 to 3:1) yielded 3.53 g (82%) of 
alcohol S3 as a red solid. 
 
Rf = 0.5 (PE/EtOAc = 2:1). 
 
mp (PE/EtOAc) = 37 ºC. 
 
UV (DMSO): λmax = 325 nm. 
 
IR (ATR): ṽ = 3191 (br m), 1586 (w), 1472 (m), 1448 (m), 1360 (m), 1243 (m), 1148 (m), 
1124 (m), 1019 (s), 918 (m), 799 (s), 770 (s) cm–1. 
 
1H NMR (CD3CN, 400 MHz) δ 7.96-7.86 (m, 3H), 7.84-7.77 (m, 1H), 7.64-7.47 (m, 5H), 
4.70 (d, J = 4.9 Hz, 2H), 3.36 (t, J = 5.9 Hz, 1OH) ppm. 
 
13C NMR (CD3CN, 100 MHz) δ 115.6, 115.5, 144.7, 132.3, 130.4, 130.3, 130.2, 123.6, 122.6, 
121.2, 64.3 ppm. 
 
HRMS (ESI) Calc. for C13H13N2O+: 213.1028 [M+H]+ 
Found:    213.1022 [M+H]+. 
  
N N OH
S3
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methyl 3-((4-(dimethylamino)phenyl)diazenyl)benzoate (S4) 
 
To a solution of methyl 3-aminobenzoate (1.00 g, 6.62 mmol) in 4 N HCl (50 mL) was added 
sodium nitrite (0.456 g, 6.62 mmol) at 0 ºC and the mixture was stirred for 30 min N,N-
dimethylaniline (0.84 mL, 6.62 mmol) was added and stirring was continued for 1 h. The 
deep red solution was added to ice-cold saturated aqueous NaHCO3 (300 mL). After the CO2 
evolution had ceased, the biphasic mixture was extracted with EtOAc (3 x 150 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated to yield the 
crude product as a red solid which was recrystallized from PE/EtOAc to afford 1.53 g (82%) 
of azobenzene S4 as a red solid. 
 
Rf = 0.4 (PE/EtOAc = 4:1). 
 
m.p. (PE/EtOAc) = 93-95 ºC. 
 
UV (DMSO): λmax = 433 nm. 
 
IR (ATR): ṽ = 2947 (w), 2908 (w), 1720 (s), 1602 (s), 1521 (m), 1398 (m), 1368 (s), 1291 (s), 
1276 (s), 1141 (s), 1069 (s), 812 (s), 753 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 8.55-8.54 (m, 1H), 8.07-8.03 (m, 2H), 7.88 (d, J = 9.3 Hz, 
2H), 7.65 (td, J = 7.8 Hz, J = 0.5 Hz, 1H), 6.85 (d, J = 9.3 Hz, 2H), 3.94 (s, 3H), 3.11 (s, 
6H) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 167.0, 154.1 (2x), 144.1, 132.2, 130.7, 130.3, 127.4, 
126.0, 123.3, 112.4, 52.6, 40.4 ppm. 
 
HRMS (ESI) Calc. for C16H18N3O2+: 284.1399 [M+H]+ 
Found:    284.1394 [M+H]+. 
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Me2N
Experimental 
165 
3-((4-(dimethylamino)phenyl)diazenyl)phenyl)methanol (96) 
 
To a solution of ester S4 (500 mg, 1.76 mmol) in THF (20 mL) was added LiAlH4 (3.18 mL, 
3.18 mmol; 1.0 M in THF) at 0 ºC and the mixture was stirred for 30 min at room 
temperature. The reaction was poured on ice-cold saturated aqueous NH4Cl. The mixture was 
extracted with EtOAc (3 x 50 mL) and the combined organic extracts were dried over MgSO4, 
filtered and concentrated. Normal phase flash column chromatography (SiO2, PE/EtOAc = 
3:1) yielded 435 mg (97%) of alcohol 14 as golden plates. 
 
Rf = 0.4 (PE/EtOAc = 2:1). 
 
mp (PE/EtOAc) = 118-120 ºC. 
 
UV (DMSO): λmax = 421 nm. 
 
IR (ATR): ṽ = 3401 (br, w), 2961 (w), 2904 (w), 1594 (m), 1520 (m), 1372 (m), 1258 (s), 
1060 (s), 1020 (s), 820 (s), 795 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 7.89-7.81 (m, 3H), 7.73-7.69 (m, 1H), 7.47 (at, J = 7.6 Hz, 
1H), 7.44-7.40 (m, 1H), 6.90-6.81 (m, 2H), 4.74 (d, J = 5.9 Hz, 2H), 4.35 (t, J = 5.9 Hz, 
1OH), 3.10 (s, 6H) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 154.0, 153.7, 144.6, 144.2, 129.6, 128.4, 125.6, 121.7, 
120.6, 112.4, 64.4, 40.3 ppm. 
 
HRMS (ESI) Calc. for C15H18N3O+: 256.1450 [M+H]+ 
Found:    256.1449 [M+H]+. 
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(3-((4-iodophenyl)diazenyl)phenyl)methanol (S5) 
 
To a solution of 1-iodo-4-nitrosobenzene[317] (500 mg, 2.15 mmol) in glacial AcOH (40 mL) 
was added (3-aminophenyl)methanol (264 mg, 2.15 mmol) and the mixture was stirred at 
room temperature overnight. The solvent was removed under reduced pressure and the 
residue partitioned between EtOAc (200 mL) and saturated aqueous NaHCO3 solution (100 
mL). The organic phase was washed with brine (100 mL), dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 5:1 to 2:1) 
yielded 620 mg (85%) of azobenzene S5 as an orange solid. 
 
Rf = 0.5 (PE/EtOAc= 2:1). 
 
mp (PE/EtOAc) = 115 ºC. 
 
UV (DMSO): λmax = 341 nm. 
 
IR (ATR): ṽ = 3330 (br s), 2923 (w), 2868 (w), 1575 (m), 1564 (m), 1392 (m), 1044 (s), 1022 
(s), 998 (s), 827 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 8.02-7.92 (m, 3H), 7.87-7.78 (m, 1H), 7.74-7.69 (m, 2H), 
7.61-7.50 (m, 2H), 4.7 (d, J = 5.7 Hz, 2H), 4.40 (t, J = 5.8 Hz, 1OH) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 153.4, 152.9, 145.1, 139.5, 130.5, 130.0, 125.3, 122.5, 
121.3, 98.1, 64.2 ppm. 
 
HRMS (ESI) Calc. for C13H12IN2O+: 338.9994 [M+H]+ 
Found:    338.9992 [M+H]+.  
N N
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N-(4-((3-(hydroxymethyl)phenyl)diazenyl)phenyl)acetamide (S6) 
 
To a s solution of azobenzene S5 (250 mg, 0.739 mmol) in DMF (12 mL) was added 
acetamide (87.3 mg, 1.48 mmol), N,N'-dimethylethylenediamine (24 µL, 0.222 µmol) and 
potassium phosphate (314 mg, 1.48 mmol). The mixture was degassed and CuI (14.1 mg, 73.9 
µmol) was added. The mixture was stirred at 80ºC for 5 h. The reaction was allowed to cool 
to room temperature and then poured on saturated aqueous NaHCO3 (30 mL). The mixture 
was extracted with EtOAc (4 x 50 mL) and the combined organic extracts were dried over 
MgSO4, filtered and concentrated. Normal phase flash column chromatography 
(CH2Cl2/MeOH = 95:5 to 93:7) yielded 133 mg (67%) of acetamide S6 as an orange solid. 
 
Rf = 0.33 (CH2Cl2/MeOH = 93:7). 
 
mp (PE/EtOAc) = 175-176 ºC. 
 
UV (DMSO): λmax = 361 nm. 
 
IR (ATR): ṽ = 3304 (br m), 3264 (br m), 3200 (br m), 1681 (s), 1668 (s), 1592 (s), 1544 (s), 
1502 (s), 1405 (s), 1304 (s), 1151 (s), 1012 (s) cm–1. 
 
1H NMR (acetone-d6, 400 MHz) δ 9.45 (br s, 1H), 7.96-7.83 (m, 5H), 7.80-7.74 (m, 1H), 
7.55-7.44 (m, 2H), 4.76 (d, J = 5.8 Hz, 2H), 4.36 (t, J = 5.8 Hz, 1OH), 2.14 (s, 3H) ppm. 
 
13C NMR (acetone-d6, 100 MHz) δ 169.2, 153.6, 149.1, 144.9, 143.4, 129.8, 129.6, 124.5, 
122.1, 121.0, 120.0, 64.2, 24.4 ppm. 
 
HRMS (ESI) Calc. for C15H16N3O2+: 270.1243 [M+H]+ 
Found:    270.1239 [M+H]+. 
  
N N
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tert-butyl 3-(3-(allyloxy)-5-(2-(4-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-yl)-
2-(bis(tert-butoxycarbonyl)amino)propanoate (S1a) 
 
To a solution of DEAD (167 µL, 363 µmol; 40% in toluene) and tetrazole 95 (150 mg, 
280 µmol) in THF (10 mL) was added PPh3 (95.3 mg, 363 µmol) and the mixture was stirred 
for 5 min at room temperature. Then a solution of alcohol S2 (77.1 mg, 363 µmol) in THF (10 
mL) was added and the reaction was stirred overnight at room temperature. EtOAc (30 mL) 
and saturated aqueous NH4Cl solution (25 mL) were added. The biphasic mixture was 
extracted with EtOAc (3 x 50 mL). The combined extracts were dried over MgSO4, filtered 
and concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 6:1 to 5:1) 
yielded 156 mg (76%) of N-1 and N-2 alkylated tetrazoles S1a (1:2.5 ratio by NMR) as an 
orange resin. 
 
Rf = 0.3 (PE/EtOAc = 4:1). 
 
UV (DMSO): λmax = 322 nm. 
 
IR (ATR): ṽ = 2979 (m), 2932 (m), 1790 (w), 1734 (s), 1699 (s), 1536 (m), 1502 (m), 1366 
(s), 1286 (s), 1231 (s), 1141 (s), 1119 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz; 1:2.5 mixture of regio-isomers) δ 7.93-7.87 (m, 3.3 H), 
7.58-7.48 (m, 4.2H), 7.30-7.17 (m, 0.9H), 6.85-6.81 (m, 0.6H), 6.09-6.03 (m, 1.0H), 
5.95-5.90 (m, 1.63H), 5.78-5.76 (m, 0.4H), 5.44-5.39 (m, 1.0H), 5.31-5.28 (m, 1.0H), 
5.25-5.16 (m, 1.0H), 4.82 (add, J = 5.7 Hz, J = 1.3 Hz, 1.93H), 3.50-3.38 (m, 2.1H), 1.46 (s, 
9.1H), 1.37-1.34 (m, 18.0H) ppm. 
 
13C NMR (CDCl3, 100 MHz; 1:2.5 mixture of regio-isomers) δ 171.4, 171.1, 168.9, 168.6, 
156.6, 155.5, 153.0, 152.8, 152.6, 152.5, 152.1, 144.5, 136.0, 135.2, 132.2, 131.7, 131.7, 
131.5, 131.5, 129.5, 129.3, 129.3, 129.1, 129.0, 127.9, 123.6, 123.6, 123.1, 123.1, 121.2, 
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120.6, 119.4, 119.0, 111.4, 108.0, 83.0, 82.8, 81.9, 81.8, 71.5, 71.1, 58.0, 57.8, 56.86, 56.6, 
52.3, 28.1, 28.0 (2x), 22.2, 21.9 ppm. 
 
HRMS (ESI) Calc. for C37H46N8NaO8+: 753.3336 [M+Na]+ 
Found:    753.3331 [M+Na]+. 
 
tert-butyl 3-(3-(allyloxy)-5-(2-(3-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-yl)-
2-(bis(tert-bu-toxycar-bonyl)amino)propanoate (S1b) 
 
To a solution of DEAD (113 µL, 287 µmol; 40% in toluene) and tetrazole 95 (140 mg, 261 
µmol) in THF (5 mL) was added PPh3 (75 mg, 287 µmol) and the mixture was stirred for 5 
min at room temperature before a solution of alcohol S3 (60.9 mg, 287 µmol) in THF (2 mL) 
was added and the reaction was stirred overnight at room temperature. EtOAc (20 mL) and 
saturated aqueous NH4Cl solution (20 mL) were added. The biphasic mixture was extracted 
with EtOAc (3 x 50 mL), the combined extracts were dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 6:1) yielded 
167 mg (88%) of N-1 and N-2 alkylated tetrazoles S1b (5.7:1 ratio by NMR) as an orange 
resin. 
 
Rf = 0.3 (PE/EtOAc = 4:1). 
 
UV (DMSO): λmax = 324 nm. 
 
IR (ATR): ṽ = 2980 (w), 2935 (w), 1791 (w), 1734 (s), 1700 (s), 1537 (m), 1503 (m), 1366 
(s), 1282 (m), 1231 (s), 1141 (s), 1119 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz; 1:2.5 mixture of regio-isomers) δ 8.01-7.84 (m, 3.2H), 7.60-7.42 
(m, 4.2H), 7.32-6.72 (m, 1.2H), 6.14-6.00 (m, 0.94H), 5.99-5.91 (m, 1.7H), 5.75-5.66 (m, 
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0.3H), 5.44-5.38 (m, 1.0H), 5.35-5.27 (m, 1.2H), 5.25-5.16 (m, 1.0H), 4.81 (add, J = 5.8 Hz, J 
= 1.3 Hz, 2.0H), 3.61-3.32 (m, 2.1H), 1.48-1.44 (m, 9.1H), 1.39-1.31 (m, 18.0H) ppm. 
 
13C NMR (CDCl3, 100 MHz; 1:2.5 mixture of regio-isomers) δ 171.4, 171.1, 168.9, 168.6, 
156.5, 155.5, 153.1, 152.5, 152.1, 152.1, 144.5, 134.6, 133.9, 132.2, 131.7, 131.6, 131.5, 
130.9, 130.5, 130.1, 130.0, 129.3, 129.2, 128.9, 127.8, 127.4, 124. 0, 123.3, 123.1, 122.9, 
122.8, 120.5, 119.4, 119.0, 111.4, 108.0, 83.0, 82.9, 82.8, 81.9, 81.8, 71.5, 71.1, 58.1, 57.8, 
57.0, 52.4, 28.1, 28.0, 22.2, 21.9 ppm. 
 
HRMS (ESI) Calc. for C37H46N8NaO8+: 753.3336 [M+Na]+ 
Found:    753.3332 [M+Na]+. 
 
tert-butyl 3-(3-(allyloxy)-5-(2-(3-((4-(dimethylamino)phenyl)diazenyl)benzyl)-2H-tetrazol 
-5-yl)isoxa-zol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propanoate (97) 
 
To a solution of DEAD (222 µL, 485 µmol; 40% in toluene) and tetrazole 95 (200 mg, 
373 µmol) in THF (10 mL) was added PPh3 (127 mg, 485 µmol) and the mixture was stirred 
for 5 min at room temperature. Alcohol 96 (124 mg, 485 µmol) was added to the mixture and 
the reaction was stirred overnight at room temperature. EtOAc (20 mL) and saturated aqueous 
NH4Cl solution (20 mL) were added. The biphasic mixture was extracted with EtOAc (3 x 
50 mL), the combined extracts were dried over MgSO4, filtered and concentrated. Normal 
phase flash column chromatography (SiO2; PE/EtOAc = 4:1) yielded 250 mg (87%) of N-1 
and N-2 alkylated tetrazoles 97 (2:3 ratio by NMR) as a red solid. 
 
Rf = 0.6 (PE/EtOAc = 2:1). 
 
mp (PE/EtOAc) = 57 ºC. 
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UV (DMSO): λmax = 429 nm. 
 
IR (ATR): ṽ = 2979 (w), 2934 (w), 1791 (w), 1733 (s), 1699 (s), 1600 (s), 1557 (s) 1519 (s), 
1505 (s), 1365 (s), 1283 (s), 1230 (s), 1135 (s), 1119 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz; 2:3 mixture of regio-isomers) δ 7.93-7.76 (m, 3.9 H), 7.50-7.31 
(m, 2.0H), 6.76 (d, J = 9.0 Hz, 2.0H), 5.94 (s, 0.9H), 5.93-5.87 (m, 1.2H), 5.45-5.39 (m, 
1.0H), 5.33-5.27 (m, 1.0H), 5.26-5.17 (m, 1.0H), 4.86-4.79 (m, 2.0H), 3.61-3.35 (m, 2.1H), 
3.10 (s, 6.0H), 1.46-1.45 (m, 9.0H), 1.36 (s, 7.3H), 1.33 (s, 10.6H) ppm. 
 
13C NMR (CDCl3, 150 MHz; 2:3 mixture of regio-isomers) δ 171.3, 171.1, 168.9, 168.6, 
156.5, 155.6, 152.6, 152.1, 152.0, 144.5, 134.4, 133.6, 132.2, 131.8, 129.9, 129.8, 129.2, 
128.8, 125.5, 125.4, 123.4, 122.6, 122.2, 122.2, 119.4, 118.9, 111.7, 111.3, 107.9, 83.0, 82.8, 
81.9, 81.7, 71.5, 71.1, 58.1, 57.9, 57.2, 52.6, 40.5, 28.1, 28.0, 28.0, 22.2, 22.0 ppm. 
 
HRMS (ESI) Calc. for C39H52N9O8+: 774.3939 [M+H]+ 
Found:    774.3938 [M+H]+. 
 
tert-butyl 3-(5-(2-(3-((4-acetamidophenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-(allyloxy) 
isoxazol-4-yl)-2-(bis (tert-butoxycarbonyl)amino)propanoate (S1c) 
 
To a solution of DEAD (167 µL, 364 µmol; 40% in toluene) and tetrazole 95 (150 mg, 280 
µmol) in THF (10 mL) was added PPh3 (88.1 mg, 336 µmol) and the mixture was stirred for 
5 min at room temperature before alcohol S6 (90.5 mg, 336 µmol) was added and the reaction 
was stirred overnight at room temperature. EtOAc (20 mL) and saturated aqueous NH4Cl 
solution (20 mL) were added. The biphasic mixture was extracted with EtOAc (3 x 50 mL), 
the combined extracts were dried over MgSO4, filtered and concentrated. Normal phase flash 
O
N O
NBoc2
COOt-Bu
N
NN
N
NN
S1c
AcHN
Experimental 
172 
column chromatography (SiO2; CH2Cl2/MeOH = 97:3) yielded 168 mg (76%) of N-1 and N-2 
alkylated tetrazoles S1c (8:9 ratio by NMR) as an orange solid. 
 
Rf = 0.4 (CH2Cl2/MeOH = 95:5). 
 
m.p. (CH2Cl2/MeOH) = 45 ºC. 
 
UV (DMSO): λmax = 365 nm. 
 
IR (ATR): ṽ = 3253 (w), 3189 (w), 2980 (w), 1732 (s), 1697 (s), 1594 (m), 1538 (s), 1503 (s), 
1437 (s), 1366 (s), 1229 (s), 1142 (s), 1118 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz; 9:8 mixture of regio-isomers and rotamers) δ 7.89-7.83 (m, 
4.1H), 7.73-7.65 (m, 2.1H), 7.59-7.42 (br m, 3.5H), 6.11-6.03 (m, 1.0H), 6.00-5.94 (m, 1.0H), 
5.94-5.89 (m, 1.1H), 5.42 (addd, J = 17.3 Hz, J = 7.0 Hz, J = 1.3 Hz, 0.9H), 5.30 (addd, J = 
15.5 Hz, J = 10.5Hz, J = 1.2 Hz, 1.1H), 5.24-5.17 (m, 0.9H), 4.87-4.80 (m, 2.2H), 3.56-3.38 
(m, 1.9H), 2.22 (s, 3.0H), 1.46-1.44 (m, 8.9H), 1.38-1.30 (m, 18.1H) ppm. 
 
13C NMR (CDCl3, 150 MHz; 9:8 mixture of regio-isomers and rotamers) δ 171.4, 171.1, 
168.9, 168.6, 156.5, 155.5, 153.1, 153.1, 152.6, 152.1, 152.1, 148.9, 148.9, 144.5, 134.6, 
133.8, 132.2, 131.7, 130.7, 130.2, 130.1, 123.0, 124.4, 124.3, 123.9, 123.2, 122.8, 122.8, 
119.8, 119.7, 119.4, 119.0, 111.4, 108.0, 83.0, 82.9, 82.0, 81.8, 81.8, 71.5, 71.1, 58.1, 57.9, 
57.0, 52.4, 28.1, 28.0, 28.0, 25.0, 22.2, 22.0 ppm. 
 
HRMS (ESI) Calc. for C39H49KN9O9+: 826.3285 [M+K]+ 
Found:    826.3284 [M+K]+. 
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tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-3-(3-hydroxy-5-(2-(4-(phenyldiazenyl)ben-
zyl)-2H-tetra-zol-5-yl)isoxazol-4-yl)propanoate (S7a) 
 
To a solution of protected isoxazole S1a (140 mg, 192 µmol) in MeOH (10 mL) was added 
Pd(PPh3)4 (22.2 mg, 19.2 µmol) and the mixture was stirred for 5 min K2CO3 (53.1 mg, 
384 µmol) was added and stirring was continued for 2 h. The mixture was diluted with EtOAc 
(60 mL) and washed with saturated aqueous NH4Cl (15 mL) and brine (15 mL). The organic 
phase was dried over MgSO4, filtered and concentrated. Normal phase flash column 
chromatography (SiO2; CH2Cl2/MeOH = 97:3 to 95:5) yielded the free hydroxy isoxazole S7a 
as an orange wax, which was used directly in the next step. 
 
Rf = 0.3 (CH2Cl2/MeOH = 95:5). 
 
tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-3-(3-hydroxy-5-(2-(3-(phenyldiazenyl)ben-
zyl)-2H-tetra-zol-5-yl) isoxazol-4-yl)propanoate (S7b) 
 
To a solution of protected isoxazole S1b (160 mg, 219 µmol) in MeOH (10 mL) was added 
Pd(PPh3)4 (25.3 mg, 21.9 µmol) and the mixture was stirred for 5 min. K2CO3 (60.5 mg, 438 
µmol) was added and stirring was continued for 2 h. The mixture was diluted with EtOAc (60 
mL) and washed with saturated aqueous NH4Cl and brine (15 mL each). The organic phase 
was dried over MgSO4, filtered and concentrated. Normal phase flash column 
chromatography (SiO2; CH2Cl2/MeOH = 95:5 to 94:6) yielded the free hydroxy isoxazole 
S7b as an orange wax, which was used directly in the next step. 
 
Rf = 0.2 (CH2Cl2/MeOH = 95:5). 
  
O
N OH
NBoc2
COOt-Bu
N
NN
N
S7a
N
N
O
N OH
NBoc2
COOt-Bu
N
NN
N
NN
S7b
Experimental 
174 
tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-3-(5-(2-(3-((4-(dimethylamino)phenyl)dia-
zenyl)benzyl)-2H-tetra-zol-5-yl)-3-hydroxyisoxazol-4-yl)propanoate (98) and tert-butyl 
2-(bis(tert-butoxycar-bonyl)amino)-3-(5-(1-(3-((4-(dimethylamino)phenyl)diazenyl)ben-
zyl)-1H-tetrazol-5-yl)-3-hydroxyiso-xazol-4-yl)propanoate (98’) 
 
To a solution of isoxazole 97 (200 mg, 258 µmol) in MeOH (10 mL) was added Pd(PPh3)4 
(14.9 mg, 12.9 µmol). After stirring for 5 min, K2CO3 (71.4 mg, 517 µmol) was added and 
stirring was continued for 2 h at room temperature. The mixture was diluted with EtOAc (50 
mL) and the organic phase was washed with saturated aqueous NH4Cl solution and brine (20 
mL each). The organic phase was dried over MgSO4, filtered and concentrated. The crude 
product was first passed over a short plug of silica (eluting with CH2Cl2/MeOH = 9:1) and – 
after evaporation of the solvent – was purified by reversed phase HPLC (Varian Dynamax 
250x21.4 mm Microsorb 60-8 C18 column equipped with a Dynamax HPLC guard column 
operating on a Varian PrepStar HPLC system; H2O/MeCN/0.1% formic acid; 15 mL/min; 
gradient program: t = 0 min, 80% MeCN; t = 90 min, 85% MeCN) to yield 84 mg (44%) of 
N-2-alkylated tetrazole 98 (Rt = 24.8 min) and 46 mg (24%) of its N-1-alkylated isomer 98’ 
(Rt = 22.6 min) as red solids. 
 
98: 
Rf = 0.5 (CH2Cl2/MeOH = 9:1). 
 
mp (H2O/MeCN) = 95 ºC. 
 
UV (DMSO): λmax = 429 nm. 
 
IR (ATR): ṽ = 2979 (w), 2932 (w), 1790 (w), 1733 (s), 1699 (s), 1600 (s), 1520 (s), 1365 (s), 
1232 (s), 1150 (s), 1122 (s) cm–1. 
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1H NMR (CDCl3, 600 MHz) δ 7.90 (t, J = 1.7 Hz, 1H), 7.87 (mc, 2H), 7.83 (mc, 1H), 6.75 (d, 
J = 9.2 Hz, 2H), 5.91 (mc, 2H), 5.17 (dd, J = 8.3 Hz, J = 5.6 Hz, 1H), 3.55 (dd, J = 14.7 Hz, J 
= 5.5 Hz, 1H), 3.43 (dd, J = 14.7 Hz, J = 8.3 Hz, 1H), 3.09 (s, 6H), 1.45 (s, 9H), 1.36 (s, 
18H) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 170.6, 170.2, 156.3, 155.4, 153.7, 152.8, 152.1, 143.6, 133.6, 
129.9, 129.2, 125.4, 123.4, 122.2, 111.6, 108.2, 83.2, 82.5, 58.2, 57.2, 40.4, 28.1, 28.0, 
22.4 ppm. 
 
HRMS (ESI) Calc. for C36H48N9O8+: 734.3626 [M+H]+ 
Found:    734.3628 [M+H]+. 
 
The N-2 alkylation was evident due to the following HMBC correlations: 
HMBC H C 
 5.91 122.2 
 5.91 129.2 
 5.91 133.6 
 
98’: 
Rf = 0.5 (CH2Cl2/MeOH = 9:1). 
 
mp (H2O/MeCN) = 98-103 ºC. 
 
UV (DMSO): λmax = 428 nm. 
 
IR (ATR): ṽ = 2978 (w), 2933 (w), 1732 (m), 1698 (m), 1600 (s), 1520 (m), 1365 (s), 1231 
(s), 1135 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.87-7.82 (m, 3H), 7.77 (dd, J = 7.9 Hz, J = 1.1 Hz, 1H), 7.42 
(t, J = 7.8 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 6.72 (d, J = 9.2 Hz, 2H), 5.95 (s, 2H), 5.12 (dd, J 
= 6.7 Hz, J = 5.8 Hz, 1H), 3.55 (dd, J = 14.8 Hz, J = 6.8 Hz, 1H), 3.32 (dd, J = 14.8 Hz, J = 
5.7 Hz, 1H), 3.08 (s, 6H), 1.45 (s, 9H), 1.40 (s, 18H) ppm. 
13C NMR (CDCl3, 150 MHz) δ 171.7, 170.6, 153.7, 152.8, 152.6, 152.2, 144.3, 143.6, 134.2, 
129.8, 128.9, 125.4, 122.8, 122.3, 111.6, 111.3, 83.7, 83.6, 58.5, 52.7, 40.4, 28.0, 28.0, 
23.3 ppm. 
Experimental 
176 
HRMS (ESI) Calc. for C36H48N9O8+: 734.3626 [M+H]+ 
Found:    734.3625 [M+H]+. 
 
The N-1 alkylation was evident due to the following HMBC correlations: 
HMBC H C 
 5.95 122.3 
 5.95 128.9 
 5.95 134.2 
 5.95 144.3 
 
tert-butyl 3-(5-(2-(3-((4-acetamidophenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-hydroxyi-
soxazol-4-yl)-2-(bis(tert -butoxycarbonyl)amino)propanoate (S7c) 
 
To a solution of protected isoxazole S1c (132 mg, 168 µmol) in MeOH (10 mL) was added 
Pd(PPh3)4 (9.68 mg, 8.38 µmol) and the mixture was stirred for 5 min. K2CO3 (43.3 mg, 335 
mmol) was added and stirring was continued for 1 h. EtOAc (40 mL) was added and the 
organic phase was washed with a saturated aqueous NH4Cl solution and brine (15 mL each). 
The organic phase was dried over MgSO4, filtered and concentrated. Normal phase flash 
column chromatography (SiO2, CH2Cl2/MeOH = 93:7) yielded the free hydroxy isoxazole 
S7c as a red wax, which was used directly in the next step. 
 
Rf = 0.4 (CH2Cl2/MeOH = 9:1). 
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2-amino-3-(3-hydroxy-5-(2-(4-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-
yl)propanoic acid (ATA-1, 89a) 
 
To a solution of hydroxyl isoxazole S7a in CH2Cl2 (15 mL) was added TFA (15 mL) at 0 ºC 
and the mixture was stirred for 2 h. The solvent was removed under reduced pressure and the 
residue purified using reversed phase flash column chromatography (C18; H2O/MeCN/FA = 
100:0:0.1% to 6:4:0.1%) to yield 39 mg (49%, 2 steps) of ATA-1 (89a) as a mixture of regio-
isomers as a yellow solid. The N1- and N2-alkylated isomers (2:7 by NMR) could not be 
separated. 
 
Rf = 0.5 (H2O/MeCN/FA = 1:1:0.1%). 
 
mp (H2O/MeCN) > 170 ºC (decomp.). 
 
UV (HEPES-ringer): λmax = 320 nm. 
 
IR (ATR): ṽ = 3156 (w), 2960 (w), 1607 (br m), 1486 (s), 1308 (s), 1201 (m), 1119 (w), 
1062 (w) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 7.93-7.85 (m, 4.1H), 7.68-7.54 (m, 4.7H), 7.47 (d, J = 8.7 
Hz, 0.4H), 6.19 (mc, 1.6H), 6.03-5.97 (m, 0.5H), 3.78-3.70 (m, 1.0), 3.34-3.23 (m, 1.2H), 
3.16-3.03 (0.8H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 171.7, 171.2, 156.0, 153.2, 151.9, 151.9, 151.7, 150.1, 
145.0, 137.6, 136.8, 131.8, 131.8, 129.7, 129.5, 129.5, 128.9, 123.0, 123.0, 122.6, 122.6, 
107.8, 55.9, 52.5, 51.5, 24.2 ppm. 
 
HRMS (ESI) Calc. for C20H17N8O4–: 433.1378 [M-H]– 
Found:    433.1377 [M-H]–. 
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2-amino-3-(3-hydroxy-5-(2-(3-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-
yl)propanoic acid (ATA-2, 89b) 
 
To a solution of hydroxyl isoxazole S7b in CH2Cl2 (15 mL) was added TFA (15 mL) at 0 ºC 
and the mixture was stirred for 2 h. The solvent was removed under reduced pressure and the 
residue purified using reversed phase flash column chromatography (C18; H2O/MeCN/FA = 
100:0:0.1% to 6:4:0.1%) to yield 44 mg (47%, 2 steps) of ATA-2 (89b) as a mixture of regio-
isomers as a yellow solid. The N1- and N2-alkylated isomers (1:3 by NMR) could not be 
separated. 
 
Rf = 0.5 (H2O/MeCN/FA = 1:1:0.1%). 
 
mp (H2O/MeCN) > 209 ºC (decomp.). 
 
UV (HEPES-ringer): λmax = 320 nm. 
 
IR (ATR): ṽ = 3189 (w), 1609 (br m), 1485 (s), 1401 (m), 1318 (s), 1262 (m), 1244 (m), 
1060 (m) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 11.05-8.90 (br s, 1.8H), 8.01-7.83 (m, 3.3H), 7.70-7.56 (m, 
4.2H), 7.39-6.72 (m, 0.5H), 6.22 (mc, 1.3H), 6.05 (s, 0.5H), 3.80-3.72 (m, 1.0H), 3.36-3.24 
(m, 1.1H), 3.19-3.06 (m, 1.0H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 171.7, 171.2, 171.0, 156.0, 153.2, 152.1, 152.0, 151.8, 
151.8, 150.2, 145.0, 135.9, 135.1, 131.8, 131.5, 130.8, 130.2, 130.1, 129.5, 129.5, 128.7, 
123.2, 122.6, 122.3, 121.9, 119.7, 111.0, 107.8, 55.9, 52.5, 52.2, 51.5, 39.5, 24.4, 24.2 ppm. 
 
HRMS (ESI) Calc. for C20H17N8O4–: 433.1378 [M-H]– 
Found:    433.1379 [M-H]–.  
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2-amino-3-(5-(2-(3-((4-(dimethylamino)phenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-
hydroxyisoxazol-4-yl)propanoic acid (ATA-3, 89c) 
 
To a solution of hydroxy-isoxazole 98 (65 mg, 88.6 µmol) in CH2Cl2 (25 mL) was added 
TFA (25 mL) at 0 ºC and the mixture was stirred for 1 h at that temperature and then for 
additional 2 h at room temperature. The solvent was removed and the residue purified using 
reversed phase flash column chromatography (C18; H2O/MeCN/FA = 9:1:0.1% to 6:4:0.1%) 
to yield 31 mg (73%) of ATA-3 (89c) as an orange solid. 
 
Rf = 0.5 (H2O/MeCN/FA = 6:4:0.1%). 
 
mp (H2O/MeCN) > 188 ºC (decomp.). 
 
UV (HEPES-ringer): λmax = 456 nm. 
 
IR (ATR): ṽ = 3055 (w), 1634 (m), 1610 (s), 1521 (m), 1480 (s), 1362 (s), 1336 (s), 1320 (s), 
1170 (s), 1161 (s), 1134 (s) 1122 (s), 810 (s) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 11.87-8.00 (br s, 3H), 7.85 (mc, 1H), 7.81-7.76 (m, 3H), 
7.56 (at, J = 7.8 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 9.2 Hz, 2H), 6.17 (mc, 2H), 
3.73 (dd, J = 7.0 Hz, J = 3.7 Hz, 1H), 3.31 (dd, J = 15.9 Hz, J = 3.6 Hz, 1H), 3.10 (dd, J = 
16.0 Hz, J = 7.0 Hz, 1H), 3.06 (s, 6H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 171.8, 171.2, 156.0, 153.2, 152.7, 152.7, 142.5, 134.8, 
129.9, 129.4, 124.9, 122.4, 121.6, 111.6, 107.9, 56.1, 52.5, 39.8, 24.2 ppm. 
 
HRMS (ESI) Calc. for C22H24N9O4+: 478.1946 [M+H]+ 
Found:    478.1947 [M+H]+. 
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3-(5-(2-(3-((4-acetamidophenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-hydroxyisoxazol-4-
yl)-2-aminopropanoic acid (ATA-4, 89d) 
 
To a solution of hydroxy-isoxazole S7c in CH2Cl2 (20 mL) was added TFA (20 mL) at 0 ºC 
and the mixture was stirred for 1 h at that temperature and then for additional 2 h. at room 
temperature. The solvent was removed and the residue purified using reversed phase flash 
column chromatography (C18; H2O/MeCN/FA = 9:1:0.1% to 1:1:0.1%) to yield 56 mg (68%, 
2 steps) of ATA-4 (89d) as an orange solid. The N-1- and N-2-alkylated isomers could not be 
separated. By trituration with H2O/MeCN, the ratio could be enhanced to up to 2:9. 
 
Rf = 0.5 (H2O/MeCN/FA = 1:1:1%). 
 
mp (H2O/MeCN) > 213 ºC (decomp.). 
 
UV (HEPES-ringer): λmax = 349 nm. 
 
IR (ATR): ṽ = 3299 (w), 3160 (w), 3014 (w), 1668 (s), 1595 (m), 1524 (s), 1487 (s), 1405 (s), 
1304 (s), 1262 (s), 1243 (s), 1202 (m), 1152 (m) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 10.52 (s, 1.0H), 8.38 (s, 1.6H), 7.93-7.74 (m, 5.8H), 
7.65-7.52 (m, 2.0H), 6.16 (s, 1.7H), 5.99 (s, 0.4H), 3.55-3.46 (m, 1.0H), 3.36-3.31 (m, 1.0H), 
2.91-2.76 (m, 0.9H), 2.13-2.06 (m, 3.0H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 175.8, 175.5, 171.3, 170.8, 168.9, 165.3, 157.0, 152.2, 
152.2, 151.0, 147.9, 147.3 (2x), 145.7, 142.8, 136.2, 135.2, 130.8, 130.1, 123.8, 122.9, 122.2, 
122.0, 121.6, 119.1, 114.7, 111.2, 55.8, 54.6, 51.4, 39.5, 25.5, 24.2. ppm. 
 
HRMS (ESI) Calc. for C22H21N9NaO5+: 514.1558 [M+Na]+ 
Found:    514.1558 [M+Na]+.  
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3) Triazolyl-Substituted AMPA derivatives – Synthetic Procedures 
 
tert-butyl 3-(3-(allyloxy)-5-formylisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propa-
noate (102) 
 
To a solution of nitrile 95 (100 mg, 203 µmol) in MePh (5 mL) was drop-wise added RedAl® 
(125 µL, 405 µmol; 65% in MePh) at -50 ºC and the resulting mixture was stirred for 60 min. 
The reaction as quenched by addition of 5% aqueous H2SO4 (5 mL) at 0 ºC and the biphasic 
mixture was allowed to warm to RT over 30 min. Brine (15 mL) was added and the mixture 
extracted with EtOAc (4 x 20 mL). The combined organic extracts were dried over MgSO4, 
filtered and concentrated. The obtained aldehyde 102 was sufficiently pure to be used directly 
in the next step. An analytical sample was obtained by preparative TLC (SiO2; CH2Cl2/MeOH 
= 95:5). 
 
Rf = 0.2 (PE/EtOAc = 10:1). 
 
IR (ATR): ṽ = 2980 (w), 2927 (w), 1735 (s), 1700 (s), 1510 (s), 1367 (s), 1279 (s), 1253 (m), 
1147 (s), 1123 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 9.82 (s, 1H), 6.07 (ddt, J = 17.2 Hz, J = 10.5 Hz, J = 
5.7 Hz, 1H), 5.43 (addd, J = 17.3 Hz, J = 1.5 Hz, J = 1.5 Hz, 1H), 5.32 (addd, J = 10.5 Hz, 
J = 1.2 Hz, J = 1.2 Hz, 1H), 4.42 (dd, J = 10.8 Hz, J = 4.4 Hz, 1H), 4.82 (dt, J = 5.7 H, 
J = 1.2, 2H), 3.43 (dd, J = 14.5 Hz, J = 10.8 Hz, 1H), 3.30 (dd, J = 14.6 Hz, 4.4 Hz, 1H), 1.47 
(s, 9H), 1.43 (s, 18H) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 179.2, 170.9, 168.5, 161.7, 152.4, 131.8, 119.4, 113.2, 83.4, 
82.2, 71.4, 57.5, 28.1 (2x), 21.6 ppm. 
 
HRMS (ESI) Calc. for C24H37N2NaO9+: 519.2313 [M+Na]+ 
Found:    519.2312 [M+Na]+. 
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tert-butyl 3-(3-(allyloxy)-5-ethynylisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)pro-
panoate (101) 
 
To a suspension of K2CO3 and crude aldehyde 102 in MeOH (10 mL) was added the Ohira-
Bestmann reagent[130] (49.5 mg, 258 µmol) at 0 ºC and the mixture was allowed to warm to 
RT over 3 h. Saturated aqueous NH4Cl solution (25 mL) was added and most of the MeOH 
removed on the rotavap. Water (just enough to dissolve all salts) was added and the mixture 
extracted using EtOAc (4 x 25 mL). The combined organic extracts were dried over MgSO4, 
filtered and concentrated. Normal phase flash-column chromatography (SiO2; PE/EtOAc = 
7:1) yielded 50 mg (63%, 2 steps) of alkyne 101 as a colorless oil. 
 
Rf  = 0.3 (PE/EtOAc = 7:1). 
 
IR (ATR): ṽ = 3247 (w), 2981 (m), 2119 (w), 1736 (s), 1702 (s), 1514 (s), 1368 (s), 1282 (m), 
1147 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 6.06 (ddt, J = 17.3 Hz, J = 10.5 Hz, J = 5.7 Hz, 1H), 5.40 
(addd, J = 17.3 Hz, J = 1.5 Hz, J = 1.5 Hz, 1H), 5.29 (addd, J = 10.5 Hz, J = 1.3 Hz, J = 
1.3 Hz, 1H), 4.99 (dd, J = 10.7 Hz, J = 4.4 Hz, 1H), 4.76 (mc, 2H), 3.57 (s, 1H), 3.17 (dd, J = 
14.8 Hz, J = 10.7 Hz, 1H), 3.09 (dd, J = 14.8 Hz, J = 4.4 Hz, 1H), 1.46 (s, 9H), 1.44 (s, 
18H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 170.2, 168.8, 152.2, 150.9, 132.2, 119.0, 111.1, 87.8, 83.0, 
82.0, 71.0, 70.3, 57.8, 28.1 (2x), 22.1 ppm. 
 
HRMS (ESI) Calc. for C25H36N2NaO8+: 515.2364 [M+Na]+ 
Found:    515.2362 [M+Na]+. 
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tert-butyl 3-(3-(allyloxy)-5-(1-benzyl-1H-1,2,3-triazol-4-yl)isoxazol-4-yl)-2-(bis(tert-buto-
xycarbonyl)amino)propanoate (104) 
 
To a solution of alkyne 101 (5.0 mg, 12.7 µmol) in THF/water (1 mL, 1:1) was added benzyl 
azide (2.5 mg, 19.1 µmol),[LIT] CuSO4•5H2O (0.6 mg, 2.55 µmol) and sodium ascorbate 
(0.6 mg, 3.19 µmol). After stirring overnight at RT or for 30 min. at 40 ºC in a sonicator bath, 
the reaction was diluted with brine (10 mL) and extracted with EtOAc (5 x 5 mL). The 
organic extracts were combined, dried over MgSO4, filtered and concentrated. Normal phase 
flash-column chromatography (SiO2; CH2Cl2/MeOH = 97:3) yielded 6.0 mg (90%) of triazole 
104 as a colorless oil. 
 
Rf  = 0.3 (CH2Cl2/MeOH = 97:3). 
 
IR (ATR): ṽ = 2980 (m), 2934 (w), 2363 (w), 1736 (s), 1701 (s), 1502 (s), 1456 (m), 1367 (s), 
1289 (m), 1144 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.82 (s, 1H), 7.43-7.28 (m, 5H), 6.07 (mc, 1H), 5.59 (d, J = 
14.8 Hz, 1H), 5.55 (d, J = 14.8 Hz, 1H), 5.40 (addd, J = 17.3 Hz, J = 1.5 Hz, J = 1.5 Hz), 
5.29-5.23 (m, 2H), 4.77 (mc, 2H), 3.48 (dd, J = 14.7 Hz, J = 4.1 Hz, 1H), 3.39 (dd, J = 14.7 
Hz, J = 10.9 Hz, 1H), 1.47 (s, 9H), 1.36 (s, 18H) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 171.3, 169.1, 159.0, 152.2, 138.3, 134.3, 132.5, 129.4, 129.1, 
128.6 (rotamer), 128.3, 127.7 (rotamer), 126.7 (rotamer), 121.9, 118.6, 103.5, 82.6, 81.6, 
70.8, 58.4, 54.5, 28.1, 28.0, 21.9 ppm. 
 
HRMS (ESI) Calc. for C32H43N5NaO8+: 648.3004 [M+Na]+ 
Found:    648.3005 [M+Na]+. 
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tert-butyl 3-(5-(1-benzyl-1H-1,2,3-triazol-4-yl)-3-hydroxyisoxazol-4-yl)-2-(bis(tert-buto-
xycarbonyl)amino)propanoate (S8) 
 
To a solution of allyl ether 104 (6.0 mg, 11.4 µmol) in MeOH (1.5 mL) was added Pd(PPh3)4 
(1.3 mg, 1.14 µmol) and K2CO3 (9.5 mg, 68.5 µmol) at RT and the suspension was stirred for 
1 h. Brine (4 mL) was added and the resulting mixture extracted with EtOAx (4 x 3 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated. Normal phase 
flash column chromatography (SiO2; CH2Cl2/MeOH = 95:5) yielded 5.0 mg (90%) of the free 
hydroxy isoxazole S8 as a colorless oil, which was used directly in the next step. 
 
Rf = 0.5 (CH2Cl2/MeOH = 9:1). 
 
2-amino-3-(5-(1-benzyl-1H-1,2,3-triazol-4-yl)-3-hydroxyisoxazol-4-yl)propanoic acid hy-
drochloride (105•HCl) 
 
A solution of hydroxyisoxazole S8 in EtOAc (1 mL) was saturated with HCl (generated from 
NaCl and conc. H2SO4) and the resulting mixture was stirred for 1 h at RT. The product was 
triturated with Et2O and pentane and collected by sedimentation. Thus, 1 mg (30%, 2 steps) of 
HCl-salt 105•HCl were obtained as a colorless, hygroscopic solid. Using a modified route, 
removing the allyl group before the click reaction and then treating the hydroxyisoxazole with 
HCl-saturated EtOAc as before, the yields could be improved drastically (60%, 2 steps). 
 
Rf  = 0.6 (C18, H2O/MeCN = 3:2). 
 
m.p. (EtOAc/Et2O) >180 (decomp.). 
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IR (ATR): ṽ = 1734, 1635, 1521, 1497, 1435, 1229, 1179, 1050 (no relative intensities 
assigned due to strong OH band from hydrate water) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.50-7.39 (m, 5H), 5.71 (s, 2H), 3.46 (dd, J = 9.7 Hz, J = 
4.9 Hz, 1H), 2.88 (dd, J = 14.3 Hz, J = 5.0 Hz, 1H), 2.66 (dd, J = 14.3, J = 9.7 Hz, 1H) (1 H 
obscured) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 182.2, 177.4, 156.6, 137.7, 134.6, 129.1, 128.8, 128.1, 106.8, 
55.6, 54.0, 27.6 (1 C obscured) ppm. 
 
HRMS (ESI) Calc. for C15H15N5NaO4+: 352.1016 [M+Na]+ 
Found:    352.1014 [M+Na]+. 
 
4) A Kainate-Derived Photoswitch – Synthetic Procedures 
 
Kainic acid (17) 
 
Kainic acid (17) was synthesized from (+)-carvone according to known procedures.[149] The 
spectral data matched those reported previously. 
 
(2S,3S,4S)-1-tert-butyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-(prop-1-en-2-yl)pyrrolidine-
1,2-dicarboxylate (110) 
 
Boc-protected kainic acid dimethyl ester (110) was synthesized according to known literature 
procedures.[83a, 146c] The spectral data matched those reported previously. 
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(2S,3S,4R)-1-tert-butyl 2-methyl 4-acetyl-3-(2-methoxy-2-oxoethyl)pyrrolidine-1,2-dicar-
boxylate (114) 
 
Ketone 114 was synthesized according to known literature procedures.[83a] The spectral data 
matched those reported previously. 
 
(2S,3S,4R)-1-tert-butyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-vinylpyrrolidine-1,2-dicar-
boxylate (111) 
 
To a solution of ketone 114 (20 mg, 58.2 µmol) in THF (2 mL) was added KHMDS (128 µL, 
64.1 µmol; 0.5 M in toluene) at -78 ºC and the mixture was stirred for 25 min. To this, a 
precooled solution of PhNTf2 (25.0 mg, 69.9 mmol) in THF (1 mL) was added drop-wise and 
stirring was continued for 1.5 h. The reaction was quenched by addition of saturated 
aqueous NH4Cl (5 mL) and was allowed to warm to room temperature. The biphasic mixture 
was extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts were dried 
over MgSO4, filtered and concentrated. 
 
Rf (OTf ether) = 0.4 (CH2Cl2/EtOAc = 20:1). 
 
To a solution of the crude triflic enol ether in DMF (2 mL) was added PPh3 (3.06 mg, 
11.6 µmol) and the mixture was degassed with Ar for 10 min. NEt3 (24.3 µL, 175 µmol) and 
Pd(OAc)2 (1.31 mg, 5.58 µmol) were added. The reaction was stirred for 5 min. at room 
temperature, formic acid (6.04 µL, 160 µmol) was added and the mixture stirred at 60 ºC for 
30 min. (Note: after some minutes, the reaction color changes from yellow to dark 
red/brownish within a couple seconds.) After cooling to room temperature, the reaction 
mixture was diluted with saturated aqueous NH4Cl (20 mL) and extracted with ethyl acetate 
(3 x 20 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; CH2Cl2:EtOAc = 22:1) 
yielded 5.0 mg (26%) of  protected nor-kainic acid 111 as a colorless oil. 
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Rf  = 0.3 (CH2Cl2/EtOAc = 15:1). 
 
1H NMR (CDCl3, 400 MHz; 4:6 ratio of Boc-rotamers) δ 5.65 (ddd, J = 17.1 Hz, J = 10.4 Hz, 
J = 8.5 Hz, 1H), 5.19-5.06 (m, 2H), 4.05-3.89 (m, 1H), 3.76-3.72 (m, 3H), 3.71-3.62 (m, 4H), 
3.53-3.36 (m, 1H), 3.10-3.00 (m, 1H), 2.78 (mc, 1H), 2.55-2.38 (m, 2H), 1.46 (s, 4H), 1.40 (s, 
5H) ppm. 
 
13C NMR (CDCl3, 100 MHz; Boc-rotamers) δ 172.9, 172.6, 172.2 (2x), 154.5, 153.8, 134.5, 
118.3, 80.5, 80.4, 63.4, 63.2, 52.5, 52.3, 50.4, 50.1, 44.3, 43.6, 42.9, 33.5, 33.4, 28.5, 28.4 
ppm. 
 
(2S,3S,4S)-1-tert-butyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-((E)-1-(4-((E)-phenyldiaze-
nyl)phenyl)prop-1-en-2-yl)pyrrolidine-1,2-dicarboxylate (119) 
 
To a solution of protected kainic acid 110 (200 mg, 586 µmol) in degassed DMF (20 mL) was 
added Pd(OAc)2 (26.3 mg, 117 µmol), tetrabutylammonium chloride (212 mg, 762 µmol), 
NaHCO3 (98.4 mg, 1.17 mmol) and 1-(4-iodophenyl)-2-phenyl-diazene (235 mg, 762 µmol) 
and the mixture was 60 ºC overnight. Saturated aqueous NH4Cl (20 mL) and brine (20 mL) 
were added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic 
extracts were washed with 10% aqueous NaCl solution (3 x 20 mL) and brine (1 x 20 mL), 
were dried over MgSO4, filtered and concentrated. Normal phase flash column 
chromatography (SiO2; PE/EtOAc = 5:1 to 3:1) yielded 46 mg (15%) of azobenzene-
substituted kainic acid derivative 119 as an orange thick oil. 
 
Rf  = 0.3 (CH2Cl2/EtOAc = 4:1). 
 
IR (ATR): ṽ = 3321 (w), 1737 (s), 1694 (s), 1575 (m), 1391 (m), 1202 (w), 1161 (w) cm–1. 
 
UV (CH2Cl2): λmax = 344 nm. 
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[!]!!" = -38.0 (c = 0.1, CH2Cl2). 
 
1H NMR (CDCl3, 400 MHz; 2:3 mixture of rotamers) δ 7.94-7.85 (m, 4H), 7.55-7.44 (m, 3H), 
7.36-7.32 (m, 2H), 6.30 (s, 1H), 4.20 (d, J = 3.8 Hz, 0.4 H), 4.11 (d, J = 4.1 Hz, 0.5H), 3.87-
3.73 (m, 4H), 3.73-3.57 (m, 4H), 3.28-3.16 (m, 1H), 3.04-2.94 (m, 1H), 2.51-2.32 (m, 2H), 
1.87 (s, 3H), 1.52-1.40 (m, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz; 2:3 mixture of rotamers) δ 172.8, 172.6, 172.4, 172.3, 154.4, 
153.8, 152.8, 151.1, 140.3, 136.5, 136.4, 131.1 (2x) 129.8 (2x), 129.2, 127.4, 127.2, 
122.9 (2x), 80.6, 64.3, 64.0, 52.6, 52.4, 52.1 (2x), 48.3, 48.0, 47.8, 47.6, 42.7, 41.7, 33.5 (2x), 
28.6, 28.4, 18.0, 17.8 ppm. 
 
HRMS (ESI) Calc. for C29H36N3O6+: 522.2595 [M+H]+ 
Found:    522.2599 [M+H]+. 
 
AzKA•Na (107•Na) 
 
Protected kainic acid derivative 119 (25 mg, 47.9 µmol) was heated under reflux in 1N KOH 
(30 mL) and MeOH (just enough to dissolve everything) for 18 h. MeOH was distilled off and 
the mixture was heated under reflux for another 18h. The mixture was acidified to pH = 3 by 
addition of AcOH, solids were filtered off and washed with water. The filtrate was neutralized 
by addition of saturated aqueous NaHCO3 solution and placed on a RP18 column. Reversed 
phase flash column chromatography (C18; H2O/MeCN = 100:0 to 50:50) yielded 
12 mg (60%) of the sodium salt AzKA•Na (107•Na) as an orange solid. 
 
Rf  = 0.4 (C18; H2O/MeCN = 3:2). 
 
IR (ATR): ṽ = 2927 (w), 1628 (m), 1576 (s), 1437 (m), 1392 (s), 1223 (m), 1049 (m) cm–1. 
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UV (HEPES-ringer): λmax = 368 nm. 
 
1H NMR (D2O, 400 MHz) δ 7.52-7.21 (m, 7H), 6.99 (d, J = 8.2 Hz, 2H), 5.82 (s, 1H), 3.16 (d, 
J = 3.4 Hz, 1H), 3.02-2.88 (m, 1H), 2.73-2.53 (m, 3H), 2.06-1.89 (m, 2H), 1.60 (s, 3H) ppm. 
 
13C NMR (D2O, 100 MHz) δ 181.3 (2x), 151.8, 149.6, 141.3, 139.2, 129.7, 129.3, 125.3, 
122.2 (2x), 67.0, 50.5, 47.3, 44.1, 37.4, 18.1 ppm. 
 
HRMS (ESI) Calc. for C22H24N3O4+: 394.1761 [M+H]+ 
Found:    394.1759 [M+H]+. 
 
5) 3-D-Substituted Glutamate Analogues – Synthetic Procedures 
 
(S)-Garner’s aldehyde (123) 
 
(S)-Garner’s aldehyde (123) was synthesized according to literature procedures and used 
directly in the next step.[157] The spectral data matched those reported previously. 
 
Rf = 0.6 (PE/EtOAc = 2:1). 
 
(S,E)-tert-butyl 4-(3-methoxy-3-oxoprop-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
(122a) 
 
To a solution of the (S)-Garners aldehyde 123 (3.97 g, 17.3 mmol) in MeCN (80 mL), lithium 
chloride (0.806 g, 19.0 mmol), DIPEA (3.30 mL, 19.0 mmol) and trimethyl phosphonoacetate 
(3.47 g, 19.0 mmol) were added at 0 °C. The mixture was stirred for 3 h at 0 °C and then 1 h 
at RT. Water (160 mL) was added to the reaction mixture and the acetonitrile was removed 
under reduced pressure. The residue was extracted with ether (4 x 100 mL) and the combined 
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organic extracts were washed with aqueous HCl (1 M, 100 mL) and brine (100 mL), dried 
over MgSO4 and concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc 
= 14:1 to 10:1) yielded 3.01 g (61%) of enone 122a and 1.20 g (24%) of its Z-isomer 122b as 
colorless solids. 
 
Rf  = 0.4 (PE/EtOAc = 4:1); Rf (Z-isomer) = 0.6 (PE/EtOAc = 4:1). 
 
IR (ATR): ṽ = 3388 (w), 2975 (m), 1721 (s), 1697 (s), 1660 (m), 1364 (m), 1167 (m) cm–1. 
 [!]!!" = +63.6 (c = 0.5, CH2Cl2). 
 
1H NMR (CDCl3, 400 MHz, rotamers) δ 6.85-6.73 (m, 1H), 5.89 (dd, J = 1.2 Hz, J = 15.6 Hz, 
1H), 4.61-4.31 (m, 1H), 4.08 (dd, J = 9.1, J = 6.4 Hz, 1H), 3.78 (dd, J = 9.1, J = 2.4 Hz, 1H), 
3.74 (br s, 3H), 1.69-1.32 (m, 15H) ppm. 
 
13C NMR (CDCl3, 100 MHz, rotamers) δ 167.5, 153.0, 147.9 (2x), 122.8, 95.3 81.1, 68.4, 
59.2 (2x), 52.2, 28.9, 27.5, 24.7 ppm. 
 
HRMS (ESI) Calc. for C14H27N2O5+: 303.1914 [M+NH4]+ 
Found:    303.1914 [M+NH4]+. 
 
(S)-tert-butyl 4-((R)-4-methoxy-4-oxo-1-phenylbutan-2-yl)-2,2-dimethyloxazolidine-3-
carboxylate (S9) 
 
To a suspension of LiBr (541 mg, 6.3 mmol) and CuBr·SMe2 (647.4 mg, 3.1 mmol, 3.0 eq) in 
THF (10.8 mL) was drop-wise added benzylmagnesium chloride (6.3 mL, 6.3 mmol; 1 M in 
THF) and the mixture was stirred for 40 min. A pre-cooled solution of oxazolidine 122a 
(300 mg, 1.05 mmol) and TMSCl (402 µL, 3.14 mmol) in THF (9 mL) was added in portions 
and the reaction was stirred 2 h at -40 °C. The reaction was quenched by addition of saturated 
aqueous NH4Cl (6 mL) and the biphasic mixture was allowed to warmed to RT. More 
saturated ammonium chloride solution (30 mL) was added and the phases were separated. The 
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aqueous phase was extracted with EtOAc (4 x 50 mL) and the combined organic phases were 
washed with brine (50 mL), dried over MgSO4, filtered and concentrated. Purification by 
normal phase flash column chromatography (SiO2; PE/EtOAc = 10:1) yielded 344 mg (87%) 
of ester S9 as a colorless oil. 
 
Rf  = 0.6 (PE/EtOAc = 4:1). 
 
IR (ATR): ṽ = 2976 (m), 1735 (s), 1693 (s), 1363 (m), 1162 (m) cm–1. 
 [!]!!" = +9.6 (c = 0.25, CH2Cl2). 
 
1H NMR (CD3CN 400 MHz, 70 ºC) δ 7.32-7.25 (m, 2H), 7.24-7.15 (dd, J = 8.1, J = 6.4 Hz, 
3H), 3.97-3.88 (m, 2H), 3.84-3.77 (m, 1H), 3.55 (s, 3H), 2.90-2.78 (m, 1H), 2.68 (dd, J = 
13.8, J = 6.5 Hz, 1H), 2.51 (dd, J = 15.9, J = 4.3 Hz, 2H), 2.24-2.11 (m, 1H), 1.59-1.29 (m, 
15H) ppm. 
 
13C NMR (CD3CN, 100 MHz, 70 ºC) δ 174.4, 153.8, 141.2, 130.4, 129.5, 127.3, 95.2, 80.9, 
64.8, 60.0, 52.0 (2x), 39.92, 39.14, 35.01, 28.95, 27.09, 23.75, 1.32. ppm. 
 
HRMS (ESI) Calc. for C21H32NO5+: 378.2275 [M+H]+ 
Found:      378.2274 [M+H]+. 
 
(3R,4S)-methyl 3-benzyl-4-(tert-butoxycarbonylamino)-5-hydroxypentanoate (S10) 
 
To a solution of oxazolidine S9 (343 mg, 0.913 mmol) and pTsOH (26.1 mg, 0.137 mmol) in 
MeOH (10 mL) was added water (8.2 µL, 0.46 mmol) and the reaction was stirred for 3 d at 
RT. Pyridine (19.2 µL, 0.237 mmol) was added and the reaction mixture was concentrated. 
The residue was purified using normal phase flash column chromatography (SiO2; 
CH2Cl2/MeOH = 98:2) to yield 277 mg (90%) of alcohol S10 as a colorless oil which was 
used directly in the next step without further characterization. 
 
Rf  = 0.3 (CH2Cl2/MeOH = 97.5:2.5).  
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(2S,3R)-dimethyl 3-benzyl-2-(tert-butoxycarbonylamino)pentanedioate (S11) 
 
To a biphasic mixture of alcohol S10 (200 mg, 0.622 mmol) in CH2Cl2 (3 mL) and water 
(6 mL) was added TEMPO (48 µL, 0.311 mmol) and DAIB (501 mg, 1.56 mmol). The 
reaction mixture was stirred 3 h at RT, when water (60 mL) was added and the pH was 
adjusted with KHSO4 to pH = 2. The phases were separated and the aqueous solution was 
extracted with EtOAc (6 x 30 mL). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated. The residue was dissolved in MeOH (20 mL) and the resulting 
solution was cooled to 0 °C. TMS-diazomethane (3.9 mL, 8.28 mmol) was added in portions 
over 3 h. The excess of the reagent was quenched by addition of acetic acid (267 µL, 
4.67 mmol) and the crude reaction mixture was concentrated. Purification by normal phase 
flash column chromatography (SiO2; PE/EtOAc = 7:1) yielded 151 mg (68%, 2 steps) of 
diester S11 as a colorless oil. 
 
Rf  = 0.3 (PE/EtOAc = 4:1). 
 
IR (ATR): ṽ = 3368 (m), 2952 (m), 1735 (s), 1711 (s), 1365 (m), 1162 (m) cm–1. 
 [!]!!" = +26.8 (c = 0.5, CH2Cl2). 
 
1H NMR (CDCl3, 400 MHz) δ 7.29-7.23 (m, 2H), 7.21-7.17 (m, 1H), 7.14 (dd, J = 8.1 Hz, J = 
1.4 Hz, 2H), 5.11 (d, J = 8.3 Hz, 1H), 4.59 (d, J = 8.1 Hz, 1H), 3.66 (s, 3H), 3.59 (s, 3H), 
2.91-2.80 (m, 1H), 2.64 (dd, J = 13.8, J = 5.7 Hz, 1H), 2.5-2.33 (m, 2H,), 2.30-2.14 (m, 1H), 
1.38 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 172.8, 172.45, 155.8, 138.7, 129.4, 128.6, 126.7, 80.2, 55.8, 
52. 5, 51.9, 51.8, 39.8, 36.3, 35.1, 28.4 ppm. 
 
HRMS (ESI) Calc. for C19H27KNO6+: 404.1470 [M+K]+ 
Found:      404.1475 [M+K]+. 
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(2S,3R)-3-benzyl-2-(tert-butoxycarbonylamino)pentanedioic acid (S12) 
 
To a solution of diester S12 (121 mg, 365 µmol) in THF/water (6 mL, 1:1) was added LiOH 
(159 mg, 6.62 mmol) at 0 ºC and the reaction mixture was stirred for 90 min at RT. The 
biphasic mixture was acidified by addition of FA (235 µL, 6.62 mmol) and subsequently 
purified using reverse phase flash column chromatography (C18, H2O/MeCN/FA = 
100:0:0.1% to 3:2:0.1%) to yield 91 mg (80%) of diacid S12 as a colorless solid, which was 
used directly in the next step. 
 
Rf = 0.4 (C18, H2O/MeCN/FA = 4:1:0.1%) 
 
(2S,3R)-2-amino-3-benzylpentanedioic acid formate salt (124•FA) 
 
Diacid S12 (90.5 mg, 0.268 mmol) was treated with a saturated solution of HCl in EtOAc 
(6 mL) and stirred overnight at RT. The product was precipitated by addition of Et2O (90 mL) 
and collected by sedimentation. Due to formation of byproducts, the product was purified by 
reversed phase flash column chromatography (C18, water/0.1% FA) to yield 10 mg (15%) of 
formate salt 124•FA as a colorless solid. 
 
Rf  = 0.2 (C18, H2O/0.1% FA). 
 
m.p. (H2O) > 300 ºC (decomp.). 
 
IR (ATR): ṽ = 3511 (m), 2583 (m), 2786 (m), 1601 (s), 1421 (s), 1365 (m), 1162 (m) cm–1. 
 [!]!!" = +14.0 (c = 0.2, H2O). 
 
1H NMR (D2O, 400 MHz) δ 7.32-7.21 (m, 2H), 7.20-7.11 (m, 3H), 3.25-3.19 (m, 1H), 2.60-
2.46 (m, 1H), 2.41-2.29 (m, 2H), 2.15-2.01 (m, 1H), 2.00-1.89 (m, 1H) ppm. 
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13C NMR (D2O, 100 MHz) δ 181.8, 181.6, 140.5, 129.4, 128.4, 126.0, 57.9, 42.1, 39.0, 
35.0 ppm. 
 
HRMS (ESI) Calc. for C12H14NO4–: 236.0928 [M-H]– 
Found:    236.0927 [M-H]–. 
 
(S)-tert-butyl 4-((R)-1-methoxy-1-oxohex-5-en-3-yl)-2,2-dimethyloxazolidine-3-carboxy-
late (128) 
 
To a solution of tetraallyl tin (593 µL, 2.47 mmol) in Et2O (5 mL) was added MeLi (5.2 mL, 
10.3 mmol; 1.6 M in Et2O) at 0 ºC and the mixture was stirred for 20 min. This salt-free 
allyllithium solution was transferred to a suspension of CuBr·SMe2 (984 mg, 4.80 mmol) and 
SMe2 (8.3 mL, 114 mmol) in Et2O (15 mL) at -78 °C and then stirred for 10 min. To the dark 
mixture was added a solution of oxazolidine 122a (447 mg, 1.6 mmol) and TMSCl (599 µL, 
4.70 mmol) in Et2O (5 mL) in portions. After stirring for 16 h at -78 °C, the reaction mixture 
was warmed to -60 °C and stirred at that temperature for further 3 h before it was quenched 
by fast addition of saturated aqueous NH4Cl (30 mL). After warming to RT, more saturated 
NH4Cl (20 mL) was added to dissolve all of the precipitate. The mixture was stirred until the 
lower, aqueous phase turned blue. EtOAc (20 mL) was added, the phases were separated and 
the aqueous phase was extracted with EtOAc (4 x 50 mL). The combined organic extracts 
were washed with aqueous KF (10 mL; 10%), dried over MgSO4, filtered and concentrated. 
Normal phase flash column chromatography (SiO2; PE/EtOAc = 10:1) gave 345 mg (67%) of 
allylated ester 128 as a colorless solid and a single diastereomer, which was proven by X-ray 
crystallography (P. Mayer). Suitable crystals for X-ray analysis were grown by diffusion of 
PE into a solution of 128 in Et2O.  
O NBoc
H
128
COOMe
Experimental 
195 
Supporting Table 1. Crystallographic data for 128. 
net formula C17H29NO5 
Mr/g mol−1 327.416 
crystal size/mm 0.50 × 0.15 × 0.11 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1 
a/Å 5.9071(11) 
b/Å 9.248(2) 
c/Å 9.547(2) 
α/° 102.27(2) 
β/° 104.524(19) 
γ/° 103.797(19) 
V/Å3 469.29(17) 
Z 1 
calc. density/g cm−3 1.1585(4) 
µ/mm−1 0.084 
absorption correction 'multi-scan' 
transmission factor range 0.77914–1.00000 
refls. measured 2925 
Rint 0.0382 
mean σ(I)/I 0.0655 
θ range 4.53–25.48 
observed refls. 1393 
x, y (weighting scheme) 0.0801, 0 
hydrogen refinement constr 
Flack parameter −0.7(19) 
refls in refinement 2140 
parameters 208 
restraints 3 
R(Fobs) 0.0514 
Rw(F2) 0.1298 
S 0.924 
shift/errormax 0.001 
max electron density/e Å−3 0.293 
min electron density/e Å−3 −0.174 
 
	  
Supporting Figure 1. X-Ray crystal structure of 128. 	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Rf  = 0.6 (PE/EtOAc = 4:1). 
 
m.p. (PE/Et2O) = 61-64 ºC. 
 
IR (ATR): ṽ = 3367 (m), 3075 (w), 2975 (m), 1737 (s), 1689 (s), 1363 (s), 1164 (m) cm–1. 
 [!]!!" = +13.2 (c = 0.5, CH2Cl2). 
 
1H NMR (CDCl3, 600 MHz; rotamers) δ 5.83-5.67 (m, 1H), 5.07-4.98 (m, 2H), 4.12-2.86 (m, 
2H), 3.79 (dd, J = 9.3 Hz, J = 1.8 Hz, 1H), 3.64 (s, 3H), 2.71-2.45 (m, 2H), 2.25-2.09 (m, 
2H), 1.66-1.52 (m, 3H), 1.48 (s, 9H), 1.44 (s, 3H) ppm. 
 
13C NMR (CDCl3, 150 MHz; rotamers) δ 207.0, 173.7, 136.2, 117.0, 94.5, 94.0, 80.29, 63.8, 
59.5, 58.6, 51.6, 36.8, 36.4, 34.2, 33.9, 28.6, 28.5, 27.0, 26.3, 24.1, 22.6 ppm. 
 
HRMS (ESI) Calc. for C17H29KNO5+: 366.1677 [M+K]+ 
Found:    366.1683 [M+K]+. 
 
(2S,3R)-dimethyl 3-allyl-2-(tert-butoxycarbonylamino)pentanedioate (129) 
 
To a solution of hemi-aminal 128 (500 mg, 1.53 mmol) in acetone (50 mL) was added Jones 
Reagent (3.43 mL, 9.16 mmol; 2.67 M) at 0 ºC and the mixture was allowed to warm to 15 ºC 
over 4 h. Excess of Jones Reagent was quenched by addition of i-PrOH and stirring for 
15 min at RT. The pH was adjusted to pH = 3-4 by addition of saturated aqueous NaHCO3. 
The mixture was diluted with EtOAc (100 mL) and solids were filtered off over a celite-plug 
eluting with EtOAc. To the biphasic mixture was added brine (100 mL) and 2N HCl (a few 
drops to ensure pH = 3-4) and extracted with EtOAc (3 x 50 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated. The residue was dried on high-
vacuum, dissolved in MePh/MeOH (7:1, 80 mL) and TMSCHN2 (1.15 mL, 2.29 mmol; 2M in 
hexanes) was drop-wise added at 0ºC. Stirring was continued for 15 min, then the excess 
of TMSCHN2 was destroyed by addition of AcOH. The solvent was removed under reduced 
pressure and the residue was purified using normal phase flash column chromatography 
129
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(SiO2; PE/EtOAc = 7:1) to yield 406 mg (84%; 2 steps) of dimethyl ester 129 as a colorless 
oil. 
 
Rf = 0.4 (PE/EtOAc = 4:1). 
 
IR (ATR): ṽ = 3372 (w), 3077 (w), 2977 (w), 1735 (s), 1711 (s), 1366 (m), 1157 (s) cm–1. 
 [!]!!" = +26.8 (c = 0.5, CH2Cl2). 
 
1H NMR (CDCl3, 400 MHz) δ 5.76-5.61 (m, 1H), 5.20-5.12 (m, 1H), 5.10-5.02 (m, 2H), 
4.55-4.47 (m, 1H), 3.73 (s, 3H), 3.66 (s, 3H), 2.62-2.49 (br m, 1H), 2.37 (dd, J = 16.7 Hz, J = 
7.6 Hz, 1H), 2.29 (dd, J = 16.7 Hz, J = 6.3 Hz, 1H), 2.14-2.06 (m, 1H), 2.03-1.92 (m, 1H), 
1.42 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 172.9, 172.4, 155.7, 135.2, 118.0, 80.1, 55.8, 52.4, 51.8, 37.6, 
35.1, 34.8, 28.4 ppm. 
 
HRMS (ESI) Calc. for C15H24NO6–:  314.1609 [M-H]– 
Found:    314.1607 [M-H]–. 
 
(2S,3R)-3-allyl-2-aminopentanedioic acid TFA salt (125•TFA) 
 
To a solution of diester 129 (150 mg, 0.476 mmol) in THF/water (7 mL, 1:1) was added 
LiOH (228 mg, 9.51 mmol) and the reaction was stirred for 4 h at 0 °C. The reaction was 
quenched by addition of formic acid (313 µL, 9.51 mmol) and the pH value was adjusted with 
KHSO4 to pH = 2. The resulting mixture was diluted with water (5 mL) and the aqueous 
solution was extracted with EtOAc (6 x 10 mL). The combined organic extracts were dried 
over Na2SO4, filtered and concentrated. The residue was cooled to 0 °C, dissolved in 
TFA/CH2Cl2 (9 mL, 1:1) and stirred for 2 h. Water (10 mL) was added and the crude reaction 
mixture was concentrated. The resulting syrup was re-dissolved in water (15 mL) and 
125•TFA
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extracted with EtOAc (1 x 5 mL) and ether (1 x 5 mL). The aqueous layer was lyophilized 
over night to yield 120 mg (89%) of TFA-salt 125•TFA as a colorless solid. 
 
Rf = 0.6 (C18; H2O, 0.1% FA). 
 
IR (ATR): ṽ = 3372 (w), 2972 (m), 2551 (w), 1974 (br), 1656 (m), 1418 (m), 1182 (s), 
1140 (s) cm–1. 
 
m.p. (H2O) = 117-122 ºC (decomp). 
 [!]!!" = +10.0 (c = 0.2, H2O). 
 
1H NMR (D2O, 400 MHz) δ 5.67-5.54 (m, 1H), 4.91-4.80 (m, 2H), 3.01 (d, J = 4.0 Hz, 1H), 
2.05-1.91 (m, 3H), 1.90-1.71 (m, 2H) ppm. 
 
13C NMR (D2O, 100 MHz) δ 182.0, 181.8, 136.9, 116.6, 58.3, 39.6, 39.5, 33.6 ppm. 
 
HRMS (ESI) Calc. for C15H24NO6–: 186.0766 [M-H]– 
Found:    186.0771 [M-H]–. 
 
(2S,3R)-2-amino-3-propylpentanedioic acid TFA salt (127•TFA) 
 
To a solution of 3-allyl-glutamic acid TFA salt 125•TFA (20 mg, 69.9 µmol) in MeOH (3 
mL) was added Pd/C (7.5 mg, 7.0 µmol; 10% on charcoal) and the vessel was purged with N2 
and then charged with H2. After stirring for 4.5 h at RT, solids were filtered off over a short 
celite column (eluting with MeOH) and the solvent was removed under reduced pressure to 
yield 20 mg (quant.) of glutamate-analogue TFA salt 127•TFA as a colorless solid. 
 
Rf = 0.6 (C18; H2O, 0.1% FA). 
 
127•TFA
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IR (ATR): ṽ = 3217 (m), 2963 (m), 2545 (w), 1994 (br), 1710 (s), 1581 (s), 1431 (m), 
1209 (s) cm–1. 
 
m.p. (MeOH) > 117 ºC (decomp). 
 [!]!!" = +6.0 (c = 0.1, H2O). 
 
1H NMR (D2O, 400 MHz) δ 3.85-3.79 (m, 1H), 2.41-2.30 (m, 3H), 1.31-1.13 (m, 4H), 0.80-
0.64 (m, 3H) ppm. 
 
13C NMR (D2O, 100 MHz) δ 176.6, 172.4, 56.7, 35.2 (2x), 31.7, 19.4, 12.9 ppm. 
 
HRMS (ESI) Calc. for C8H14NO4–:  188.0928 [M-H]– 
Found:    188.0926 [M-H]–. 
 
(2S,3R)-dimethyl 2-(tert-butoxycarbonylamino)-3-((E)-3-(4-(phenyldiazenyl)phenyl)al-
lyl)pentanedioate (130) 
 
To a solution of diester 129 (150 mg, 476 µmol) in degassed DMF (20 mL) was added 
Pd(OAc)2 (21.4 mg, 95.1 µmol), NaHCO3 (79.9 mg, 951 µmol), tetrabutylammonium 
chloride (172 mg, 618 µmol) and 1-(4-iodophenyl)-2-phenyl-diazene (191 mg, 618 µmol). 
The suspension was degassed with Ar and then stirred overnight at 60 ºC. The reaction was 
quenched by addition of saturated aqueous NH4Cl (20 mL) and the mixture was extracted 
with EtOAc (3 x 20 mL). The combined organic extracts were washed with 10% aqueous 
NaCl solution (2 x 30 mL) and brine (1 x 30 mL), dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc= 5:1 to 3:1) 
yielded 213 mg (90%) of azobenzene 130 as an orange wax. 
Rf = 0.4 (PE/EtOAc = 3:1). 
 
MeOOC COOMe
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IR (ATR): ṽ = 3430 (w), 2960 (w), 1724 (s), 1709 (s), 1507 (m), 1232 (w), 1152 (m) cm–1. 
 
UV (CH2Cl2): λmax = 364 nm. 
 [!]!!" = +7.0 (c = 0.1, CH2Cl2). 
 
1H NMR (CDCl3, 400 MHz) δ 7.95-7.83 (m, 4H), 7.57-7.41 (m, 5H), 6.47 (d, J = 15.7 Hz, 
1H), 6.28-6.18 (m, 1H), 5.27-5.14 (m, 1H), 4.62-4.50 (m, 1H), 3.73 (s, 3H), 3.64 (s, 3H), 
2.81-2.65 (m, 1H), 2.48 (dd, J = 16.7 Hz, J = 7.2 Hz, 1H), 2.40-2.27 (m, 2H), 2.25-2.15 (m, 
1H), 1.45 (s, 9H) ppm. 
 
13C NMR (D2O, 100 MHz) δ 172.9, 172.4, 155.8, 152.9, 151.9, 139.9, 132.3, 131.0, 129.2, 
129.1, 126.9, 123.4, 122.9, 80.3, 56.0, 52.6, 51.9, 38.2, 35.7, 34.2, 28.4 ppm. 
 
HRMS (ESI) Calc. for C27H33N3NaO6+: 518.2262 [M+H]+ 
Found:    518.2255 [M+H]+. 
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6) A Photoswitched Tethered Ligand of mGluRs – Synthetic Procedures 
 
Overview: 
	  
Supporting Scheme 2. Stereoselective synthesis of D-MAG0 (198•HCl) starting from L-glutamic 
acid (1).  
HOOC COOH
NH2
1
1) MeOH, TMSCl
2) Boc2O, NEt3
    83% (2 steps)
MeOOC COOMe
NHBoc
191
1) LiHMDS
2) allyl bromide
    83% (2 steps)
MeOOC COOMe
NHBoc
192
acrylic acid
Grubbs II
MeOOC COOMe
NHBoc
HOOC
(not isolated)
Pd/C, H2
EtOAc
81% (2 Steps)
MeOOC COOMe
NHBoc
HOOC
194
MeOOC COOMe
NHBocO
NH
N
N
H2N
195
4,4'-azo dianiline
HBTU, DIPEA
67%
1) Fmoc-Gly-Cl,
     DMAP
2) piperidine
    60% (2 steps)
MeOOC COOMe
NHBocO
NH
N
N
H
N
O
H2N
196
HOOC COOH
NHBocO
NH
N
N
H
N
O
H2N
197
LiOH
THF/H2O
73%
1) N-methoxycarbonyl 
    maleimide, NaHCO3
2) HCl
    70% (2 steps)
HOOC COOH
NH2 • HClO
NH
N
N
H
N
O
N
O
O
D-MAG0 (198•HCl)
Experimental 
202 
 (S)-dimethyl 2-(tert-butoxycarbonylamino)pentanedioate (191) 
 
Boc glutamic acid dimethyl ester 191 was synthesized according to literature procedures.[189] 
The spectral data matched those reported previously. 
 
(2S,4S)-dimethyl 2-allyl-4-(tert-butoxycarbonylamino)pentanedioate (192) 
 
Allylated glutamic acid derivative 192 was synthesized according to literature procedures.[188] 
The analytical data matched those reported previously. 
 
(5S,7S)-7-(tert-butoxycarbonylamino)-8-methoxy-5-(methoxycarbonyl)-8-oxo-octanoic 
acid (194) 
 
To a solution of pentanedioate 192 (1.50 g, 4.76 mmol) and freshly distilled acrylic acid (0.46 
mL, 6.66 mmol) in degassed CH2Cl2 (25 mL) was added solid Grubbs II catalyst (238 mg, 
0.238 mmol) and the mixture was heated under reflux for 4 h. The reaction was allowed to 
cool to room temperature and was passed over a plug of celite eluting with EtOAc (100 mL). 
After removal of the solvent under reduced pressure, the tan residue was dissolved in EtOAc 
(100 mL) and Pd/C (507 mg, 0.476 mmol; 10% Pd on charcoal) was added. The vessel was 
purged with N2, charged with H2 and the reaction was stirred overnight at room temperature. 
The mixture was filtered over a plug of celite eluting with EtOAc (100 mL) and the solvent 
was removed under reduced pressure. Normal phase column chromatography (SiO2; 
CH2Cl2/EtOAc/AcOH = 4:1:1% to 3:2:1%) yielded 1.40 g (81%, 2 steps) of acid 194 as a tan 
oil.  
 
Rf = 0.6 (CH2Cl2/EtOAc/AcOH = 3:2:1%). 
 
IR (ATR): ṽ = 2954 (w), 1708 (s), 1515 (m), 1436 (m), 1367 (m), 1212 (m), 1157 (s), 1052 
(m), 1023 (w) cm–1. [!]!!" = +8.8 (c = 1.0, CH2Cl2). 
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1H NMR (CDCl3, 300 MHz) δ 4.99 (d, 3J = 8.6 Hz, 1H), 4.42-4.25 (m, 1H), 3.72 (s, 3H), 3.68 
(s, 3H), 2.60-2.42 (m, 1H), 2.34 (t, 3J = 6.7 Hz, 2H), 2.12-1.86 (m, 2H), 1.76-1.54 (br m, 4H), 
1.43 (s, 9H) ppm. 
 
13C NMR (CDCl3, 75.5 MHz) δ 178.4, 175.9, 172.9, 155.5, 80.3, 52.6, 52.3, 52.0, 42.0, 34.6, 
33.7, 31.7, 28.4, 22.2 ppm. 
 
HRMS (ESI) Calc. for C16H27NNaO8+: 384.1634 [M+Na]+ 
Found:    384.1626 [M+Na]+. 
 
(2S,4S)-dimethyl 2-(4-(4-((E)-(4-aminophenyl)diazenyl)phenylamino)-4-oxobutyl)-4-
(tert-butoxycarbonylamino)pentanedioate (195) 
 
To a solution of acid 194 (1.20 g, 3.32 mmol) in DMF (150 mL) was added 4,4’-azo dianiline 
(1.41 g, 6.64 mmol), DIPEA (2.30 mL, 13.3 mmol) and HBTU (1.39 g, 3.65 mmol) and the 
mixture was stirred overnight at room temperature. The solvent was removed under reduced 
pressure and the residue was partitioned between ethyl acetate (500 mL) and a saturated 
aqueous solution of NaHCO3 (200 mL). The organic phase was washed with saturated 
aqueous NaHCO3 (200 mL), water (200 mL) and brine (200 mL), dried over MgSO4, filtered 
and concentrated. Normal phase flash column chromatography (SiO2; CH2Cl2/EtOAc = 4:1 to 
3:2) afforded 1.23 g (67%) of amide 195 as an orange solid. 
 
Rf = 0.3 (CH2Cl2/EtOAc/ACOH = 7:3:1%). 
 
m.p. (CH2Cl2/EtOAc) = 82.8-88.5 ºC. 
 [!]!!" = +32.0 (c 0.1, CH2Cl2). 
 
UV (CH2Cl2): λmax = 384 nm. 
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IR (ATR): ṽ = 3356 (w), 2950 (w), 1686 (m), 1625 (m), 1594 (s), 1527 (s), 1505 (s), 1424 
(m), 1392 (m), 1366 (m), 1297 (m), 1241 (s), 1150 (s), 1139 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 8.28-8.05 (m, 1H), 8.05-7.77 (m, 4H), 7.74-7.58 (m, 2H), 6.73 
(d, J = 8.9 Hz, 2H), 5.12 (d, J = 9.0 Hz, 1H), 4.43-4.30 (m, 1H), 4.21-3.95 (m, 2H), 3.72 (s, 
3H), 3.69 (s, 3H), 2.60-2.53 (m, 1H), 2.43-2.26 (m, 2H), 2.06-1.90 (m, 2H), 1.89-1.57 (m, 
4H), 1.46 (s, 9H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 176.0, 172.7, 171.2, 155.9, 149.5, 149.3, 145.7, 139.9, 125.1, 
123.4, 119.9, 114.8, 80.6, 52.7, 52.1, 52.0, 41.3, 36.7, 35.5, 30.9, 28.5, 23.1 ppm. 
 
HRMS (ESI) Calc. for C28H37N5NaO7+: 578.2591 [M+Na]+ 
Found:    578.2584 [M+Na]+. 
 
(2S,4S)-dimethyl 2-(4-(4-((E)-(4-(2-aminoacetamido)phenyl)diazenyl)phenylami no)-4-
oxobutyl)-4-(tert-butoxycarbonylamino)pentanedioate (196) 
 
To a solution of Fmoc glycine (1.31 g, 4.39 mmol) in THF (20 mL) was added oxalyl chloride 
(2.31 mL; 4.61 mmol; 1 M in CH2Cl2) and one drop of DMF and the mixture was stirred for 
45 min. at 0 ºC. The solvent was distilled off with a short distillation bridge under reduced 
pressure. The residue was dissolved in THF (20 mL) and added to a solution of aniline 195 
(1.22 g, 2.20 mmol), DIPEA (1.52 mL, 8.78 mmol) and DMAP (26.8 mg, 0.220 mmol) in 
THF at 0 ºC. The mixture was stirred for 1 h at 0 ºC and then for 1 h at room temperature. The 
reaction was diluted with EtOAc (500 mL) and washed successively with a saturated aqueous 
solution of NH4Cl (200 mL), water (200 mL) and brine (200 mL), dried over MgSO4, filtered 
and concentrated.  
 
Rf (FmocGly adduct) = 0.3 (CH2Cl2/MeOH = 95:5). 
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The residue was dissolved in DMF (200 mL) and piperidine (1.30 mL, 13.2 mmol) was 
added. The mixture was stirred overnight at room temperature and then concentrated under 
reduced pressure. The residue was partitioned between saturated aqueous NaHCO3 (300 mL) 
and EtOAc (150 mL). The organic phase was washed with saturated aqueous NaHCO3 
solution (2 x 100 mL), water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and 
concentrated. The product was purified using normal phase column chromatography (SiO2; 
CH2Cl2/MeOH/AcOH/H2O = 9:1:1%:1% to 4:1:1%:1%). The product containing fractions 
were washed with saturated aqueous NaHCO3 (1 x 200 mL), dried over Na2SO4, filtered and 
concentrated to yield 803 mg (60%, 2 steps) of the primary amine 196 as a red solid.  
 
Rf = 0.4 (CH2Cl2/MeOH/AcOH/H2O = 7:3:1%:1%). 
 
m.p. (CH2Cl2/MeOH) = 146-156 ºC. 
 [!]!!"  = +30.0 (c 0.1, CH2Cl2). 
 
UV (CH2Cl2): λmax = 368 nm. 
 
IR (ATR): ṽ = 3282 (w), 2920 (m), 2850 (m), 1682 (m), 1591 (m), 1528 (s), 1500 (m), 1434 
(m), 1409 (m), 1366 (m), 1299 (m), 1249 (s), 1153 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 9.64 (s, 1H), 8.35-8.20 (m, 1H), 8.00-7.84 (m, 4H), 7.83-7.64 
(m, 4H), 5.13 (d, J = 8.9 Hz, 1H), 4.44-4.26 (m, 1H), 3.72 (s, 3H), 3.69 (s, 3H), 3.51 (s, 2H), 
2.62-2.47 (m, 1H), 2.46-2.22 (m, 2H), 2.09-1.91 (m, 2H), 1.89-1.62 (m, 6H), 1.46 (s, 
9H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 176.0, 172.7, 171.3, 171.1, 155.9, 149.2, 149.0, 140.0, 129.3, 
124.0, 123.9, 119.8, 119.6, 80.6, 52.7, 52.1, 52.0, 45.3, 41.3, 36.7, 35.5, 30.9, 28.5, 23.1 ppm. 
 
HRMS (ESI) Calc. for C30H41N6O8+:  613.2986 [M+H]+ 
Found:    613.2975 [M+H]+.  
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(2S,4S)-2-(4-(4-((E)-(4-(2-aminoacetamido)phenyl)diazenyl)phenylamino)-4-oxo butyl)-
4-(tert-butoxycarbonylamino)pentanedioic acid (197) 
 
To a solution of diester 196 (760 mg, 1.24 mmol) in THF/water (100 mL; 2:1) was added 
LiOH (743 mg, 31.0 mmol) at 0 ºC and the reaction was stirred for 1 h. The mixture was 
neutralized by addition of formic acid (1.17 mL, 31.0 mmol) and THF was removed under 
reduced pressure. The residual aqueous solution was added on top of a RP18 column, washed 
with water/formic acid (100 mL, 0.1% FA) and the crude product was purified by reversed 
phase flash column chromatography (C18; H2O/MeCN/FA = 99.9:0:0.1 to 74.9:25:0.1) to 
yield 529 mg (73%) of diacid 197 as an orange solid. 
 
Rf = 0.4 (C18; H2O/MeCN/FA = 65:35:1%). 
 
mp (H2O/MeCN) > 180 ºC decomp. 
 [!]!!"  = -14.8 (c 0.1, MeCN/H2O = 9:1). 
 
UV (MeCN): λmax = 369 nm. 
 
IR (ATR): ṽ = 2929 (w), 2362 (m), 2337 (m), 1662 (m), 1592 (m), 1534 (m), 1497 (m), 1301 
(m), 1248 (m), 1153 (m) cm–1. 
 
1H NMR (DMSO-d6, 400 MHz) δ 10.3-10.2 (m, 1H), 8.27 (br s, 3H), 7.89-7.84 (m, 2H), 
7.82-7.78 (m, 6H), 6.63 (d, J =  7.9 Hz, 1H), 3.91 (dd, J = 8.0 Hz, J = 8.1 Hz, 1H), 3.80 (s, 
2H), 2.43-2.30 (m, 3H), 1.86-1.84 (m, 6H), 1.36 (s, 9H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz) δ 176.4, 174.3, 171.5, 164.2, 155.1, 148.0, 147.5, 142.2. 
140.8, 123.5, 123.4, 119.5, 119.3, 77.9, 52.2, 41.7, 36.6, 34.5, 33.5, 30.9, 28.2, 23.0 ppm. 
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HRMS (ESI) Calc. for C28H37N6O8+: 585.2673 [M+H]+ 
Found:    585.2665 [M+H]+. 
 
(2S,4S)-2-amino-4-(4-(4-((E)-(4-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamido)-
phenyl)diazenyl)phenylamino)-4-oxobutyl)pentanedioic acid hydrochloride (D-MAG0, 
198•HCl) 
 
To a solution of diacid 197 (50.0 mg, 42.8 µmol) in saturated aqueous NaHCO3 (7 mL) was 
added finely ground N-methoxycarbonylmaleimide (26.5 mg, 117 µmol) under vigorous 
stirring at 0 ºC. The mixture was stirred for 30 min and then diluted with THF (7 mL). The ice 
bath was removed for 10 min. The solution was re-cooled to 0 ºC, acidified to pH 1-2 with 
aqueous 1.0 M H2SO4 and extracted with ethyl acetate (2 x 25 mL). The combined organic 
extracts were dried over Na2SO4, filtered and concentrated. Normal phase flash column 
chromatography (SiO2; CH2Cl2/MeOH/AcOH/H2O = 9:1:0.6%:0.6%) yielded the maleimide 
adduct as an orange solid. 
 
Rf (maleimide diacid) = 0.5 (SiO2; CH2Cl2/MeOH/AcOH/H2O = 4:1:1%:1%). 
 
The crude product was directly treated with a saturated solution of HCl in EtOAc (20 mL). 
After stirring for 2 h at room temperature, the resulting purple suspension was diluted with 
Et2O (30 mL) and the solid was collected by sedimentation. The product was re-suspended in 
Et2O (20 mL) and sedimented again. Removal oft the solvent afforded 40.0 mg (70%, 2 steps) 
of D-MAG0 (198•HCl) as a purple solid. 
 
Rf = 0.3 (C18; H2O/MeCN/FA = 3:2:0.1%). 
 
m.p. (Et2O/EtOAc) > 180 ºC (decomp.). 
 [!]!!"   = +81.8 (c = 0.1, HEPES buffer + 0.1% DMSO). 
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UV (HEPES ringer, 0.1% DMSO): λmax = 362 nm. 
 
IR (ATR): ṽ = 2916 (w), 1710 (s), 1592 (s), 1535 (s), 1499 (m), 1428 (m), 1412 (m), 1300 
(m), 1250 (s), 1151 (s) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 10.8 (s, 1H), 10.4 (s, 1H), 8.42 (br s, 3H), 7.86-7.74 (m, 
8H), 7.19 (s, 2H), 4.32 (s, 2H), 3.79 (br s, 1H), 2.64-2.56 (m, 1H), 2.42-2.29 (m, 2H), 2.09-
2.01 (m, 1H), 1.84 (ddd, J = 6.0 Hz, J = 7.8 Hz, J = 13.9 Hz, 1H), 1.66-1.51 (m, 4H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 175.5, 171.4, 170.7, 170.6, 165.3, 147.8, 147.5, 142.1, 
141.1, 135.0, 123.4 (2 C), 119.4, 119.2, 50.3, 40.5, 40.3, 36.2, 31.7, 31.1, 22.2 ppm. 
 
HRMS (ESI) Calc. for C27H29N6O8+: 565.2047 [M+H]+ 
Found:    565.2039 [M+H]+. 
 
(2S,4S)-dimethyl 2-(tert-butoxycarbonylamino)-4-(4-oxo-4-(phenylamino)butyl) pentane-
dioate (S13) 
 
To a solution of acid 194 (50 mg, 0.138 mmol) in DMF (5 mL) was added HBTU (56 mg, 
152 µmol), DIPEA (48 µL, 277 µmol) and aniline (16 mg, 166 µmol) and the solution was 
stirred overnight at room temperature. EtOAc (20 mL) and saturated aqueous NaHCO3 
(30 mL) were added and the mixture was extracted with EtOAc (4 x 20 mL). The combined 
organic extracts were washed with 10% aqueous NaCl (2 x 20 mL) and brine (1 x 20 mL). 
The organic phase was dried over MgSO4, filtered and concentrated. Normal phase flash 
column chromatography (SiO2; CH2Cl2/MeOH = 97:3) yielded 42 mg (97%) of amide S13 as 
a colorless oil. 
 
Rf = 0.3 (CH2Cl2/MeOH = 95:5). 
 [!]!!"   = -16.6 (c = 1.0, CH2Cl2). 
 
MeOOC COOMe
NHBocO
NH
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IR (ATR): ṽ = 3318 (w), 2951 (w), 1731 (s), 1715 (s), 1690 (s), 1668 (s), 1599 (s), 1538 (s), 
1499 (s), 1441 (s), 1366 (m), 1249 (m), 1159 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 7.91 (br s, 1H), 7.60-7.46 (m, 2H), 7.30 (t, J = 7.9 Hz, 2H), 
7.08 (t, J = 7.4 Hz, 1H), 5.08 (d, J = 8.9 Hz, 1H), 4.42-4.25 (m, 1H), 3.71 (s, 3H), 3.68 (s, 
3H), 2.56-2.45 (m, 1H), 2.38-2.29 (m, 2H), 2.03-1.91 (m, 2H), 1.88-1.58 (m, 4H), 1.45 (s, 
9H) ppm. 
 
13C NMR (CDCl3, 100 MHz) δ 176.0, 172.8, 171.1, 155.8, 136.3 129.1, 124.2, 120.0, 80.5, 
52.6, 52.1, 41.4, 38.8, 36.7, 35.4, 31.1, 28.5, 23.1 ppm. 
 
HRMS (ESI) Calc. for C22H32N2NaO7+: 459.2107 [M+Na]+ 
Found:    459.2100 [M+Na]+. 
 
(2S,4S)-2-amino-4-(4-oxo-4-(phenylamino)butyl)pentanedioic acid hydrochloride (TM-0, 
199•HCl) 
 
To a solution of diester S13 (30 mg, 69 µmol) in THF/H2O (6 mL, 1:1) was added LiOH 
(66 mg, 2.7 mmol) at 0 ºC and the mixture was stirred for 1 h. The mixture was neutralized by 
addition of formic acid (104 µL, 2.7 mmol) and THF was removed under reduced pressure. 
The crude product was placed on a RP18 column and washed with H2O/0.1% FA. Reversed 
phase flash column chromatography (C18; H2O/MeOH/FA = 9:1:0.1% to 3:2:0.1%) yielded 
Boc-protected 199 as a colorless solid, which was used directly in the next step. 
 
Rf (diacid) = 0.5 (C18; H2O/MeOH/FA = 3:2:0.1%). 
 
The obtained diacid was treated with HCl-saturated EtOAc (10 mL) and stirred for 2 h at 
room temperature. The suspension was treated with Et2O (50 mL) and the product was 
collected by sedimentation. The residual solvent was removed under reduced pressure to yield 
11 mg (46%, 2 steps) of HCl-salt 199•HCl as a colorless, hygroscopic solid.  
 
HOOC COOH
NH2O
NH
TM0 (199•HCl)
• HCl
Experimental 
210 
m.p. (Et2O/EtOAc) > 200 ºC (decomp.). [!]!!"   = +68.0 (c 0.1, HEPES ringer). 
 
IR (ATR): ṽ = 2924 (w), 1701 (m), 1656 (m), 1595 (s), 1539 (s), 1498 (s), 1442 (s), 1311 (w), 
1199 (s), 1154 (m) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 9.97 (s, 1H), 7.59 (dd, J = 0.9Hz, J = 8.5 Hz, 2H), 7.27 (dd, 
J = 7.5 Hz, J = 8.5 Hz, 2H), 7.02 (dd, J = 4.2 Hz, J = 10.5 Hz, 1H), 3.73 (mc, 1H), 2.64-2.53 
(m, 1H), 2.29 (t, J = 6.9 Hz, 2H), 2.04-1.97 (m, 1H), 1.87-1.80 (m, 1H), 1.63-1.46 (m, 
4H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 175.5, 170.9, 170.6, 139.3, 128.6, 122.9, 119.0, 50.5, 40.5, 
36.1, 32.0, 31.1, 22.4 ppm. 
 
HRMS (ESI) Calc. for C15H20N2NaO5+: 331.1270 [M+Na]+ 
Found:    331.1264 [M+Na]+. 
 
(2S,4S)-dimethyl 2-(tert-butoxycarbonylamino)-4-(4-oxo-4-(2-oxo-2-(phenylamino)ethyl-
amino)butyl)pentanedioate (S14) 
 
To a solution of acid 194 (50 mg, 138 µmol) in DMF (5 mL) was added HBTU (58 mg, 152 
µmol), DIPEA (48 µL, 277 µmol) and 2-amino-N-phenylacetamide hydrochloride (28 mg, 
152 µmol). The solution was stirred overnight at room temperature. Saturated aqueous 
NaHCO3 (30 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The 
combined organic extracts were washed with saturated aqueous NH4Cl (1 x 30 mL), 10% 
aqueous NaCl (2 x 20 mL) and brine (1 x 20 mL). The organic phase was dried over MgSO4, 
filtered and concentrated. Normal phase flash column chromatography (SiO2; CH2Cl2/MeOH 
= 97:3) yielded 68 mg (99%) of amide S14 as a colorless oil. 
 
Rf = 0.2 (CH2Cl2/MeOH = 95:5). 
MeOOC COOMe
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[!]!!"   = +3.2 (c = 1, CH2Cl2). 
 
IR (ATR): ṽ = 3296 (w), 2952 (w), 1731 (s), 1697 (s), 1652 (s), 1600 (m), 1526 (s), 1499 (s), 
1443 (s), 1366 (m), 1249 (m), 1160 (s) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 8.91 (s, 1H), 7.53 (d, J = 7.7 Hz, 2H), 7.30 (t, J = 7.9 Hz, 
2H), 7.09 (t, J = 7.4 Hz, 1H), 6.92 (br s, 1H), 5.05 (d, J = 8.9 Hz, 1H), 4.32 (mc, 1H), 4.13 
(mc, 2H), 3.70 (s, 3H), 3.64 (s, 3H), 2.52-2.45 (m, 1H), 2.29 (mc, 2H), 2.00-1.90 (m, 2H), 
1.77-1.54 (m, 4H), 1.42 (s, 9H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 175.9, 173.8, 172.8, 167.4, 155.7, 137.9, 129.1, 124.5, 
120.0, 80.4, 52.6, 52.2, 52.0, 44.7, 41.8, 35.7, 34.9, 31.5, 28.4, 23.1 ppm. 
 
HRMS (ESI) Calc. for C24H35N3NaO8+: 516.2322 [M+Na]+ 
Found:    516.2312 [M+Na]+. 
 
(2S,4S)-2-amino-4-(4-oxo-4-(2-oxo-2-(phenylamino)ethylamino)butyl)pentane-dioic acid 
hydrochloride (TM-1, 200•HCl) 
 
To a solution of diester S14 (40 mg, 81 µmol) in THF/water (6 mL, 1:1) was added LiOH (78 
mg, 3.24 mmol) at 0 ºC and the mixture was stirred for 1 h. The solution was neutralized by 
addition of formic acid (122 µL, 3.24 mmol) and THF was removed under reduced pressure. 
The crude product was placed on a RP18 column and washed with H2O/0.1% formic acid. 
Reversed phase flash column chromatography (C18; H2O/MeOH/FA = 9:1:0.1% to 3:2:0.1%) 
yielded Boc-protected 200 as a colorless solid which was used directly in the next step.  
 
Rf (diacid) = 0.4 (C18; H2O/MeOH/FA = 7:3: 1%). 
 
The obtained diacid was treated with HCl-saturated EtOAc (10 mL) and stirred for 2 h at RT. 
The suspension was treated with Et2O (50 mL) and the product was collected by 
HOOC COOH
NH2O
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O
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sedimentation. Removal of the residual solvent afforded 24 mg (74%, 2 steps) of HCl-salt 
200•HCl as a colorless, hygroscopic solid. 
 
m.p. (Et2O/EtOAc) > 210 ºC (decomp). 
 [!]!!"   = +62.4 (c = 0.1, HEPES buffer). 
 
IR (ATR): ṽ = 2929 (w), 1597 (m), 1542 (s), 1498 (s), 1445 (m), 1411 (m), 1312 (m), 
1202 (s) cm–1. 
 
1H NMR (DMSO-d6, 600 MHz) δ 10.15 (s, 1H), 8.49 (br s, 3H), 8.25 (t, J = 5.8 Hz, 1H), 7.60 
(d, J = 7.7 Hz, 2H), 7.28 (mc, 2H), 7.02 (t, J = 7.4 Hz, 1H), 3.87 (d, J = 5.9 hz, 2H), 3.78 (t, 
J = 7.1 Hz, 1H), 2.59 (mc, 1H), 2.25-2.10 (mc, 2H), 1.10-1.99 (m, 1H), 1.88-1.75 (m, 1H), 
1.60-1.39 (m, 4H) ppm. 
 
13C NMR (DMSO-d6, 150 MHz) δ 175.6, 172.4, 170.7, 168.0, 139.0, 128.7, 123.2, 119.1, 
50.3, 42.7, 40.3, 35.0, 31.8, 31.1, 22.5 ppm. 
 
HRMS (ESI) Calc. for C17H24N3O6+: 366.1665 [M+H]+ 
Found:    366.1659 [M+H]+.  
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7) Toward an Orthogonal Receptor-Ligand Pair based on iGluRs – Synthetic 
Procedures 
 
di-tert-butyl 2-methylenepentanedioate (232) 
 
Diester 232 was synthesized according to known procedures.[256] The spectral data matched 
those reported previously. 
 
Rf = 0.6 (PE/EtAOc = 16:1). 
 
di-tert-butyl 2-((dibenzylamino)methyl)pentanedioate (233) 
 
To a solution of dibenzylamine (616 mg, 3.12 mmol) in THF (10 mL) was added n-butyl 
lithium (1.21 mL, 3.02 mmol; 2.5 M in hexanes) at -78 ºC and the mixture was stirred for 
30 min. To the deep violet solution was added precooled acrylate 232 (500 mg, 1.95 mmol) in 
THF (5 mL) and stirring was continued for 20 min. Saturated aqueous NH4Cl solution 
(20 mL) was added and the mixture was allowed to warm to RT. The biphasic mixture was 
extracted with EtOAc (3 x 50 mL) and the combined organic extracts were dried over MgSO4, 
filtered and concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 
16:1) yielded 210 mg (24%) of protected homoglutamate 233 as a colorless liquid. 
 
Rf = 0.3 (PE/EtOAc = 16:1). 
 
IR (ATR): ṽ = 2976 (w), 2931 (w), 2798 (w), 1724 (s), 1494 (w), 1452 (w), 1365 (m), 1248 
(m), 1144 (s), 1028 (w), 846 (w) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 7.34-7.27 (m, 8H), 7.25-7.20 (m, 2H), 3.62 (d, J = 13.6 Hz, 
2H), 3.46 (d, J = 13.6 Hz, 2H), 2.80 (dd, J = 8.7 Hz, J = 12.4 Hz, 1H), 2.67-2.58 (m, 1H), 
2.40 (dd, J = 5.9 Hz, J = 12.4 Hz, 1H), 2.18 (ddd, J = 5.0 Hz, J = 6.7 Hz, J = 8.3 Hz, 2H), 
1.85-1.61 (m, 2H), 1.46 (s, 9H), 1.44 (s, 9H) ppm. 
 
t-BuOOC COOt-Bu
232
t-BuOOC COOt-Bu
NBn2
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13C NMR (CDCl3, 100 MHz) δ 174.3, 172.5, 139.2, 129.2, 128.2, 127.0, 80.5, 80.3, 58.5, 
56.2, 44.5, 33.1, 28.3, 28.3, 26.0 ppm. 
 
HRMS (ESI) Calc. for C28H40NO4+: 454.2952 [M+H]+ 
Found:    454.2948 [M+H]+. 
 
(R/S)-di-tert-butyl 2-((benzyl((R)-1-phenylethyl)amino)methyl)pentanedioate (235) 
 
To a solution of chiral amine 234 (1.69 g, 8.0 mmol) in THF (20 mL) was added n-butyl 
lithium (3.1 mL, 7.8 mmol; 2.5 M in hexanes) at -78 ºC and the mixture was stirred for 20 
min. To the deep violet solution was added precooled acrylate 232 (1.00 g, 3.90 mmol) in 
THF (10 mL) and stirring was continued for 4 h. Saturated aqueous NaHCO3 solution (20 
mL) was added and the mixture was allowed to warm to RT. The biphasic mixture was 
extracted with EtOAc (3 x 50 mL) and the combined organic extracts were dried over MgSO4, 
filtered and concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 
20:1 to 16:1) yielded 566 mg (31%) of a diastereomeric mixture (3.4:1 by NMR) of protected 
homoglutamate 235 as a colorless oil.  
 
Rf = 0.4 (PE/EtOAc = 16:1). 
 
IR (ATR): ṽ = 2974 (w), 2928 (w), 1725 (s), 1494 (w), 1452 (w), 1365 (m), 1248 (m), 1141 
(s), 697 (m) cm–1. 
 
1H NMR (CDCl3, 400 MHz; 3.4:1 mixture of diastereomers) δ 7.39-7.27 (m, 8.96 H). 7.26-
7.18 (m, 2.21H), 3.97 (q, J = 7.0 Hz, 0.92H), 3.86 (q, J = 7.0 Hz, 0.27H), 3.66 (mc, 2.4 H), 
3.00 (dd, J = 8.4 Hz, J =12.8 Hz, 0.26H), 2.74-2.64 (m, 0.96 H), 2.57-2.42 (mc, 2.12H), 2.26-
2.03 (m, 2.15H), 1.89-1.60 (m, 2.77H), 1.45-1.42 (m, 18.0H), 1.40-1.35 (m, 3.59H) ppm. 
 
13C NMR (CDCl3, 100 MHz; 3.4:1 mixture of diastereomers) δ 174.7, 174.3, 172.5, 172.5, 
142.7, 141.8, 140.4, 140.3, 129.0, 128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 126.9, 80.4, 80.3, 
57.6, 57.4, 54.9, 54.6, 52.5, 52.0, 45.2, 45.0, 33.3, 33.1, 26.2, 26.0, 15.4, 14.2 ppm. 
 
t-BuOOC COOt-Bu
N
235
Bn
Ph
Me
Experimental 
215 
HRMS (ESI) Calc. for C29H42NO4+: 468.3108 [M+H]+ 
Found:    468.3103 [M+H]+. 
 
(R/S)-2-(aminomethyl)pentanedioic acid hydrochloride (228•HCl) 
 
Exemplary procedure: 
To a solution of protected homoglutamate 233 (100 mg, 0.21 mmol) in methanol (5 mL) was 
added Pd(OAc)2 (14 mg, 64 µmol). The vessel was flushed with N2 and then charged with H2 
and the mixture was stirred under an H2 atmosphere overnight.  
 
Rf (primary amine) = 0.1 (CH2Cl2/MeOH/AcOH/H2O = 9:1:0.1:0.1). 
 
Palladium was filtered off over celite eluting with methanol (80 mL) and the solvent was 
removed under reduced pressure. To the resulting colorless oil was added 6 M HCl (3 mL) 
and the mixture was stirred for 2 h at room temperature. The solvent was removed under 
reduced pressure and the residue co-evaporated with water (3x) and dried to yield 38 mg 
(90%) of HCl salt 228•HCl as a colorless, hygroscopic solid. 
 
IR (ATR): ṽ = 1705 (s), 1609 (m), 1457 (w), 1402 (w), 1197 (m), 1021 (w) cm–1. 
 
1H NMR (D2O, 400 MHz) δ 3.32 (dd, J = 9.1 Hz, J = 13.2 Hz, 1H), 3.21 (dd, J = 4.5 Hz, J = 
13.2 Hz, 1H), 2.95-2.85 (m, 1H), 2.56 (td, J = 3.1 Hz, J = 7.3 Hz, 2H), 2.10-1.90 (m, 
2H) ppm. 
 
13C NMR (D2O, 100 MHz) δ 177.0, 176.0, 41.6, 39.8, 30.7, 24.1 ppm. 
 
  
HOOC COOH
NH2• HCl
228•HCl
Experimental 
216 
(R/S)-di-tert-butyl 1-(1,5-dimethoxy-1,5-dioxopentan-2-yl)hydrazine-1,2-dicarboxylate 
(244) 
 
To a solution of dimethyl glutarate (500 mg, 3.12 mmol) in THF (10 mL) was added KHMDS 
(7.49 mL, 3.75 mmol; 0.5 M in THF) at -78 ºC and the mixture was stirred for 20 min. A 
solution of di-tert-butyl azodicarboxylate (934 mg, 4.06 mmol) in THF (5 mL) was slowly 
added to the reaction mixture and stirring was continued for 1 h. The reaction was quenched 
by addition of AcOH (1 mL) at -78 ºC. Saturated aqueous NH4Cl solution (20 mL) was added 
and the mixture was allowed to warm to RT. The biphasic mixture was extracted with EtOAc 
(3 x 50 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 5:1 to 4:1) 
yielded  394 mg (32%) of protected hydrazine 244 as a colorless oil. 
 
Rf = 0.3 (PE/EtOAc = 4:1). 
 
IR (ATR): ṽ = 327 (w), 2978 (w), 1312 (s), 1710 (s), 1478 (w), 1456 (w), 1392 (m), 1366 (m), 
1241 (m), 1148 (s) cm–1. 
 
1H NMR (CDCl3, 400 MHz; mixture of rotamers) δ 6.50-6.14 (br m, 1H), 4.98-4.67 (br m, 
1H), 3.73 (s, 3H), 3.66 (s, 3H), 2.83-2.45 (m, 2H), 2.36-2.19 (m, 1H), 2.09-1.98 (m, 1H), 
1.53-1.38 (m, 18H) ppm. 
 
13C NMR (CDCl3, 100 MHz; mixture of rotamers) δ 173.8, 172.0, 171.6, 155.9, 155.7, 155.2, 
82.7, 82.2, 81.6, 81.1, 61.2, 59.3, 52.6, 51.7, 30.9, 30.5, 28.3 (2x), 28.2, 24.2, 23.9 ppm. 
 
HRMS (ESI) Calc. for C17H30N2NaO8+: 413.1894 [M+Na]+ 
Found:    413.1892 [M+Na]+. 
 
  
MeOOC COOMe
BocN NHBoc
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8) Toward the Total Synthesis of Herquline A & B – Synthetic Procedures 
 
(5aS,10aS)-tetrahydrodipyrrolo[1,2-a:1',2'-d]pyrazine-3,5,8,10(5aH,10aH)-tetraone 
(S15) 
 
Tricycle S15 was synthesized according to literature procedures.[287] 
 
m.p. (Ac2O/pyridine) > 295 ºC (decomp). 
 [!]!!"   = –96.0 (c = 1.0, DMSO). 
 
IR (ATR): ṽ = 1763 (s), 1696 (m), 1680 (m), 1322 (s), 1296 (s), 1257 (s), 1214 (s), 
948 (m) cm–1. 
 
1H NMR (DMSO-d6, 400MHz) δ 4.84 (t, J = 8.5 Hz, 2H, H-2), 2.58 (ddd, J = 17.6 Hz, J = 
10.9 Hz, J = 9.5 Hz, 2H, Ha-4), 2.43 (ddd, J = 17.6 Hz, J = 9.2 Hz, J = 3.1 Hz, 2H, Hb-4), 
2.27-2.11 (m, 4H, H-3) ppm. 
 
13C NMR (DMSO-d6, 100 MHz) δ 172.7 (C-5), 165.6 (C-1), 58.4 (C-2), 31.3 (C-4), 18.9 (C-
3) ppm. 
 
HRMS (ESI) Calc. for C10H10N2NaO4+: 245.0533 [M+Na]+ 
Found:    245.0531 [M+Na]+. 
 
3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoic acid (268) 
 
Glutamic diketopiperazine (268) was synthesized according to literature procedures.[287] 
 
m.p. (H2O) > 263 ºC (decomp). 
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[!]!!"   = –41.9 (c = 1.0, DMSO). 
 
IR (ATR): ṽ = 3209 (w), 2360 (w), 1700 (s), 1628 (m), 1422 (m), 1318 (m), 1262 (s), 1220 
(m), 1122 (m) cm–1. 
 
1H NMR (DMSO-d6, 400MHz) δ 8.17 (d, J = 1.5 Hz, 2H, H-N), 3.87 (t, J = 6.1 Hz, 2H, H-2), 
2.31 (mc, 4H, H-4), 2.00-1.80 (m, 4H, H-3) ppm. 
 
13C NMR (DMSO-d6, 100 MHz) δ 173.9 (C-5), 167.9 (C-1), 53.2 (C-2), 29.3 (C-4), 28.2 (C-
3) ppm. 
 
HRMS (ESI) Calc. for C10H14N2NaO6+: 281.0744 [M+Na]+ 
Found:    281.0740 [M+Na]+. 
 
dimethyl 3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoate (292) 
 
To a suspension of glutamic diketopiperazine 268 (12.7 g, 49.2 mmol) in MeOH (900 mL) 
was added CBr4 (4.89 g, 14.8 mmol) and the turbid mixture was heated under reflux for 12 h. 
The obtained clear solution was allowed to cool to room temperature, concentrated and the 
precipitate was re-suspended in Et2O (500 m). The colorless solid was filtered off, washed 
with Et2O (3 x 200 mL) and dried on high vacuum to yield 13.3 g (94%) of diketopiperazine 
diester 292 as a colorless, fluffy solid. 
 
Rf = 0.2 (CH2Cl2/MeOH = 95:5). 
 
m.p. (Et2O/MeOH) = 183-184 ºC. 
 [!]!!"   = –42.5 (c = 1.0, DMSO). 
 
IR (ATR): ṽ = 3199 (w), 1.737 (s), 1673 (s), 1437 (m), 1328 (m), 1259 (m), 1200 (s), 1178 
(s), 1112 (m), 1001 (m), 808 (m) cm–1. 
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1H NMR (DMSO-d6, 400 MHz) δ 8.20 (d, J = 1.0 Hz, 2H, H-N), 3.88 (td, J = 5.6 Hz, J = 1.7 
Hz, 2H, H-2), 3.59 (s, 6H, H-6), 2.40 (mc, 4H, H-4), 2.04-1.84 (m, 4H, H-3) ppm. 
 
13C NMR (DMSO-d6, 100 MHz) δ 172.8 (C-5), 167.7 (C-1), 53.2 (C-2), 51.4 (C-6), 29.0 (C-
4), 28.0 (C-3) ppm. 
 
HRMS (ESI) Calc. for C12H18N2O6Na+: 309.1057 [M+Na]+ 
Found:    309.1053 [M+Na]+. 
 
dimethyl 3,3'-((2S,5S)-3,6-dithioxopiperazine-2,5-diyl)dipropanoate (294) 
 
To a solution of diketopiperazine 292 (1.00 g, 3.49 mmol) in THF (75 mL) was added 
Lawesson's reagent (0.849 g, 2.10 mmol) and the mixture was heated under reflux for 3 h. 
The solvent was removed under reduced pressure and the crude product was purified using 
normal phase column chromatography (SiO2; dryload; CH2Cl2/MeOH = 98:2) to yield a 
yellow solid which was recrystallized from toluene to yield 906 mg (82%) of 
dithiodiketopiperazine 294 as an off-white solid. 
 
Rf = 0.4 (CH2Cl2/MeOH = 95:5). 
 
m.p. (MePh) = 178 ºC (decomp). 
 [!]!!"   = +4.7 (c = 1.0, DMSO). 
 
IR (ATR): ṽ = 3138 (m), 3039 (m), 2947 (m), 1732 (s), 1538 (s), 1433 (m), 1322 (m), 1246 
(m), 1175 (s), 1146 (s), 1045 (m) cm–1. 
 
1H NMR (DMSO-d6, 400 MHz) δ 10.89 (d, J = 2.6 Hz, H-N), 4.27-4.21 (mc, 2H, H-2), 3.60 
(s, 6H, H-6), 2.58-2.43 (m, 4+1H, H-4 and DMSO-d6), 2.40-2.30 (m, 2H, Ha-3), 2.12-2.01 (m, 
2H, Hb-3) ppm. 
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13C NMR (DMSO-d6, 100 MHz) δ 195.0 (C-1), 172.4 (C-5), 62.2 (C-2), 51.4 (C-6), 30.4 (C-
3), 29.5 (C-4) ppm. 
 
HRMS (ESI) Calc. for C12H19N2O4NaS2+: 319.0781 [M+H]+ 
Found:    319.0783 [M+H]+. 
 
(5aS,10aS)-octahydrodipyrrolo[1,2-a:1',2'-d]pyrazine-3,8-dione (295) 
 
To a slurry of Raney-Ni (0.4 mL) was added methanol (5 mL) and the supernatant was 
removed. This was repeated two times, more methanol (2 mL) was added and the suspension 
was transferred to a solution of dithioketopiperazine 294 (20 mg, 62.8 µmol) in methanol 
(2 mL). The vessel was purged with H2 and the mixture was stirred for 28 h at room 
temperature. The mixture was filtered over celite and the solvent was removed under reduced 
pressure. The crude product was purified using normal phase column chromatography (SiO2; 
CH2Cl2/MeOH =95:5 to 9:1) to yield 8 mg (66%) of tricycle 295 as a colorless oil. 
 
Rf = 0.5 (CH2Cl2/MeOH = 9:1). 
 [!]!!"   = –70.0 (c = 0.23, CH2Cl2). 
 
IR (ATR): ṽ = 3398 (br w), 1665 (s), 1416 (m), 1351 (w), 1318 (w), 1278 (w), 1260(w) cm–1. 
1H NMR (DMSO-d6, 400 MHz) δ 4.09 (dtd, J = 4.8 Hz, J = 7.1 Hz, J = 10.7 Hz, 2H, H-2), 
3.63 (dd, J = 4.8 Hz, J = 12.6 Hz, 2H, Ha-1), 3.40-3.32 (m, 2H, Hb-1), 2.52-2.39 (m, 4H, H-
4), 2.34-2.26 (m, 2H, Ha-3), 1.72 (dtd, J = 7.1 Hz, J = 9.5 Hz, J = 12.8 Hz, 2H, Hb-3) ppm. 
 
Signals corresponding to a putative diastereomer: δ 4.26 (dd, J = 4.2 Hz, J = 12.9 Hz), 3.54-
3.56 (m), 2.26-2.21 (m) ppm. 
 
13C NMR (DMSO-d6, 100 MHz) δ 174.6 (C-5), 52.6 (C-2), 46.6 (C-1), 30.6 (C-4), 24.3 (C-
3) ppm. 
 
Signals corresponding to a putative diastereomer: δ 54.9, 46.0, 30.3, 21.8 ppm. 
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HRMS (ESI) Calc. for C10H15N2O2+: 195.1128 [M+H]+ 
Found:    195.1126 [M+H]+. 
 
(2S,5S)-di-tert-butyl 2,5-bis(3-methoxy-3-oxopropyl)piperazine-1,4-dicarboxylate (296) 
 
To a solution of Raney-Ni in water (0.1 mL) was added repeatedly THF (2 mL) and, after the 
solids had settled again, the supernatant was removed. The washed catalyst was suspended in 
THF (2 mL), thio-amide 294 (50 mg, 157 µmol) and Boc2O (85.7 mg, 393 µmol) were added 
and the vessel was purged with argon and then charged with H2. After stirring for 3 h more 
Raney-Ni (0.4 mL suspension, washed) was added and stirring was continued for 30 min. The 
suspension was filtered over celite eluting with EtOAc (20 mL). The solvent was removed 
under reduced pressure and the crude product purified by normal phase flash column 
chromatography (SiO2; CH2Cl2/MeOH = 98:2 to 95:5) to yield 18 mg (< 25%) of piperazine 
296 and possibly diastereomers as a colorless oil. 
 
Rf = 0.4 (CH2Cl2/MeOH = 95:5). 
 
1H NMR (DMSO-d6, 400 MHz; mixture of rotamers) δ 4.31-3.94 (m, 3H), 3.88 (d, J = 13.9 
Hz, 0.5H), 3.73 (d, J = 13.8 Hz, 0.5 H), 3.69-3.64 (m, 6H), 3.11 (dt, J = 4.1 Hz, J = 13.8 Hz, 
0.5H), 3.01 (dt, J = 4.1 Hz, J = 13.8 Hz, 0.5 H), 2.52 (dd, J = 10.6 Hz, J = 13.9 Hz, 1H), 2.42-
2.18 (m, 4H), 1.89-1.85 (m, 1H), 1.85-1.63 (m, 3H), 1.47-1.39 (m, 18H) ppm. 
 
13C NMR (DMSO-d6, 100 MHz; mixture of rotamers) δ 173.7, 173.5, 173.5, 173.4, 155.6, 
155.2, 155.2, 155.1, 80.5, 80.4, 80.3, 52.7, 51.8 (2x), 50.5, 50.3, 49.1, 49.0, 41.9, 41.7, 40.4, 
40.3, 30.7, 30.6, 30.5, 30.3, 28.5, 27.0, 24.0, 23.9, 23.8, 23.8 ppm. 
 
HRMS (ESI) Calc. for C22H38N2NaO8+: 481.2520 [M+Na]+ 
Found:    481.2526 [M+Na]+. 
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(2S,5S)-di-tert-butyl 2,5-bis(3-hydroxypropyl)piperazine-1,4-dicarboxylate (266) 
 
To a suspension of LiAlH4 (9.54 g, 251 mmol) in THF (350 mL) was added ester 292 (7.20 g, 
25.1 mmol) at 0ºC in portions and the resulting mixture was heated under reflux for 22 h. The 
grey suspension was cooled to 0 ºC and diluted with Et2O (150 mL). To the mixture were 
carefully added water (10 mL), aqueous NaOH (10 mL; 15%) and again water (30 mL). The 
white suspension was allowed to warm to RT and stirred for 30 min. Na2SO4 (10 g) were 
added and stirring was continued for 20 min. Solids were filtered off and washed with THF 
(2 x 200 mL). The filtrate was concentrated and the residue dissolved in THF (100 mL) and 
EtOH (just enough to dissolve all solids). To the clear solution was added Boc2O (11.5 g, 
52.8 mmol) at 0 ºC and the solution was allowed to warm to RT over night. The crude 
reaction mixture was diluted with saturated aqueous NaHCO3 (100 mL) and extracted with 
EtOAc (4 x 100 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated (water bath temperature: 30 ºC). Normal phase flash column chromatography 
(SiO2; CH2Cl2/MeOH = 98:2 to 95:5) yielded 4.72 g (47%) of diol 266 as a colorless solid. 
 
Rf = 0.3 (CH2Cl2/MeOH = 95:5). 
 
m.p. (CH2Cl2/MeOH) = 103-104ºC. 
 [!]!!"   = +84.2 (c = 0.5, CH2Cl2). 
 
IR (ATR): ṽ = 3452 (m), 2976 (w), 2942 (w), 2867 (w), 1670 (s), 1419 (s), 1366 (s), 1152 (s), 
1052 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 4.05-3.89 (br s, 4H, H-2 + Ha-1), 3.65-3.54 (mc, 4H, H-5), 2.58 
(dd, J = 11.6 Hz, J = 13.7 Hz, 2H, Hb-1), 1.59-1.48 (m, 6H, H-3 and H-4), 1.46-1.34 (m, 20H, 
H-8 and H-3 or H-4) ppm. 
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13C NMR (CDCl3, 150 MHz) δ 155.6 (C-6), 80.2 (C-7), 62.4 (C-5), 53.1 (C-2), 42.1 (br, C-1), 
28.6 (C-3 or C-4), 28.5 (C-8 and C-3 or C-4) ppm. 
 
HRMS (ESI) Calc. for C20H38N2NaO6+: 425.2622 [M+Na]+ 
Found:    425.2627 [M+Na]+. 
 
(2S,5S)-di-tert-butyl 2,5-bis(3-oxopropyl)piperazine-1,4-dicarboxylate (262) 
 
To a solution of DMSO (2.91 mL, 41.0 mmol) in CH2Cl2 (120 mL) was added (COCl)2 
(12.3 mL, 24.6 mmol; 2M in CH2Cl2) at -78 ºC and the solution was stirred for 30 min. A 
solution of diol 266 (3.30 g, 8.20 mmol) in CH2Cl2 (30 mL) was added with a cannula and 
stirring was continued for 1 h. NEt3 (11.4 mL, 82.0 mmol) was added drop-wise and the 
mixture was allowed to warm to room temperature over 12 h. The reaction was poured on 
10% aqueous NaCl solution (150 mL) and the resulting biphasic mixture was extracted 
with CH2Cl2 (4 x 100 mL). The combined organic extracts were washed successively with 1N 
HCl (2 x 100 mL), saturated aqueous NaHCO3 (2 x 100 mL) and brine (1 x 100 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated. Normal phase flash column 
chromatography (SiO2; PE/EtOAc = 2:1 to 3:2) yielded 2.82 g (86%) of aldehyde 262 as a 
colorless oil. 
 
Rf = 0.4 (PE/EtOAc = 1:1). 
 [!]!!"   = +71.0 (c = 1.0, CH2Cl2). 
 
IR (ATR): ṽ = 2973 (w), 2932 (w), 1724 (m), 1685 (s), 1403 (s), 1365 (s), 1248 (m), 1154 (s), 
1137 (s), 865 (m), 770 (m) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 9.77 (s, 2H, H-5), 4.16-3.89 (br m, 4H, H-2 and Ha-1), 2.52 
(mc, 6H, Hb-1 and H-4), 1.82-1.62 (m, 4H, H-3), 1.43 (s, 18H, H-8) ppm. 
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13C NMR (CDCl3, 100 MHz) δ 201.4 (C-5), 155.7 (C-6), 80.6 (C-7), 52.7 (C-2), 42.0 (br, C-
1), 40.4 (C-4), 28.5 (C-8), 24.1 (C-3) ppm. 
 
HRMS (EI) Calc. for C20H34N2O6+: 398.2411 [M]+ 
Found:    398.2410 [M]+. 
 
(2S,5S)-di-tert-butyl 2,5-bis(2-formyl-5-oxohexyl)piperazine-1,4-dicarboxylate (261) 
 
Procedure A (TMSNEt2): 
To a solution of aldehyde 262 (2.8 g, 7.03 mmol) in MeCN (100 mL) was added MVK 
(1.71 mL, 21.1 mmol) and TMSNEt2 (663 µL, 3.51 mmol) and the mixture was heated under 
reflux overnight. The solvent was removed under reduced pressure and the residue purified 
using normal phase flash column chromatography (SiO2; PE/EtOAc = 2:3 to 1:2) to yield 
2.80 g (74%) of keto-aldehyde 261 (mixture of diastereomers) as a colorless oil. NMR 
indicated a ratio of 1:1 for the two aldehyde signals at 9.60 and 9.53 ppm (200 MHz). 
 
Procedure B ((S)-2-(methoxydiphenylmethyl)pyrrolidine): 
To a solution of aldehyde 262 (50.0 mg, 125 µmol) in MVK (31 µL, 376 µmol) was added 
(S)-2-(methoxydiphenylmethyl)pyrrolidine (3.4 mg, 12.5 µmol) and ethyl 3,4-dihydroxy-
benzoate (9.1 mg, 50.2 µmol) at 0 ºC and the resulting mixture was stirred at 4 ºC for 4 d. 
NMR indicated a ratio of 1:3.1 for the two aldehyde signals at 9.60 and 9.53 ppm (200 MHz). 
Normal phase flash column chromatography (SiO2; PE/EtOAc = 2:3 to 1:2) yielded 34 mg 
(74%) of keto-aldehyde 261 (mixture of diastereomers) as a colorless oil. 
 
Procedure B ((R)-2-(methoxydiphenylmethyl)pyrrolidine): 
To a solution of aldehyde 262 (25.0 mg, 62.7 µmol) in MVK (31 µL, 376 µmol) was added 
(R)-2-(methoxydiphenylmethyl)pyrrolidine (3.4 mg, 12.5 µmol) and ethyl 3,4-dihydroxy-
benzoate (4.6 mg, 25.1 µmol) at 0 ºC and the resulting mixture was stirred at 4 ºC for 4 d. 
NMR indicated a ratio of 1.7: 1 for the two aldehyde signals at 9.60 and 9.53 ppm (200 MHz). 
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Normal phase flash column chromatography (SiO2; PE/EtOAc = 2:3 to 1:2) yielded 15 mg 
(44%) of keto-aldehyde 261 (mixture of diastereomers) as a colorless oil. 
 
Analytical data for the stochastic mixture (Procedure A): 
 
Rf = 0.4 (PE/EtOAc = 1:2). 
 [!]!!"   = +42.6 (c = 1.0, CH2Cl2). 
 
IR (ATR): ṽ = 2975 (w), 2931 (w), 1686 (s), 1478 (w), 1413 (m), 1365 (m), 1247 (w), 1153 
(m), 1108 (m) cm–1. 
 
1H NMR (CDCl3, 600 MHz, mixture of diastereomers and rotamers) δ 9.60 (mc, 1H, H-9), 
9.54 (mc, 1H, H-9*), 4.24-3.80 (br m, 4H, H-2 and Ha-1), 2.83-2.30 (m, 8H, Hb-1 and H-4 and 
H-6), 2.13 (mc, 6H, H-8), 1.97-1.84 (m, 3H, Ha-3 and Ha-5), 1.84-1.73 (m, 3H, Ha*-3 and Hb-
5), 1.48-1.29 (m, 20H, H-12 and Hb-3/Hb-3*) ppm. 
 
13C NMR (CDCl3, 150 MHz, mixture of diastereomers and rotamers) δ 207.7 (C-7), 203.4 (C-
9), 155.5 (C-10), 80.8 (C-11), 51.4 (C-2), 48.1 (C-4*), 47.4 (C-4), 42.1 (br, C-1), 40.6 (C-1*), 
40.4 (C-6), 31.3 (C-3*), 30.8 (C-3*), 30.7 (C-3), 30.2 (2x, C-8), 28.5 (C-12), 23.1 (C-5), 22.8 
(C-5*) ppm. 
 
HRMS (EI) Calc. for C28H46N2O8+: 538.3254 [M]+ 
Found:    538.3264 [M]+. 
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(2S,5S)-di-tert-butyl 2,5-bis((4-oxocyclohex-2-enyl)methyl)piperazine-1,4-dicarboxylate 
(260) 
 
To a solution of stochastic keto-aldehyde 261 (500 mg, 0.928 mmol) in THF/Et2O 
(300 mL,1:2) was added an aqueous solution of KOH (100 mL; 0.1 M) and n-Bu4NOH 
(186 µL, 0.186 mmol; 1M in H2O) at 0ºC and the mixture was heated under reflux for 24 h. 
The reaction was diluted with saturated aqueous NH4Cl solution (20 mL) and extracted with 
EtOAc (3 x 25 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated. Normal phase flash column chromatography (SiO2; PE/EtOAc = 2:3) yielded 
266 mg (57%) of enone 260 (mixture of diastereomers) as a colorless wax. The (R,S) isomer 
could not be discriminated from its C2-symmetrical diastereomers. The ratio of the α-protons 
of the enone indicated a 1:1 ratio of (R)- and (S)-configured cyclohexenone moieties. 
 
Rf = 0.2 (PE/EtOAc = 2:3). 
 [!]!!"   = –6.2 (c = 1.0, CH2Cl2). 
 
IR (ATR): ṽ = 3353 (w), 2973 (w), 2929 (w), 1737 (w), 1676 (s), 1392 (w), 1665 (m), 1245 
(m), 1153 (m), 1033 (w) cm–1. 
 
1H NMR (CDCl3, 600 MHz, mixture of diastereomers and Boc rotamers) δ 7.01-6.89 (br s, 
1H, H-9), 6.80 (add, J = 2.4 Hz, J = 10.2 Hz, 1H, H-9*), 5.98 (addd, J = 2.2 Hz, J = 8.2 Hz, J 
= 10.2 Hz, 2H, H-8), 4.41-3.86 (br m, 4H, H-2 and Ha-1), 2.59-2.44 (m, 6H, Hb-1 and H-4 and 
Ha-3 and Ha-6), 2.40-2.26 (m, 3H, Hb-3 or Hb-6 and Ha-5), 2.16-2.07 (m, 1H, Ha-5*), 1.79-
1.65 (m, 3H, Ha-3 or Ha-6 and Hb-5*), 1.64-1.57 (m, 1H, Hb-3* or Hb-6*), 1.44 (mc, 19H, H-12 
and Hb-3* or Hb-6*), 1.37-1.30 (m, 1H, Hb-3* or Hb-6*) ppm. 
 
13C NMR (CDCl3, 150 MHz, mixture of diastereomers and Boc rotamers) δ 199.4 (C-7), 
155.7 (C-10), 155.6 (C-10*), 154.2 (br, C-9), 153.9 (C-9*), 129.6 (C-8), 129.3 (C-8*), 80.9 (C-
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11), 51.3 (C-2), 51.2 (C-2’), 50.9 (C-2*), 50.8 (C-2*’), 42.0 (br, C-1), 36.9 (C-3 or C-6), 36.8 
(C-6 or C-3), 33.2 (C-4), 32.6 (C-4*), 29.2 (C-5), 29.0 (C-5*), 28.5 (2x, C-12) ppm. 
 
HRMS (EI) Calc. for C28H42N2O6+: 502.3037 [M]+ 
Found:    502.3032 [M]+. 
 
(2S,5S)-di-tert-butyl 2,5-bis(((R)-3-iodo-4-oxocyclohex-2-enyl)methyl)piperazine-1,4-di-
carboxylate, (2S,5S)-di-tert-butyl 2,5-bis(((S)-3-iodo-4-oxocyclohex-2-enyl)methyl) 
piperazine-1,4-dicarboxylate and (2S,5S)-di-tert-butyl 2-(((R)-3-iodo-4-oxocyclohex-2-
enyl)methyl)-5-(((S)-3-iodo-4-oxocyclohex-2-enyl)methyl)piperazine-1,4-dicarboxylate 
(259a, 259b and 259c) 
 
To a solution of the diastereomeric mixture of enones 260 (1.00 g, 1.99 mmol) in 
CH2Cl2/pyridine (120 mL, 5:1) was added I2 (1.10 g, 4.38 mmol) at 0ºC. The solution was 
allowed to warm to RT and stirred for 8 h. The reaction mixture was diluted with CH2Cl2 
(200 mL) and poured on a saturated aqueous solution of NH4Cl and a few drops of saturated 
NaS2O3 solution. The mixture was extracted with CH2Cl2 (3 x 40 mL) and the combined 
organic fractions were washed successively with 1N HCl (2 x 40 mL) and brine (1 x 40 mL). 
The CH2Cl2-phase was dried over MgSO4, filtered and concentrated. Normal phase flash 
column chromatography (SiO2; PE/EtOAc = 1:1) yielded 1.46 g (97%) of a mixture of the 
vinyl iodides 259 as a colorless oil. HPLC showed a 1:2:1 ratio of diastereomers. Separation 
by preparative HPLC (Varian Microsorb60Si8; flow = 80 mL/min; gradient program: t = 0: 
PE/EtOAc = 10%; t = 25 min: PE/EtOAc = 90%) yielded 213 mg (14%), 496 mg (33%) and 
313 mg (21%) of the individual diastereomeric α-iodo enones 259a, 259b and 259c as 
colorless, light- and temperature-sensitive solids. The absolute configuration of the fast and 
the slow eluting C2-symmetric fractions (259a, 259c) could not be assigned. 
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Analytical data for the fast eluting diastereomer (259a or 259c): 
Rf = 0.5 (PE/EtOAc = 1:1). 
 
Rt = 15.6 min. 
 
m.p. (PE/EtOAc) > 119 ºC (decomp.). 
 [!]!!"   = –4.0 (c = 0.2, CH2Cl2). 
 
IR (ATR): ṽ = 2971 (w), 2923 (w), 1682 (s), 1583 (w), 1414 (m) 1364 (w), 1320 (w), 
1249 (w), 1153 (m) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.59 (d, J = 2.4 Hz, 2H, H-9), 4.36-4.13 (br m, 2H, H-2), 4.13-
3.87 (br m, 2H, Ha-1), 2.76 (ddd, J = 4.4 Hz, J = 5.2 Hz, J = 16.7 Hz, 2H, H-4), 2.68-2.59 (br 
m, 2H, Hb-1 and Hb-1), 2.57-2.48 (m, 4H, Ha-5), 2.47-2.32 (br m, 2H, Hb-5), 1.83-1.67 (m, 
4H, Hb-5 and Ha-3), 1.46 (s, 18H, H-12), 1.40-1.31 (m, 2H, Hb-3) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 192.1 (C-7), 162.7 (br, C-9), 155.7 (C-10), 104.1 (C-8), 81.1 
(C-11), 51.1 (C-2), 42.2 (br, C-1), 37.9 (br, C-4), 36.5 (C-3), 35.8 (C-6), 29.0 (C-5), 28.6 (C-
12) ppm. 
 
HRMS (ESI) Calc. for C28H44I2N3O6+: 772.1314 [M+NH4]+ 
Found:    772.1306 [M+NH4]+. 
 
Analytical data for the (R,S) isomer 259b: 
Rf = 0.4 (PE/EtOAc = 1:1). 
 
Rt = 16.6 min. 
 
m.p. (PE/EtOAc) > 120 ºC (decomp.). 
 [!]!!"   = –44.0 (c = 0.2, CH2Cl2). 
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IR (ATR): ṽ = 2971 (w), 2923 (w), 1682 (s), 1578 (w), 1414 (w), 1364 (w), 1320 (w), 
1272 (w), 1243 (w), 1153 (m) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.74 (br s, 1H, H-9), 7.59 (d, J = 2.4 Hz, 1H, H-9*), 4.35-4.14 
(br m, 2H, H-2), 4.13-3.89 (br m, 2H, Ha-1), 2.81-2.72 (m, 2H, Ha-6), 2.67-2.58 (br m, 2H, H-
4), 2.58-2.45 (m, 4H, Hb-6 and Hb-1), 2.38 (br s, 1H, Ha-5), 2.19-2.12 (m, 1H, Ha-5*), 1.86-
1.75 (m, 2H, Hb-5 and Hb-5*), 1.74-1.68 (m, 1H, Ha-3), 1.63-1.55 (m, 2H, Ha-3* and H2O), 
1.52-1.42 (m, 19H, Hb-3*), 1.38-1.31 (m, 1H, Hb-3) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 192.0 (C-7), 162.8 (C-9), 162.2 (C-9*), 155.7 (C-10), 155.6 
(C-10*), 104.2 (C-8), 104.1 (C-8*), 81.3 (C-11), 81.2 (C-11*), 51.1 (C-2), 50.7 (C-2*), 42.0 (br 
C-1), 37.8 (C-2), 37.2 (C-2*), 36.5 (C-3), 36.3 (C-3*), 35.9 (C-6), 35.8 (C-6*), 29.3 (C-5), 29.0 
(C-5*), 28.6 (C-12), 28.6 (C-12*) ppm. 
 
HRMS (ESI) Calc. for C28H44I2N3O6+: 772.1314 [M+NH4]+ 
Found:    772.1308 [M+NH4]+. 
 
Analytical data for the slow eluting diastereomer (259c or 259a): 
Rf = 0.3 (PE/EtOAc = 1:1). 
 
Rt = 17.9 min. 
 
m.p. (PE/EtOAc) > 112 ºC (decomp.). 
 [!]!!"   = –93.0 (c = 0.2, CH2Cl2). 
 
IR (ATR): ṽ = 2970 (w), 2923 (w), 1682 (s), 1582 (w), 1416 (m), 1364 (m), 1322 (w), 
1268 (w), 1158 (m) cm–1. 
 
1H NMR (CDCl3, 400 MHz) δ 7.74 (s, 1H, H-9), 4.36-4.20 (br m, 2H, H-2), 4.15-3.96 (br m, 
2H, Ha-1), 2.78 (dt, J = 4.5 Hz, J = 16.6 Hz, 2H, Ha-6), 2.68-2.42 (m, 6H, Hb-1 and H-4 and 
Hb-6), 2.21-2.09 (m, 2H, Ha-5), 1.89-1.74 (m, 2H, Hb-5), 1.64-1.54 (m, 3H, Ha-3 and H2O), 
1.51-1.39 (m, 20H, Hb-3 and H-12) ppm. 
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13C NMR (CDCl3, 100 MHz) δ 192.0 (C-7), 162.2 (C-9), 155.7 (C-10), 104.1 (C-8), 81.33 (C-
11), 50.7 (C-2), 41.8 (C-1), 37.2 (C-4), 36.4 (C-3), 35.9 (C-6), 29.4 (C-5), 28.6 (C-12) ppm. 
 
HRMS (ESI) Calc. for C28H44I2N3O6+: 772.1314 [M+NH4]+ 
Found:    772.1307 [M+NH4]+. 
 
(2S,5S)-di-tert-butyl 2,5-bis(((R)-4-oxo-3-(trimethylstannyl)cyclohex-2-enyl)methyl)pipe-
razine-1,4-dicarboxylate (309a) or (2S,5S)-di-tert-butyl 2,5-bis(((S)-4-oxo-3-(trimethyl-
stannyl)cyclohex-2-enyl)methyl)piperazine-1,4-dicarboxylate (309b) 
 
To a solution of the fast eluting iodoenone 259 (15 mg, 19.9 µmol) in degassed MePh 
(2.5 mL) was added hexamethylditin (14.3 mg, 43.7 µmol) and Pd(PPh3)4 (2.3 mg, 
1.99 µmol) and the resulting yellow solution was stirred for 5 h at 80 ºC. The resulting dark 
solution was concentrated and the residue purified by normal phase flash column 
chromatography (SiO2 + 10w% K2CO3;[318] PE/EtOAc = 3:1) to yield 7 mg (43%) of 
distannane 309 as a colorless oil. 
 
Rf = 0.2 (PE/EtOAc = 2:1). 
 [!]!!"   = –4.0 (c = 0.2, CH2Cl2). 
 
IR (ATR): ṽ = 2973 (w), 2913 (w), 1693 (s), 1656 (s), 1583 (w), 1416 9m), 1365 (m), 1267 
(w), 1240 (w), 1153 (m) cm–1. 
 
1H NMR (CD2Cl2, 600 MHz) δ 6.93 (mc, 2H, H-9), 4.33-3.19 (br m, 2H, C-2), 4.08-4.93 (br 
m, 2H, Ha-2), 2.54 (dd, J = 10.7 Hz, J = 14.1 Hz, 2H, Hb-2), 2.39-2.25 (m, 4H, H-4 and Ha-6), 
1.76-1.61 (m, 4H, Ha-3 and Hb-5), 1.44 (s, 18H, H-12), 1.36-1.27 (m, 2H, Hb-3), 0.14 (mc, 
18H, H-13) ppm. 
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13C NMR (CD2Cl2, 150 MHz) δ 202.3 (C-7), 163.6 (C-9), 155.9 (C-10), 144.9 (C-8), 80.5 (C-
11), 51.6 (C-2), 42.5 (br, C-1), 37.2 (C-6), 37.1 (C-3), 35.3 (C-4), 29.6 (C-5), 28.6 (C-12), -
7.6 (2x, C-13), -9.3 (C-13), -11.1 (2x, C-13) ppm. 
 
HRMS (ESI) Calc. for C34H62N3O6119Sn2+: 846.2699 [M+NH4]+ 
Found:    846.2680 [M+NH4]+. 
 
(S)-tert-butyl 2,2-dimethyl-4-(((R/S)-4-oxocyclohex-2-enyl)methyl)oxazolidine-3-carboxy-
late (302) 
 
Cyclohexenone 302 was synthesized according to a procedure developed by G. Volpin. [275] 
The spectral data matched those reported earlier. 
 
(S)-tert-butyl 4-(((R/S)-3-iodo-4-oxocyclohex-2-enyl)methyl)-2,2-dimethyloxazolidine-3-
carboxylate (303)  
 
To a solution of enone 302 (20.0 mg, 64.6 µmol) in CH2Cl2/pyridine (1.8 mL, 5:1) was added 
I2 (20.0 mg, 77.6 mmol) and the mixture was stirred overnight at RT. The mixture was diluted 
with EtOAc (50 mL) and washed with on a solution of saturated aqueous Na2S2O3, brine and 
water (1:2:1, 1 x 40 mL), 1 N HCl (2 x 20 mL) and again brine. The organic extract was dried 
over MgSO4, filtered and concentrated Normal phase flash column chromatography (SiO2; 
PE/EtOAc = 6:1) yielded 14 mg (50%) of vinyl iodide 303 (mixture of diastereomers) as a 
colorless, light- and temperature-sensitive oil. NMR indicated a ratio of 1:3 for the vinyl-
protons. 
 
Rf = 0.6 (PE/EtOAc = 2:1). 
 [!]!!"   = –6.4 (c = 0.86, CH2Cl2). 
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IR (ATR): ṽ = 2977 (m), 2935 (m), 2872 (m), 1683 (s), 1584 (w), 1386 (s), 1364 (s), 1256 
(m), 1169 (m), 1087 (m), 1071 (m) cm–1. 
 
1H NMR (CDCl3, 400 MHz; mixture of diastereomers and Boc rotamers) δ 7.76-7.57 (m, 1H, 
H-9), 4.16-3.86 (m, 2H, Ha-1 and H-2), 3.79-3.67 (m, 1H, Hb-1), 2.78 (ddd, J = 4.2 Hz, J = 
5.9 Hz, J = 16.7 Hz, 1H, Ha-6), 2.64-2.48 (m, 2H, H-4 and Hb-6), 2.47-2.12 (m, 1H, Ha-5), 
2.04-1.72 (m, 3H, H-3 and Hb-5), 1.62-1.54 (br m, 3H, H-14), 1.53-1.43 (m, 12H, H-12 and 
H-14) ppm. 
 
13C NMR (CDCl3, 100 MHz; mixture of diastereomers and Boc rotamers) δ 192.3 (C-7), 
192.2 (C-7’), 192.0 (C-7*), 191.9 (C-7*’), 163.3 (C-9), 163.0 (C-9’), 162.9 (C-9*), 161.4 (C-
9’), 152.7 (C-10), 152.4 (C-10’), 151.6 (C-10*), 151.5 (C-10*’), 104.5 (C-8), 104.1 (C-8’), 
103.9 (C-8*), 103.8 (C-8*’), 94.2 (2x, C-13), 93.7 (C-13*), 93.6 (C-13*’), 80.6 (C-11), 80.4 
(C-11*), 67.5 (C-1), 67.3 (C-1’), 67.2 (C-1*), 67.1 (C-1*’), 55.5 (C-2), 55.3 (C-2’), 55.1 (C-
2*), 54.9 (C-2*’), 38.6 (C-3), 38.3 (C-3’), 38.1 (C-4), 38.0 (C-4’), 37.8 (C-3*), 36.2 (C-6), 36.0 
(C-6’), 35.7 (C-6*), 35.5 (C-6*’), 30.0 (C-5), 29.7 (C-5’), 28.8 (C-12), 28.7 (C-12’), 28.5 (C-
12* and C-5*), 28.4 (C-12*’ and C-5*’), 28.0 (2x, C-14), 27.3 (C-14’), 27.1 (C-14*), 24.5 (C-
14*’), 23.2 (C-14’’) ppm. 
 
HRMS (EI) Calc. for C17H26127INO4+: 435.0901 [M]+ 
Found:    435.0920 [M]+. 
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Note: The following molecules have been isolated repeatedly from different experiments. Only 
exemplary procedures are given. 
 
(R/S,2S,2'S,5S,5'S)-1,4-di-tert-butyl 5,5'-((3R/S,3'R/S)-6,6'-dioxo-1,1'-bi(cyclohex-1-ene)-
3,3'-diyl)bis(methylene)bis(2-(((R/S)-3-iodo-4-oxocyclohex-2-enyl)methyl)piperazine-1,4-
dicarboxylate) (305) 
 
To a suspension of Ni(COD)2 (6 mg, 21.9 µmol) in degassed THF (5 mL) was added PBu3 
(10 µL, 41.8 µmol) and solid, fast eluting iodoenone 259 (15 mg, 19.9 µmol) at  
-78 ºC. The mixture was warmed to -20 ºC and stirred for 1 h, then warmed to RT and stirred 
for additional 2 h. The reaction was poured on an aqueous NH4Cl solution (20 mL) and 
extracted with EtOAc (3 x 20 mL). The combined extracts were dried over Na2SO4, filtered 
and concentrated. Preparative TLC (SiO2; CH2Cl2/MeOH  = 95:5) yielded 4 mg (16%) of 
dimer 305 as a colorless wax. 
 
Rf = 0.4 (CH2Cl2/MeOH  = 95:5). 
 
IR (ATR): ṽ = 2927 (w), 1689 (s), 1475 (w), 1416 (m), 1364 (m), 1267 (m), 1250 (m), 
1164 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 7.60 (d, J = 2.6 Hz, 2H, H-9), 6.62 (d, J = 2.0 Hz, 2H, H-21), 
4.37-4.16 (br m, 4H, H-2 and H-14), 4.13-3.91 (br m, 4H, Ha-1 and Ha-13), 2.77 (dt, J = 
4.5 Hz, J = 9.5Hz, 2H, Ha-6), 2.68-2.47 (m, 12H, Hb-1 and H-4 and Hb-6 and H-16 and Ha-
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18), 2.47-2.30 (m, 6H, Ha-5 and Ha-17 and Hb-18), 1.82-1.67 (m, 8H, Ha-3 and Hb-5 and Ha-
15 and Hb-17), 1.51-1.42 (m, 36H, H-12 and H-24), 1.39-1.32 (m, 4H, Hb-3 and Hb-15) ppm. 
 
13C NMR (CDCl3, 150 MHz) δ 197.2 (C-19), 192.0 (C-7), 162.1 (C-9), 155.8 (C-10 and C-
22), 152.9 (C-21), 136.1 (C-20), 104.5 (C-8), 81.1 (C-11 or C-23), 81.0 (C-23 or C-11), 51.2 
(C-2 and C-14), 37.9 (C-16), 37.1 (2x) (C-3 or C-15, and C-18), 36.5 (C-15 or C-3), 35.8 (C-
6), 33.7 (C-4), 29.1 (C-5 or C-17), 28.9 (C-17 or C-5), 28.6 (C-12 and C-24) ppm.  
 
Note: Due to the low amount of material, 13C-signals were in part reconstructed from 2D-
spectra (HSQC, HMBC). C-1 and C-13 could not be assigned owing to their low intensity due 
to ring inversion. 
 
HRMS (ESI) Calc. for C56H84I2N5O12+: 1272.4200 [M+NH4]+ 
Found:    1272.4201 [M+NH4]+. 
 
[1,4-di-tert-butyl (2S,5S)-2,5-bis[(3-iodo-4-oxocyclohex-2-en-1-yl)methyl]piperazine-1,4-
dicarboxylate; 15,17-di-tert-butyl (1S,14S)-6,9-dioxo-15,17-diazatetracyclo [12.2.2. 
13,7.18,12]icosa-7(20),8(19)-diene-15,17-dicarboxylate; 15,31,33,37-tetra-tert-butyl (1S,14S, 
17S,30S)-6,9,22,25-tetraoxo-15,31,33,37-tetraazaheptacyclo[28.2.2.214,17.13,7.18,12.119,23. 
124,28]tetraconta-7(40),8(39),23(36),24(35)-tetraene-15,31,33,37-tetracarboxylate]] (306) 
 
Procedure A: 
Solid bis(triphenylphosphine)nickel(II) chloride (28.6 mg, 43.7 µmol), PPh3 (22.9 mg, 
87.5 µmol), KI (7.3 mg, 43.7 µmol) and Zn (2.9 mg, 43.7 µmol) were mixed in a flask. The 
vessel was flushed with argon three times, degassed DMF (1 mL) was added and the resulting 
mixture was heated to 55 ºC for 30 min. The solution turned to a dark red. (R,S)-diiodide 
259b in degassed DMF (2 mL) was added drop-wise over 5 min and heating was continued 
for 3 h. The reaction was allowed to cool to RT and aqueous 10% NaCl solution (5 mL) was 
added. To the mixture was added EtOAc (30 mL) and the organic phase was extracted 
successively with aqueous 10% NaCl (2 x 5 mL), 2 M HCl (1 x 5 mL) and brine (1 x 5 mL). 
The organic extract was dried over MgSO4, filtered and concentrated. Normal phase flash 
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column chromatography (SiO2; CH2Cl2/MeOH = 98:2 to 95:5) yielded 1 mg (5%) of 
macrocycle 306 as a colorless film. 
 
Procedure B: 
To a solution of CuCl (11.8 mg, 119 µmol) in degassed DMF (3 mL) was added distannane 
309 (7 mg, 8.45 µmol) in degassed DMF (1.5 mL) over 15 min. at 70 ºC. The mixture was 
stirred for further 30 min and then saturated aqueous NH4Cl (5 mL) and aqueous NH3 (a few 
drops) and EtOAc (10 mL) were added and the open flask was stirred vigorously for 15 min. 
The phases were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL). 
The combined organic extracts were washed with brine, dried over MgSO4, filtered and 
concentrated. Preparative TLC (SiO2; CH2Cl2/MeOH = 95:5) yielded 2 mg (24%) of 
macrocycle 306 as a colorless film. 
 
Rf = 0.2 (CH2Cl2/MeOH  = 95:5). 
 
IR (ATR): ṽ = 2971 (w), 2927 (w), 1687 (s), 1477 (w), 1453 (w), 1417 (m), 1365 (m), 
1249 (m), 1161 (s) cm–1. 
 
1H NMR (CDCl3, 600 MHz) δ 6.71-6.32 (m, 4H), 3.37-4.16 (br m, 4H), 4.11-3.81 (br m, 4H), 
2.90-2.73 (m, 2H), 2.70-2.10 (m, 17H), 1.91-1.65 (m, 7H), 1.55-1.31 (m, 42H) ppm. 
 
Note: Due to the low amount of material, neither a 13C NMR nor suitable 2D-spectra could be 
obtained. 
HRMS (ESI) Calc. for C56H80N4NaO12+: 1023.5665 [M+Na]+ 
Found:    1023.5660 [M+Na]+. 
Note: The [M+Na]+ peak was confirmed by FAB-MS. 
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1) General Experimental Details and Instrumentation 
 
a) Cell Culture and Transfection 
HEK293T cells were plated on poly-L-lysine-coated glass coverslips (VWR, 12 mm, No. 1) 
and maintained in DMEM (Biochrom, 4.5 g/L D-glucose) with 10% FBS (Biochrom) at 37 °C 
and 10% CO2 atmosphere. Cells were transiently transfected with plasmids (gracious gift 
from Ehud Isacoff) using the Optifect reagent (Invitrogen). The amount of total transfected 
cDNA per 0.5 mL well was fixed at 0.8 µg. Visualization was achieved by co-transfection 
with YFP (1:20) for GluA2- and GluK2-type channels or by a GFP-fusion construct (LiGluR-
type). Recordings of GluA2- and GluK2-derived channels were carried out 24 h and 48 h 
respectively after transfection. 
 
b) Mouse Cortical Slice Preparation 
After cervical dislocation, the brain of wt mice (BL/6; P10-P16) was removed and placed in 
ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): 87 NaCl, 75 Sucrose, 25 
NaHCO3, 2,5 KCl, 1,25 NaH2PO4, 0,5 CaCl2, 7 MgCl2, 25 Glucose, bubbled with 95% O2 
and 5% CO2. 300 µm coronal slices were cut from the visual cortex using a custom made 
slicer and kept in ACSF for 1 h at 34 °C and then for up to 8 h at RT. 
 
c) Mouse Retina Preparation 
Four to eight weeks old triple knock-out mice (cng-/-;rho-/-;opn4-/-) were euthanized and 
their retinae dissected in normal ringer (NR; in mM: 125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 
1.25 NaH2PO4, 26 NaHCO3, 20 glucose) at RT. The NR was bubbled with carbogen gas (95% 
oxygen, 5% carbon dioxide) to reach pH = 7.3. 
 
d) Patch Clamp 
Patch clamp recordings were carried out using a HEKA Patch Clamp EPC10 USB amplifier 
in whole cell mode. HEK cells and cortical neurons were voltage-clamped at –70 mV. 
Pipettes (Science Products GB200-F-8P with filament) were pulled with a Narishige PC-10 
pipette puller and had resistances of 6-7 MΩ. For the experiments patch-pipettes were filled 
with a solution containing (in mM): 140 K-gluconate, 4 NaCl, 12 KCl, 4 Mg-ATP and 10 
HEPES at pH = 7.2 (adjusted with KOH). For HEK cells the extracellular solution contained 
(in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES and 10 D-glucose at pH = 7.4 
(adjusted with NaOH). For experiments in hippocampal neurons the extracellular solution 
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contained (in mM): 125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 
20 glucose at pH 7.3 (with carbogen). HEK293T cells expressing GluK2-type channels were 
preincubated for 10 min in external solution containing 300 mg/L concanavalin A[252] (Con-A, 
type VI, Sigma-Aldrich) and for GluA2-type a construct bearing the L504Y mutation was 
used in order to block desensitization. L-Glutamate and the other compounds were applied as 
reported in text and figures with complete exchange of the bath solution occurring in less than 
30 s. Bath perfusion was stopped prior to switching illumination wavelengths. Illumination 
was applied using a TILL Photonics Polychrome 5000 monochromator through a Nicon Fluor 
60x/1.00w objective. The power output of the system was determined with a Thor Labs 
PM100USB power and energy meter: 
 
Supporting Table 2. Power output of the Polychrom 5000 monochromator. 
Entry Wavelength l [nm] Power Output[a] 
[mW/mm2] 
1 360 nm 5.15 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
380 nm 
400 nm 
420 nm 
440 nm 
460 nm 
480 nm 
500 nm 
520 nm 
540 nm 
560 nm 
9.07 
12.7 
15.4 
17.0 
20.5 
20.3 
18.1 
16.9 
15.7 
14.3 
[a] Calculated for the field of view area = 70.7•10-3 mm2 (ø = 300 µm). 
 
The supplied HEKA PatchMaster software (V2x60) was used to control the monochromator 
and to record the data. The results are representative data from multiple cells as indicated in 
the graphs. 
 
e) MEA Recordings 
After mounting the retinae on a 60-electrode multielectrode array (MEA; USB ME64 from 
Multichannel Systems), they were perfused with ringer’s solution (NR + carbogen gas) at 
34 ºC with a flow rate of approx. 3-4 ml/min for 15-20 min, before the experiments were 
started. As a control experiment for ATA3 light switches between 480 nm and dark (each 20s) 
were applied to the retinae in the absence of the photoswitch. No light induced stimulation 
could be observed. Only retinae that had a viable spiking frequency right after mounting were 
taken for experiments and were analyzed. If retinae had no intrinsic activity, they were 
discarded. The light stimulation was done with a hand lamp (Ultrafire), which produces a 
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spectrum of illumination around 480 nm with high intensity (4.5 mW/cm2). The analysis of 
the spiking frequency (rate, spikes) was done using a threshold of -4 STD of the noise level in 
each of the single channels and a high pass filter of 330 Hz to exclude population stimulations 
within the retina. Spike sorting was done with the MC-Rack software (Multichannel 
Systems). 
 
2) A Photochromic Agonist of AMPA Receptors – Supporting Information 
 
a) On Kinetics of ATA3 (89c) at GluA2 (L504Y) 
 
Supporting Figure 2. Relative photocurrent evoked by 50 µM ATA-3 (89c) acting on HEK293T cells 
expressing GluA2 (L504Y). The cells were exposed to darkness or illuminated with the respective 
wavelength for 5 s (n = 5). 
 
b) Off Kinetics of ATA-3 (89c) at GluA2 (L504Y) 
 
	  
Supporting Figure 3. Voltage-clamp recording of ATA3 (89c) at 50 µM concentration acting on a 
HEK293T cell expressing GluA2 (L504Y). The traces show distinctive off-kinetics when switching from 
darkness to different wavelengths of light. 
  
Experimental 
240 
Supporting Table 3. Time-constant τoff to reach a plateau current (n = 5).[a] 
Entry[b] Wavelength l τoff[c] 
1 360 nm 888 ± 54 ms 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
380 nm 
400 nm 
420 nm 
440 nm 
460 nm 
480 nm 
500 nm 
520 nm 
540 nm 
560 nm 
440 ± 34 ms 
158 ± 19 ms 
72.1 ± 6.3 ms 
47.0 ± 11 ms 
48.0 ± 4.7 ms 
47.2 ± 7.7 ms 
49.5 ± 4.0 ms 
78.9 ± 6.3 ms 
197 ± 35 ms 
763 ± 80 ms 
[a] reference: 415 nm [b] c = 50 µM ATA-3 (89c) [c] mean ± SEM 
c) EC50 of trans-ATA-3 (89c) acting on GluA2 L504Y 
 
	  
Supporting Figure 4. Dose-response curve for ATA-3 (89c) in the dark recorded from HEK293T cells 
expressing GluA2 L504Y. Efficacy relative to saturating L-glutamate (300 µM). Data (±SEM) were fitted 
to the Hill-equation (n = 5 to 15 for each concentration). Due to insolubility, data points for 
concentrations higher than 120 µm could not be obtained.  
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3) Mutagenesis and Cloning 
Numbering of protein positions is assigned according to the direct translation of genes 
deposited at the NCBI. ATG = Met = position 1. Mutations were introduced into plasmids 
using the QuickChange method (Agilent) with custom primers: 
 
GluK2 D776K f: 
CCTATGGGCTCTCCATATCGAAAGAAAATCACCATAGCAATTCTT 
GluK2 D776K r: 
AAGAATTGCTATGGTGATTTTCTTTCGATATGGAGAGCCCATAGG 
GluK2 K531G f: 
TCGTGAGAAGGTCATCGACTTTTCAGGCCCGTTTATGACACTTGGA 
GluK2 K531G r: 
TCCAAGTGTCATAAACGGGCCTGAAAAGTCGATGACCTTCTCACGA 
GluA2 Q607R f: 
GTGCCTTTATGCGGCGCGGATGCGATATTTC 
GluA2 Q607R r: 
GAAATATCGCATCCGCGCCGCATAAAGGCAC 
GluA2 L671G f: 
CAGAAATTGCTTATGGAACAGGCGACTCTGGCTCCACTAAAG 
GluA2 L671G r: 
CTTTAGTGGAGCCAGAGTCGCCTGTTCCATAAGCAATTTCTG 
GluA2 L671A f: 
GAAATTGCTTATGGAACAGCCGACTCTGGCTCCACTAAAG 
GluA2 L671A r: 
CTTTAGTGGAGCCAGAGTCGGCTGTTCCATAAGCAATTTC 
GluA2 L671S f: 
GAAATTGCTTATGGAACAAGCGACTCTGGCTCCACTAAAG 
GluA2 L671S r: 
CTTTAGTGGAGCCAGAGTCGCTTGTTCCATAAGCAATTTC 
GluK2 V685G f: 
GATAGAGTATGGAGCAGGCGAGGACGGCGCAACCATG 
GluK2 V685G r: 
CATGGTTGCGCCGTCCTCGCCTGCTCCATACTCTATC 
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GluA2 YeastKozak f: 
CATACTCTAGAACTAGTCCAAAAAAATGCAAAAGATTATGCATAT 
GluA2 YeastKozak r: 
ATATGCATAATCTTTTGCATTTTTTTGGACTAGTTCTAGAGTATG 
GluK2 YeastKozak f: 
ACTCTAGAACTAGTCCAAAAAAATGAAGATTATTTCCCCA 
GluK2 YeastKozak r: 
TGGGGAAATAATCTTCATTTTTTTGGACTAGTTCTAGAGT 
 
For cloning of iGluRs DNA into yeast expression plasmids (pMet promoter), genes were 
amplified using PfuX polymerase (Jena Bioscience) and custom primers: 
 
GluA2 XbaI f: 
GAACTCTAGACCATGCAAAAGATTATGCATATTTCTGTCCTCC 
GluA2 XhoI r: 
GAACCTCGAGCTAAATTTTAACACTCTCGATGCCATATACGT 
GluK2 XbaI f: 
GAAC TCTAGA CC ATGAAGATTATTTCCCCAGTTTTAAGTAATCTAGT 
GluK2 XhoI r: 
GAAC CTCGAG TCATGCCATGGTTTCTTTACCTGGCAACCTTC 
 
Vector and amplified genes were cut with XBaI and XhoI (NEB) restriction enzymes, purified 
and ligated in 1:1 to 1:3 molar ratios (vector:iGluR gene) using T4 ligase (NEB).  
Clones were selected by ampicillin/kanamycin selection and verified by sequencing of both 
strands. 
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1) A Photochromic Agonist of AMPA Receptors 
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3-(allyloxy)isoxazole-5-carbonitrile (92) 
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tert-butyl 3-(3-(allyloxy)-5-cyanoisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propa-
noate (94) 
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tert-butyl 3-(3-(allyloxy)-5-(2H-tetrazol-5-yl)isoxazol-4-yl)-2-(bis(tert-butoxycarbonyl) 
amino)propanoate (95) 
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(4-(phenyldiazenyl)phenyl)methanol (S2) 
 
  
N N
S2
OH
Spectra 
249 
(3-(phenyldiazenyl)phenyl)methanol (S3) 
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methyl 3-((4-(dimethylamino)phenyl)diazenyl)benzoate (S4) 
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3-((4-(dimethylamino)phenyl)diazenyl)phenyl)methanol (96) 
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(3-((4-iodophenyl)diazenyl)phenyl)methanol (S5) 
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N-(4-((3-(hydroxymethyl)phenyl)diazenyl)phenyl)acetamide (S6) 
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tert-butyl 3-(3-(allyloxy)-5-(2-(4-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-yl)-
2-(bis(tert-butoxycarbonyl)amino)propanoate (S1a) 
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tert-butyl 3-(3-(allyloxy)-5-(2-(3-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-yl)-
2-(bis(tert-bu-toxycar-bonyl)amino)propanoate (S1b) 
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tert-butyl 3-(3-(allyloxy)-5-(2-(3-((4-(dimethylamino)phenyl)diazenyl)benzyl)-2H-tetrazol 
-5-yl)isoxa-zol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propanoate (97) 
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tert-butyl 3-(5-(2-(3-((4-acetamidophenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-(allyloxy) 
isoxazol-4-yl)-2-(bis (tert-butoxycarbonyl)amino)propanoate (S1c) 
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tert-butyl 2-(bis(tert-butoxycarbonyl)amino)-3-(5-(2-(3-((4-(dimethylamino)phenyl)dia-
zenyl)benzyl)-2H-tetra-zol-5-yl)-3-hydroxyisoxazol-4-yl)propanoate (98) 
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tert-butyl 2-(bis(tert-butoxycar-bonyl)amino)-3-(5-(1-(3-((4-(dimethylamino)phenyl)di-
azenyl)ben-zyl)-1H-tetrazol-5-yl)-3-hydroxyiso-xazol-4-yl)propanoate (98’) 
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2-amino-3-(3-hydroxy-5-(2-(4-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-
yl)propanoic acid (ATA-1, 89a) 
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261 
2-amino-3-(3-hydroxy-5-(2-(3-(phenyldiazenyl)benzyl)-2H-tetrazol-5-yl)isoxazol-4-
yl)propanoic acid (ATA-2, 89b) 
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2-amino-3-(5-(2-(3-((4-(dimethylamino)phenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-
hydroxyisoxazol-4-yl)propanoic acid (ATA-3, 89c) 
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3-(5-(2-(3-((4-acetamidophenyl)diazenyl)benzyl)-2H-tetrazol-5-yl)-3-hydroxyisoxazol-4-
yl)-2-aminopropanoic acid (ATA-4, 89d) 
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2) Triazolyl-Substituted AMPA derivatives 
tert-butyl 3-(3-(allyloxy)-5-formylisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)propa-
noate (102) 
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265 
tert-butyl 3-(3-(allyloxy)-5-ethynylisoxazol-4-yl)-2-(bis(tert-butoxycarbonyl)amino)pro-
panoate (101) 
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266 
tert-butyl 3-(3-(allyloxy)-5-(1-benzyl-1H-1,2,3-triazol-4-yl)isoxazol-4-yl)-2-(bis(tert-buto-
xycarbonyl)amino)propanoate (104) 
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Spectra 
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2-amino-3-(5-(1-benzyl-1H-1,2,3-triazol-4-yl)-3-hydroxyisoxazol-4-yl)propanoic acid hy-
drochloride (105•HCl) 
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3) A Kainate-Derived Photoswitch 
(2S,3S,4R)-1-tert-butyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-vinylpyrrolidine-1,2-dicar-
boxylate (111) 
	  	   	  
N
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269 
(2S,3S,4S)-1-tert-butyl 2-methyl 3-(2-methoxy-2-oxoethyl)-4-((E)-1-(4-((E)-phenyldiaze-
nyl)phenyl)prop-1-en-2-yl)pyrrolidine-1,2-dicarboxylate (119) 
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AzKA•Na (107•Na) 
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4) 3-D-Substituted Glutamate Analogues 
(S,E)-tert-butyl 4-(3-methoxy-3-oxoprop-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
(122a) 
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H
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Spectra 
272 
(S)-tert-butyl 4-((R)-4-methoxy-4-oxo-1-phenylbutan-2-yl)-2,2-dimethyloxazolidine-3-
carboxylate (S9) 
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(2S,3R)-dimethyl 3-benzyl-2-(tert-butoxycarbonylamino)pentanedioate (S11) 
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 (2S,3R)-2-amino-3-benzylpentanedioic acid formate salt (124•FA) 
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Spectra 
275 
 (2S,3R)-dimethyl 3-allyl-2-(tert-butoxycarbonylamino)pentanedioate (129) 
 
  
129
MeOOC COOMe
NHBoc
Spectra 
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(2S,3R)-3-allyl-2-aminopentanedioic acid TFA salt (125•TFA) 
 
  
125•TFA
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(2S,3R)-2-amino-3-propylpentanedioic acid TFA salt (127•TFA) 
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Spectra 
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(2S,3R)-dimethyl 2-(tert-butoxycarbonylamino)-3-((E)-3-(4-(phenyldiazenyl)phenyl)al-
lyl)pentanedioate (130) 
 
  
MeOOC COOMe
NHBoc
130
N
N
Spectra 
279 
5) A Photoswitched Tethered Ligand of mGluRs 
(5S,7S)-7-(tert-butoxycarbonylamino)-8-methoxy-5-(methoxycarbonyl)-8-oxo-octanoic 
acid (194) 
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(2S,4S)-dimethyl 2-(4-(4-((E)-(4-aminophenyl)diazenyl)phenylamino)-4-oxobutyl)-4-
(tert-butoxycarbonylamino)pentanedioate (195) 
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(2S,4S)-dimethyl 2-(4-(4-((E)-(4-(2-aminoacetamido)phenyl)diazenyl)phenylami no)-4-
oxobutyl)-4-(tert-butoxycarbonylamino)pentanedioate (196) 
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(2S,4S)-2-(4-(4-((E)-(4-(2-aminoacetamido)phenyl)diazenyl)phenylamino)-4-oxo butyl)-
4-(tert-butoxycarbonylamino)pentanedioic acid (197) 
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Spectra 
283 
(2S,4S)-2-amino-4-(4-(4-((E)-(4-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamido)-
phenyl)diazenyl)phenylamino)-4-oxobutyl)pentanedioic acid hydrochloride (D-MAG0, 
198•HCl) 
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284 
(2S,4S)-dimethyl 2-(tert-butoxycarbonylamino)-4-(4-oxo-4-(phenylamino)butyl) pentane-
dioate (S13) 
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Spectra 
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(2S,4S)-2-amino-4-(4-oxo-4-(phenylamino)butyl)pentanedioic acid hydrochloride (TM-0, 
199•HCl) 
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• HCl
Spectra 
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(2S,4S)-dimethyl 2-(tert-butoxycarbonylamino)-4-(4-oxo-4-(2-oxo-2-(phenylamino)ethyl-
amino)butyl)pentanedioate (S14) 
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Spectra 
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(2S,4S)-2-amino-4-(4-oxo-4-(2-oxo-2-(phenylamino)ethylamino)butyl)pentane-dioic acid 
hydrochloride (TM-1, 200•HCl) 
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Spectra 
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6) Toward an Orthogonal Receptor-Ligand Pair basedon iGluRs 
di-tert-butyl 2-((dibenzylamino)methyl)pentanedioate (233) 
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(R/S)-di-tert-butyl 2-((benzyl((R)-1-phenylethyl)amino)methyl)pentanedioate (235) 
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(R/S)-2-(aminomethyl)pentanedioic acid hydrochloride (228•HCl) 
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291 
(R/S)-di-tert-butyl 1-(1,5-dimethoxy-1,5-dioxopentan-2-yl)hydrazine-1,2-dicarboxylate 
(244) 
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Spectra 
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7) Toward the Total Synthesis of Herquline A & B 
(5aS,10aS)-tetrahydrodipyrrolo[1,2-a:1',2'-d]pyrazine-3,5,8,10(5aH,10aH)-tetraone 
(S15) 
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Spectra 
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3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoic acid (268) 
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Spectra 
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dimethyl 3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoate (292) 
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295 
dimethyl 3,3'-((2S,5S)-3,6-dithioxopiperazine-2,5-diyl)dipropanoate (294) 
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Spectra 
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(5aS,10aS)-octahydrodipyrrolo[1,2-a:1',2'-d]pyrazine-3,8-dione (295) 
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297 
(2S,5S)-di-tert-butyl 2,5-bis(3-methoxy-3-oxopropyl)piperazine-1,4-dicarboxylate (296) 
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(2S,5S)-di-tert-butyl 2,5-bis(3-hydroxypropyl)piperazine-1,4-dicarboxylate (266) 
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(2S,5S)-di-tert-butyl 2,5-bis(3-oxopropyl)piperazine-1,4-dicarboxylate (262) 
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(2S,5S)-di-tert-butyl 2,5-bis(2-formyl-5-oxohexyl)piperazine-1,4-dicarboxylate (261) 
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301 
(2S,5S)-di-tert-butyl 2,5-bis((4-oxocyclohex-2-enyl)methyl)piperazine-1,4-dicarboxylate 
(260) 
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(2S,5S)-di-tert-butyl 2,5-bis(((R)-3-iodo-4-oxocyclohex-2-enyl)methyl)piperazine-1,4-di-
carboxylate or (2S,5S)-di-tert-butyl 2,5-bis(((S)-3-iodo-4-oxocyclohex-2-enyl)methyl) 
piperazine-1,4-dicarboxylate (259a or 259c)	  
  
or
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Spectra 
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(2S,5S)-di-tert-butyl 2-(((R)-3-iodo-4-oxocyclohex-2-enyl)methyl)-5-(((S)-3-iodo-4-oxocy-
clohex-2-enyl)methyl)piperazine-1,4-dicarboxylate (259b)	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(2S,5S)-di-tert-butyl 2,5-bis(((S)-3-iodo-4-oxocyclohex-2-enyl)methyl) piperazine-1,4-
dicarboxylate or (2S,5S)-di-tert-butyl 2,5-bis(((R)-3-iodo-4-oxocyclohex-2-enyl)methyl) 
piperazine-1,4-di-carboxylate (259c or 259a)	   
  
or
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(2S,5S)-di-tert-butyl 2,5-bis(((R)-4-oxo-3-(trimethylstannyl)cyclohex-2-enyl)methyl)pipe-
razine-1,4-dicarboxylate (309a) or (2S,5S)-di-tert-butyl 2,5-bis(((S)-4-oxo-3-(trimethyl-
stannyl)cyclohex-2-enyl)methyl)piperazine-1,4-dicarboxylate (309b) 
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Spectra 
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(S)-tert-butyl 4-(((R/S)-3-iodo-4-oxocyclohex-2-enyl)methyl)-2,2-dimethyloxazolidine-3-
carboxylate (303) 
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(R/S,2S,2'S,5S,5'S)-1,4-di-tert-butyl 5,5'-((3R/S,3'R/S)-6,6'-dioxo-1,1'-bi(cyclohex-1-ene)-
3,3'-diyl)bis(methylene)bis(2-(((R/S)-3-iodo-4-oxocyclohex-2-enyl)methyl)piperazine-1,4-
dicarboxylate) (305) 
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Spectra 
309 
[1,4-di-tert-butyl (2S,5S)-2,5-bis[(3-iodo-4-oxocyclohex-2-en-1-yl)methyl]piperazine-1,4-
dicarboxylate; 15,17-di-tert-butyl (1S,14S)-6,9-dioxo-15,17-diazatetracyclo [12.2.2. 
13,7.18,12]icosa-7(20),8(19)-diene-15,17-dicarboxylate; 15,31,33,37-tetra-tert-butyl (1S,14S, 
17S,30S)-6,9,22,25-tetraoxo-15,31,33,37-tetraazaheptacyclo[28.2.2.214,17.13,7.18,12.119,23. 
124,28]tetraconta-7(40),8(39),23(36),24(35)-tetraene-15,31,33,37-tetracarboxylate]] (306) 
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